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Mutations in the tumour suppressor gene Adenomatous polyposis coli (APC) are found 
in 80 % of sporadic colorectal cancer (CRC) tumours and are also responsible for the 
inherited form of CRC, Familial adenomatous polyposis (FAP). In order to identify novel 
therapeutic targets for the treatment of APC mutated CRC, we have generated an in 
vitro model of APC mutant CRC using CRISPR-cas9 gene editing. Using the APC 
wildtype colorectal carcinoma cell line RKO, we targeted the cells with guide RNA 
(gRNA) targeting exon 2 or exon 15 (encodes 80 % of APC) of the APC gene. We 
generated isogenic cell lines which differed in the expression of APC, the controls were 
APC wildtype and the APC mutant (APC Lys736fs) cell lines expressed a truncated 
~80 kDa APC protein.  
 
We used these cell lines to perform an siRNA screen against 720 kinases and kinase-
related genes. We selected seven genes to investigate further, unfortunately none of 
the potential hits validated. Additionally, we performed an FDA-approved compound 
screen targeting over 1000 compounds. From this, we identified a group of HMG-CoA 
reductase (HMGCR) inhibitors known as statins, which selectively cause a greater loss 
in cell viability in the APC mutated cell lines, compared to the APC wildtype cells. 
Mechanistically, our data suggests this synthetic lethal relationship is due to a greater 
decrease in the anti-apoptotic protein survivin. We propose this is due to statins 
altering the localisation of Rac1, reducing Pak1 activation and reducing the level of Wnt 
signalling. This results in the reduction of the Wnt target gene survivin. We have 
successfully identified an FDA-approved family of compounds, which show synthetic 







aa    Amino acids  
15aa   15 amino acid repeats  
20aa    20 amino acid repeats 
AFAP    Attenuated familial adenomatous polyposis 
AML    Acute myloid leukemia  
AMPK    AMP-activated protein kinase 
APC    Adenomatous polyposis coli  
AP1   Activator protein 1 
ARF6    GTPase ADP-ribosylation factor 6 
5-ASA    5-Aminosalicyclic acid  
ASEF1   APC-stimulated guanine nucleotide exchange factor 1 
ASEF2   APC-stimulated guanine nucleotide exchange factor 2 
A.terreus  Aspergillus terreus  
ATG13   Autophagy related 13 
BCI    Barts Cancer Institute 
Bcl-2   B-cell lymphoma 2 
BER   Base excision repair  
BID    B3 interacting-domain death agonist 
BIRC5   Baculoviral IAP repeat containing 5  
BMP    Bone morphogenic protein 
Bp   Base pair 
BRCA1   Breast cancer 1  
BRCA2   Breast cancer 2 
BSA    Bovine serum albumin 
CAC    Colitis associated colon cancer model  
Cas   CRISPR associated protein 
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CD40   Cluster of differentiation 40 
Cdc42   Cell division cycle 42 
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C.elegans   Caenorhabditis elegans 
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CK1   Casein kinase 1 
CK1α    Casein kinase 1α 
CMS   Consensus molecular subtypes 
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cPPT     Central polypurine tract 
CRC    Colorectal cancer 
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CRP    C-reactive protein 
crRNA   CRISPR RNA 
CTG   CellTiter-glo  
CTLA4   Cytotoxic T-lymphocyte associated protein 4 
CTNNB1  Catenin beta 1  
CTT    Cholesterol treatment trialists 
COX2   Cyclooxygenase 2 
CVD    Cardiovascular disease  
DCC    Deleted in colorectal cancer 
DLG   Discs large  
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D.melanogaster  Drosophila melanogaster 
DMEM   Dulbecco’s Modified Eagles Medium 
DMSO   Dimethyl sulfoxide 
DNA-Pkcs  DNA dependent protein kinase catalytic subunit 
dsRNA   Double stranded RNA 
DTT    Dithiothreitol 
DYRK2  Dual-specificity tyrosine (y) phosphorylation regulated kinase 2  
EB1   End-binding protein 1 
4E-BP1  Eukaryotic translation initiation factor 4E-binding protein 1 
EBP   Emopamil-binding protein  
E-cadherin   Epithelial-cadherin 
E.coli    Escherichia coli  
eEF2   Eukaryotic elongation factor 2 
EGFR    Epidermal growth factor receptor 
eIF4E   Inhibition of eukaryotic translation initiation factor 4E 
EMT    Epithelial to mesenchyal transition  
EphB4   EPH receptor B4 
ER   Endoplasmic reticulum 
ERBB2   Erb-B2 receptor tyrosine kinase 2 
FA   Folinic acid  
FAP     Famalial adenomatous polyposis 
FBS   Fetal bovine serum  
FDA    Food and drug administration  
Fen-1    Flap endonuclease 1  
FIP200  FAK family kinase-interacting protein of 200 kDa 
FLT3   Fms related tyrosine kinase 3  
FN3KRP   Fructosamine 3 kinase related protein 
Fox01   Forkhead box O1 
Fox03a   Forkhead box O3a 
FPP    Farnesyl pyrophosphate 
FTase    Farnesyl transferase 
FTI    Farnesyl transferase inhibitor 
5-FU    5-fluorouracil 
GAP    GTPase-activating proteins  
GDI   Guanine nucleotide dissociation inhibitors  
GDP    Guanosine diphosphate  
GEF    Guanine nucleotide exchange factors 
GGPP    Geranylgeranyl pyrophosphate  
GGTase   Geranylgeranyl transferase  
GGTI    Geranylgeranyltransferase inhibitor 
GlcNAc   N-acetylglucosamine 
gRNA    Guide RNA 
GSK3β   Glycogen synthase kinase 3β 
GTP    Guanosine triphosphate  
HCEC    Human colonic epithelial cell lines 
HDAC    Histone deacetylases 
HDL    High density lipoprotein 
HDR   Homology directed repair 
HMG-CoA  3-hydroxyl-3-methylglutaryl coenzyme  
HMGCR   3-hydroxyl-3-methylglutaryl coenzyme A reductase 
HNPCC   Hereditary nonpolyposis colorectal cancer  
HR    Homologous recombination  
hTERT   Human telomerase reverse transcriptase  
IAP    Inhibitor of apoptosis 
IBD     Inflammatory bowel disease 
ICAM1   Intercellular adhesion molecule 1  
Icm1    Isoprenylcysteine-O-carboxyl methyltransferase 
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IL-1B    Interleukin1 beta  
IL6   Interleukin 6  
IQGAP1  IQ motif containing GTPase activating protein 1 
JNK2    C-jun N-terminal kinase 2  
Kap3   Kinesin associated protein 3 
KB   Kilobase 
kDa    Kilodaltons 
Kif3   Kinesin superfamily protein 3 
KLF2   Kruppel like factor 2 
LB    Lysogeny broth 
LDL    Low density lipoprotein  
LFA1   Lymphocyte functions-associated antigen 1 
LRP5    Low density lipoprotein receptor related proteins 5 
LRP6   Low density lipoprotein receptor related proteins 6 
MAD   Median absolute deviation 
MAPK   Mitogen activated protein kinase  
MAP3K12  Mitogen activated protein kinase kinase kinase 12 
MCR    Mutation cluster region 
mDia   Diaphanous-related formin-1  
MHC-II   Major histocompatibility class II  
miRNA   Micro RNA 
MLH1   MutL homolog 1  
mLST8  Mammalian lethal with SEC13 protein 8 
MMR   Mismatch repair 
MNP    Micellar nanoparticles  
MSH2   MutS protein homolog 2 
MSH6   MutS homolog 6 
MSI   Microsatellite instability  
Msin1   Mammalian stress-activated map kinase-interacting protein 1 
mTOR   Mammalian target of rapamycin  
mTORC1  Mammalian target of rapamycin complex 1  
mTORC2  Mammalian target of rapamycin complex 2  
MVA    Mevalonic acid 
NAGK   N-acetylglucosamine kinase 
N4BP2   NEDD4 binding protein 2 
NES    Nuclear export signal 
NF-kB    NF-kappaB 
NHEJ   Non-homologous end joining  
NKD1   Naked cuticle homolog 1 
NLS    Nuclear localisation sequence 
NMD    Non-sense mediated mRNA decay 
NSAID   Non-steroidal anti-inflammatory drug  
NSCLC  Non-small cell lung cancer 
NT    Nucleotides 
NTC    No template control 
8-oxo G  8-Oxoguanine  
PA    Phosphatidic acid 
Pak1   p21 activated kinase 1 
PAM   Protospacer adjacent motif  
PARP    Poly (ADP-ribose) polymerase 
PBD    p21(rac1)-binding domain 
PBS    Phosphate buffered saline 
PCNA   Proliferating cell nuclear antigen  
PD1   Programmed cell death protein 1  
PD-L1   Programmed death ligand 1 
P.citrinum   Penicillium citrinum 
PFA    Paraformaldehyde 
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PGC1α  Peroxisome proliferator-activated receptor gamma coactivator 1 
alpha  
PI3K    Phosphoinositide 3-kinase 
PIM2   Proviral integrations of moloney virus 2  
PINK1   PTEN induced putative kinase 1 
PKCα   Protein kinase C alpha  
PLD    Phospholipase D 
PLK1   Polo like kinase 1 
PMS2   PMS1 homolog 2 
Pol- β    Polymerase β  
Pol-γ    DNA polymerase γ  
PP2A    Protein phosphatase 2A 
PPARα   Peroxisome proliferator-activated receptor alpha 
PPAR β   Peroxisome proliferator-activated receptor beta 
PPARγ   Peroxisome proliferator-activated receptor gamma 
pras40   Proline-rich Akt substrate of 40kDa 
pre-miRNA      Precursor miRNA 
pri-miRNA   Primary miRNA 
PrxII    Peroxiredoxin type II 
Ptgs2   Prostaglandin-endoperoxide synthase 2 
Rac1   Rac family small GTPase 1 
RBD    Rhotekin-binding domain 
Rce1   Endoprotease Ras-converting enzyme 1  
Rheb   Ras homolog enriched in brain  
RhoA     Ras homolog gene family member A  
RISC    RNA-induced silencing complex 
RNAi   RNA interference  
RNF146   Ring finger protein 146  
RPMI   Roswell Park Memorial Institute 
RRE    Rev response element 
RTK   Receptor tyrosine kinase 
S6   Ribosomal protein s6  
S.cerevisiae   Saccharomyces cerevisiae 
SCID    Severely compromised immunodeficient 
SCNA   Somatic copy number alterations  
Scr    Non-targeting gRNA  
SD    Standard deviation 
SEM    Standard error of the mean 
shRNA   Short hairpin RNA 
siCON   Non-targeting siRNA control 
siRNA    Short interfering RNA 
S6K1   S6 kinase beta-1 
SMG1   Suppressor with morphogenetic effect on genitalia 
S.pyogenes   Streptococcus pyogenes 
SREBP1  Sterol regulatory element-binding protein 1 
SREBP2  Sterol regulatory element-binding protein 2  
TALENS   Transcription activator-like effector nuclease 
TASIN-1  Truncated APC selective inhibitor-1 
TCF/LEF   T cell factor/Lymphoid enhancer factor 
TGF-β   Transforming growth factor beta  
TNFα    Tumour necrosis factor alpha  
TNKS    Tankyrase 
TNKS1   Tankyrase 1 
TNKS2   Tankyrase 2 
Topo IIα   Topoisomerase IIα 
TP53   Tumour protein p53 
tracrRNA  Trans-activating crRNA  
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βTrCP   β-transducing repeat containing protein 
TRE    TCF response element 
TSC    Tuberous sclerosis complex  
TSC1    Tuberous sclerosis 1  
TSC2    Tuberous sclerosis 2  
UKL1   Uridine kinase-like protein 1 
VEGF    Vascular endothelial growth factor 
VEGF-A   Vascular endothelial growth factor A 
WPRE    WHP post transcriptional regulatory element 
XIAP    X-linked inhibitor of apoptosis 
 YY1   Ying yang 1  
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1 Introduction to colorectal cancer  
1.1 Colorectal cancer 
Colorectal cancer (CRC) is divided into colon or rectal cancer depending on the 
anatomical location of the tumour (Pabla 2015). CRC has the second highest cancer 
mortality worldwide and over 20 % of patients develop metastatic disease, with under 
15 % of patients surviving past 5 years (Rao & Kühl 2010; Pabla 2015). This high 
mortality rate highlights why many countries have screening programs to help prevent 
and increase early diagnosis, therefore reducing incidence and levels of metastatic 
disease. Screening programs help to identify adenomatous polyps which can be 
removed during colonscopy before they become carcinomas, which is a type of cancer 
arising from the epithelium (Pabla 2015). Early diagnosis increases the chance that the 
tumour can be entirely removed and can increase the disease free period. 
CRC risk is determined by the complex interaction of environmental and genetic 
factors. The risk for all cancers increases with age, due to the accumulation of cancer 
causing mutations. Dietary and lifestyle factors play an important role in CRC risk, a 
diet high in unsaturated fats, red meats, high alcohol intake and a low level of physical 
exercise is associated with an increased risk (Fearon 2011). Some patients have CRC 
related syndromes such as Famalial adenomatous polyposis (FAP) and Hereditary 
nonpolyposis colorectal cancer (HNPCC) caused by germline mutations in key tumour 
suppressors, Adenomatous polyposis coli (APC) and DNA mismatch repair genes 
respectively. Both syndromes are responsible for causing an extremely high risk, in 
patients with FAP the risk of developing CRC is 100 % and for HNPCC patients the risk 
is 50-80 % if left untreated (Jasperson et al. 2010). Inflammatory bowel disease (IBD) 
is the 3rd highest condition risk factor and the risk increases with disease duration, after 
30 years the risk is thought to be up to 30 % (Kim & Chang 2014). Other conditions 
increasing the risk of CRC include type 2 diabetes and obesity (Pabla 2015). Type 2 
diabetes is believed to cause a 1.3 fold higher risk of CRC, whilst for obesity studies 
are inconclusive and suggest an increased risk ranging from 7-60 % (Peeters et al. 
2015; Ma et al. 2013).  
 
1.2 Colorectal cancer subtypes 
To help treat patients with cancer it helps to be able to group patients according to 
certain characteristics. Breast cancer has well studied distinct subtypes, guiding 
treatment for patients, in comparison CRC does not have clear subtypes. Many groups 
have used gene expression studies to suggest CRC subtypes and recently a large 
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collaboration has combined six of these studies to derive a new classification system 
called Consensus molecular subtypes (CMSs) (Guinney et al. 2015). The system 
highlights the poor genotype-phenotype correlation in CRC because none of the 
subtypes can be defined by either gene mutations or somatic copy number alterations, 
instead all common drivers of CRC (discussed in 1.3) are found in all of the suggested 
subtypes. This system divides CRC into four subtypes; CMS1 (microsatellite instability 
and immune - 14 %), CMS2 (canonical - 37 %), CMS3 (metabolic - 13 %) and CMS4 
(mesenchymal - 23 %) (Guinney et al. 2015). 
The CMS1 subtype is characterised by microsatellite instability (MSI) caused by 
mutations in the DNA mismatch repair genes, immune activation, widespread 
hypermethylation, hypermutated, low prevelance of somatic copy number alterations 
(SCNA), activation of receptor tyrosine kinase (RTK) and mitogen activated protein 
kinase (MAPK) pathways (Guinney et al. 2015). This subtype harbours more mutations 
in BRAF in comparison to the other subtypes. This subtype has been associated with 
very poor survival rates after relapse and this reinforces other studies showing MSI 
tumours in combination with BRAF mutations confer a poorer prognosis (Guinney et al. 
2015). Whereas most CMS1 show MSI, the other three subtypes are all characterised 
by higher chromosomal instability (CIN), supporting the traditional view that CIN and 
MSI are mutually exclusive (Walther et al. 2009). 
CMS2 is known as the canonical subtype because this group is characterised by strong 
Wnt and c-myc activation, which is seen as a key driver in the progression to 
tumourigenesis in CRC (Guinney et al. 2015). Wnt activation is not unique to this 
subtype because it is found in over 90 % of patients with CRC (Cancer Genom Atlas 
2012). In addition to strong Wnt activation, this subtype has a high rate of SCNA and 
the best survival rates after relapse (Guinney et al. 2015). 
The CMS3 group shares some features with the subtype CMS1 including 
hypermutated, MSI, low prevalence of SCNA and activation of the RTK and MAPK 
pathways. Unique features of this subtype are the over-representation of mutations in 
KRAS and metabolic deregulation (Guinney et al. 2015).  
The CMS4 subtype is characterised by an increase in the activation of genes involved 
in the epithelial to mesenchyal transition (EMT), which is part of the process of 
metastasis (Guinney et al. 2015). EMT involves the activation of transforming growth 
factor beta (TGF-β) signalling, angiogensis, matrix re-modelling and activation of the 
complement mediated inflammatory system. Extracellular matrix proteins are also 
overexpressed. Due to the pro-metastasis signature of this subtype, patients are often 
diagnosed later and survival rates are the lowest (Guinney et al. 2015). Understanding 
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potential groups of patients can help to develop more targeted therapies depending on 
the key characteristics of the group, for example CMS2 could potentially benefit from 
drugs targeting the Wnt pathway whilst CMS4 could potentially benefit from drugs 
targeting the TGF-β pathway. 
 
1.3 The adenoma – carcinoma sequence 
A unique feature of CRC is typically the development of tumourgenesis is characterised 
by a specific set of mutations, which drive initiation and progression. In 1990, Fearon 
and Vogelstein first presented their ideas in the multistep progression of CRC (Fearon 
& Vogelstein 1990). This model is based on the idea that most colorectal carcinomas 
develop from pre-existing benign tumours (adenoma) in the glandular epithelium. 
Progression from an adenoma involves mutations in at least 4 to 5 genes causing 
activation of oncogenes and inactivation of tumour suppressors (Fearon & Vogelstein 
1990). The mutations generally occur in a specific order, but they are not restricted to 
the order shown in the model. Loss of chromosomal regions can also be responsible 
for the inactivation of tumour suppressors. The genes/regions lost in the model include 
chromosome 5 (now known to be loss of APC), KRAS, 18q loss (Deleted in Colorectal 
Cancer (DCC)), 17p loss (Tumour protein p53 (TP53)) and additional mutations allow 
the carcinoma to metastasise (Fearon & Vogelstein 1990). The model presented by 
Fearon and Vogelstein (1990) is still applicable today and an updated version is shown 
in figure 1.   
A useful way to look at the adenoma - carcinoma sequence is in terms of pathways 
affected. The first pathway altered is the Wnt pathway, this becomes hyperactivated. In 
80 % of patients this occurs through a mutation in APC (Fearon 2011). Hyperactivation 
of the Wnt pathway can also occur through mutations in catenin beta 1 (CTNNB1), this 
gene encodes β-catenin (Fearon 2011). Deregulation of the Wnt pathway occurs in 
over 90 % of patients with CRC, highlighting the importance of this pathway (Cancer 
Genom Atlas 2012). The next pathway hyperactivated is the epidermal growth factor 
receptor (EGFR) pathway and this mostly occurs through mutations in RAS or RAF or 
Phosphoinositide 3-kinase (PI3K) (Fearon 2011). A member of the RAS superfamily, 
KRAS is the most frequently mutated gene in this pathway (40 % of CRC patients). 
Mutated KRAS remains in its active form, causing hyperactivation of the pathway 
(Schubbert et al. 2007). The next pathway, TGF-β pathway is inactivated to promote 
tumourgenesis, the genes commonly mutated include SMAD2, SMAD3 and SMAD4 
(Fearon 2011). The next tumour suppressor to be mutated is TP53 and this occurs in 
over 60 % of CRC patients (Fearon 2011). Alongside these mutations the transition to 
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carcinoma involves an increasing level of genomic instability through either MSI or CIN 
(Walther et al. 2009). The adenoma - carcinoma pathway described highlights the key 
mutations which occur in CRC, but it does not reflect all the mutations found in 
patients, many contributing mutations occur at lower frequencies and it is important to 
consider these as well. 
 
Figure 1 The adenoma - carcinoma sequence 
The typical progression for the development of colorectal cancer. The genes commonly 
mutated include; APC, KRAS/BRAF, SMAD2/3/4 and TP53. The mutations frequently 
occur in the order shown but are not restricted to this. Adapted from (Walther et al. 
2009; Fearon & Vogelstein 1990). 
 
1.4 Inherited and somatic colorectal cancer 
Both inherited and somatic CRC follow the adenoma - carcinoma pathway, however, 
inherited forms develop earlier and some progress more quickly. There are a number 
of inherited syndromes which predispose to CRC and the germline mutations 
responsible also occur in sporadic CRC. Studying inherited forms of CRC has 
significantly helped our understanding of sporadic CRC. The main inherited syndromes 
are either caused by mutations in APC or the DNA mismatch repair genes (Fearon 
2011). Over 90 % of FAP patients have mutations in APC and if left untreated all 
patients will develop CRC (Fearon 2011). FAP is responsible for 0.5 % of all CRC 
patients and interestingly the location of the mutation in APC appears to effect the 
severity, this will be discussed in section 2.5 (Fearon 2011). Mutations in APC also 
occur in Turcots syndrome and Gardener syndrome (Fearon 2011). HNPCC 
predisposes individuals to multiple cancer types, predominantly CRC and accounts for 
up to 5 % of CRC patients (Fearon 2011). These patients have germline mutations in 
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the DNA mismatch repair genes (mutL homolog 1 (MLH1), MutS protein homolog 2 
(MSH2), mutS homolog 6 (MSH6), PMS1 homolog 2 (PMS2)) causing MSI, 70 % of 
mutations in HNPCC occur in MLH1 and MSH2 (Fearon 2011). In sporadic CRC 
mutations in the APC gene frequently occur in up to 80 % of all CRC patients. 
Mutations in the DNA mismatch repair genes are less common in sporadic cancers, 
instead hypermethylation of the MLH1 promoter is more frequent (accounting for 12 % 
of all CRC patients) and results in reduced MLH1 expression causing MSI (Fearon 
2011; Boland & Goel 2010).  
 
1.5 Treatment options for colorectal cancer 
The treatment available for CRC depends on the stage of the tumour, of which there 
are four (Damin & Lazzaron 2014). Stage I is when the cancer has grown into the inner 
lining or muscle wall of the bowel. In Stage II, the cancer has grown to the outer 
covering of the bowel and may have spread to local tissues, but there is no sign of 
cancer cells in the lymph nodes. Stage III is when cancer cells have spread to nearby 
lymph nodes and stage IV is when the cancer has metastasised to other parts of the 
body (Damin & Lazzaron 2014). The standard treatment involves a combination of 
surgery, chemotherapy and radiation. Often stage I can be treated with surgery alone, 
whereas stages II upwards include courses of chemotherapy and radiation often before 
surgery, to try to shrink the tumour (Damin & Lazzaron 2014). Chemotherapy drugs 
can be used alone or in combination and include; 5-fluorouracil (5-FU), folinic acid 
(FA), oxaliplatin and irinotecan (Chee & Sinicrope 2010). Newly developed targeted 
agents against the EGFR and vascular endothelial growth factor (VEGF) pathway have 
been approved for use in stage IV CRC and are either used in combination with 
chemotherapy or as single agents (Chee & Sinicrope 2010).   
Targeted agents against the EGFR pathway include cetuximab and panitumumab. The 
EGFR pathway is important in CRC and research has shown higher EGFR expression 
is associated with poorer prognosis (Rego et al. 2010). Cetuximab and panitumumab 
are monoclonal antibodies, binding to the extracellular domain of the EGFR, preventing 
receptor phosphorylation and dimerisation when a ligand binds, reducing the level of 
EGFR pathway activation (Pabla 2015). Cetuximab is approved for use alone or in 
combination, whilst panitumumab is approved as a single agent (Chee & Sinicrope 
2010). There are well validated biomarkers to predict response to EGFR inhibitors. 
KRAS and BRAF status are assessed before considering EGFR inhibitors because 
patients with a mutation in KRAS codon 12, 13 or 61 or mutations in BRAF do not 
respond to EGFR inhibitors, because these mutations cause the pathway to be 
hyperactive and unresponsive to signals from EGFR (Figure 2) (Walther et al. 2009). 
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Despite this marker, only 35 % patients with wildtype KRAS respond and ultimately 
even those that do initially respond will develop resistance, highlighting the problem of 
targeted therapy (Linnekamp et al. 2015). Mechanisms of resistance include 
emergence of KRAS or BRAF mutations in previously wildtype cancer populations and 
the upregulation of RTK pathways including C-Met and Erb-B2 receptor tyrosine kinase 
2 (ERBB2) (Morkel et al. 2015; Pabla 2015). 
 
Figure 2 EGFR inhibitors in KRAS wt and mutant tumours 
In KRAS wildtype cells EGFR inhibitors (eg cetuximab and panitumumab) bind to the 
extracellular domain of EGFR and prevent activation of KRAS, inhibiting proliferation 
and survival. In KRAS mutant cells the EGFR pathway is constantly activated and 
therefore the cells do not respond to EGFR inhibitors.  
 
Additionally targeted agents have been developed and approved to target 
angiogenesis which is required for tumour growth and to promote metastasis. 
Bevacizumab is approved for use in combination with chemotherapy because it has 
been shown to increase the efficiency of chemotherapy (Chee & Sinicrope 2010). The 
reason for this is tumour vessels are leaky and poorly organised, inhibiting 
angiogenesis leads to the normalisation of vessels, which increases delivery of 
therapeutics (Mulcahy 2008). Bevacizumab is a monoclonal antibody which binds 
vascular endothelial growth factor A (VEGF-A), preventing this ligand from binding its 
receptor, reducing pathway activation and levels of angiogenesis (Chee & Sinicrope 
2010). Unlike EGFR inhibitors there are no markers to predict patient response to 
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bevacizumab and the protein level of VEGF does not correlate with response (Chee & 
Sinicrope 2010). Interestingly a recent paper suggests patients with KRAS mutations 
also have a poorer outcome in comparison to patients with wildtype KRAS to 
bevacizumab (Fiala et al. 2015). As with EGFR therapy patients have innate resistance 
or develop resistance, although the mechanisms of resistance are poorly understood. 
Suggested mechanisms include the increase in autocrine VEGF signalling to promote 
angiogenesis (Mésange et al. 2014).  
Recently a new targeted therapy has been approved for the treatment of metastatic 
MSI CRC, known as pembrolizumab (Marginean & Melosky 2018). Pembrolizumab is a 
programmed cell death protein 1 (PD1) inhibitor and is broadly known as an immune 
checkpoint inhibitor. Other immune checkpoint inhibitors are directed against 
programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 
(CTLA4) (Viale et al. 2017). There has been growing interest into the potential of 
immune checkpoint inhibitors to re-activate the immune system, helping to eliminate 
the tumour cells. Responses to these drugs have not been as substantial as hoped. 
Therefore, the identification of biomarkers is essential to enable the treatment to be 
given to patients who could benefit, MSI has been recently shown to be a good 
biomarker (Marginean & Melosky 2018). The theory behind this is MSI tumours have a 
higher mutational load, leading to an increase in neoantigens, this upregulates immune 
checkpoint molecules resulting in immune suppression. Inhibiting the immune 
checkpoint molecules reverses the immune suppression (Marginean & Melosky 2018). 
Currently there are no targeted therapies to treat patients with stage I – III CRC, 
although many avenues are being explored.  
 
2 Adenomatous polyposis coli 
2.1 Discovery 
Studying FAP, an inherited condition predisposing to CRC development played an 
important role in the discovery of the APC gene. FAP was first described and linked to 
cancer in the early 20th century and advances in technology lead to the discovery of the 
disease-causing gene, APC (Thomson 1990). In 1986 studying the banding pattern of 
chromosomes in a patient with FAP gave the first clue to the location of the APC gene, 
because a segment of DNA was missing from the long arm of chromosome 5 (Herrera 
et al. 1986). Next two groups narrowed down this region of chromosome 5 to the 
segment 5q21, one group studied FAP patients and the other group studied sporadic 
cases of CRC (Bodmer et al. 1987; Solomon et al. 1987). This research supported 
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Knudsons theory that genes causing inherited forms of cancer can also be responsible 
for sporadic cases of cancer (Knudson 1971). Over 10 years later, from searching over 
8000 kilobases (kb) of DNA researchers identified two candidate genes. Mutations 
found just in FAP patients were identified in just one of the candidate genes and this is 
now known to be APC (Kinzler et al. 1991; Groden et al. 1991). Since its discovery the 
APC gene has been shown to play a key role as a tumour suppressor in CRC. 
 
2.2 Structure of APC 
The APC gene covers 8535 base pairs (bp) and contains at least 21 exons, 17 are 
coding exons and 4 are non coding (Figure 3) (De Rosa et al. 2007). The most studied 
APC transcripts listed on NCBI include transcript 1 NM_001127511.2, transcript 2 
NM_001127510.2 and transcript 3 NM_000038.5 (Gene Id 324) and are shown in 
figure 4. Transcript 1 contains 14 exons and encodes protein isoform A (2825 amino 
acids (aa), 310 kilodaltons (kDa)). This transcript lacks exon 6 and uses promoter 1B 
(Rohlin et al. 2011). Transcript 2 and 3 both contain 15 coding exons (the transcripts 
differ in the number of non coding exons), use promoter 1A and encode protein isoform 
B (2843 aa, 312 kDa), the most abundant full length APC product (Fearnhead et al. 
2001). Promoter 1A is believed to play the larger role in the regulation of APC, though 
emerging evidence is suggesting promoter 1B might contribute more than once thought 
(Rohlin et al. 2011). An interesting feature of APC is that exon 15 is the longest exon 
and encodes over 75 % of the coding sequence of APC (Fearnhead et al. 2001). 
Alongside the two APC protein isoforms listed on NCBI there are 11 newer APC protein 
isoforms, which range from 281 kDa to 315 kDa.  
 
Figure 3 The exon structure of the APC gene. 
The arrows indicate initiation codons which are inframe with exon 2. Adapted from 
(Santoro & Groden 1997). 
Introduction Page 27 
 
In addition research suggests there are shorter APC transcripts translating into proteins 
90 kDa and larger. The following exons have been suggested to be alternatively 
spliced; 0.1, 0.2, 0.3, BS, 1, 2, 3, 4, 7, 9, 10A, 11, 12, 13 and 14 (De Rosa et al. 2007; 
Santoro & Groden 1997). Some APC splice variants may be tissue specific (Horii et al. 
1993; Santoro & Groden 1997). For example, APC splice variants lacking exon 1 are 
generally less common apart from in the brain, heart and skeletal muscle tissues where 
higher levels without exon 1 have been found (Santoro & Groden 1997). Without exon 
1 APC is unable to homodimerize suggesting this function is less important in 
terminally differentiated cells (Santoro & Groden 1997). The role of the different splice 
variants of APC is unclear and under investigation, some may have no function and 
others could be degraded by non-sense mediated decay (NMD) (De Rosa et al. 2007).  
 
 
Figure 4 The most studied full length APC transcripts 
Transcripts encoded by the genomic sequence NG_008481.4. Schematic shows the 
exons included in the transcripts and the resulting protein isoform they encode. We 
refer to protein isoform B and transcript variant 3 NM_000038.5 throughout the thesis. 
 
Full length APC contains an oligomerization domain, armadillo region, 15 amino acid 
repeats (15aa), 20 amino acid repeats (20aa), SAMP repeats, basic domain, end-
binding protein 1 (EB1) binding domain and discs large (DLG) binding domain (Figure 
5). The oligomerization domain consists of heptad repeats through which APC forms 
homodimers or heterodimers. For example, homodimers form if two full length APC 
proteins dimerize and heterodimers form if full length APC binds truncated forms of 
APC (Fearnhead et al. 2001). The armadillo region contains seven repeats and is 
named because the region shares homology with β-catenin and the drosophila 
homologue armadillo (Fearnhead et al. 2001). The proteins APC-stimulated guanine 
nucleotide exchange factor 1 and 2 (ASEF1/ASEF2) and protein phosphatase 2A 
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(PP2A) interact with the armadillo region (Fearnhead et al. 2001; Aoki & Taketo 2007). 
The 15aa repeats consist of three repeats and are β-catenin binding sites. The seven 
20aa repeats also bind β-catenin, glycogen synthase kinase 3β (GSK3β) uses the 
SXXXS consensus site as a substrate for phosphorylation, enabling β-catenin to bind 
and APC regulates its levels (M. Sieber et al. 2000). Only the first repeat is required for 
β-catenin binding, the regulation of β-catenin degradation requires three or more 20aa 
repeats. The SAMP repeats enable APC to interact with Axin (Fearnhead et al. 2001). 
The basic domain has a high percentage of arginine, lysine and proline amino acids 
and EB1 binding domain is where the protein EB1 interacts with APC (Fearnhead et al. 
2001). The DLG binding domain interacts with proteins containing the PDZ domain 
including Dlg (Näthke 2006). The various domains of APC allow the interaction with a 
wide range of proteins and result in APC playing a role in a wide range of functions. 
 
2.3 Localisation of APC  
The majority of APC is found in the cytoplasm and can be found at various sites 
(Brocardo et al. 2005). APC can shuttle between the nucleus and cytoplasm, nuclear 
import requires sequences, known as a nuclear localisation sequence (NLS), found at 
the N-terminal. Nuclear export occurs through CRM1 export receptors and requires a 
nuclear export signal (NES) also found in the N-terminus (Brocardo & Henderson 
2008). Truncated APC has been shown to shuttle between the nucleus and the 
cytoplasm more efficiently, this could be due to alterations in its functions in the 
cytoplasm which are discussed later in section 2.5 (Brocardo & Henderson 2008).  
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Figure 5 Structure of APC and the common mutation sites 
A) Full length APC contains eight different domains and APC interacts with different 
proteins through these domains. The most common mutations in APC occur in the 
MCR region where APC interacts with β-catenin, resulting in a C-terminal truncated 
APC product with less domains and therefore different functions. Adapted from (Aoki & 
Taketo 2007).  B) Image from (Miyaki et al. 1994), the APC gene was characterised in 
309 tumours from FAP and non-FAP patients (sequencing covered the first 60 % of the 
coding region of APC). The mutation frequencies are shown along APC and are 
separated into germline and somatic mutations. The distribution of mutations along 
APC is different between germline and somatic mutations. The majority of somatic 
mutations occur in the MCR region.  
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2.4 Role of APC in the cell 
2.4.1 Wnt signalling 
The Wnt signalling pathways play an important role in cell proliferation, cell polarity and 
cell fate determination during embryogenesis and tissue homeostasis (MacDonald et 
al. 2009). Typically, Wnt pathways are divided into the canonical pathway (involves β-
catenin) and the non-canonical pathways (independent of β-catenin). APC is involved 
in the canonical Wnt signalling pathway and this is one of the best characterised roles 
of APC (Figure 6). APC forms part of the β-catenin destruction complex along with 
Axin, GSK3β and casein kinase 1α (CK1α) to negatively regulate levels of β-catenin. 
The pathway is switched off when Wnt ligands are absent from the frizzled receptor. 
APC and Axin act as scaffold proteins interacting with β-catenin and recruiting CK1α 
and GSK3β to the complex to phosphorylate the N-terminal of β-catenin (Burgess et al. 
2011; Klaus & Birchmeier 2008; Voloshanenko et al. 2013). An E3 ubiquitin ligase 
known as β-transducing repeat containing protein (βTrCP) then ubiquitinates β-catenin 
leading to its degradation (Klaus & Birchmeier 2008). As β-catenin is degraded, the 
transcription factors T cell factor/ lymphoid enhancer factor (TCF/LEF) remain bound to 
the co-repressor Groucho (Klaus & Birchmeier 2008). The pathway is activated when a 
Wnt ligand binds to the frizzled receptor, dishevelled is recruited to the membrane to 
interact with frizzled whilst CK1α and GSK3β phosphorylate low density lipoprotein 
receptor related proteins 5 and 6 (LRP5 and LRP6), Axin is recruited to the membrane 
through its interaction with phosphorylated LRP5/6 and dishevelled. This results in the 
dissociation of the β-catenin destruction complex, whereby β-catenin is not 
phosphorylated by CK1α/GSK3β and is free to translocate to the nucleus and form a 
transcriptionally active complex with TCF/LEF, leading to the transcription of Wnt target 
genes. Wnt target genes include; Axin2, Cyclin D, c-myc and Cyclooxygenase 2 
(COX2) (Burgess et al. 2011; Lesko et al. 2014; Davidson & Niehrs 2010). APC 
additionally prevents transcription of Wnt target genes through its ability to bind to β-
catenin, blocking β-catenin binding to TCF/LEF and APC has been shown to promote 
β-catenin export from the nucleus (Aoki & Taketo 2007). 
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Figure 6 The canonical Wnt signalling pathway 
When no Wnt ligand is bound to frizzled the β-catenin destruction complex forms (APC-
Axin-GSK3β-CK1α) and this phosphorylates β-catenin for degradation. When a Wnt 
ligand binds to frizzled the β-catenin destruction complex does not form so β-catenin is 
free to translocate to the nucleus and activate Wnt target genes.  
 
2.4.2 Cell adhesion and polarity 
To maintain tissue organisation it is important that each cell maintains contact with 
neighbouring cells and maintains its own apical-basal polarity, loss of this organisation 
has been linked to more aggressive tumours (Lesko et al. 2014). APC is believed to 
associate through the homologous proteins β-catenin and plakoglobin at two cell-cell 
contacts; desmosomes (provide tissue strength) and adheren junctions (Zhurinsky et 
al. 2000; Harris & Tepass 2010). β-catenin and plakoglobin (also known as y-catenin) 
share some functions for example both are found at adheren junctions, whilst other 
functions are unique, only plakoglobin forms part of desmosomes (Zhurinsky et al. 
2000). We will focus on β-catenin because of its clear role in Wnt signalling (discussed 
in section 2.4.1) and the resulting interplay with cell adhesion. Adheren junctions link 
the actin cytoskeleton between neighbouring cells (Harris & Tepass 2010). It is thought 
that β-catenin is either bound to APC or β-catenin is bound to the actin cytoskeleton 
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through E-cadherin (Prosperi & Goss 2011). Therefore APC regulates adhesion by 
controlling the amount of β-catenin available by directly binding to β-catenin or by 
negativity regulating its level through Wnt signalling, additionally E-cadherin is a Wnt 
target gene providing an additional level of regulation (Prosperi & Goss 2011). 
 
APC may associate with polarity complexes which control cell polarity (Prosperi & Goss 
2011). There are three main polarity complexes; PAR (cdc42-PAR3-PAR6-aPKC) and 
Crumbs (Crb-PALS-PATJ) controlling apical polarity whilst Scribble (Scrib-Dlg-LG1) 
controls the basolateral polarity in epithelial cells (Bryant & Mostov 2008). APC may act 
as a scaffold for the Scribble complex because the three proteins do not interact 
together and APC has been shown to bind both Scrib and Dlg (Prosperi & Goss 2011). 
APC might play a role in the formation of the PAR complex because APC can interact 
with PAR3 to enable the transport of APC along microtubules (Prosperi & Goss 2011). 
The potential role of APC in polarity is summarised in figure 7A. 
 
2.4.3 Interaction with the cytoskeleton network  
The cytoskeleton has three main functions, it organises the contents of the cell, it 
connects the cell to the outside environment and generates forces to enable the cell to 
change shape and migrate (Fletcher & Mullins 2010). Key components of the 
cytoskeleton network are actin filaments, microtubules and intermediate filaments 
(Fletcher & Mullins 2010). APC binds directly and indirectly to both actin filaments and 
microtubules. The actin cytoskeleton plays an important role in cell migration and 
maintaining cell morphology (Lesko et al. 2014; Näthke 2006). APC works alongside 
diaphanous-related formin-1 (mDia) to promote nucleation. APC is thought to recruit 
actin monomers and directly binds through the armadillo region and/or the basic region 
(Lesko et al. 2014). APC also indirectly influences the actin cytoskeleton through 
directly binding IQ motif containing GTPase activating protein 1 (IQGAP1), ASEF1 and 
ASEF2. Both proteins activate cell division cycle 42 (Cdc42) and Rac family small 
GTPase 1 (Rac1) (Aoki & Taketo 2007). Cdc42 and Rac1 are Rho GTPases involved 
in regulating the actin cytoskeleton, when activated they promote actin polymerisation 
(Spiering & Hodgson 2011).  
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Figure 7 Roles independent of Wnt signalling 
A) Schematic showing mechanisms to maintain apical-basal polarity in cells. Cell to cell 
contacts through desmosomes and adherens are important alongside polarity 
complexes.  APC interacts with PAR3 and may play a role in the formation of the PAR 
complex (cdc42-PAR3-PAR6-aPKC) which controls apical polarity. APC may act as a 
scaffold for the Scribble complex which controls basolateral polarity. APC has been 
shown to interact with both Scrib and Dlg and the three proteins in the complex do not 
interact together. B) APC interacts with a variety of proteins, actin and microtubules at 
migrating cellular protrusions. C) APC localisation alongside kinesin 2 and EB1 at 
corticol attachments, kinetochores and centrosomes. B) C) are adapted from 
(McCartney & Näthke 2008).  
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Microtubules are part of the cytoskeleton and play a role in maintaining cell structure, 
cell migration, intracellular transport, meiosis and mitosis (Fletcher & Mullins 2010; Aoki 
& Taketo 2007). APC can directly bind microtubules through the basic region and 
indirectly through the EB1 and mDia to promote microtubule polymerisation at the distal 
end (Lesko et al. 2014). Interestingly if APC is bound to EB1 and microtubules, the C-
terminus of APC cannot interact with the actin cytoskeleton (Aoki & Taketo 2007). A 
polarity protein mentioned earlier Dlg promotes the accumulation of APC at microtubule 
tips and the attachment with the plasma membrane (Prosperi & Goss 2011). Through 
APC interacting with EB1, Dynein (which binds EB1) contributes to the microtubule 
attachment at the plasma membrane (McCartney & Näthke 2008). APC is transported 
along microtubules through its interaction with kinesin associated protein 3 (Kap3) and 
kinesin superfamily protein 3 (Kif3) forming kinesin 2. Typically APC is directed towards 
the microtubule clusters at cell protrusions and to the leading edge of migrating cells 
(Lesko et al. 2014). A summary of some of the interactions between APC and the 
cytoskeleton are shown in figure 7B and 7C. 
 
2.4.4 Cell cycle  
APC is expressed and phosphorylated throughout the cell cycle. APC becomes 
hyperphosphorylated during mitosis. During mitosis, APC localises at the cell cortex, 
centrosomes and kinetochores (Figure 7C) (Prosperi & Goss 2011). APC associates 
with cyclinA-cdk2 in G2/M and phosphorylates APC to control the attachment of the 
spindle to the cell cortex during mitosis (Prosperi & Goss 2011). Additionally at G2/M, 
data suggests APC interacts with topoisomerase IIα (topo IIα) and proliferating cell 
nuclear antigen (PCNA), which both participate in DNA replication (Prosperi & Goss 
2011; Wang et al. 2008). During mitosis APC co-localises with cyclinB-cdk1 which 
phosphorylates the C-terminus allowing EB1 to bind, EB1 is an important link between 
APC and the cytoskeleton. The APC/EB1 complex is joined by Bub1 and Bub3 which 
phosphorylates APC creating stable kinetochore attachment for proper chromosome 
alignment (Prosperi & Goss 2011). Currently the exact role of APC in chromosome 
segregation is controversial, some research suggests APC is important because loss of 
APC causes cells to suffer severe chromosomal and mitotic spindle defects (Lesko et 
al. 2014). Localisation of APC at the centrosomes occurs without microtubules and 
APC may play a role in the mitotic spindle checkpoint (Lui et al. 2012). Interestingly β-
catenin is also found at the centrosomes during interphase and mitosis, therefore APC 
may function through β-catenin (Bahmanyar et al. 2009). APC also negatively regulates 
the cell cycle through its role in the Wnt signalling pathway which activates many genes 
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involved in the cell cycle including c-myc and Cyclin D, which are both involved in the 
G1/S checkpoint (Davidson & Niehrs 2010).  
 
2.4.5 Other less defined roles of APC 
There is evidence suggesting APC plays opposing roles in DNA repair. Upon DNA 
double strand breaks, APC is recruited to the site of damage and promotes repair by 
stimulating the marker of DNA damage, histone H2AX phosphorylation and by 
interacting with DNA dependent protein kinase catalytic subunit (DNA-Pkcs) (Prosperi 
& Goss 2011). APC is also thought to interact with 14-4-3σ which is involved in the 
DNA damage response (Prosperi & Goss 2011). APC inhibits the base excision repair 
(BER) pathway through its interaction with polymerase β (Pol-β) and flap endonuclease 
1 (Fen-1) (Prosperi & Goss 2011).  
APC can regulate apoptosis through multiple mechanisms. Firstly APC indirectly 
affects apoptosis through negative regulation of the Wnt target gene baculoviral IAP 
repeat containing 5 (BIRC5), which encodes a anti-apoptotic protein known as survivin 
(Prosperi & Goss 2011). APC may also bind and regulate B-cell lymphoma 2 (Bcl-2), 
an anti-apoptotic factor. Research suggests truncated APC binds Bcl-2 and may shuttle 
it to the mitochondria to increase survival (Lui et al. 2012). Additionally APC is cleaved 
by caspase 3 and the 90 kDa cleaved fragment binds to hTID1 and modulates 
apoptosis (Prosperi & Goss 2011). 
In addition to roles in DNA repair and apoptosis researchers have suggested over 100 
proteins bind to APC, resulting in potential new roles in nuclear transporting, 
membrane trafficking and metabolism (Nelson & Näthke 2013).  
 
2.5 APC in colorectal cancer 
APC mutations typically occur in both alleles as a result of nonsense mutations, 
frameshifts and allelic loss. The majority of mutations occur between residues 1263 
and 1589 which is also known as the mutation cluster region (MCR) (Kohler et al. 
2008). This region is where APC interacts with β-catenin, negatively regulating levels of 
the Wnt signalling pathway. Mutations in this region lead to a truncated protein which 
cannot regulate β-catenin levels to the same degree as full length, resulting in 
hyperactivation of the pathway (Figure 5).  
Understanding the inherited syndrome FAP has helped develop our understanding of 
APC mutations because the precise location of the germline APC mutation affects the 
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severity of the syndrome (Zeineldin & Neufeld 2013; Nieuwenhuis & Vasen 2007). 
Germline mutations in the MCR leads to the most severe phenotype, then mutations 
either side of the MCR display an intermediate phenotype and mutations after residue 
1595 or before 157 yield a mild phenotype often referred to as attenuated familial 
adenomatous polyposis (AFAP). Complete deletion of APC can occur and leads to an 
intermediate phenotype (Zeineldin & Neufeld 2013). Explanations for this observation is 
that different APC truncations promote different levels of Wnt signalling activation, too 
low or high reduces proliferation. Mutations around the MCR appear to produce the 
right level of Wnt signalling for optimal proliferation and this idea has been developed 
into the ‘just right’ signalling model (Zeineldin & Neufeld 2013).  
In support of the ‘just right’ signalling model, studying FAP has developed the idea that 
APC is not a typical tumour suppressor (Figure 8). The Knudsons two hit hypothesis 
states that independent mutations occur on both copies of the tumour suppressor, 
however the 2nd mutation in APC in CRC seems to be dependent on the location of the 
first (Albuquerque et al. 2002). Albuquerque et al. (2002) showed in FAP patients the 
different scenarios; 1) If the germline mutation occurs leaving no 20aa repeats, then 
the second mutation will be after the first or second 20aa repeats. 2) If the germline 
mutation occurs after one 20aa then the 2nd hit is often allelic loss or a mutation before 
the 20aa repeats. 3) If the germline mutation is after two 20aa, the 2nd hit is most 
commonly before the 20aa repeats or less often allelic loss. This selection for retention 
of some ability of APC to regulate β-catenin levels supports the idea of a specific 
activation of Wnt signalling being required to promote tumourigenesis.  
 
Figure 8 Knudsons two hit hypothesis in FAP 
The location of the germline mutation affects the location of the second mutation. This 
is also applicable to patients with sporadic CRC. 15aa repeats are pink, 20aa repeats 
are green. Adapted from (Albuquerque et al. 2002).  
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Hyperactivation of the Wnt pathway plays an important role in CRC development due 
to the role of this pathway in colonic homeostasis (Burgess et al. 2011). Wnt signalling 
hyperactivation causes transcriptional changes of Wnt regulated genes and peripheral 
changes causing disrupted crypt architecture and formation of aberrant crypt foci 
(Burgess et al. 2011). APC mutations cause hyperactivation of the pathway leaving it 
unresponsive to Wnt ligands, however researchers have suggested cells remain 
responsive to Wnt ligands but the threshold for pathway activation is lowered 
(Voloshanenko et al. 2013). 
Promoting hyperactivation of the Wnt signalling pathway is just one consequence of C-
terminal truncated APC, other consequences are increased cell migration, changes in 
cell adhesion and induction of CIN (Rao and Yamada 2013; Aoki and Taketo 2007). C-
terminally truncated APC binds more strongly to ASEF, enhancing its guanine 
nucleotide exchange factor (GEF) activity, promoting increased cell migration (Aoki & 
Taketo 2007). Loss of APC is thought to not be sufficient for promoting an invasive 
phenotype as additional mutations are required (Aoki & Taketo 2007). Constitutively 
active ASEF also alters cell adhesion because it decreases the amount of E-cadherin 
and β-catenin at the junctions (Akiyama & Kawasaki 2006). This might explain why the 
armadillo repeats remain in truncated forms of APC. Hyperactivation of Wnt signalling 
further reduces the pool of β-catenin at the junctions, weakening cell adhesion. Without 
the N-terminus of APC, the region which binds microtubules through mDia and EB1 is 
lost, leading to spindle dysfunction and CIN (Aoki & Taketo 2007).  
 
2.6 Current models of APC loss in colorectal cancer 
2.6.1 In vitro models 
There are a wide range of human cell lines which have been established from patients 
with CRC and they represent the range of different combinations of mutations seen in 
CRC making them useful to study. Cell lines are cheap and easy to work with, 
however, because they are grown in 2D, any 3D interactions are lost (Young et al. 
2013). 
 
2.6.2 In vivo models 
One of the disadvantages of human cell lines is that you can’t investigate the 
interaction between the tumour cells and the tissue microenvironment. The use of in 
vivo models such as xenografts and genetically engineered mice help to extend work 
shown in vitro. Xenografts involve implanting murine or human tumour cells into an 
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immunocompromised mouse (nude or severely compromised immunodeficient (SCID)) 
to prevent the host immune system from rejecting the cells. The disadvantage of 
xenografts as models is you miss the interaction between the tumour cells and the host 
immune system, additionally the cells may undergo changes in the time from 
harvesting to implanting (Young et al. 2013). 
Another type of in vivo models is genetically engineered mice harbouring different 
germline mutations in APC. As occurs in FAP, the APC mutant mice must develop a 
mutation in the second copy of APC for polyps to develop (Zeineldin & Neufeld 2013). 
The location of the mutation appears to effect the severity of the phenotype, another 
commonality with FAP patients (Heyer et al. 1999). A significant difference between 
patients and the APC mutated mice models is adenomas generally develop more in the 
small intestine than the colon and are often benign. It is thought this could be due to 
the short lifespan of mice and the additional mutations required for the adenomas to 
progress to a carcinoma do not have a chance to occur (Young et al. 2013).  
There are a number of mice generated with APC mutations and these are shown in 
figure 9. APC14 expresses a very short APC product containing part of the ASEF 
binding domain. These mice develop around 65 polyps mostly in the colon and in older 
mice some invasion has been reported (Young et al. 2013). APC580 has a conditional 
mutation in APC at codon 580 and when deleted it leads to adenomas in the colon 
within 4 weeks (Heyer et al. 1999). APC716 expresses an APC truncated product 
containing the ASEF binding domain and these mice develop around 300 polyps in the 
small intestine. APCmin has a mutation at codon 850 causing a truncated APC product 
which is slightly longer than seen in the APC716 mice. These mice develop 
approximately 30 polyps in the small intestine. APC1309 contains APC with a truncation 
in the MCR and contains the first 20aa repeat, these mice develop around 35 polyps in 
the colon and small intestine. These mice have a shorter lifespan than APCmin mice 
which correlates with FAP patients who harbor this mutation and develop CRC earlier 
(Young et al. 2013). APC1638N produce an unstable APC and develop under 10 polyps 
in the small intestine but research has shown increased tumour invasion (Young et al. 
2013). APC1638T produces a stable 182 kDa protein with the first two 20aa repeats. 
Interestingly this leads to a normal phenotype and this model is not embryonic lethal in 
the homozygous state (Heyer et al. 1999). APCneoF/R doesn’t harbor a specific mutation, 
instead APC has reduced expression to 10-20 % in the mice and surprisingly this 
results in less than one polyp developing by 15 months (Young et al. 2013; Zeineldin & 
Neufeld 2013).  
Introduction Page 39 
 
All the mice models discussed above support the evidence that a mutation in APC 
alone is not sufficient to promote tumourigenesis. In support of this, additional mice 
models have been generated with additional mutations in genes found later in the 
adenoma - carcinoma sequence, for example APC716(+/-) DPC4(+/-) mice with an APC 
mutation and a SMAD4 mutation (encoded by DPC4) (Young et al. 2013). SMAD4 is 
part of the TGF-β pathway and although there were no changes in size or number of 
adenomas compared to APC716 mice the adenomas did show signs of invasion (Young 
et al. 2013). This supports evidence that TGF-β pathway disruption is required for later 
stages of the adenoma - carcinoma pathway and not initiation. In comparison a 
mutation in EPH Receptor B4 (EphB4) combined with APCmin mice, APCmin+/- EphB4+/- 
leads to a larger number of polyps in the colon and more invasion (Young et al. 2013). 
The genetically engineered mice modelling different APC mutations develop varying 
phenotypes as seen in FAP patients and helped to develop the theory that APC 
mutations are not mutually exclusive as discussed in section 2.5.  
 
 
Figure 9 In vivo models of APC mutated mice 
Schematic shows the location of the APC mutations in the mice and the resulting effect 
on the APC protein product. 
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3 Targeting APC in colorectal cancer 
Targeting the tumour suppressor APC is one avenue being explored and has the 
potential to benefit up to 80 % of CRC patients. Unfortunately because a significant 
proportion of the APC protein is lost in the cell it is hard to directly target.  
 
3.1 Restore wildtype APC 
One approach being explored is correcting the faulty expression of APC, this could 
help to reverse the consequences of mutant APC. If APC is still driving tumour 
development then tumour growth could be inhibited and even reversed. An early 
approach investigated was the use of gene therapy to reintroduce wildtype APC in 
APCmin mice. The APCmin mice were treated every 72 hours for two months with 
liposomes containing a plasmid expressing full length APC. This approach restored 
levels of APC without toxic side effects, but they did not see a large therapeutic 
difference in the control and treated groups (Arenas et al. 1996). Lee et al. (2004) used 
a similar approach in APCmin mice and found 25 % less polyps developed in the mice 
treated with liposomes containing full length APC. Research into this approach has not 
been focused on, however, a recent paper emphasises the striking impact of re-
expressing full length APC in vivo (Dow et al. 2015). The group developed a mouse 
model with doxycycline inducible short hairpin RNA (shRNA) against APC, treating the 
mice with doxycycline lead to tumour development in the small and large intestine, 
representing clinical disease in humans. Removal of doxycycline treatment lead to re-
expression of APC, tumour regression, re-establishment of colon crypt homeostatsis 
and after 30 days there was no relapse in disease (Dow et al. 2015). This study 
suggests APC is involved in tumour maintenance and therefore restoring wildtype APC 
could be an effective therapeutic strategy. 
Another approach to correct the faulty expression of APC is to use aminoglysides and 
macrolides to read through the premature stop codon resulting in the expression of full 
length APC (Floquet et al. 2011; Zilberberg et al. 2010). Zilberberg et al. (2010) 
successfully showed the effectiveness of the approach in the APCmin mouse model and 
xenograft experiments using the HT29 cell line, both experiments demonstrated 
restoring full length APC expression reduced the tumourigeneic phenotype. However, 
there were concerns over this approach because aminoglysides and macrolides are 
not specific to just the APC premature stop codon, other genes would also be affected 
causing a high risk of toxicity problems (Lesko et al. 2014). 
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3.2 mTOR inhibitors 
Another approach is to indirectly target the APC mutation by targeting another 
pathway. The mammalian target of rapamycin (mTOR) pathway lies downstream of 
many of the key deregulated pathways in CRC including, Wnt signalling, PI3K/AKT 
pathway, EGFR and p53 (Wang & Zhang 2014). Details of the mTOR pathway are 
discussed later in section 6. The potential of mTOR inhibitors in CRC has not often 
been specifically linked to the APC mutation. Researchers have suggested mTOR 
inhibitors could be used in early tumour development to selectivity kill APC mutated 
cells (Faller et al. 2014). The in vivo study showed that intestinal lining cells from APC 
deficient mice displayed increased Wnt activation and therefore expression of the Wnt 
target gene c-myc. This in turn was required for mammalian target of rapamycin 
complex 1 (mTORC1) mediated inhibition of eukaryotic elongation factor 2 kinase 
(eEF2K), resulting in activation of translation elongation and subsequent cell 
proliferation (Faller et al. 2014). The group showed the use of mTOR inhibitors such as 
rapamycin inhibited proliferation of adenomas in APC deficient mice. This suggests 
existing mTOR inhibitors could be used for prevention of CRC or for early stage 
disease. In support of this, research into the chemopreventative effects of aspirin and 
5-aminosalicyclic acid (5-ASA) suggests both drugs inhibit the mTOR pathway through 
different mechanisms (Din et al. 2012; Baan et al. 2012). Aspirin was shown to activate 
AMP-activated protein kinase (AMPK) resulting in decreased ribosomal protein S6 
kinase beta-1 (S6K1), ribosomal protein s6 (S6) and eukaryotic translation initiation 
factor 4E-binding protein 1 (4E-BP1), causing autophagy (Din et al. 2012). Whereas, 5-
ASA was shown to inhibit phospholipase D (PLD) dependent generation of 
phosphatidic acid (PA), inhibiting mTOR and resulting in cell cycle arrest (for 
background to mTOR pathway see section 6) (Baan et al. 2012).  
 
3.3 Targeting the Wnt pathway  
A key consequence of the APC mutation is the resulting hyperactivation of the Wnt 
signalling pathway. Targeting components of the pathway downstream of APC are 
being explored as potential therapeutic strategies for targeting APC. These are 
depicted in figure 10. 
3.3.1 Targeting β-catenin 
To reduce Wnt signalling mediated transcription, researchers have investigated the 
potential of two approaches; 1) reducing β-catenin expression and 2) reducing the 
interaction between β-catenin and transcription factors or transcriptional co-activators. 
Antisense oligonucleotides designed to specifically target β-catenin mRNA can be used 
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to reduce β-catenin expression. Antisense oligonucleotides bind to complementary 
mRNA and cause mRNA degradation mediated by the nuclease RNaseH. Roh et al. 
(2001) used antisense oligonucleotides against β-catenin in CRC cell lines and in 
xenograft models. The research was promising because the treatment inhibited tumour 
growth in both models and some tumours in the xenograft models completely shrank. 
Similar results were also shown in the APCmin mouse model, those treated with 
antisense oligonucleotides developed less intestinal adenomas (Foley et al. 2008). 
However, this approach lowers all β-catenin levels in the cell and could be quite toxic, 
because β-catenin also has roles in cell adhesion (Lesko et al. 2014). 
 
Figure 10 Targeting the Wnt pathway 
Schematic showing a number of approaches discussed to lower Wnt signalling by 
targeting β-catenin, TNKS and COX2.  
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Small molecule inhibitors can interfere with the interaction of β-catenin to transcription 
factors and transcriptional co-activators. FH535, PKF115-584 and CGP049090 all 
reduce the transcriptional activity of β-catenin and TCF/LEF complexes in vitro (Handeli 
& Simon 2008; Lepourcelet et al. 2004). Another small molecule inhibitor ICG-001 has 
been shown to prevent β-catenin binding to the transcriptional co-activator CREB 
binding protein (CBP). In CRC cell lines, treatment with ICG-001 caused a reduction in 
proliferation (Emami et al. 2004). Additionally ICG-001 treatment in the APCmin mouse 
model resulted in a 42 % reduction in the formation of polyps and in a xenograft model 
using SW620 cell line ICG-001 treatment resulted in a large reduction in tumour size 
(Emami et al. 2004). A second generation ICG-001 inhibitor was developed called PRI-
724 and was tested in a phase 1 trial. This drug has a lower IC50 of 150 nM (compared 
to 3 µM for ICG-001) and was tolerated well in the phase 1 clinical trial (Emami et al. 
2004; Lenz & Kahn 2014; El-Khoueiry et al. 2013). 
 
3.3.2 Tankyrase inhibition 
Tankyrases (TNKS) were first identified to have a role in the Wnt signalling pathway 
through investigating the mechanism of the compound XAV939 (Huang et al. 2009). 
TNKS consist of two members tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2) and 
they are part of the poly (ADP-ribose) polymerase (PARP) superfamily of enzymes 
(Haikarainen et al. 2014). PARP enzymes add ADP-ribose groups onto proteins, also 
referred to as PARsylation (Riffell et al. 2012). In addition to TNKS role in Wnt 
signalling, TNKS also play a role in regulating telomeres, mitosis, vesicle transport and 
viral replication (Lehtiö et al. 2013). The expression of TNKS has been shown to be 
altered in many cancers including CRC (Lehtiö et al. 2013). Inhibitors of TNKS are 
being explored as potential therapeutic agents in cancer. 
TNKS PARsylate axin and direct ubiquitination by ring finger protein 146 (RNF146) 
resulting in Axin degradation. The level of axin is regulated by TNKS and self regulated 
through the pathway because it is a Wnt target gene (Huang et al. 2009). Axin is tightly 
regulated and is thought to be the rate limiting step in the formation of the β-catenin 
destruction complex (Huang et al. 2009). TNKS inhibitors prevent TNKS from signalling 
axin for degradation, therefore axin is available to form part of the β-catenin destruction 
complex. Increased formation of the β-catenin destruction complex increases the 
degradation of β-catenin and decreases the activation of Wnt target genes. The first 
inhibitors identified were XAV939 and IWR-1 and now there are many published 
inhibitors including WIK14, JW55, JW67, JW74, G007-LK and G244-LM (Lehtiö et al. 
2013; Waaler et al. 2011; Waaler et al. 2012; Lau et al. 2013). TNKS inhibitors are 
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being investigated in CRC to lower the hyperactivation of the Wnt signalling pathway 
commonly seen in CRC. Sensitivity to TNKS inhibitors in a range of CRC cell lines has 
been variable and not all APC mutant lines are sensitive. For example, Lau et al. 
(2013) tested 11 APC mutant CRC cell lines and found only six showed a decrease in 
Wnt signalling when treated with G007-LK or G244-LM. SW480 was one of the cell 
lines, which did not respond to G007-LK/G244-LM. However, treatment with JW74 in 
SW480 reduced cell line growth and tumour growth in an xenograft model suggesting 
differences in sensitivities between different TNKS inhibitors (Lau et al. 2013; Waaler et 
al. 2011). Recently a group suggested the location of the APC mutation explained why 
not all APC mutant cell lines respond to TNKS inhibitors. Cell lines with APC mutations 
lacking all seven 20aa repeats were sensitive and those with two or more 20aa repeats 
were resistant to TNKS inhibitors (Tanaka et al. 2017). The group further validated this 
model in patient samples and therefore this finding has the potential to be used as a 
biomarker for patients who would benefit from TNKS inhibitors (Tanaka et al. 2017). 
Further research will be required to see if this is applicable to all TNKS inhibitors 
developed and in development. Another reason some cell lines may be less responsive 
is if they have become less dependent on Wnt signalling for proliferation. A recent 
study investigated drug resistance to the TNKS inhibitor IWR-1 and found the mTOR 
pathway was upregulated in colo-320DM cells made resistant to IWR-1 (Mashima et al. 
2017). Interestingly TNKS mRNA has been reported to be lower in more advanced 
CRC and this could suggest TNKS inhibitors may be more effective at early stages 
(Gelmini et al. 2006). TNKS inhibitors have the potential to treat CRC, however findings 
ways to minimise the toxicity effects on normal cells in the intestine is essential for this 
treatment to reach the clinic (Zhong et al. 2016; Lau et al. 2013). 
A recent paper has uncovered a new way to potentially target TNKS which is specific to 
APC mutated cells and therefore may be better tolerated as a treatment. Mammalian 2-
Cys peroxiredoxin type II (PrxII) has been shown to regulate TNKS in APC mutant 
CRC (Kang et al. 2017). PrxII binds directly to TNKS and protects the zinc binding 
domain on TNKS from oxidative inactivation by H2O2, the zinc binding domain is 
essential for TNKS to PARsylate axin and signal its degradation, promoting Wnt 
signalling. It is believed the mechanism is specific to APC mutated cells because the 
APC mutation seems to increase levels of H2O2 in the cell and causes a change to both 
PrxII and TNKS allowing them to bind. Inhibiting PrxII prevents TNKS from destabilising 
axin resulting in reduced Wnt signalling and inhibition of growth in APC mutant CRC 
cell lines and xenograft experiments (Kang et al. 2017). Interestingly PrxII is 
overexpressed in CRC regardless of APC status (Kang et al. 2017). Currently, the only 
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available compound to specifically inhibit PrxII is conoidin A and therefore there is an 
opportunity to develop more compounds (Kang et al. 2017). 
 
3.4 COX2 inhibitors 
COX2 is one of two cycloxygenase isozymes which catalyze the conversion of 
arachidonic acid to prostaglandin H2 (Oshima et al. 1996). COX2 has been identified as 
a Wnt target gene and APC mutant cells show increased expression of COX2 (Lesko 
et al. 2014). Therefore, targeting COX2 has the potential to be a therapeutic strategy 
for APC mutant CRC. Loss of prostaglandin-endoperoxide synthase 2 (Ptgs2) which 
encodes COX2 in the APC716 mice resulted in a decrease in the number of polyps and 
size (Oshima et al. 1996). Additionally treating APC716 mice with MF-tricyclic (COX2 
specific inhibitor) and the non-steroidal anti-inflammatory drug (NSAID) sulindac (COX1 
and COX2 inhibitor) resulted in a reduction in polyp formation. MF-tricyclic was shown 
to be more effective than sulindac (Oshima et al. 1996). 
COX2 inhibitors have been tested in combination with other drugs, for example EGFR 
inhibitors. Research showed combining celecoxib (COX2 inhibitor) with erlotinib (EGFR 
inhibitor) resulted in less polyps in the APCmin mouse model and reduced tumour 
volume in CRC xenografts (Buchanan et al. 2007). Unfortunately, a phase 2 clinical 
trial on recurrent metastatic CRC suggested the combined inhibition of COX2 and 
EGFR does not increase the benefit of treating with the EGFR inhibitor alone (Chan et 
al. 2011). Another clinical trial explored the potential of COX2 inhibitors and EGFR 
inhibitors in preventing tumourigenesis. The randomised trial combined sulindac and 
erlotinib (EGFR inhibitor) to treat FAP patients who develop many polyps which are 
precursors to tumourigensis. This combination decreased the duodenal polyp burden, 
however at the doses used there were concerns over toxicity and this may limit its 
potential (Samadder et al. 2016). More research is needed into this field to see if 
inhibiting COX2 could benefit patients with APC mutations. 
 
3.5 TASIN-1 
A recent paper has identified truncated APC selective inhibitor-1 (TASIN-1) as a 
compound which induces apoptotic cell death in APC mutant CRC (Zhang et al. 2016). 
The compound was originally identified from a screen against 200,000 compounds 
using isogenic immortilised human colonic epithelial cell lines (HCEC) derived from 
ICT. Both cell lines expressed KRAS G12V, TP53 shRNA, APC shRNA and one of the 
lines additionally ectopically expressed APC1309 truncation. This resulted in two cell 
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lines known as ICTRPA and ICTRPA A1309 which differed just in the presence of 
truncated APC (Zhang et al. 2016). TASIN-1 was then shown to be effective in other 
models including commonly used APC mutant CRC cell lines, xenograft models (using 
APC mutant HT29 and DLD1 cell lines) and the mouse model APC580.TASIN-1 was 
identified to potentially target emopamil-binding protein (EBP) which is part of the 
cholesterol synthesis pathway (downstream of 3-hydroxyl-3-methylglutaryl coenzyme A 
reductase (HMGCR)). In APC mutant cell lines cholesterol synthesis decreases upon 
TASIN-1 treatment and these cell lines are unable to respond to this decrease because 
they are unable to upregulate sterol regulatory element-binding protein 2 (SREBP2) 
and SREBP2 target genes (Zhang et al. 2016). This study shows promise in 
developing a targeted therapy specific for patients with APC mutations. 
 
4 Using RNAi to identify synthetic lethal interactions 
4.1 Silencing genes using RNAi 
4.1.1 Discovery of RNAi 
By the early 1990’s evidence was developing to suggest gene expression was not only 
mediated before transcription by protein transcription factors but also occurred post 
transcription (Fellmann & Lowe 2014). One example was the discovery of the lin4 gene 
in Caenorhabditis elegans (C.elegans) which encodes a pair of small RNA responsible 
for regulating the levels of the protein LIN-14 (Fellmann & Lowe 2014). By the late 
1990’s researchers had discovered a mechanism of double stranded RNA (dsRNA) 
mediated sequence specific gene silencing in C.elegans, similar mechanisms were 
also identified in eukaryotic organisms, enabling the mechanism to be exploited as a 
scientific tool by the early 21st century (Fellmann & Lowe 2014). 
 
4.1.2 Mechanism 
The endogenous system in mammalian cells is mediated by micro RNA (miRNA) which 
is transcribed from the genome as long primary miRNA (pri-miRNA) and are processed 
into precursor miRNA (pre-miRNA). Exportin 5 exports pre-miRNA from the nucleus to 
the cytoplasm (Fellmann & Lowe 2014). In the cytoplasm Dicer cleaves the pre-miRNA 
into small RNA duplexes (approximately 22 nucleotides (nt)), these duplexes are 
loaded onto the RNA-induced silencing complex (RISC) complex and one strand is 
selected as the guide strand. The guide strand binds complementary mRNA 
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sequences, perfect matching results in cleavage and degradation whilst partial 
matching leads to translational repression (Fellmann & Lowe 2014). 
 
 
Figure 11 Experimentally exploiting RNAi to silence genes 
Introducing siRNA, shRNA or miRNA into cells and these are processed by the RNAi 
machinery. The guide strand is incorporated into a RISC complex and this binds to the 
target mRNA and results in the degradation of the target mRNA. Adapted from (Wittrup 
& Lieberman 2015).  
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To experimentally exploit the system, exogenous triggers can be introduced directly, for 
mammalian cells short interfering RNA (siRNA), plasmids expressing shRNA or miRNA 
are commonly introduced into cells (Figure 11) (Lord et al. 2009). Synthetic siRNA is 
loaded directly into the RISC complex whilst both shRNA and miRNA undergo 
processing first, shRNA mimic the pre-miRNA. Synthetic siRNA can be used for short 
term gene silencing whilst shRNA is used for stable gene silencing because the 
sequence is incorporated into the host genome (Lord et al. 2009). This technology has 
become a very useful and widespread tool for loss of function studies. It is a great 
counterpart to small molecule inhibitors and enables undruggable targets to be 
targeted (Fellmann & Lowe 2014). The use of this technology for high throughput 
screens utilises the advantage of this tool and can be used to investigate gene 
function, understand mechanisms of drug resistance and search for synthetic lethal 
interactions on a genome wide scale to name a few. 
 
4.2 Synthetic lethality 
4.2.1 Discovery  
Originally described in bacteria and yeast synthetic lethality was suggested as a new 
approach to identify new targets in cancer therapy (Canaani 2014; Hartwell 1997). 
Synthetic lethality is the concept that when gene A or gene B alone are inactive the cell 
survives, but if both gene A and gene B are inactive together the cell dies. In cancer 
cells, gene A could be a mutation and gene B becomes a potential therapeutic target. 
Targeting gene B would be a cancer cell specific target because normal cells would 
have a normal non-mutated form of gene A, therefore survive the targeted treatment. 
Genes identified to be in a synthetic lethal relationship could be in the same complex, 
same pathway, parallel pathways, divergent pathways or even in unrelated pathways 
(Chan & Giaccia 2011). 
There are numerous benefits to this approach, firstly it enables the treatment to 
specifically target just the cancer cells, enhancing the therapeutic index and reducing 
chemotherapy associated side effects. Secondly the approach is ideal for targeting 
tumour suppressor genes which are hard to target because unlike oncogenes there is 
often no protein to inhibit. Finally the therapy could be used as a monotherapy or in 
combination with conventional treatments, enhancing the effect of radiotherapy or 
chemotherapy enabling lower doses to be given and reducing side effects (Chan & 
Giaccia 2011).  
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4.2.2 High throughput screens to identify synthetic lethal interactions  
After the initial idea of applying synthetic lethality to cancer therapeutics, genetic 
screens to investigate the theory were performed in model genetic systems using 
classical genetics including Saccharomyces cerevisiae (S.cerevisiae), C.elegans and 
Drosophila melanogaster (D.melanogaster). For example, S.cerevisiae mutants where 
screened with 50 FDA chemotherapeutics to increase understanding of these agents 
and one of the findings was that yeast strains defective in post replicative repair were 
more sensitive to cisplatin (Hartwell 1997). These early screens provided proof of 
concept and with the development of RNA interference (RNAi) it became possible to 
perform data rich high throughput screens, identifying synthetic lethal interactions 
directly in human cancer cell lines. 
As described earlier siRNA and shRNA can be used in mammalian cells to post 
transcriptionally repress gene expression of specific genes and this technology enables 
large scale loss of function screens to be performed. The choice of siRNA or shRNA 
depends on the cell line and experimental design because siRNA is transiently 
transfected into cells using lipid and peptide based transfection or electroporation, 
whereas shRNA is stably delivered using a viral based vector. shRNA is preferred for 
longer term silencing and cell lines which are hard to transfect (Echeverri & Perrimon 
2006). Screens can involve different sized RNAi libraries targeting the whole genome 
or specific groups of proteins including kinases, DNA repair or tumour suppressors. 
The benefit of looking for synthetic lethal interactions with kinases is that these genes 
are easier to target with drugs, with many existing compounds already available.  
There are two main screening approaches, target each gene individually (systematic) 
or target multiple genes in a pool (pooled). Systematic approaches typically use an 
arrayed format, this approach can be expensive but has the advantage that it provides 
information on each gene in the library individually. A pooled approach delivers a whole 
library to a population of cells and a phenotype is selected (for example resistance to a 
drug) to identify genes of interest. DNA is then extracted from the cells, amplified and 
sequenced to identify the gene the shRNA targeted (Lord et al. 2009). There are many 
screen read out options for example; cellular viability, cell morphology, reporter assays 
and functional assays (Falschlehner et al. 2010). To obtain these read outs a variety of 
technologies are used including; fluorescence, microscopy, microfluidics and flow 
cytometry (Janzen 2014). Screens collecting multiple measurements are known as 
high content screens (Lord et al. 2009). 
In addition to using RNAi to identify synthetic lethal interactions, small molecule 
libraries and CRISPR-cas9 (discussed in section 5) can also be used. The advantage 
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of screening with small molecule libraries is any findings can be quickly translated into 
the clinic because an inhibitor is already available and may just need to be modified to 
increase efficiency (Chan & Giaccia 2011). 
 
4.2.3 Examples in cancer therapy 
Numerous synthetic lethal interactions have already been identified using RNAi in a 
range of cancers, offering a wide range of potential new therapeutic strategies. In CRC 
deficiencies in the mismatch repair pathway have been shown to be synthetically lethal 
with DNA Polymerases. More specifically MSH2 loss was synthetically lethal with Pol-β 
inhibition and MLH1 loss was synthetically lethal with DNA Polymerase γ (Pol-γ). Both 
relationships lead to an increase in 8-Oxoguanine (8-oxo G) levels resulting in lethal 
DNA breaks due to the inability to repair the damage caused by 8-oxo G (Martin et al. 
2010). More potent inhibitors of both DNA polymerase β and γ are required for clinical 
trials.  
An example in non-small cell lung cancer (NSCLC) is the identification of a synthetic 
lethal relationship between cdk4 and KRASG12V. The synthetic lethal interaction was not 
shared with cdk2 or cdk6, highlighting why broad cdk inhibitors may have limited 
efficiency in this mutational background (Chan & Giaccia 2011). In support of this work 
Mao et al. (2014) showed it was possible to deliver siRNA targeting CDK4 in micellar 
nanoparticles (MNP) into A549 mice xenografts, resulting in the inhibition of tumour 
growth.  
A well known synthetic lethal interaction which has now reached the clinic occurs 
between breast and ovarian cancer patients with breast cancer 1 or 2 (BRCA1 or 
BRCA2) mutations and inhibition of PARP. These cancers are sensitive to PARP 
inhibition because homologous recombination (HR) is compromised upon BRCA1/2 
loss and PARP inhibition halts single stranded repair, so any unrepaired single strand 
breaks become double stranded and prove lethal for the cells (Canaani 2014). After 
years of clinical trials PARP inhibitors have recently been approved for use in BRCA 
deficient patients (Bose & Basu 2015). This demonstrates identifying synthetic lethal 
relationships using high throughput screens can deliver new treatments for cancer 
patients. 
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5 CRISPR-cas9 to edit genes 
5.1 Discovery 
The CRISPR-cas9 story started back in 1987 with the identification of unusual 
repetitive elements in Escherichia coli (E.coli), instead of forming tandem repeats the 
29 nt repeats were interspaced by five intervening 32 nt non-repetitive sequences. As 
the number of genome sequences increased, this type of repetitive element was also 
identified in over 40 % of bacteria sequenced and 90 % of archaea. In 2002 these 
repetitive elements became known as clustered regularly interspaced short palindromic 
repeats (CRISPR). Further characterisation of these regions lead to the discovery of 
well conserved regions located alongside CRISPR. These CRISPR associated genes 
translate into CRISPR associated proteins (cas). Continued research lead to the 
classification of three microbial CRISPR systems; type I, type II and type III (Hsu et al. 
2014). The systems were found to be adaptable immune mechanisms used to provide 
protection from foreign nucleic acids (Sander & Joung 2014). The big revelation arrived 
when researchers demonstrated the ability to utilise this naturally occurring mechanism 
to perform genome editing in eukaryotic cells (Hsu et al. 2014). 
 
5.2 Mechanism  
For genome editing the type II system from Streptococcus pyogenes (S.pyogenes) has 
been most commonly utilised, other type II systems from other species have also been 
used (Sander & Joung 2014). There are three essential components; cas9, guide RNA 
(gRNA) and the protospacer adjacent motif (PAM). Cas9 is an endonuclease which can 
cleave DNA 3-4 nt upstream of the PAM sequence (Sander & Joung 2014). This 
enzyme undergoes large conformational changes when it binds to the gRNA and again 
when it binds to the target site in the DNA (Doudna & Charpentier 2014). The 20 nt at 
the 5’ of gRNA directs cas9 to the specific DNA site for editing (Sander & Joung 2014). 
The PAM sequence is critical for DNA binding and the sequence is specific for the 
species cas9 is derived from, for example S.pyogenes requires a PAM sequence of 5’ 
NGG (Sander & Joung 2014). Once cas9 is at the correct site it cleaves the DNA 
causing a DNA break which is repaired by non-homologous end joining (NHEJ) or 
homology directed repair (HDR). This results in either a truncated protein or a complete 
knockout due to NMD (Figure 12) (Barrangou et al. 2015).  
The cas9 is encoded by a plasmid and some plasmids also express the gRNA. To 
select the cells which have received the cas9 plasmid, the plasmid also contains an 
antibiotic resistance gene or a fluorescent protein such as mKate2. The gRNA can be 
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encoded by a plasmid or can be delivered as synthetic RNA. The cas9 and gRNA can 
be delivered using a range of methods including electroporation, nucleofection, 
lipofectamine or viral-mediated (Sander & Joung 2014). Transient methods have been 
shown to be sufficient for editing and have the advantage that the expression of the 
components is only temporary, reducing off target effects from cas9. Constitutive 
expression of components using viral delivery methods is ideal for hard to transfect 
cells and could lead to higher efficiencies (Sander & Joung 2014). 
A potential problem with CRISPR-cas9 is the potential for off target effects. Cas9 has 
been shown to tolerate sequence mismatches and bulges between the target DNA and 
the gRNA, suggesting off target effects are a problem (Sander & Joung 2014). Many 
ways have been suggested to minimise off target effects including; using minimal 
reagents, careful design of gRNAs or using paired nickases to generate adjacent off 
set nicks in the DNA (Sander & Joung 2014).  
 
5.3 Applications 
CRISPR-cas9 has been developed into a powerful tool in genome engineering to 
facilitate studies into gene function, perform genome wide screens, developing disease 
models and potentially as new therapeutic agents (Barrangou et al. 2015). CRISPR-
cas9 can be used to completely knock out a protein, insert epitope tags or fluorescent 
proteins to gene products and to specifically alter a gene sequence. Any alteration 
occurs at the DNA level and is therefore inherited to daughter cells.  
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Figure 12 CRISPR-cas9 mechanism 
The gRNA directs the cas9 to the correct site in the genome to cleave the DNA. The 
DNA break is then repaired and could result in an alteration to the DNA sequence 
which either causes the expression of a C-terminally truncated protein or no protein. 
Adapted from (Barrangou et al. 2015).  
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6 mTOR and colorectal cancer 
6.1 mTOR pathway 
The mTOR pathway is a central regulator of key cellular processes and consists of two 
main signalling hubs called mTORC1 and mammalian target of rapamycin complex 2 
(mTORC2). The main protein in both complexes is a serine threonine kinase called 
mTOR, it forms part of the PI3K family (Laplante & Sabatini 2009). Both complexes 
contain the mTOR inhibitor proline-rich akt substrate of 40kDa (pras40), the scaffold 
proteins tti1 and tel2, and protein mammalian lethal with SEC13 protein 8 (mLST8) 
whose function is unclear (Laplante & Sabatini 2012). The mTORC1 complex 
additionally consists of the scaffold protein raptor and the mTORC2 complex is joined 
by protein observed with rictor 1/2 (protor 1/2) and the scaffold protein mammalian 
stress-activated map kinase-interacting protein 1 (msin1) (Laplante & Sabatini 2012). 
 
The mTOR pathway integrates intracellular and extracellular signals including; oxygen, 
amino acids, stress, energy levels and growth factors (Laplante & Sabatini 2012). 
Therefore many signalling pathways feed into this pathway (eg Wnt pathway, MAPK 
pathway and PI3K pathway) resulting in a wide range of changes downstream of 
mTORC1 and mTORC2 (Figure 13). 
 
6.2 Roles of the mTOR pathway 
The mTOR pathway has a wide range of functions in the cell including activating 
macromolecule synthesis, cell cycle progression, growth, metabolism, cytoskeletal 
organisation, cell survival and the inhibition of autophagy (Laplante & Sabatini 2012). 
mTORC1 is responsible for the majority of these roles and will be discussed first. 
Firstly the activation/inhibition of mTORC1 relies on signals from growth factors, energy 
levels, oxygen, amino acids and stress. Some of these signals feed through a sensor 
known as tuberous sclerosis complex (TSC), this is a heterodimer consisting of 
tuberous sclerosis 1 (TSC1) and tuberous sclerosis 2 (TSC2) which are GTPase-
activating proteins (GAP) for ras homolog enriched in brain (Rheb) causing guanosine 
triphosphate (GTP) bound to Rheb to hydrolyse to guanosine diphosphate (GDP). 
Rheb interacts with mTOR and when bound GDP it inhibits the mTORC1 complex 
(Laplante & Sabatini 2012). For example, growth factors activate key signalling proteins 
including AKT, ERK1/2 and S6K1, resulting in the phosphorylation of TSC2 and 
subsequent activation of mTORC1. If energy is high or adequate oxygen is available, 
AMPK remains inactive, TSC2 is inactive and this results in mTORC1 remaining active. 
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When AMPK is activated due to low energy or hypoxia the inhibition of mTORC1 can 
occur through TSC2 or independently through raptor (Laplante & Sabatini 2012).  
 
 
Figure 13 Summary of the mTOR pathway 
Schematic showing the inputs and outputs of the two main signalling complexes in 
mTOR signalling. Adapted from (Laplante & Sabatini 2012).  
 
Once mTORC1 is activated it leads to the activation of protein synthesis, lipid 
synthesis, mitochondrial metabolism and inhibition of autophagy. mTORC1 directly 
activates protein synthesis through the phosphorylation of 4E-BP1, S6K1 and PP2A 
(Laplante & Sabatini 2009). The phosphorylation of 4E-BP1 prevents binding and 
inhibition of eukaryotic translation initiation factor 4E (eIF4E), enabling eIF4E to 
promote cap-dependent translation. Phosphorylated S6K1 activates mRNA biogenesis, 
cap dependent translation, elongation and translation of ribosomal proteins. The 
phosphorylation of PP2A inhibits this protein, resulting in the transcription of ribosomal 
RNA, the machinery required for protein synthesis. Lipid synthesis occurs through 
mTORC1 direct activation of transcription factors sterol regulatory element-binding 
transcription factor 1 (SREBP1) and peroxisome proliferator-activated receptor gamma 
(PPARγ). mTORC1 activates mitochondrial metabolism and biogenesis through 
altering peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC1α) 
interaction with another transcription factor ying yang 1 (YY1). Under normal conditions 
mTORC1 represses autophagy, which can be used to provide biological material when 
nutrient sources are low. This occurs through mTORC1 phosphorylation and 
repression of uridine kinase-like protein 1 (UKL1), autophagy related 13 (ATG13) and 
FAK family kinase-interacting protein of 200 kDa (FIP200) (Laplante & Sabatini 2009). 
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The less well known mTOR complex is mTORC2 and it plays a role in cell survival, 
metabolism and regulation of the cytoskeleton. mTORC2 is required for the full 
activation of AKT and this prevents the activation of transcription factors forkhead box 
O1 (Fox01) and forkhead box O3a (Fox03a). When activated Fox01/03a activate 
transcription of genes involved in stress resistance, metabolism, cell cycle arrest and 
apoptosis (Laplante & Sabatini 2009). mTORC2 acts on the cytoskeleton through 
phosphorylating protein kinase C alpha (PKCα) (Laplante & Sabatini 2009).  
 
6.3 Deregulation in cancer 
Many of the pathways feeding into the mTOR pathway are commonly mutated in 
cancers leading to deregulation of the pathway, additionally familial syndromes arise 
from mutations in genes upstream of mTOR (Laplante & Sabatini 2012). In CRC 
mutations in Ras, p53, Wnt pathway and PI3K/PTEN/AKT pathways are common 
resulting in hyperactivation of the mTOR pathway (Wang & Zhang 2014). It is thought 
that the increase in protein synthesis through phosphorylation of 4E-BP1 is the main 
contributor to tumour development through hyperactivation of the mTOR pathway 
because this provides the cell with proteins required for cell survival, cell cycle 
progression, angiogenesis, energy metabolism and metastasis. Therefore it is believed 
the ability of mTOR inhibitors to inhibit this particular part of the mTOR pathway is key 
to the success of inhibiting this pathway (Laplante & Sabatini 2012). 
Rapamycin was the first mTOR inhibitor discovered and was found to inhibit mTORC1 
with a high specificity, but is thought to only partially phosphorylate 4E-BP1. Limitations 
in solubility and pharmokinetic properties lead to the development of improved versions 
known as rapalogs and included; temsirolimus, everolimus and ridaforolimus (Zaytseva 
et al. 2012). Rapamycin and the rapalogs appear to inhibit mTORC2 complex to some 
extent but this depends on the cell line and impacts on the ability to induce apoptosis 
(Zaytseva et al. 2012). The next generation of mTOR inhibitors were designed on the 
importance of inhibiting both mTORC1 and mTORC2, therefore the kinase activity of 
the protein mTOR was targeted. mTOR kinase inhibitors are more potent than 
rapamycin and rapalogs, they completely inhibit phosphorylation of 4E-BP1 and are 
currently being tested in the clinic (Laplante & Sabatini 2012). The broader inhibition of 
mTOR has increased the toxicity to normal tissues and there has been limited success 
in KRAS driven tumours (Zaytseva et al. 2012). Another approach is dual inhibitors of 
PI3K and mTOR, due to the similarity of the catalytic domains, these show higher 
potency in clinical trials, however, the toxicity to normal tissues is higher (Laplante & 
Sabatini 2012). 
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A wide range of mTOR inhibitors have been trialled and are ongoing, results are 
varying. Some have received food and drug administration (FDA) approval for example 
temisirolimus is approved for advanced stage renal cell carcinoma (Laplante & Sabatini 
2012). In general the response to mTOR inhibitors is not as anticipated, it is a complex 
pathway and potentially the number of feedback loops poses limitations to the inhibition 
of this pathway. Despite this responses are seen in some tumours, therefore a greater 
understanding and clear biomarkers are required to identify patients who could benefit 
the most from this therapeutic strategy (Laplante & Sabatini 2012).  
 
7 Statins 
7.1 Introduction to statins 
In 1987 the first statin was approved by the FDA for the prevention of cardiovascular 
disease (CVD). Statins are a family of drugs which are small molecule inhibitors of 
HMGCR in the mevalonate pathway. HMGCR catalyses the conversion of 3-hydroxyl-
3-methylglutaryl coenzyme A (HMG-CoA) to mevalonate and this is the rate limiting 
step in the pathway resulting in cholesterol production (Figure 14) (Bardou et al. 2010). 
Inhibition of HMGCR results in the reduction of plasma cholesterol levels and there is 
strong evidence showing that this reduces your risk and this reduction in risk continues 
over treatment time (Collins et al. 2016). In recent years it has been suggested that the 
use of statins could be broadened to a wide range of additional conditions including; 
multiple sclerosis, IBD, rheumatoid arthritis, systemic lupus erythematosus, chronic 
obstructive pulmonary disease, cancer, strokes, HIV, parkinsons and alzheimers 
(Davies et al. 2016). This is due to statins also modulating immune responses, 
enhancing anti-inflammatory processes and altering signalling pathways (Davies et al. 
2016). 
 
7.2 Mechanism of action 
7.2.1 HMGCR dependent  
Cholesterol is made in hepatocytes and statins compete with HMG-CoA to bind 
HMGCR in hepatocytes. Cholesterol is mostly transported by low density lipoprotein 
(LDL) and is then referred to as LDL-C (‘Bad’ cholesterol). Cholesterol bound to high 
density lipoprotein (HDL) is destined for recycling and excretion at the liver and often 
called ‘good’ cholesterol. When statins bind to HMGCR, cholesterol production is 
reduced and intracellular levels decrease, causing LDL-C to be transported into the cell 
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to restore intracellular levels. This in turn results in a reduction in levels of LDL-C in the 
plasma (Davies et al. 2016). 
 
 
Figure 14 Mevalonate pathway 
The Mevalonate pathway synthesises cholesterol, squalene, dolichol, ubiquinone and 
isoprenoids. Statins compete with HMG-CoA to bind HMGCR which is the first step in 
the Mevalonate pathway, resulting in a reduction in all Mevalonate pathway products. 
Adapted from (Demierre et al. 2005).  
 
Another impact of the inhibition of HMGCR is the reduction in isoprenoids including 
farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) (Figure 14). 
Isoprenoids are added to certain proteins as a post translational modification, known as 
prenylation. Prenylation adds long hydrophobic molecules to proteins enabling proteins 
to anchor to cell membranes. Prenylation is mediated by either farnesyl transferase 
(FTase) or geranylgeranyl transferase (GGTase) and occurs at a CAAX, CXC or CC 
sequence (Figure 15) (Greenwood et al. 2006). The Ras superfamily commonly 
undergoes prenylation and alongside other post translational modifications determines 
the correct localisation and functioning of these proteins (discussed later in section 9) 
(Demierre et al. 2005; Roberts et al. 2008). Ras, Rac and Rho are commonly 
deregulated in cancers and reducing isoprenoids effects the function of these proteins 
and is potentially how statins exert their pro-apoptotic, anti-proliferative, angiogenic and 
inflammatory effects on cancer cells (Lochhead & Chan 2013; Demierre et al. 2005).  
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Figure 15 Protein prenylation 
Prenylation adds a hydrophobic molecule to proteins. Proteins containing CaaX 
sequence can be prenylated by either FTase of GGTase resulting in the addition of 
either FPP or GGPP. Proteins containing the CXC sequence are only prenylated by 
GGTase resulting in the addition of GGPP. Adapted from (Greenwood et al. 2006). 
 
7.2.2 HMGCR independent  
Statins also function independently of HMGCR causing a range of additional changes 
in the body. Statins inhibit the lymphocyte functions-associated antigen 1 (LFA1) 
integrin which modulates leukocyte trafficking and T cell activation and intercellular 
adhesion molecule 1 (ICAM1) which sustains leukocyte adhesion and facilitates 
migration (Davies et al. 2016). A range of signal transduction molecules are inhibited 
including AKT, ERK/MAPK, JAK/STAT resulting in changes in cell proliferation, 
apoptosis and the immune system. Statins inhibit transcription factors involved in pro-
inflammatory responses (including NF-kappaB (NF-kB), activator protein 1 (AP1), 
histone deacetylases (HDAC) and STAT1/3/4) and activate transcription factors with an 
anti-inflammatory role (including Kruppel like factor 2 (KLF2) and peroxisome 
proliferator-activated receptor alpha/beta (pPARα/β)) (Davies et al. 2016). Statins 
further modulate the immune system through the following inflammatory mediators 
cluster of differentiation 40 (CD40), interleukin1 beta (IL-1B), interleukin 6 (IL6), tumour 
necrosis factor alpha (TNFα), major histocompatibility class II (MHC-II), T-helper 1 and 
2 cytokines and c-reactive protein (CRP) (Demierre et al. 2005). Statins also influence 
angiogenesis, it is thought that statins may be pro-angiogenic at low doses and anti-
angiogenic at high doses (Demierre et al. 2005). Given all the HMGCR independent 
roles of statins these drugs induce a wide range of changes resulting in altering 
antioxidant activity, cell adhesion, inflammation, immunomodulation, angiogenesis, cell 
apoptosis and proliferation (Lochhead & Chan 2013).  
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7.3 Concerns for statin use  
Statins have proven benefits in patients at risk of CVD, unfortunately there are 
concerns over safety. Some concerns are genuine, whilst others are a result of 
misleading data from observational studies which includes case-control cohort studies 
and retrospective cohort studies. The cholesterol treatment trialists (CTT) collaboration 
recently published a paper discussing results of a meta-analysis of all randomised 
controlled trials (with over 2 years statin treatment in over 1,000 patients) and 
highlighted the facts from the fiction (Collins et al. 2016).  
The use of statins has three proven adverse effects; myopathy, diabetes mellitus and 
haemorrhagic stroke. Myopathy is described as muscle pain, tendernesss or weakness 
and is associated with increased blood creatine kinase concentration. The risk is 
relatively low with one case for every 10,000 patients treated with statins and the 
myopathy normally resolves when treatment is stopped (Collins et al. 2016). The risk of 
diabetes is more pronounced, on standard doses the risk increases by 10 %, whilst on 
stronger doses the risk increases to 20 %. The risk of haemorrhagic stroke increases 
with reduction in LDL-C levels but this risk is thought to be outweighed by the 
decreased risk of ischaemic stroke (Collins et al. 2016). Other adverse effects with no 
proven link to the use of statins include memory problems, cataracts and kidney related 
problems. Unfortunately it is believed that statin uptake is severely affected because of 
misleading information on the adverse effects. 
A potential adverse effect suggested years ago was the link of statin use and cancer 
seen in some observational studies and early laboratory data. Since the original 
observations there is now mounting evidence that statins either have no impact on 
cancer development or may have a protective effect (Collins et al. 2016). Data from 
observational studies taken from cohorts and health care databases are often 
misleading due to inherent biases in the data and design (Collins et al. 2016). 
Additionally many of the studies available have been designed to test the safety and 
efficacy of preventing CVD with statins. Resulting in insufficient data to interpret due to 
limited information and a short follow up period, cancer takes years to develop so a 
long follow up is essential. Additionally the trial population is often biased to those at 
high risk of CVD, who are often also at higher risk of cancer due to low physical 
exercise and poor diet (Lochhead & Chan 2013).  
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7.4 Statins in colorectal cancer 
7.4.1 The protective role of statins 
There is growing evidence of statins preventing CRC and this is supported by both 
population studies and laboratory data. Case-control studies have shown varying levels 
of effect, for example, a case control study with over 4,000 people in Israel found a 47 
% decreased risk in CRC whilst a case control study in US veterans with diabetes 
showed a 9 % decreased CRC risk (Poynter et al. 2005; Hachem et al. 2009). Many 
other case-control studies across the globe have shown no significant associations 
(Lochhead & Chan 2013). Retrospective cohort studies show a similar pattern too, a 
study of 37,000 US veterans using statins identified a 35 % reduction in CRC risk whilst 
a number of other studies have shown no effect (Farwell et al. 2008; Lochhead & Chan 
2013). Many of the randomised controlled trials, which are more reliable than 
observational studies suggest statins do not increase the risk of CRC (Lochhead & 
Chan 2013). Most importantly these studies may not strongly support a protective 
effect, but they highlight that statins do not appear to cause CRC. 
Laboratory data is more supportive for the protective effect of statins against CRC. A 
key step in the development of CRC is the development of polyps in the colon or 
rectum, reducing the number of polyps reduces your risk of developing CRC. In the 
APCmin mice statins alone have been shown to reduce the number of polyps by a third 
(Teraoka et al. 2011; Swamy et al. 2006). A study in F344 rats chemically induced to 
develop CRC, showed treatment with prevastatin significantly reduced the 
development of tumours (Narisawa et al. 1996). Similar effects have also been seen in 
a colitis associated colon cancer model (CAC) where tumours were chemically induced 
in C57/BL6 mice, the development of tumours was reduced in the mice treated with 
simvastatin (Cho et al. 2008). This is an important model because patients with 
ulcerative colitis have a high risk of developing bowel cancer.  
NSAIDs have protective effects against CRC and many studies are investigating 
combining statins and NSAIDs. The advantage of using both together is the use of 
lower doses of both drugs, reducing concerns over side effects. Various statins and 
NSAIDs have been trialled in vitro and in vivo. Combining lovastatin with the NSAID 
sulindac increased apoptosis up to five times more in HCT116, SW480 and LOVO cell 
lines (Agarwal, Rao, et al. 1999). The same combination of lovastatin and sulindac 
showed similar results in vivo in the Azomethane rat model, showing a reduction in 
decreased tumour growth by 30 % (Agarwal, Rao, et al. 1999). Other combinations 
have been trailed including atrovastatin and the NSAID celecoxib in APCmin mice, 
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tumour growth was suppressed by over 86 % and levels of apoptosis increased by 2/3 
times (Swamy et al. 2006).  
 
7.4.2 Statins alone to treat colorectal cancer 
There is promising data suggesting the potential of statins to be used to treat CRC. 
Numerous studies show statins cause tumour cell death in vivo and in vitro. In vitro 
data have shown statins cause varying levels of apoptosis in the following CRC cell 
lines HT29, HCT116, SW480, LS180, LOVO, colo205 (Chang et al. 2013; Cho et al. 
2008; Kaneko et al. 2007; Agarwal, Bhendwal, et al. 1999; Agarwal, Rao, et al. 1999). 
There are a range of mechanisms suggested for statin induced apoptosis. Some 
studies suggest apoptosis occurs through the inhibition of the anti-apoptotic protein 
survivin. Inhibition of survivin has been reported to occur by different mechanisms, 
activation of p38MAPK-p53 (HCT116 cells treated with simvastatin) and through the 
inhibition of Ras induced PI3K (SW480 cells treated with lovastatin) (Chang et al. 2013; 
Kaneko et al. 2007). Other studies suggest statin induced apoptosis occurs through the 
activation of NF-kB pathway or the bone morphogenic protein (BMP) pathway (Cho et 
al. 2008; Kodach et al. 2007). Furthermore Kodach et al. (2007) suggests sensitivity to 
statin treatment is related to the expression of SMAD4 which is part of the BMP 
pathway, this work helps to identify the patients who may benefit the most. More in vitro 
research is needed to understand the different mechanisms leading to this activation of 
apoptosis and understanding whether it is due to different types of statins, doses or 
mutational backgrounds. Research in vivo also shows promising results for the use of 
statins as a cancer treatment. For example, an xenograft model in mice injected with 
colo205 cell line and treated with simvastatin had smaller tumour volumes, larger 
necrotic areas, less angiogensis and more apoptosis compared to the mice treated 
without simvastatin (Cho et al. 2008).  
Understanding why normal cells are less sensitive to statins is an important avenue to 
explore. Research suggests tumours cells are more sensitive to HMGCR inhibition 
because tumour cells upregulate HMGCR due to abnormal feedback, increasing 
isopenoid levels, which are required for the Ras superfamily, in turn promoting 
tumourigensis (Demierre et al. 2005; Hentosh et al. 2001). A concern for using statins 
alone to treat CRC is the dose required in many of the in vivo and in vitro studies (1-
200 μM) is higher than currently used for treating CVD (10-200 nM). Statins may not be 
safe to give at the higher doses showing anti-tumour effects, however by 
understanding the mechanisms of effects seen this may lead to the identification or 
development of a drug which inhibits the target more effectively (Demierre et al. 2005). 
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7.4.3 Other uses in colorectal cancer treatment 
Researchers are investigating combining statins with chemotherapy to enhance the 
effect of the chemotherapeutics. A study pretreating SW480, HCT116, LOVO and 
HT29 with lovastatin before 5-FU or cisplatin treatment showed increased levels of 
apoptosis (Agarwal, Bhendwal, et al. 1999). Recently a phase III trial was completed 
where simvastatin was combined with chemotherapy in patients with metastatic 
colorectal disease. Unfortunately there was no improvement in progression free 
survival, however this may be because statins may be more effective against early 
stage disease (Lim et al. 2015).  
An interesting avenue of research is using statins to sensitise cells resistant to EGFR 
therapy, normally KRAS mutant cancers are not treated with EGFR therapy. In vitro 
data showed combining simvastatin with cetuximab reduced cell proliferation in KRAS 
mutant cell lines and tumour growth in a xenograft model (Lee et al. 2011). However, 
the same effect was not seen in a phase 2 clinical trial using this concept (Baas et al. 
2015). 
 
8 Survivin  
8.1 Roles of survivin  
Survivin (encoded by the gene BIRC5) is one of eight members of the inhibitor of 
apoptosis (IAP) family, the family also includes cellular inhibitor of apoptosis protein 1 
(cIAP1), cellular inhibitor of apoptosis protein 2 (cIAP2) and x-linked inhibitor of 
apoptosis (XIAP) (Chen et al. 2016). Survivin contributes to two major cellular 
processes, apoptosis and the cell cycle. Survivin prevents apoptosis by interacting and 
inhibiting caspase 9 and the effector caspases 3 and 7, causing the inhibition of both 
intrinsic (via mitochondria) and extrinsic (via death receptor) apoptosis (Figure 16) 
(Chen et al. 2016). This inhibition of effector caspases prevents the cleavage of cellular 
substrates and therefore prevents apoptosis. Research also suggests survivin enables 
cancer cells to avoid apoptosis induced by immune cells by increasing the expression 
of FasL on the cancer cell surface, resulting in the apoptosis of immune cells via 
extrinsic apoptosis (Asanuma et al. 2004). 
Survivin is carefully regulated during the cell cycle and it is thought to be part of the 
chromosomal passenger complex (CPC) (Lens et al. 2006). The expression of survivin 
peaks in G2/M phase then reduces in G1 (Chen et al. 2016). At G2 survivin 
accumulates at the centromeres, during prophase and metaphase survivin becomes 
diffuse along the chromosome arms and remains concentrated at the centromere. As 
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the cell enters anaphase survivin dissociates from the centromere and localises to the 
central spindle. Then during cytokinesis survivin moves to the midbody before removal 
from the cell (Lens et al. 2006). This localisation pattern during the cell cycle supports a 
role for survivin in the CPC, additionally survivin interacts with other members of the 
complex including INCENP, aurora B and borealin (Lens et al. 2006). Survivin has also 
been shown to be phosphorylated by cyclin dependent kinase 1 (CDK1) during mitosis 
resulting in the stabilisation of survivin (Chen et al. 2016). This evidence supports a 
role for survivin in the cell cycle. 
 
Figure 16 Survivin and apoptosis 
Survivin inhibits caspase 9 and effector caspases resulting in the inhibition of both 
intrinsic (via mitochondria) and extrinsic apoptosis (via death receptor). Adapted from 
(Chen et al. 2016).  
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Research has also suggested survivin may enhance levels of telomerase, which is 
responsible for the maintenance of the telomeres, preventing DNA damage and cell 
death (Endoh et al. 2005). The paper suggests survivin enhances the transcription of 
human telomerase reverse transcriptase (hTERT) leading to enhanced telomerase 
activity (Endoh et al. 2005). The emerging roles of survivin support a key role for this 
protein in tumourigenesis and indicate treatment strategies which lower levels of this 
protein could be successful.  
 
8.2 Survivin transcripts 
The BIRC5 gene is composed of six exons and is transcribed into at least six different 
transcripts. The wildtype transcript is 142 aa and this translates into a 16 kDa protein 
and has been widely studied. Alternatively spliced variants include survivin 2B (18 
kDa), survivin ∆Ex3 (15 kDa), survivin 2α (8 kDa), survivin 3α (7 kDa) and survivin 3B 
(13 kDa) (Necochea-Campion et al. 2013). The resulting proteins arising from the 
different isoforms all share the same N-terminus (preserving the region known to 
interact with the apoptotic pathway) but differ in the C-terminus (Necochea-Campion et 
al. 2013). The alternative splice variants survivin 2B and survivin ∆Ex3 were discovered 
earlier and therefore have been investigated more frequently than the other variants 
(Necochea-Campion et al. 2013). 
 
8.3 Survivin expression 
Survivin localises to the cytosol, mitochondria, nucleus and the mitotic apparatus 
(Altieri 2008). Normally survivin is highly expressed in embryonic and fetal organs, 
whilst in adult normal cells it is mostly undetectable. The following adult normal cells do 
express survivin; thymocytes, CD34+ bone marrow derived stem cells and basal 
colonic epithelial cells (Altieri 2008). The regulation of survivin expression is controlled 
by a wide range of pathways including; microRNA, RTK, PI3K/AKT, MEK/MAPK, NF-
kB, mTOR, STAT3, p53, Wnt, hypoxia, TGF and Notch (Chen et al. 2016).  
 
8.4 Survivin and cancer 
In contrast to the majority of adult normal tissues survivin expression is high in 
tumourigenesis and this has been shown in the following cancers; colorectal, lung, 
breast, oesophagus, stomach, pancreas, liver, uterus, ovaries, leukemia, lymphoma, 
neuroblastoma, phaechromocytoma, sarcomas, gliomas and melanoma (Kaneko et al. 
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2007; Altieri 2003). Survivin overexpression is believed to be caused by transcriptional 
deregulation and would confer cells with a growth and survival advantage. Many 
deregulated pathways in cancer are involved in the transcriptional regulation of survivin 
and these pathways could be responsible for the overexpression of survivin in cancer. 
For example TP53 mutations are common in cancers and only wildtype p53 can 
negatively regulate survivin expression (Chen et al. 2016). Research has shown 
patients with tumours expressing survivin is linked to poor survival, higher risk of 
recurrence and resistance to treatments (Altieri 2003). Therefore targeting survivin is a 
potential therapeutic strategy being investigated (Chen et al. 2016). 
 
8.5 Survivin in normal colon cells and colorectal cancer 
In CRC it is hypothesised that levels of survivin are high because it is a Wnt target 
gene and the majority of CRC display hyperactivation of the Wnt signalling pathway 
(Altieri 2003). Other pathways could equally be responsible but the Wnt pathway is 
likely to play a large role in CRC. Several papers have linked high survivin expression 
to poor prognosis in CRC (Kawasaki et al. 1998; Sarela et al. 2000). There is some 
controversy over survivin levels in normal colon cells. Kawasaki et al. (1998) reported 
survivin is not expressed in normal cells. Sarela et al. (2000) suggested expression is 
lower than in tumourigenic cells. Gianani et al. (2001) found survivin expression was 
restricted to the crypt. The differences reported from these studies could be down to 
the technique used to detect survivin expression and the methodology. Many studies 
indicate survivin is expressed in basal colonic epithelial cells and it has been suggested 
that APC and survivin are important regulators of colon homeostasis, Zhang et al. 
(2001) showed survivin levels are highest at the lower crypt, protecting the stem cells 
which are essential for the colon renewal process. APC is thought to negatively 
regulate survivin levels at the crypt through the Wnt signalling pathway. APC 
expression is highest at the top of the crypt. Therefore when APC is mutated survivin 
expression is no longer regulated resulting in constitutive expression, promoting cell 
survival and growth (Zhang et al. 2001). This highlights the importance in CRC 
between APC, Wnt signalling and survivin.  
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9 Rho protein family 
9.1 Roles and regulation 
The Rho family is part of the Ras superfamily of small GTPases and consists of at least 
20 proteins in eight subgroups (Wennerberg & Der 2004; Hodge & Ridley 2016). The 
majority of our understanding of this family comes from the study of classical members; 
ras homolog gene family member A (RhoA), Rac1 and Cdc42 (Roberts et al. 2008). 
Rho proteins have roles in regulating cytoskeletal rearrangements, cell motility, cell 
polarity, axon guidance, vesicle trafficking and the cell cycle (Hodge & Ridley 2016). As 
GTPases Rho proteins alternate between an inactive (GDP bound) and active (GTP 
bound) state and this process is regulated by GEF, GAP and guanine nucleotide 
dissociation inhibitors (GDI). GEF exchange GDP for GTP therefore converting Rho 
proteins into the active state. GAP increase the rate of GTP hydrolysis, resulting in the 
inactivation of Rho proteins. GDI bind prenylated inactive Rho proteins (bound GDP), 
inhibit the dissociation of GDP and inhibit GTP hydrolysis, therefore preventing the 
activation of Rho protein effectors (Figure 17) (DerMardirossian & Bokoch 2005). GDI 
play a role in the cycling of Rho proteins between the cytosol and membranes. The 
isoprenoid added by prenylation hide in a pocket on the GDI, therefore the GDI must 
be displaced to allow the Rho protein to associate with the membrane and activate 
downstream effectors. To end the signal propagation GDI rebind to Rho proteins 
causing dissociation from the membrane (DerMardirossian & Bokoch 2005). 
Spatiotemporal regulation is very important for GTPases to ensure the correct 
downstream signalling pathways are activated. The pathway activated depends on the 
stimulus and cell type (Hodge & Ridley 2016). Multiple post translational modifications 
play an important role in this regulation. Lipid modifications including prenylation (see 
section 7.2.1) and s-palmitoylation make the proteins more hydrophobic, helping to 
determine localisation to specific membrane compartments. A factor independent of 
lipid modifications which also controls localisation is the presence of polybasic residues 
near the C-terminus. Additionally, if phosphorylation occurs near the lipid modification 
then this can also influence the localisation. Phosphorylation also regulates the activity 
of Rho proteins, if the phosphorylation occurs within the GTPase domain then this 
either affects the cycling between GTP and GDP or the interaction with downstream 
effectors. Ubiquitination and sumoylation regulates the turnover of Rho proteins (Hodge 
& Ridley 2016). All these post translational modifications play an important role in 
regulating the proper activation of Rho proteins and initiating the appropriate 
downstream signalling pathways. 
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Figure 17 The Rho family are GTPases 
The main proteins involved in altering the cycling of Rho proteins between inactive and 
active state.  
 
9.2 Localisation of Rho proteins 
Rho proteins can be found in many cellular compartments including; cytosol, 
endoplasmic reticulum (ER), plasma membrane, golgi, endosomes, nuclear envelope, 
endomembranes, mitochondria and vesicles (Roberts et al. 2008). Each Rho protein 
localises differently, for example Rac1 is localised to the plasma membrane and 
cytosol, in comparison Cdc42 is localised to the plasma membrane, golgi, ER and 
nuclear envelope (Roberts et al. 2008). The localisation to specific compartments is 
essential to the downstream functions of each Rho protein and is influenced by 
different factors. Currently the factors are not completely understood for all Rho 
proteins. For localisation to membranes prenylation is the first and essential step, it 
provides proteins with a hydrophobic C-terminal, enabling the protein to associate with 
membranes (Seabra 1998; Wang & Casey 2016). Mutation of the -CAAX in Rac1 (site 
required for prenylation), results in reduced activation of the Rac1 effector p21 
activated kinase 1 (Pak1), due to Rac1 mislocalisation (del Pozo et al. 2000).  
 
Introduction Page 69 
 
Prenylated proteins have a high affinity to the ER, Rho proteins localising to the ER do 
not require further modification eg Cdc42 (Michaelson et al. 2005). Further modification 
after prenylation involves the cleavage of -AAX amino acids by the endoprotease Ras-
converting enzyme 1 (Rce1), this enables the addition of a methyl group to the 
prenylated cysteine residue by isoprenylcysteine-O-carboxyl methyltransferase (Icm1) 
(Roberts et al. 2008). Some Rho proteins will then be further modified by the 
attachment of palmitate groups on cysteine residues, which promotes localisation to 
the plasma membrane (Bustelo et al. 2007; Michaelson et al. 2005). There is currently 
debate whether the steps mediated by Rce1 and Icm1 are essential for membrane 
localisation for all Rho proteins, this is due to conflicting data on the effects of mutating 
Rce1 and Icm1 on Rho protein localisation (Michaelson et al. 2005; Roberts et al. 
2008). Other factors influencing the localisation of Rho proteins include the presence of 
additional structural determinants and the activation of upstream signalling (discussed 
in 9.3.3).  
 
9.3 Rac1  
Rac1 is part of the Rac subgroup of the Rho family and plays a role in regulating 
intracellular adhesion, membrane ruffling, cell migration and proliferation (Jamieson et 
al. 2015). 
 
9.3.1 Rac1 and tumourigenesis 
Evidence suggests Rac1 is commonly overexpressed in tumours and is considered to 
be a driver of tumourigenesis. The importance of Rac1 in CRC has been shown in 
various studies. In intestinal stem cells, Rac1 activation has been shown to be 
upregulated after APC loss and the upregulation of active Rac1 triggers ROS 
production and NF-kB activation, promoting tumour initiation (Myant et al. 2013). Rac1 
may also play a role at later stages of CRC too. The SW620 cell line (lymph node 
metastasis from a colorectal adenocarcinoma) was altered to overexpress Rac1 or lack 
Rac1 and these cell lines were orthotopically injected into the cecal wall of athymic 
nude mice. The overexpression of Rac1 accelerated tumourigenesis whilst the 
suppression of Rac1 expression inhibited tumour formation (Espina et al. 2008). This 
research supports a key role for Rac1 in promoting CRC tumourigenesis.  
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9.3.2 Rac1 and Wnt signalling 
The Wnt signalling pathway is particularly important in CRC and Rac1 is proposed to 
have a role in the canonical Wnt signalling pathway, but the exact mechanism is 
currently disputed. The first potential mechanism involves active Rac1 activating c-jun 
n-terminal kinase 2 (JNK2), JNK2 then phosphorylates β-catenin at ser191 and ser605. 
The phosphorylation of β-catenin at these residues is required for β-catenin to 
translocate to the nucleus (Wu et al. 2008). The second mechanism also involves Rac1 
activating JNK2 and JNK2 phosphorylating β-catenin at the same residues, however 
the phosphorylation of β-catenin is thought to enhance β-catenin binding to TCF/LEF 
and not the transport of β-catenin into the nucleus (Jamieson et al. 2015). 
 
9.3.3 Rac1 and localisation 
Rac1 is found in the cytosol and at the plasma membrane, the majority of Rac1 is in 
the cytosol (Das et al. 2015). In addition to prenylation many factors contribute to Rac1 
localising at the plasma membrane, Rac1 does not undergo palmitoylation, this 
modification helps other proteins to localise to the plasma membrane (Roberts et al. 
2008). Rac1 does contain a specific polybasic amino acid sequence upstream of the 
CAAX sequence and this contributes towards Rac1 localisation at the plasma 
membrane. Mutation of this sequence causes less Rac1 to accumulate at the plasma 
membrane (Del Pozo et al. 2002). Interestingly, a slight variation in this sequence 
contributes to Rac2 localising to the endosome (Bustelo et al. 2007). The signalling 
mechanisms contributing to Rac1 localisation are still under investigation and here are 
some of the current ideas. Research suggests integrins potentially increase the affinity 
of membranes to Rac, promoting Rac dissociation from GDI and activation of 
downstream effectors (Del Pozo et al. 2002). This would enable activation at specific 
sites, which is essential for Rac processes such as the formation of lamellipodia (Del 
Pozo et al. 2002). Another suggested mechanism involves GTPase ADP-ribosylation 
factor 6 (ARF6) (part of the endocytosis pathway) which is thought to play a role in 
transporting Rac1 from the endosomes to the plasma membrane (Symons 2000; 
Palamidessi et al. 2008). Additionally, a recent paper suggests phospholipids play a 
role in localising Rac1 to the plasma membrane (Das et al. 2015). At the moment it is 
not clear whether these are distinct or overlapping mechanisms enabling Rac1 to 
localise at the plasma membrane.  
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Due to the importance of APC in the development of CRC we investigated ways to 
target APC using the concept of synthetic lethality. We created an in vitro model using 
CRISPR-cas9 to mutate APC, resulting in the following; control cell lines (APC WT) 
and APC mutant cell lines (APC Lys736fs). We used this model to perform siRNA and 
compound screens to identify synthetic lethal relationships with mutated APC. We 
investigated a potential synthetic lethal relationship between APC and the mTOR 
pathway in our in vitro model. Our research focused on investigating the synthetic 
lethal relationship between statins and mutant APC in our in vitro model. Statins have 
been shown to have an impact on Rho proteins (including Rac1) and Rac1 plays a key 
role in CRC, therefore we focused on analysing if Rac1 was involved in the 
mechanism. We also analysed the involvement of the anti-apoptotic protein survivin in 
the mechanism. This enabled us to suggest a potential mechanism explaining the 
synthetic lethal relationship we see between the APC mutation and statins.  




The tumour suppressor gene Adenomatous polyposis coli (APC) is commonly mutated 
in over 80 % of patients with colorectal cancer (CRC) (Fearon 2011). Designing 
therapies against the loss of APC has the potential to treat a large number of patients. 
The development of targeted therapies against EGFR, VEGF and PD-1 has resulted in 
new options for CRC (Chee & Sinicrope 2010; Marginean & Melosky 2018). Our aim 
was to uncover new therapeutic strategies specific for CRC patients with APC 
mutations by using the concept of synthetic lethality. This strategy is ideal for tumour 
suppressor genes because you can indirectly target APC by targeting another gene, 
resulting in cell death specific to the cells with the APC mutation (Figure 18). 
1) Create an in vitro model of APC mutation in a wildtype APC CRC cell line 
2) Identify synthetic lethal interactions with the APC mutation using an siRNA kinome 
screen and FDA-approved compound screen 





Figure 18 The synthetic lethality approach 
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1 Cell culture 
1.1 Cell lines and reagents 
The human colorectal cancer cell lines DLD1, HCT116, HT29, RKO, SW48, SW620 
were obtained from ATCC and the human embryonic kidney cell line HEK293T was a 
kind gift from the Sharp lab, Barts Cancer Institute (BCI). HCT116, HEK293T, HT29, 
RKO, SW48 and SW620 were all grown in Dulbecco’s Modified Eagles medium 
(DMEM) supplemented with heat inactivated fetal bovine serum (FBS) (10 % v/v) and 
penicillin-streptomycin (1 % v/v). DLD1 were grown in Roswell Park Memorial Institute 
(RPMI) supplemented with FBS (10 % v/v) and penicillin-streptomycin (1 % v/v). FBS 
was from Gibco and the following reagents were purchased from Sigma; DMEM, 
trypsin-EDTA, penicillin-streptomycin. 
 
1.2 Growing and seeding conditions 
All cells were routinely grown in T75 flasks and maintained at 37 °C, 5 % CO2. Stocks 
were kept frozen in FBS supplemented with 10 % dimethyl sulfoxide (DMSO) in -80 °C 
and liquid nitrogen. Depending on the cell line, cells were passaged every 2-4 days 
when 70-90 % confluent and grown for 10 passages. Cells were routinely visually 
checked, tested for mycoplasma and STR profiled. To passage the cells the media was 
removed and the cells were washed with 1x phosphate buffered saline (PBS), then 3 
mLs 1x trypsin was added to the flasks and incubated for 5 mins at 37 °C or until cells 
detached. Next the 1x trypsin was neutralised with 7 mLs media and spun down at 
1200 rpm for 3 mins to pellet the cells. Finally the media was removed and the cells 
resuspended in fresh media and a proportion of the cells were transferred to a new 
flask depending on the experiments planned. 
To seed cells the same protocol was followed as described for passaging, up until fresh 
media was added. Next after seeding a new flask the cells were counted, for this 10 μL 
cell suspension was added to the dual chamber cell counter slides (Bio-rad)/countess 
cell counting chamber slides (Invitrogen) and counted using the TC20 cell counter (Bio-
rad)/Countess II automated cell counter (Life technologies). Next depending on the size 
and setup of the experiment the appropriate number of cells were added to media and 
plated. 
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1.3 Proliferation assay 
Cells were plated at a density of 1000 cells/well in five 96 well plates and labelled day 
0, day 1, day 2, day 3 and day 4. Cell viability was measured using CellTiter-glo (CTG) 
and the luminescence setting on the Perkin Elmer 1420 multilabel counter victor 3 plate 
reader (Section 7). The day 0 plate was read six hours after plating to account for 
differences in the starting number. Subsequent plates were read every 24 hours. The 
fold difference was calculated by dividing every value by the average day 0 value for 
the cell line. The fold difference was plotted on a graph. The doubling time was then 
calculated, using just the time period representing linear growth. For example we saw 
this between day 2 and day 4. We then used the fold change values to calculate 
doubling time (Td) (Uzbekov 2004). 
Td=t / log2 (N1/N0) 
t=time between two time points, N0 = cell number at start, N1 = cell number at end 
 
2 CRISPR-cas9 
2.1 Designing the gRNA 
To design APC targeted gRNA, we used the gRNA design tool from DNA2.0 (now 
renamed to Atum), see table 1 for the sequences and target locations. 
https://www.atum.bio/eCommerce/cas9/input   
Name gRNA sequence Exon targeted 
gRNA APC #2 TTGGCATCCTTGTACTTCGC 15 
gRNA APC #3 GCATGTTAGTTTTACACCGG 15 
gRNA APC #4 AGCATGTTAGTTTTACACCG 15 
gRNA APC #5 TTTTATGGGCTAGGTCGGCT 15 
gRNA APC #6 CCTATTATCATCATGTCGAT 15 
gRNA APC #8 GATTTATTAGAGCGTCTTAA 2 
gRNA APC #9 GATGAAGCTATGGCTTCTTC 2 
Table 1 The gRNA used to target APC 
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2.2 Dharmacon Edit-R approach 
We ordered custom Edit-R crRNA from Dharmacon, see table 1 for sequences. On day 
1 60,000 cells/well were plated into a 24 well plate. On day 2 cells were transfected 
with Edit-R cas9 expression plasmid with puromycin resistance, Edit-R synthetic 
tracrRNA and Edit-R crRNA targeting APC, using DharmaFECT Duo transfection 
reagent (Dharmacon). Per well we added 3 μL DharmaconDuo reagent, 10 μL cas9 
plasmid, 2.5 μL tracrRNA, 2.5 μL crRNA (either one or combination of two) and made 
the volume up to 100 μL with optimen. We had two controls; 1) received the cas9 
plasmid containing puromycin resistance without crRNA, 2) received the cas9 plasmid 
containing mKate2 (instead of puromycin resistance). After 20 mins incubation the 
transfection mixes were added to the cells. After 24 hours we checked for mKate2 
expression using the fluorescence microscope to check transfection efficiency. On day 
4 0.5 μg/mL puromycin was added to the cells and cells were removed from selection 
on day 8. Single colony selection was started as described in section 2.4. 
 
2.3 Lentivirus approach 
2.3.1 Site directed mutagenesis 
The lentiCRISPRv2 plasmid encoding cas9 and the gRNA were a kind gift from the 
Sharp lab (BCI) and were developed by F.Zhang (Sanjana et al. 2014). We designed 
primers (Table 2) to alter the gRNA sequence in the lentiCRISPRv2 plasmid using the 
Q5 site directed mutagenesis kit (New England Biolabs) with some modifications. Per 
reaction, 12.5 μL of 2x phusion hot start master mix, 1.25 μL 10 μM forward and 
reverse primers, 1 μL of 10 ng template DNA, 0.7 μL DMSO and 8.3 μL water. 
Samples then underwent the following thermocycling conditions; 98 °C for 30 sec, 25 
cycles of 98 °C 10 sec, 61 °C for 20 sec, 72 °C for 3 mins, after the 25 cycles 72 °C for 
5 mins. 
The next step was the kinase, ligase and dpn1 (KLD) reaction involving 1 μL PCR 
product, 1x KLD reaction buffer, 1x KLD enzyme mix and water up to 10 μL, this 
reaction was left to incubate for 5 mins at room temp. The KLD product was then 
transformed into E.coli competent cells (NEB C2987), 2.5 μL KLD product was added 
to 25 μL competent cells and incubated on ice for 30 mins. Next the cells were 
heatshocked for 30 sec at 42 °C, then incubated on ice for 2 mins. Then 500 μL SOC 
media was added and cells were left at 37 °C for 1 hour, then 150 μL was spread onto 
an agar plate and incubated overnight at 37 °C. Colonies were picked and grown up for 
DNA extraction in LB broth using the Qiagen DNA mini prep kit (see section 5.1). After 
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extraction DNA was sequenced to check whether the site directed mutagenesis had 
been successful. 
We sent 1 μg of DNA in 10 μL water and 3.2 pmol/μL primers to Source Bioscience for 
sanger sequencing. LentiCRISPRv2 hU6-F was used to check whether the site 
directed mutagenesis of the gRNA site had been successful (see table 2 for sequence). 




2.3.2 Virus production 
The plasmids required were a kind gift from the Sharp lab (BCI) and were developed by 
L.Naldini (Naldini et al. 1996). The lentiCRISPRv2 plasmids designed to target APC 
were each individually packaged into lentivirus before infecting RKO cells. On day 1, 
HEK293T cells were plated in 6 well plates. On day 2 fugene (Promega) was used to 
transfect HEK293T cells with 1.5 μg lentiCRISPRv2 along with 0.6 μg pCMV 
(packaging) and 1.1 μg pMDG2 (envelope). On day 4 the lentivirus containing media 
from the HEK293T cells was removed and filtered and added to the RKO cell line 
plated in a 6 well plate. Positive cells were then selected for, using 0.5 μg/mL 
puromycin for 10 days. After puromycin selection, cells were single colony selected as 
described in section 2.4. 
 
2.4 Single colony selection 
After puromycin selection, single colony selection was started and we used two 
different approaches. Method one involved plating 200 cells in a 15 cm dish and 
leaving for 14 days. Then individual colonies were picked using filter paper soaked in 
trypsin and transferred to a 96 well plate. The next day the filter paper was removed 
Name Primers (5’-3’) 
gRNA APC #2 F TGTACTTCGCGTTTTAGAGCTAGAAATAGCAAG 
gRNA APC #2 R AGGATGCCAACGGTGTTTCGTCCTTTCC 
gRNA APC #3 F TTTACACCGGGTTTTAGAGCTAGAAATAGCAAG 
gRNA APC #3 R ACTAACATGCCGGTGTTTCGTCCTTTCC 
gRNA APC #4 F TTTTACACCGGTTTTAGAGCTAGAAATAGCAAG 
gRNA APC #4 R CTAACATGCTCGGTGTTTCGTCCTTTCC 
gRNA APC #5 F TAGGTCGGCTGTTTTAGAGCTAGAAATAGCAAG 
gRNA APC #5 R GCCCATAAAACGGTGTTTCGTCCTTTCC 
gRNA APC #6 F TCATGTCGATGTTTTAGAGCTAGAAATAGCAAG 
gRNA APC #6 R TGATAATAGGCGGTGTTTCGTCCTTTCC 
LentiCRISPRv2 hU6-F GAGGGCCTATTTCCCATGATT 
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and the colonies were expanded. Method two involved seeding 0.8 cells per well in a 




Firstly we extracted DNA from cell pellets, see section 5.2. Next we amplified the 
region around the target site gRNA #2 using the primers gRNA 2F and gRNA 2R 
(Table 3 shows the primer sequences). We amplified 250 ng of DNA, per reaction we 
added 10 μL 5x PCR buffer, 1 μL 10 mM dNTP, 1 μL of both forward and reverse 
primers at 10 μM, 0.25 μL One Taq hot start DNA polymerase and water up to 50 μL. 
The thermocycling reaction was as follows; 94 °C for 30 sec, 30 cycles of 94 °C 20 sec, 
59 °C 30 sec, 68 °C 60 sec then 68 °C for 20-30 mins. After amplification we ran the 
PCR products on a 1 % TBE agarose gel to check for a single band of the correct size 
as described in section 5.3. 
Next we used the pcDNA4/HisMax TOPO TA Expression kit (Thermofisher). To 
perform the topocloning reaction we used 4 μL of the PCR product from the 
amplification and combined it with 1 μL salt solution and 1 μL TOPO vector and left this 
to incubate for 5-20 mins at room temperature. After the incubation the reaction was 
then stored on ice. Next 2 μL of the topocloning reaction was transformed into 25 μL 
chemically competent E.coli and incubated on ice for 30 mins. After the incubation the 
cells were heat shocked for 30 sec at 42 °C, then 250 μL SOC medium was added. 
Then the cells were left to shake at 37 °C for an hour and spread on agar plates to 
grow overnight. The next day clones were then picked to grow overnight in 4 mL LB 
with amplicillin at 100 μg/mL, DNA was extracted as in section 5.1 using the DNA mini 
kit. Samples were sent for sequencing with GATC, the DNA at 50 ng/μL and 10 μM 
XpressTM forward primer (Table 3 for primer sequence). 
 
Primer Sequence 5’-3’ 
Xpress™  forward  TATGGCTAGCATGACTGGT 
gRNA 2F  CCCCCTGCAAATGTTTTAAGCTA 
gRNA 2R  GGAGATCTGCAAACCTCGCT 
Table 3 Primers used in topocloning to sequence the 
alterations to the APC gene 
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3 Protein expression analysis 
3.1 Extraction 
All steps were performed on ice. Firstly cells were washed with PBS twice and then 
lysed with 100-200 μL NP-40 buffer (20 mM tris (pH 8.0), 200 mM NaCl, 0.5 % NP-40, 
10 % glycerol, 1 mM EDTA) with protease inhibitor (Roche) and incubated for 10 mins. 
Cells lysed from plates were scraped and transferred to tubes and incubated for a 
further 15 mins. After incubation the lysates were centrifuged for 20 mins at 4 °C for 
12,000 rpm. The supernatent was transferred to a new tube and stored at -80 °C. The 
protein concentration was measured using the bradford reagent along with bovine 
serum albumin (BSA) to create a standard curve (both Sigma). 
 
3.2 Western blotting 
For western blotting, 10-90 μg of lysate was combined with 10 % dithiothreitol (DTT) 
and 4x NuPage LDS samples buffer (Invitrogen) to a maximum final volume of 37 μL. 
After preparation lysates were denatured by incubation for 5 mins at 95 °C and 
electrophorised on Novex precast gels (Invitrogen) 3-8 % tris acetate, 4-12 % tris 
glycine or 10% bis tris using either 20x NuPAGE tris acetate SDS running buffer, 20x 
NuPAGE MOPS SDS running buffer or 20x NuPAGE MES SDS running buffer 
respectively. The gels were run for 1 hour 30 mins to 2 hours at 120 V, the protein was 
then transferred onto nitrocellulose membrane (Thermoscientific) using a wet transfer 
system for 2 hours at 25 V. 
The membrane was blocked in 5 % milk/0.1 % tween/1x TBS for an hour and 
immunoblotted in primary antibody (Table 4), typically in 5 % milk/0.1 % tween/1x TBS 
overnight at 4 °C. Next the membranes were washed three times for 5-10 mins in 0.1 
% tween/1x TBS. After washing, the membranes were incubated in either anti-rabbit or 
anti-mouse secondary anti-IgG-horseradish peroxidase (Invitrogen/Dako), for one hour 
at room temperature. After incubation in secondary antibody the membranes were 
washed as before and chemiluminescence was added to allow detection of the protein 
of interest (SuperSignal West Pico Chemiluminescent Substrate, Pierce). 
Immunoblotting for β-actin or β-tubulin was used as a loading control. The signal was 
developed either onto x-ray films or using the Amersham Imager 600. 
For quantification of western blots we used the image analysis software ImageQuant 
TL 8.1 (GE healthcare). The intensity of the band was measured by drawing a box 
around the first band, this same box was copied and placed around the remaining 
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bands on the blot. Background was subtracted by drawing a box above or below every 
band to account for differences in background across the blot. The software subtracts 
the background then calculates the percentage density for each band highlighted on 
the blot relative to one another. 
 
Antibody name Company and code Standard dilution 
APC ALi 12-28 Abcam ab58 1:1000 
APC 2504 Cell signaling 2504  1:250 
APC C28.9  Santa Cruz sc-53166 1:250 - 1:500 
β-actin-HRP  Cell signaling 5125 1:1000 - 1:20,000 
β-catenin unphosphorylated 
ser33/ser37/thr41  
Cell signaling 4270  1:5000 
β-catenin total Abcam ab32572 1:10,000 
HMGCR Abcam ab174830 1:1000 
mTOR phosphorylated 
ser2448 
Cell signaling 2971 1:1000 
mTOR total Cell signaling 2972 1:1000 
Pak1 phosphorylated ser144 Cell signaling 2606 1:1000 
Pak1 total Cell signaling 2602 1:1000 
Rac1 total From Rac1 pull down kit 
(Thermoscientific #16118) 
1:1000 
Rho total From Rho pull down kit 
(Thermoscientific #16116) 
1:650 
SMAD4 Cell signaling 9515 1:1000 
Survivin Abcam ab76424 1:1000 
β-tubulin  Sigma T8328 1:10,000 - 1:20,000 
Secondary mouse Invitrogen 62-6520 1:5000 
Secondary mouse Dako P0260 1:5000 
Secondary rabbit Invitrogen 62-6120 1:5000 
Secondary rabbit Dako P0448 1:5000 
 
Table 4 Antibodies used for western blotting 
 
 
4 RNA expression analysis 
4.1 Extraction 
The Qiagen RNeasy mini kit was used to extract RNA from either pelleted cells or cells 
grown as a monolayer in a 6 well plate. After trypsinisation, 2x106 cells were pelleted at 
300 g for 5 mins and the media was removed leaving the pellet. Next lysis buffer RLT 
was added to the cell pellet and mixed by pipetting up and down to homogenise the 
sample. Alternatively cells were grown as a monolayer on a 6 well plate, next the 
media was removed and lysis buffer RLT was added. After addition of buffer RLT the 
cells were scrapped and the resulting mixture was transferred to a 1.5 mL tube. After 
lysis with RLT buffer, 70 % ethanol was added to the sample and the sample was 
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transferred to an RNeasy spin column. The column was then spun for 15 sec at 8000 g 
and the flow through discarded. Next the wash buffer RW1 was added, the column 
spun and the flow through discarded. The wash steps were repeated twice with the 
wash buffer RPE, initially 15 sec spin at 8000 g followed by a second wash for 2 mins 
at 8000 g. After washing, the spin column was placed in a new collection tube and 
centrifuged for 1 min without any buffer. Finally the RNA was eluted by adding RNase 
free water to the centre of the column and then centrifugated for 1 min at 8000 g. The 




Firstly cDNA was generated using the Qiagen Omniscript reverse transcription kit. 
Water was added to 1 μg RNA to bring the volume up to 12 μL, next 8 μL mastermix 
was added which contained a final concentration of 1x RT buffer, 0.5 mM each dNTP, 
1 μM Oligo-dt primer, 10 units of RNase inhibitor, 4 units of omniscript reverse 
transcriptase. Tubes were then incubated at 37 °C for 60 mins to generate cDNA. 
For RT-PCR the ddCT method was used, for each sample we ran reactions containing 
taqman probes for housekeeping genes (GAPDH Vic-Tamra probe #4310884E, 
Applied Biosystems or β-actin Vic-Tamra probe #4310881E) and probes for the gene of 
interest (APC FAM-MGB probe hs01568269.m1, Applied Biosystems #4331182) in 
triplicate. We made a mastermix per probe containing; 10 μL TaqMan universal PCR 
master mix (Applied Biosystems #4304437), 8 μL H2O and 1 μL probe. To each well 19 
μL mastermix was added to the MicroAmp optical 96 well PCR plate (Applied 
Biosystems #N8010560). Next we added 1 μL of the appropriate cDNA to the PCR 
plate and added water to the no template control (NTC). The RT-PCR was run using 
the 7500 real time PCR system (Applied Biosystems)/Quantstudio5 real time PCR 
system (Thermofisher). To calculate the ddCT firstly the means were calculated for 
each cDNA reaction with either housekeeping or the probe of interest. Then the mean 
ct of the housekeeping is subtracted from the mean ct of probe of interest and this 
gives you the dCT. To calculate the ddCT you subtract the dCT of the cDNA you wish 
to normalise to. Finally the 2^(ddCT) is calculated and this is the value plotted on the 
graphs. 
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5 DNA extraction and analysis 
5.1 Extraction from bacteria 
Extracting small amounts of DNA using the DNA mini prep kit (Qiagen) involved picking 
bacterial colonies to grow overnight in 5 mL of lysogeny broth (LB) (with antibiotic) and 
incubated overnight at 37 °C. The bacterial cells were then harvested by centrifugation 
at 8000 rpm for 3 mins. The supernatant was removed and 250 μL resuspension buffer 
P1 was added to the bacterial cell pellet. Next 250 μL lysis buffer P2 was added and 
the tube was inverted six times. Next 350 μL neutralisation buffer N3 was added and 
the tube was inverted six times. The tube was then centrifuged for 10 mins at 13,000 
rpm, the supernatant was kept and then transferred to a QIAprep spin column. The 
column was centrifuged for 1 min and the flow through was discarded. Next 500 μL 
wash buffer PB was added and centrifuged for 1 min. After centrifugation the flow 
through was discarded and 750 μL wash buffer PE was added and the column was 
centrifuged for 1 min. The final flow through was discarded and the column was spun 
again for 1 min. Finally the DNA was eluted with water by adding water to the column 
and spinning the column to elute the DNA from the membrane. DNA concentration and 
purity was measured using a nanodrop (ND-1000/ND-2000 Thermofisher). 
 
5.2 Extraction from cell pellet 
DNA was extracted from a cell pellet using the DNeasy blood and tissue kit (Qiagen). 
Firstly 2x106 - 4x106 cells were pelleted by centrifugation for 5 mins at 300 g. The 
media was removed and the pellet was resuspended in 200 μL PBS, then 20 μL 
proteinase K and 200 μL lysis buffer AL was added, vortexed and the mixture was 
incubated at 56 °C for 10 mins. After the incubation 200 μL 100 % ethanol was added 
and the sample was vortexed thoroughly and added to a DNeasy mini spin column, 
then centrifuged at 6000 g for 1 min. The flow through was discarded and the spin 
column was placed in a new collection tube. Next 500 μL wash buffer AW1 was added, 
the column spun as before, flow through discarded and then placed in a new collection 
tube. Next 500 μL wash buffer AW2 was added and the column was centrifuged for 3 
mins at 20,000 g to dry the membrane in the column. The DNeasy spin column was 
then placed in a new 1.5 mL tube and 200 μL elution buffer AE was added, incubated 
for 1 min before centrifugation for 1 min at 6,000 g to elute the DNA. DNA 
concentration and purity was measured using a nanodrop (ND-1000/ND-2000 
Thermofisher). 
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5.3 Agarose gels 
Agarose gels (1%) were made by melting agarose in 1x TBE in a microwave, once fully 
dissolved and cooled to hand touch, the agarose was poured into a mould and a comb 
was added. Once set the gel was placed in the agarose gel apparatus and topped up 
with 1x TBE. To the first well 1 μL Thermo Scientific GeneRuler 1 kb plus DNA ladder 
(SM1333) was added and the remaining wells contained 1 μL sample mixed with 2 μL 
2 x loading dye (diluted from Biolabs gel loading dye purple 6x (B7024S)). The gel was 
run at 100 W for 1 hour and visualised with the G Box. 
 
6 TCF/LEF Reporter Assay 
For this assay reporter constructs were obtained from the Cignal TCF/LEF reporter 
assay kit; positive, negative and reporter (Qiagen). The luciferase signal was read 
using the dual luciferase reporter assay (Promega). 
 
6.1 Reporter constructs transfection 
We transfected 1 μL reporter constructs per well using either lipofectamine 2000 
(Invitrogen) or fugene. When lipofectamine 2000 was used the standard siRNA 
protocol was followed (Section 9.2). If fugene was used we made a mastermix of 
optimen, reporter construct and fugene, per well this contained 24.75 μL optimen, 1 uL 
reporter construct and 0.25 μL fugene. The mastermix was incubated for 10-15 mins 
and then 25 μL was added to a well containing 75 μL of media. On day 5 the plates 
were read using the dual luciferase reporter assay (Section 6.4). 
 
6.2 siRNA and reporter constructs transfection 
To transfect both siRNA and the reporter constructs into the cells, two methods were 
used. Method one involved plating cells on day 1 in a 96 well plate and on day 2 cells 
were transfected using the standard siRNA protocol (Section 9.2) with both 2.5 μL 2 
μM siRNA and 1 μL reporter constructs. The assay was read on day 5 using the dual 
luciferase reporter assay (Section 6.4).  
Method two involved plating cells on day 1 in a 96 well plate then the siRNA was 
transfected on day 2 (Section 9.2) and reporter constructs on day 3 using fugene 
(Section 6.1 describes fugene protocol). The plates were read on day 6 using the dual 
luciferase reporter assay (Section 6.4). 
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6.3 Reporter constructs transfection and compound treatment 
To transfect the constructs and follow with compound treatment, the cells were plated 
on day 1, then 1 μL reporter constructs were transfected with fugene on day 2 (Section 
6.1 describes fugene protocol). The cells were then drugged on day 3 and the plates 
were read on day 6 using the dual luciferase reporter assay. 
 
6.4 Dual luciferase reporter assay 
Media was removed from cell culture plates and the plates were firstly washed with 
PBS, next 20-30 μL of 1x passive lysis buffer (PLB) was added to each well. Then the 
plates were shaken for 15 mins at room temperature. After the incubation the cell 
lysates was transferred to a white bottom plate and 100 μL luciferase assay reagent II 
(LARII) substrate was added to the wells and the luminescence read immediately on 
the plate reader. After the first measurement 100 μL stop and glow reagent was added 
to the same wells and the luminescence was read again. To analyse the LARII values 
were divided by the stop and glow values, then values were normalised to the control 
condition negative control. When different cell lines were run in the same assay the 
data was first normalised to the cell lines average positive control before normalising to 
the average control cell line negative control. 
 
7 CellTitre-glo luminescent cell viability assay 
The CTG was diluted 1:4 with PBS, then the cell culture media in the 96 well plate was 
removed and 100 μL diluted CTG was added to each well. The plate was shaken for 2 
mins at a low speed, then left at room temperature covered from the light for 10 mins. 
After incubation the plate was read on the plate reader using the luminescence setting. 
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8 High through-put screens 
8.1 siRNA kinase screen 
8.1.1 Initial screen 
The Dharmacon human siGENOME siRNA protein kinase library targets protein 
kinases and kinase-related genes and was used at a concentration of 50 nM. The 
library was aliquoted over 9 x 96 well plates, each plate contained 5 μL of 2 μM siRNA 
and this was enough to transfect two cell line culture plates. The first and last column 
were left empty to add four wells per control; media alone (no transfection mix), mock 
(water with transfection mix), non-targeting control siRNA (siCON) and polo like kinase 
1 (PLK1) targeting siRNA (siPLK1). 
On day 1 1000-2000 cells were plated per well in a 96 well plate. On day 2 50 μL 
transfection mix was added to the kinome library after a 5 minute incubation containing 
49.5 μL optimen and 0.5 μL lipofectamine RNAimax transfection reagent (Invitrogen) 
per well. The plates were then incubated for 20 mins, after the incubation 160 μL media 
was added to each kinome plate. The media was then removed from two cell culture 
plates and 100 μL transfection mix/media was added from the kinome plate to each cell 
culture plate. After 4-5 hours the media was changed and plates were read using CTG 
on day 5 or 6 depending on the cell confluency (Section 7). 
To analyse the screen data the luminescence readings from each well were firstly log 
transformed, then normalised to the median signal on each plate. The data was then 
standardised to Z scores using the medium absolute deviation (MAD), this assumes a 
normal distribution of cell viability. 
Z score = X  - median (sample)          MAD(sample) = mediani (|Xi - medianj (Xj)|)
      MAD (sample) 
                    
Z scores enable us to see the effect of individual siRNA compared to the rest of the 
screen. We compared two cells lines and used Z scores to calculate the ∆Z score  
∆Z score = Z score (RKO APC mut) – Z score (RKO APCwt) 
Any siRNA responsible for a ∆Z score <-1.5 potentially targets a gene which is 
synthetically lethal with the APC mutation. 
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8.1.2 Validation 
Seven hit genes were selected for validation from the siRNA kinome screen. A 
personalised 96 well plate (GE Healthcare) was ordered with the siRNA SMARTpool 
and four individual siRNA (deconvoluted from the SMARTpool siRNA) for each hit gene 
(Table 5 shows siRNA details). This library was aliquoted like the original screen into 
96 well plates, each plate contained enough for two cell lines (5 μL of 2 μM siRNA). 
Controls were added; siCON and siPLK1 to access the transfection efficiency. The 
protocol was the same as the siRNA screen (Section 8.1.1). The only difference was 
the way the data was analysed, for the validation experiments survival fractions were 
calculated from the CTG readings by normalising to the average value from the siCON 
wells. 
Name siRNA Manufacturer Code 
NAGK (Pool) Dharmacon M-006750-01 
NAGK *1 Dharmacon D-006750-01 
NAGK *3 Dharmacon D-006750-03 
NAGK *4 Dharmacon D-006750-04 
NAGK *7 Dharmacon D-006750-17 
DYRK2 (Pool) Dharmacon M-004730-03 
DYRK2*1 Dharmacon D-004730-01 
DYRK2*2 Dharmacon D-004730-02 
DYRK2*3 Dharmacon D-004730-03 
DYRK2*5 Dharmacon D-004730-05 
FN3KRP (Pool) Dharmacon M-006817-00 
FN3KRP*1 Dharmacon D-006817-01 
FN3KRP*2 Dharmacon D-006817-02 
FN3KRP*3 Dharmacon D-006817-03 
FN3KRP*4 Dharmacon D-006817-04 
MAP3K15 (Pool) Dharmacon M-004847-02 
MAP3K15* Dharmacon D-004847-01 
MAP3K15 Dharmacon D-004847-02 
MAP3K15 Dharmacon D-004847-03 
MAP3K15 Dharmacon D-004847-04 
N4BP2 (Pool) Dharmacon M-019063-01 
N4BP2*1 Dharmacon D-019063-01 
N4BP2*2 Dharmacon D-019063-02 
N4BP2*3 Dharmacon D-019063-03 
N4BP2*17 Dharmacon D-019063-17 
SMG1 (Pool) Dharmacon M-005033-01 
SMG1*1 Dharmacon D-005033-01 
SMG1*2 Dharmacon D-005033-02 
SMG1*3 Dharmacon D-005033-03 
SMG1*4 Dharmacon D-005033-04 
PIM2 (Pool) Dharmacon M-005359-00 
PIM2*1 Dharmacon D-005359-01 
PIM2*2 Dharmacon D-005359-02 
PIM2*3 Dharmacon D-005359-03 
PIM2*4 Dharmacon D-005359-04 
Table 5 siRNA on the validation plate 
Materials and Methods Page 87 
 
8.2 FDA compound screen 
8.2.1 Initial screen 
The FDA compound library contains 1120 FDA-approved compounds and was 
purchased from Selleck Chemicals. The library was across 14 x 96 well plates and at a 
concentration of 10 mM. The final column contained no drugs to enable controls to be 
added; media only and DMSO (2 μL added per well). The library was diluted to 200 μM 
before use. On day 1 2000 cells/well were plated in 96 well plates. The next day cells 
were treated with 10 μM of each drug, 5 μL of the 200 μM stock was added to 95 μL 
media per well. Cells were re-drugged on day 4 then the cell viability was measured on 
day 6 using CTG (Section 7). 
The analysis followed the same methodology as the siRNA screen, the luminescence 
readings were log transformed and normalised to the median signal on each plate. The 
Z score was calculated to standardise the values and indicated drugs which showed a 
greater loss in cell viability in the RKO APC mutant lines compared to the RKO control 
cells. Any compounds responsible for a Z score <-1.5 in the RKO APC mutant lines 




Promising compounds were selected for validation and are listed alongside other 
compounds in table 6. On day 1 2000 cells/well were plated, on day 2 doses of each 
drug from 0.5 μM to 200 μM were added to the cells to enable a drug dose response 
curve to be made from the data. The plates were drugged again on day 4 and cell 
viability was measured on day 6 using CTG (Section 7). Next survival fractions were 
calculated, by normalising the treated cell viability values to the average vehicle 
(received no drug) cell viability values for each cell line. The survival fractions were 
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Drug name Company and code Stock 
concentration 
Desonide MedChemexpress LLC B0248 20 mM DMSO 
Diclofenac potassium APExBIO B1929 20 mM DMSO 
EHT1864 Sigma E1657 1 mM DMSO 
FTI-277 Santa Cruz sc215058 5 mM water 
GDP From Thermoscientific pull down kit 100 mM 
GGTI-298 Calbiochem 345883 5 mM DMSO 
GTPyS From Thermoscientific pull down kit 10 mM 
Harmine Santa Cruz sc202644 20 mM DMSO 
Losartan potassium Santa Cruz sc204796 20 mM DMSO 
Lovastatin Sigma PHR1285 20 mM DMSO 
Mesalamine Sigma PHR1060 20 mM DMSO 
Mevalonic acid Sigma 79849 20 mM water 
Mevastatin Sigma M2537 20 mM DMSO 
Moxifloxacin HCL Abmole M3514 20 mM DMSO 
3-O-Methyl-N-acetyl-D-
glucosamine 
Abcam (ab144671) 10 mM DMSO 
Rapamycin Cambridge Bioscience SM83-25 10 mM DMSO 
Ridaforolimus ApexBio B1639 10 mM DMSO 
Saxagliptin  Biovision 9528-50 20 mM DMSO 
Simvastatin Sigma S6196  20 mM DMSO 
Tizanidine HCL Santa Cruz SC200148 20 mM water 
Tolnaftate Sigma T6638 20 mM DMSO 
Troxipide APExBIO B1892 20 mM DMSO 
Table 6 compounds used 
 




PLK1 (Pool) Qiagen GS5347 
APC*3 Qiagen S100000588 
APC*6 Qiagen S102757251 
DYRK2*1 Dharmacon D-004730-01 
DYRK2*2 Dharmacon D-004730-02 
NAGK*1 Dharmacon D-006750-01 
NAGK*4 Dharmacon D-006750-04 
N4BP2*2 Dharmacon D-019063-02 
N4BP2 (Pool) Dharmacon M-019063-01 
FLT3 (Pool) Dharmacon M-003137-02 
mTOR (Pool) Dharmacon M-003008-03 
HMGCR (Pool) Dharmacon M-009811-02 
Survivin/BIRC5 (Pool)  Dharmacon M-003459-03 
Table 7 siRNA used 
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9 siRNA Transfection 
Transfections were performed in reduced serum media, optimen (Gibco) and the 
following transfection reagents were used; lipofectamine 2000 and lipofectamine 
RNAimax. Table 7 shows the siRNA used. 
 
9.1 siRNA transfection in a 6 well 
Cells were plated on day 1 100,000-200,000 cells/well. On day 2 250 μL optimen and 
2.5 μL transfection reagent per well were combined and incubated for 5 mins. After the 
incubation 2.5 μL 20 μM siRNA stocks per well were added and incubated for a further 
20 mins. After 20 mins the media was replaced on the 6 well plate and the transfection 
mix was added drop by drop to each well. After 4-5 hours the media was changed and 
lysates or RNA were collected on day 5 (Section 3.1 and 4.1 respectively). 
 
9.2 siRNA transfection in a 96 well 
Cells were plated on day 1 (1000–5000 cells/well). On day 2 mixtures of 24.75 μL 
optimen and 0.25 μL transfection reagent per well were combined and incubated for 5 
mins. After the incubation 2.5 μL 2 μM siRNA stocks per well were added and 
incubated for 20 mins. After 20 mins incubation the media was replaced in the 96 well 
plate and the transfection mix was added. After 4-5 hours the media was changed. 
CTG was used to analyse the results on day 5 or day 6 depending on the cell 
confluence (Section 7). Analysis of CTG values involved calculating the survival 
fraction by normalising to the average of CTG values of cells transfected with siCON. 
 
10 Cell viability upon compound treatment 
10.1 Compounds used 
See table 6 for the compounds used. 
 
10.2 Cell viability 
To look at differences in responses to the compounds in 9.1 a similar approach was 
used as discussed in the FDA compound screen validation. Briefly on day 1 2000 
cell/well were plated, on day 2 (and some re-drugged on day 4 depending on the drug) 
up to six different doses for each drug were added to the cells. Cell viability was 
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typically measured on day 6 using CTG (Section 7), some assays were read after 48 
hours of drug treatment and involved fewer drug concentrations. The cell viability data 
was used to calculate survival fractions by normalising to each cell lines average 
vehicle cell viability (received no drug). The survival fractions were plotted either as bar 
charts or as drug dose response curves enabling comparison between cell lines. 
 
11 Active Rac1 and Rho pull down and detection  
We used the Thermofisher active Rac1 pull down and detection kit (#16118) and the 
Thermofisher active Rho pull down and detection kit (#16116). We collected at least 
500 μg of lysate using the protocol in section 3.1. We performed the in vitro GTPyS and 
GDP treatment to check the assay was working. For this 500 μg of lysate was diluted to 
500 μL, 10 μL of 0.5 M EDTA pH 8.0 was added and the sample was vortexed. Next 5 
μL of 10 mM GTPyS or 5 μL 100 mM GDP was added and the sample was vortexed. 
Both reactions were incubated for 15 mins at 30 °C in a heated tube shaker. To stop 
the reaction the samples were placed on ice and 32 μL of 1 M MgCl2 was added and 
the sample was vortexed. These samples were then run through the pull down kit 
columns as described next, in addition samples to test were also run through these 
columns. 
To carry out the pull down reactions firstly a spin cup was placed into a collection tube. 
Next the bottle of glutathione resin was swirled and 100 μL of the resin was added to 
the spin cup in the collection tube. Next the tube was centrifuged at 6000 g for 10-30 
secs and the flow through was discarded. Next 400 μL of lysis/binding/wash buffer was 
added to the tube with the resin, then the tube was inverted several times and then 
centrifuged at 6000 g for 10-30 secs. The flow through was discarded and the GST 
fusion protein (20 μg of GST-human Pak1-PBD or 400 μg GST-Rhotekin-RBD) was 
added to the spin cup. Next 500 μg of protein lysate was added to the spin cup and the 
lid closed for vortexing. Next the cap of the collection tube was sealed with parafilm 
and the sample was vortexed again. The mixture was then incubated at 4 °C for 1 hour 
with gentle rocking. After the incubation the tube was then centrifuged at 6000 g for 10-
30 secs. Then the spin cup was transferred to a new collection tube. To wash the resin 
400 μL of lysis/binding/wash buffer was added and the tube was inverted 3 times then 
centrifuged at 6000 g for 10-30 secs. We then removed the buffer and repeated the 
wash step two more times. After the wash steps the spin cup was then transferred to a 
new collection tube. Next we prepared the reducing sample buffer by adding DTT to 2x 
SDS sample buffer to a final concentration of 200 mM. We added 50 μL 2x reducing 
sample buffer to the resin, vortexed and left to incubate for 2 mins at room 
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temperature. The tube was then centrifuged at 6000 g for 2 mins, after centrifugation 
the spin cup containing the resin was removed. 
The 2x reducing sample buffer was already added to the pull down samples (controls 
and samples to test), therefore we added this to the 10 μg of input sample. We followed 
the same western protocol described in section 3.2, except we used the 2x sample 
buffer from the pull down kit. For loading the westerns we ran 10 μg of input sample, 10 
μL of the control samples (treated with GTPyS or GDP) and 40 μL of the test samples. 




On day 1 we plated 40,000-100,000 cells/well on top of 12 mm poly-L-lysine coated 
coverslips (Corning 354085) in 24 well plates. On day 2 we treated the cells with 
vehicle or drug for 72 hours. On day 5 cells were permeabilised for 1 min in 0.1 % triton 
in 1x PBS. After permeabilisation the cells were fixed for 15-25 mins in 3.7 % 
paraformaldehyde (PFA) and 2 % sucrose in 1x PBS. The cells were then washed in 
1x PBS three times and stored in the fridge till ready to stain the coverslips. 
Primary antibodies were added (Table 8) in 2 % BSA-1x PBS to the coverslips for 40 
mins at 37 °C. After incubation in primary antibody the coverslips were washed on the 
rocker for 5 mins at low speed three times in 1x PBS. Secondary antibody (Invitrogen) 
was added 1:1000 in 2 % BSA-1x PBS at 37 °C for 30 mins and kept in the dark (Table 
8). After secondary antibody incubation the coverslips were washed 3-4 times in 1x 
PBS for 5 mins on the rocker. Next the cells were stained with DAPI (1:10,000) for 1 
min in 1x PBS. The slides were then washed twice with 1x PBS. The slides were then 
mounted with 5 μL mowiol (Calbiochem) and left in the fridge overnight before imaging. 
The coverslips were imaged using the confocal LSM 710 microscope (Zeiss), the 63x 
oil objective was used and at least 4 images were captured per condition using the 
same settings (to enable us to count 150-300 cells per condition). ImageJ was used to 
quantify the images and percentages were calculated comparing to the total number of 
cells (quantified by DAPI staining). 
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 Company and code Standard dilution 
Alexa 488  Invitrogen A11001 1:1000 
Alexa 568 Invitrogen A11036 1:1000 
β-catenin total Abcam ab32572 1:250 
Pan-cadherin Abcam 6529 1:200 




Table 8 Antibodies used for immunofluorescence 
 
 
13 Data analysis and representation  
Prism was used to generate all graphs, if multiple repeats were represented in one 
graph error bars were plotted as standard error of the mean (SEM). If results from one 
experiment were shown error bars were plotted as standard deviation (SD). 
Appropriate statistical tests were performed using prism and indicated on the graphs 
and figure legends including; t-tests, one way anovas and two way anovas. If statistical 
tests showed significance p value ≤0.05 the levels of significance were indicated by the 
following * p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001, **** p≤ 0.0001. 
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Chapter 1 - Generation of an in vitro model 
of APC mutation 
 
The APC gene is a tumour suppressor gene, mutated in over 80 % of CRC patients 
(Fearon 2011). The mutation occurs early in the development of CRC and is therefore 
seen as an ideal target for novel cancer therapeutics. The APC gene is difficult to 
target when mutated in CRC because typically a significant proportion of the protein is 
not translated, one approach to overcome this is synthetic lethality. To improve our 
chances of finding a synthetic lethal relationship with APC mutation, we generated a 
‘clean’ isogenic human cell model where the main difference in the cell lines was the 
alteration in the APC gene. 
 
1 Optimisation of APC antibodies and siRNA 
Firstly in order to create an in vitro model of APC mutation, we needed to test different 
APC antibodies and optimise each one. The most abundant full length APC protein 
isoform is 312 kDa (Fearnhead et al. 2001). There are a number of reported shorter 
transcripts but these are less abundant and their role in CRC is unknown (De Rosa et 
al. 2007). We tested the following APC specific antibodies; Abcam APC Ali12-28 
(ab58), Cell signalling APC (2504), Santa cruz APC C28.9 (Figure 19D shows the 
different binding sites). Given the large size of APC, we needed to optimise our 
antibodies and ensure the detected band was APC. To this end, we immunoblotted 
protein lysates isolated from the APC wildtype CRC cell line RKO, which had been 
transfected with either siRNA against APC (siAPC*3 or siAPC*6) or a non-targeting 
siRNA control (siCON). Figure 19A-C shows the three antibodies, we successfully 
optimised. Figure 19A shows the APC ab58 antibody detects four bands above the 150 
kDa size marker in the RKO cell line, the top three bands are more abundant than the 
lower band of ~170 kDa. The lower band completely disappears when siRNA silences 
APC, whilst the intensity of the top three bands is significantly reduced. Lysates in 
figure 19A were electrophorised on a 4-12 % tris glycine gel, the protein size marker is 
not as accurate for large proteins compared to the 3-8% tris acetate gels used for the 
lysates in figure 19B/C. Figure 19B shows the bands detected with the APC antibody 
2504 and the antibody epitope is in the middle of the N-terminal section of APC. This 
antibody detects two stronger bands above the 225 kDa marker and a very faint band 
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just above the 225 kDa marker in the RKO cell line. All three bands are reduced upon 
transfection with siRNA against APC and therefore represent different APC isoforms. 
Antibody APC C28.9 (Figure 19C) binds to the C-terminus of APC and the antibody 
detects one large band above the 225 kDa marker, this band completely disappears 
when RKO cells are transfected with siRNA targeting APC. This antibody also detects 
a weaker lower band, this band remains upon siRNA treatment targeting APC and 
therefore appears to be non specific. This antibody is less likely to detect different APC 
protein isoforms because the antibody binds to the C-terminus. To confirm the 
efficiency of our siRNA, we used RT-PCR to analyse the APC transcript levels in the 
RKO cell line transfected with non-targeting siRNA and siRNA targeted against APC 
(Figure 19E). APC transcript levels reduced up to 80 % when targeted with two 
different siRNA against APC. 
 
Figure 19 Optimisation of APC antibodies 
RKO wildtype cells transfected with water (mock), non-targeting siRNA (siCON) and 
two siRNA targeting APC (siAPC*3 and siAPC*6) and whole cell lysates collected to 
help optimise the following antibodies; A) APC ab58 (4-12% tris glycine), B) APC 2504 
(3-8% tris acetate), C) APC C28.9 (3-8% tris acetate). D) Schematic showing the 
binding sites of the three APC antibodies.  E) RKO wildtype cells transfected with 
siCON, siAPC*3 and siAPC*6 and RNA collected for RT-PCR analysis. Levels of APC 
transcript were measured and normalised to the housekeeping gene GAPDH then 
siCON. The ddCT method was used. Data from two experiments and error bars are 
SEM. One way anova (post hoc Tukey) was performed (** p≤ 0.01).  
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Table 9 CRC panel mutations 
1 information from (Ahmed et al. 2013) 
2 information from COSMIC 




















MSI c.4248delC/ LOH 
p.I1417fs*2 
No KRAS G13D S241F 
HCT116 Colorectal carcinoma -  
Primary 
MSI WT Yes KRAS G13D WT 
HT29 Colorectal 






No BRAF V600E R273H 
RKO Colonic carcinoma - 
Primary 
MSI WT No BRAF V600E WT 
SW48 Colorectal 
adenocarcinoma 
MSI WT Yes WT WT 
SW620 Colorectal 
adenocarcinoma - 
Lymph node metastasis 
MSS c.4012C>T/LOH 
p.Q1338* 
No KRAS G12V R273H;P309S 
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Figure 20 CRC cell line panel express different APC proteins 
A) RNA collected from the CRC cell lines and RT-PCR performed. APC transcript 
levels were normalised to the housekeeping gene β-actin, then RKO and the ddCT 
method was used. Data shows three repeats, error bars are SEM and a one way anova 
was non significant (ns). B) Whole cell lysates were analysed on a western blot and 
probed with APC antibody (ab58). β-actin used as loading control. C) Whole cell 
lysates were analysed on a western blot and probed with total β-catenin and 
unphosphorylated β-catenin antibodies. Experiment performed three times, a 
representative blot is shown, β-actin used as loading control. D) E) β-catenin total and 
unphosphorylated blots were quantified. Band density measured then a % was 
calculated and then normalised to % β-actin, then normalised to DLD1. Bar chart 
shows a combination of three experiments. Error bars are SEM and one way anova 
(post hoc Tukey) was performed (* p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001, **** p≤ 0.0001).  
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2 Selecting an appropriate cell line for our in vitro 
model 
2.1 CRC cell lines express different APC proteins 
To analyse the expression of APC in our panel of CRC cell lines, we compared three 
APC wildtype cell lines (HCT116, RKO and SW48) against three APC mutant cell lines 
(DLD1, HT29 and SW620) (Table 9). Firstly we confirmed by RT-PCR all six cell lines 
express the APC transcript, the probe we used binds between exon 13 and 14 and 
therefore the mutations in the CRC panel will not interfere with the probes binding. 
Figure 20A confirms the APC transcript was present in all six cell lines and there was 
some variation in levels but no significant differences. Next we confirmed the size of 
APC protein present in all six cell lines (Figure 20B). HCT116, RKO and SW48 express 
full length APC, ~312 kDa. DLD1 expresses a 155 kDa APC protein which retains the 
2nd 20aa repeat. HT29 contain two APC proteins, 93 kDa APC protein (appears quite 
faint on the western), which retains the armadillo repeats and a 171 kDa APC protein 
which includes the 3rd 20aa repeat. SW620 expresses a 147 kDa protein which retains 
the 1st 20aa repeat. Interestingly all three cell lines with truncated APC appear to 
express more truncated APC product compared to the wildtype APC lines, however 
this could be a result of large proteins transferring less efficiently in western blotting. 
The activation of Wnt signalling is critical to the progression of CRC. To determine the 
level of Wnt signalling in the cell lines, we analysed the protein levels of β-catenin 
because activation of the pathway prevents β-catenin from phosphorylation at ser33, 
ser37 and thr41. This prevents its degradation and results in an increase in 
unphosphorylated β-catenin levels. Therefore, β-catenin is free to translocate to the 
nucleus and activate Wnt target genes. We probed for total β-catenin levels and 
unphosphorylated ser33/ser37/thr41 β-catenin (indicates the proportion of total β-
catenin which is active) in whole cell lysates for the whole panel to determine the 
activation of the pathway (Figure 20C/D/E). The results show when total β-catenin 
levels are high, unphosphorylated β-catenin is also high. As expected all the lines 
except RKO have high levels of total and unphosphorylated β-catenin. The APC mutant 
lines (DLD1, HT29 and SW620) are expected to have increased levels of β-catenin due 
to the APC mutation and therefore show hyperactivation of the Wnt signalling pathway. 
The cell lines HCT116 and SW48 are APC wildtype but have β-catenin mutations 
causing hyperactivation of the Wnt signalling pathway, our results support this. The 
RKO cell line is reported to have normal levels of Wnt signalling, however one group 
suggests this cell line has a mutation in the inhibitor of dishevelled called naked cuticle 
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homolog 1 (NKD1) which could result in activation of the Wnt signalling pathway (Guo 
et al. 2009). We do not see upregulation of the Wnt signalling pathway in the RKO cell 
line in comparison to the other five cell lines which show higher levels of both total and 
unphosphorylated β-catenin. 
 
2.2 The RKO cell line is an appropriate model 
There are a limited number of APC wildtype CRC cell lines available. We selected the 
CRC cell line RKO to create our APC mutated cell lines because it is wildtype for APC 
and β-catenin and as shown in figure 20C it does not display upregulation of β-catenin 
expression, which is characteristic of activation of the Wnt signalling pathway. To 
ensure that the cell line was appropriate and responsive to an APC mutation, we 
silenced APC using two different siRNA targeting APC and analysed Wnt activation 
using a TCF/LEF luciferase reporter assay. In the TCF/LEF luciferase reporter assay, 
the firefly luciferase is under the control of the TCF response element (TRE) which the 
transcription factors TCF/LEF bind to. The assay contains a positive control with 
constitutive firefly luciferase activity and a negative control with non-inducible firefly 
luciferase. As a negative control for our experiment, we performed the same assay in 
DLD1 cells which already have a mutation in APC therefore they have endogenous 
hyperactivation of the Wnt pathway. 
In the RKO cells, we observed that silencing APC with siRNA resulted in a significant 
increase in TCF/LEF activation compared to RKO cells transfected with non-targeting 
siRNA (Figure 21A). The same effect was not seen in the DLD1 cells which have 
endogenous hyperactivation of the Wnt pathway. In DLD1 cells silencing APC with 
siRNA resulted in a slight increase in TCF/LEF activation compared to the cells 
targeted with non-targeting siRNA, this supports the specificity of our assay (Figure 
21B). The effect seen in the RKO cell line showed this cell line was suitable for use in 
our study. 
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Figure 21 The RKO cell line is an appropriate cell line for the in vitro model 
TCF/LEF reporter assay performed, cells targeted with siCON, siAPC*3 and siAPC*6. 
Data is normalised to the negative + siCON. A) RKO cell line, representative shown of 
three repeats, error bars are SD and a one way anova (post hoc Tukey) was performed 
(*** p≤ 0.001) B) DLD1 cell line, representative shown of two repeats, error bars are SD 
and a one way anova was ns.  
 
3 Using the Dharmacon Edit-R CRISPR-cas9 system to 
alter APC 
3.1 Generation of mixed populations 
Our aim was to create an in vitro model of complete APC loss and to this end, we 
designed two gRNA to target exon 2 of the APC gene using the design tool from 
dna2.0 (Figure 22A and table 1). We used the Dharmacon Edit-R system which 
involves transiently transfecting three components; cas9 plasmid containing puromycin 
resistance, trans-activating crRNA (tracrRNA) and CRISPR RNA (crRNA). The 
tracrRNA and crRNA bind together to form the gRNA. This approach has the 
advantage that the cas9 expression is only temporary. We decided to transfect gRNA 
#8 alone and gRNA #8 and #9 together because co-transfecting two gRNA could 
increase efficiency but it is of note that co-transfection may also increase levels of off 
target effects. gRNA #8 had the highest score from the design tool dna2.0 which 
indicated it was predicted to have the least off target effects. We included two controls 
which expressed the cas9 plasmid alone and no tracrRNA or crRNA. Control 1 
expressed the cas9 plasmid with puromycin resistance. This control would undergo 
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puromycin selection and then single colony selection. Control 2 expressed the cas9 
plasmid with mKATE2 expression (instead of puromycin resistance). mKATE2 is a red 
fluorescent protein and enabled us to assess the transfection efficiency. After 48 hours 
post transfection, cells transfected with the cas9 plasmid with puromycin resistance 
were selected for using 0.5 μg/mL puromycin. After four days in puromycin selection, 
we had heterogenous populations which expressed the cas9 plasmid and may or may 
not have also been transfected with the tracrRNA and crRNA. A proportion of cells may 
have alterations to the APC gene resulting in complete loss of the APC protein. To help 
decide which mixed population to select single colonies from, we analysed the APC 
protein levels from the heterogenous populations by western blotting and performed 
the TCF/LEF reporter assay (Figure 22B/C). Both populations showed a similar 
reduction in the level of full length APC in comparison to the control population targeted 
with no gRNA. However, the TCF/LEF reporter assay showed no corresponding 
increase in Wnt signalling in either mixed populations, this could be due to the 
remaining level of full length APC being too high to see an effect on Wnt signalling. 
 






Figure 22 Dharmacon Edit-R CRISPR-cas9 generated mixed populations 
A) The target sites of the gRNA in exon 2 of APC. B) Whole cell lysates collected from 
the mixed population and probed for APC on a western blot. β-actin used as a loading 
control. C) TCF/LEF assay performed on the mixed populations, data was normalised 
to each positive control then to the control cell line negative control. Error bars are SD, 
a one way anova was ns.  
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3.2 Single colony selection 
We single colony selected both heterogeneous populations and clones we successfully 
established from a single colony are shown in figure 23A. In the majority of clones, we 
could still detect full length APC with the APC antibody Ali 12-28 (ab58). Two clones 
8_1 and 8_6 seemed to be absent of any APC protein and were potentially APC knock-
outs (Figure 23A). To see if this resulted in activation of the Wnt signalling pathway, we 
determined levels of total and unphosphorylated β-catenin by western blotting. We 
observed no increase in β-catenin level (Figure 23B). Additionally, we performed the 
TCF/LEF reporter assay on these clones and found there was no increase in Wnt 
signalling, supporting the blot results (Figure 23C). We next analysed APC expression 
using two different APC antibodies targeting different regions of the protein. Both APC 
C28.9 and APC 2504 detected full length APC in the RKO 8_1 and RKO 8_6 (Figure 
23D). The APC ab58 antibody epitope is in the protein region which is encoded by the 
same region of DNA where gRNA #8 and #9 target. The gene alteration induced by 
cas9 in clones 8_1 and 8_6 was inframe and we propose the change altered the 
structure of the antibody binding site. Unfortunately from targeting exon 2 using the 
Dharmacon Edit-R system, we did not manage to generate clones with altered APC. 




Figure 23 Single colony selection of the Dharmacon Edit-R mixed populations 
A) Whole cell lysates collected from the individual clones and probed for APC. β-actin 
used as a loading control B) Whole cell lysates collected and levels of total and 
unphosphorylated β-catenin were analysed and compared to HT29 and DLD1 (APC 
truncated cell lines). β-actin used as a loading control, representative shown, 
experiment performed  three times. C) TCF/LEF assay performed twice, representative 
shown, one way anova was ns. Data normalised to each positive control then C2 
negative control. D) Whole cell lysates collected and probed for APC, β-tubulin used as 
loading control.  
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4 CRISPR-cas9 using a lentiviral system to alter APC 
4.1 Generation of mixed populations 
The Dharmacon Edit-R system relies on the cells receiving the cas9 plasmid, the 
tracrRNA and the crRNA. Therefore to increase the efficiency of generating an APC 
mutated cell line, we decided to try a lentiviral approach with all components expressed 
from one plasmid. We also designed new gRNA using the design tool from dna2.0 
targeting exon 15 which contains 80 % of the coding region. gRNA #2, #5 and #6 all 
target upstream of the MCR and gRNA #3 and #4 target downstream of the MCR 
(Figure 24A and table 1). Targeting exon 15 increases our chances of generating a 
truncated APC product, however, there is still a chance of generating an alteration, 
which causes the transcript to be degraded by NMD generating an APC knock-out. 
The lentiCRISPRv2 plasmid encoded cas9, gRNA and puromycin resistance, shown in 
figure 24B. Site directed mutagenesis was performed to clone the five gRNA 
sequences into the plasmid. The five plasmids containing gRNA targeting APC and a 
plasmid containing a non-targeting gRNA (Scr) were transfected into the HEK293T cell 
line along with the packaging plasmids to produce lentivirus to infect into the RKO cell 
line. One day after infection, 0.5 μg/mL puromycin was used to select for ‘edited cells’ 
for 10 days. 
After puromycin selection, the cell population should only contain cells, which received 
the lentiCRISPRv2 plasmid. However some cells will have received the plasmid but no 
editing occurred, whilst other cells may have been edited but this change may or may 
not have altered the APC protein. To help us determine which heterogenous population 
to single colony select, we collected lysates to analyse APC expression and performed 
the TCF/LEF reporter assay (Figure 24C and 24D). Figure 24C shows the APC 
expression in all mixed populations including the non-targeting gRNA control. The 
mixed populations targeted with gRNA #3, #4 and #6 have resulted in cells expressing 
full length APC to a similar level of the non-targeting gRNA control. This suggests 
these gRNA have not been very effective at inducing an alteration to the APC gene. In 
comparison both gRNA #2 and #5 have resulted in mixed populations with truncated 
forms of APC, ~ 80 kDa and ~ 120 kDa protein respectively. The high level of truncated 
APC suggests these gRNA have a high efficiency and this increases the likelihood of 
identifying a single clone with altered APC on both alleles. The TCF/LEF reporter assay 
on the mixed populations targeted with each gRNA support the findings from the 
western blot. The cells targeted with gRNA #3, #4 and #6 do not activate Wnt signalling 
higher than the non-targeting gRNA control. Whereas, the cells targeted with gRNA #2 
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and #5 show a significant increase in Wnt activation in comparison to the non-targeting 
gRNA control. The population targeted with gRNA #5 appears to activate Wnt 
signalling more than twice the level in the population targeted by gRNA #2. This could 
be a result of the size of the APC truncation or because the population targeted by 





Figure 24 Lentiviral CRISPR-cas9 generated mixed populations 
A) The target sites of the gRNA in exon 15 of APC in relation to the MCR region. B) 
Schematic showing the lentiCRISPRv2 plasmid, RRE = Rev response element, cPPT = 
central polypurine tract, WPRE = WHP post transcriptional regulatory element. C) 
Whole cell lysates collected from the mixed populations and probed for APC on a 
western blot. Non-targeting gRNA referred to as scrambled (scr). β-actin used as a 
loading control. D) TCF/LEF assay performed on the mixed populations, data was 
normalised to each positive control then to the scrambled negative. Error bars are SD, 
a one way anova (post hoc Dunnet) was performed (*** p ≤ 0.001).  
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4.2 Single colony selection of the mixed populations targeted 
by gRNA #2 and gRNA #5 
4.2.1 Single colony selection of the mixed population targeted by gRNA #5 
does not generate an APC mutant 
Initially we decided to single colony select the population targeted by gRNA #5, figure 
25 shows the clones we successfully expanded. All clones shown in figure 25 express 
some degree of full length APC, for example clone 5_9 seems to be heterozygous 
containing both full length APC and a truncated form ~ 120 kDa. We decided not to 





Figure 25 Single colony selection of the population targeted with gRNA #5 
Whole cell lysates collected and APC probed for on western blots. β-actin used as a 
loading control. 
 





Figure 26 Single colony selection of the population targeted with gRNA #2 
A) B) C) Whole cell lysates collected and APC probed for on western blots. β-actin 
used as a loading control.  
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4.2.2 Single colony selection of the mixed population targeted by gRNA #2 
generates the RKO APC mutated line 2_6 
Next we single colony selected the population targeted by gRNA #2 and the 
successfully expanded clones are shown in figure 26. The blots show single colony 
selection identified many clones, which were heterozygous for full length APC and an ~ 
80 kDa APC truncated protein. The RKO 2_6 clone (Figure 26C) was of particular 
interest because both copies of APC appear to harbour a truncated protein ~ 80 kDa. 
We predicted this truncation to have occurred in the 7th armadillo repeat where APC 
interacts with ASEF1/2, and we later confirmed this by topocloning (Figure 30). RKO 
2_1 appears to have low levels of both full length and the truncation which made us 
hypothesise that this was not a ‘clean’ single colony population, and therefore, we did 
not investigate this clone further (Figure 26C). We did not identify a full APC knock-out 
from this single colony selection. We have identified a clone RKO 2_6 which has an 
APC truncation and is more representative of the mutations seen in the clinic. In the 
clinic APC truncations are common and complete loss is rare. However, the RKO 2_6 
clone is more dramatically truncated than the typical truncations seen in the clinic. 
Alongside the single colony selection of the population targeted with gRNA #2, we also 
single colony selected the scrambled population, this generated two control cell lines 
with full length APC as shown in figure 26C. 
 
4.2.3 RKO APC mutant line 2_6 activates Wnt signalling 
Firstly, we checked the levels of the APC mRNA transcript in RKO 2_6. Figure 27A 
shows the APC transcript levels are similar to those of both control lines RKO 7_1 and 
RKO 7_2. Next we analysed levels of Wnt signalling by analysing levels of total and 
unphosphorylated β-catenin by western blotting and performing the TCF/LEF reporter 
assay. Figure 27B shows RKO 2_6 had significantly increased levels of both total and 
unphosphorylated β-catenin in whole cell lysates compared to the controls. This is 
supported by the TCF/LEF reporter assay which showed RKO 2_6 significantly 
increased TCF/LEF activation in comparison to the control cell lines (Figure 27C). This 
finding is supportive of evidence from patients with APC truncations. 
To generate our in vitro model of APC mutation, we used CRISPR-cas9 to alter APC in 
the RKO cell line. We attempted to generate an in vitro model with complete APC loss, 
alternatively we have generated an in vitro model with approximately 25 % of the N-
terminus of APC remaining. This cell line strongly activates Wnt signalling in 
comparison to the control cell line and is more representative of APC mutational status 
found in patients. We have three cell lines derived from the same parental APC 
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wildtype RKO cell line; RKO control cell lines (7_1 and 7_2) and RKO APC truncated 
(2_6). The main difference between these cell lines is the APC mutation (there is 
potential for off-target effects from the CRISPR-cas9 approach), enabling us to look for 




Figure 27 Characterisation of RKO 2_6 
A) RNA collected and RT-PCR performed, APC transcript levels normalised to GAPDH 
then RKO 7_1. Data analysed using ddCT. Data was repeated twice, error bars are 
SEM and one way anova was ns. B) Whole cell lysates collected and probed for total 
and unphosphorylated β-catenin, β-tubulin used as loading control. Representative is 
shown of three experiments. C) TCF/LEF reporter assay performed, data was repeated 
three times, error bars are SEM and a one way anova (post hoc Tukey) was performed 
(*** p≤ 0.001). Data normalised to each positive control then 7_1 negative control.  
 
4.3 Re-single colony selection 
It became apparent with time, that RKO 2_6 cells expressing a truncated APC also 
expressed a small level of full length APC, which could be influencing the phenotype 
observed (Figure 28A). The amount of full length APC is marginal in comparison to 
wildtype RKO and control clones RKO 7_1 and RKO 7_2, however the full length APC 
population may expand as the clone is passaged. We did not see any full length APC 
in our original blots, so we believe this population may have overtime become 
contaminated from another clone. We decided to undergo single colony selection again 
and figure 28B shows the clones successfully expanded. Figure 28C shows the clones 
RKO 2_21, RKO 2_22, RKO 2_30 and RKO 2_36 which do not express any trace of 
full length APC, as confirmed by immunoblotting with the two antibodies, APC ab58 
and APC C28.9. 
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Figure 28 Re-single colony selection of RKO 2_6 
All whole cell lysates collected and probed for APC. β-actin or β-tubulin used as loading controls.  A) RKO 2_6 contained some full length APC 
expression B) Clones established from re-single colony selection of RKO 2_6 C) The final clones probed with APC ab58 and APC C28.9. APC ab58 
repeated three times, representative shown.  
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4.4 Characterisation of final RKO APC mutated lines 
To confirm the new single colony selected cell lines have similar characteristics to RKO 
2_6 we determined the levels of APC transcript and activation of the Wnt signalling 
pathway. We used RT-PCR to analyse the level of APC transcript in the controls RKO 
7_1 and RKO 7_2 in comparison to RKO 2_30 and RKO 2_36. Figure 29A shows the 
APC mutant line RKO 2_30 has a similar level of APC transcript to the control cell 
lines, whilst RKO 2_36 has a slightly higher level of APC transcript only when 
compared to the control RKO 7_1. We analysed the activation of the Wnt signalling 
pathway by western blotting for β-catenin and performing the TCF/LEF reporter assay. 
Levels of total and unphosphorylated β-catenin were still significantly upregulated in 
comparison to the control cell lines (Figure 29B). The TCF/LEF reporter assay showed 
all the clones upregulate Wnt signalling. RKO 2_21, RKO 2_22 and RKO 2_36 showed 
a significant increase in Wnt signalling compared to the controls (Figure 29C). 
Interestingly RKO 2_30 activates Wnt signalling to a lower level, therefore we decided 
to focus on RKO 2_30 and 2_36. 
Additionally we analysed the rates of proliferation between the original RKO wildtype 
cell line and the in vitro model lines generated using CRISPR-cas9 (Figure 29D). We 
plated the cell lines into 96 well plates and measured cell viability using a ATP-based 
luminescence assay CellTiter-glo (CTG) daily for five days to enable us to analyse the 
rate of proliferation in the cell lines. We calculated the fold change in cell viability for 
each time point by comparing the CTG values (measured every 24 hours) to the 
average CTG values for time point 0 (measured 6 hours after plating). The fold change 
values were plotted to show the increase in population size for all the cell lines. The 
RKO wildtype cell line and RKO controls 7_1 and 7_2 show similar increases in 
population size throughout the experiment. In comparison, the RKO APC mutant lines 
appear to slightly increase in population size more over the course of the experiment, 
which could be explained by the higher level of Wnt signalling in these cell lines. 
Interestingly RKO 2_36 shows a higher level of Wnt signalling than RKO 2_30 but this 
is not reflected in a greater increase in population size. We then calculated the 
population doubling time (PDT), for this we used the fold change values at 48 hours 
and 96 hours because the population was growing exponentially. Table 10 shows the 
PDT for each cell line. The PDT for the cell lines varies from 18-20 hours which 
supports why there are not huge differences in the population sizes over the course of 
the experiment. Despite seeing slighter bigger increases in population size in the APC 
mutant cell lines, only RKO 2_30 has a slightly shorter PDT. 
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We also performed topocloning to determine the alterations on both alleles of the 
clones RKO 2_21, RKO 2_30 and RKO 2_36. All three RKO APC mutant clones have 
the same alterations because they are derived from the same original population RKO 
2_6. We used the APC transcript 3 (NM_000038.5) which encodes the most common 
protein isoform to enable us to describe the DNA and resulting protein changes. APC 
allele no.1 contained a 16 bp deletion causing a frameshift and a premature stop 
codon. APC allele no.2 contained a 26 bp deletion resulting in a frameshift and a 
premature stop codon (Figure 30A). The DNA nomenclature is the following in 
reference to the APC mutant cell lines; NM_000038.5 
c.[2206_2221del];[2206_2231del]. The protein nomenclature is the following in 
reference to the APC mutant cell lines; NP000029.2 p.[K736IfsTer20];[K736SfsTer11] 
and this can be shorterned to APC Lys736fs. Topocloning enabled us to confirm the 
RKO APC mutant lines contain APC mutations in the armadillo repeat 7 domain 
resulting in APC products of 82 kDa and 83 kDa (Figure 30B). 
Taken together we have generated a set of cell lines, differing in the APC status; two 
wildtype APC lines (RKO 7_1 and 7_2) and four APC truncated lines (RKO 2_21, 2_22, 
2_30 and 2_36). 




Figure 29 Characterisation of RKO 2_21, 2_22, 2_30 and 2_36 
A) RNA collected and RT-PCR performed, APC transcript levels normalised to GAPDH 
then RKO 7_1. Data analysed using ddCT. Experiment was repeated three times, error 
bars are SEM and one way anova (post hoc Tukey) was performed (* p≤ 0.01) B) 
Whole cell lysates collected and total and unphosphorylated β-catenin was probed, β-
actin used as loading control. Representative is shown of three experiments. C) 
TCF/LEF reporter assay performed, data was repeated twice, error bars are SEM and 
a one way anova (post hoc Tukey) was performed (* p≤ 0.05, *** p≤ 0.001). Data 
normalised to each positive control then 7_1 negative control D) Measured cell viability 
every 24 hours over 5 days to determine cell proliferation rates. Fold change calculated 
using the average of day 0 values for each cell line. Experiment performed twice, error 
bars are SEM. 




Cell line PDT (hrs) 
RKO WT 19.7 
RKO 7_1 20.4 
RKO 7_2 19.8 
RKO 2_30 18.5 
RKO 2_36 19.6 







Figure 30 Topocloning identified the exact APC mutations in our in vitro model 
A) The sequence alterations in our APC mutant cell lines on allele 1 and 2, numbering 
starts from the start codon and we used the coding DNA ref sequence NM_000038.5. 
Changes confirmed by at least 2 sequences for each alteration. B) Schematic showing 
the resulting APC truncation confirmed from the topocloning, with reference to the APC 
protein sequence NP000029.2 p.[K736IfsTer20];[K736SfsTer11]. 
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Chapter 2 - Searching for synthetic lethal 
interactions with APC mutation using an 
siRNA kinome screen 
 
1 Identification of potential hit kinases which are 
synthetically lethal with APC mutation 
1.1 Using an siRNA kinome screen to identify synthetic lethal 
kinases 
To identify synthetic lethal interactions with truncated APC in our in vitro model, we 
designed an siRNA screen targeting 720 kinases and kinase related genes. The same 
layout was previously used to identify PTEN induced putative kinase 1 (PINK1) as 
synthetically lethal with MMR deficiency (Martin et al. 2011). The advantage of 
searching for synthetic lethal relationships with kinases is the potential to use existing 
compounds to inhibit the target and the ability to design new compounds to interfere 
with the kinase domain. The siRNA library was aliquoted over 9 x 96 well plates and 
each well contained one siRNA SMARTpool targeting a specific gene (the pool 
consists of four deconvoluted siRNAs targeting the same gene). The use of pooled 
siRNA in a screen has been shown to have a greater phenotypic effect and identify 
more hits, in comparison to the use of individual siRNA (Parsons et al. 2009). Each 
plate contained controls in the first and last columns including; media only, mock 
transfection, non-targeting siRNA (siCON) and siRNA against PLK1 (siPLK1). We use 
siRNA against polo like kinase 1 (PLK1) as a positive control because PLK1 is part of 
the G2/M checkpoint in the cell cycle, therefore silencing of PLK1 results in reduced 
cell viability. Controls enable the transfection efficiency and plate-plate variation to be 
analysed. We performed the siRNA screen in duplicate in two cell lines, RKO APC wt 
control 7_1 and RKO APC mutant 2_6. 




Figure 31 siRNA screen identifies seven potential hit genes 
A) Schematic showing the format of the siRNA screen targeting 720 kinases and 
kinase related genes. B) ∆Z scores for all siRNA in the screen plotted for both screen 
replicates to illustrate the spread of the data. C) The seven potential hits identified from 
the siRNA screen. The Z score from both replicate 1 and 2 were plotted for both cell 
lines. Control cell line RKO 7_1 (red) and APC mutant cell line RKO 2_6 (blue).  
Results - Chapter 2 Page 118 
 
Figure 31A shows a schematic of the siRNA screen. On day 1 both cell lines were 
plated at 2000 cells/well. After 24 hrs the siRNA library was transfected into both cell 
lines using the transfection reagent RNAimax, the media was changed 4-5 hours later 
to reduce toxicity from the transfection reagent. On day 6 we used the ATP-based 
luminescence assay, CellTiter-Glo (CTG) to analyse cell viability. To ensure all the 
siRNA targeting different genes had time to be effective due to the variation in protein 
turn over time, we measured cell viability 96 hours post transfection. The luminescence 
readings were then log transformed and normalised to the median signal per plate. 
Next the values were standardised by calculating Z scores, this measure tells us how 
many standard deviations the value is from the mean, this gives a value which enables 
us to understand the effect of the siRNA compared to the rest of the siRNA in the 
screen. We used a variation known as robust Z score to reduce sensitivity to outliers, 
by using the median and median absolute deviation (MAD) instead of mean and 
standard deviation in the calculation (Birmingham et al. 2009). We then compared the 
Z scores between the control RKO 7_1 and the APC mutant RKO 2_6 cell lines, by 
calculating the ∆Z score. To classify an siRNA as a potential hit we excluded any 
siRNA which resulted in more growth in the controls (using the Z score values) and the 
siRNA required a ∆Z score of below -1.5. 
 ∆Z score 
 #1 #2 
DYRK2 -2.6865 -1.7969 
FN3KRP -2.7146 -1.3204 
MAP3K12 -1.9726 -0.5550 
NAGK -1.0286 -1.8705 
N4BP2 -1.7935 -1.2834 
PIM2 -1.8761 -0.4296 
SMG1 -1.6225 -1.3109 
 
Table 11 ∆Z score for the potential hit genes identified  
shown for each siRNA screen replicate 
 
Figure 31B shows the spread of the ∆Z score for each siRNA in each repeat of the 
screen performed. We identified seven potential hits with a lower Z score in RKO 2_6 
compared to RKO 7_1 (Figure 31C) and table 11 shows the ∆Z score for each 
replicate. The potential hit genes were dual-specificity tyrosine (y) phosphorylation 
regulated kinase 2 (DYRK2), fructosamine 3 kinase related protein (FN3KRP), mitogen 
activated protein kinase kinase kinase 12 (MAP3K12), N-acetylglucosamine kinase 
(NAGK), NEDD4 binding protein 2 (N4BP2), proviral integrations of moloney virus 2 
(PIM2) and suppressor with morphogenetic effect on genitalia (SMG1). 
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Gene Function Reference 
DYRK2 Activate apoptosis, controlling cell cycle and 
inhibit metastasis 
(Nihiraa & Yoshidaa 
2015; Yan et al. 
2016) 
 
FN3KRP Potential role in metabolism (Conner et al. 2005) 
MAP3K12 Regulator of neuronal degeneration (Huntwork-Rodriguez 
et al. 2013) 
NAGK Part of the hexosamine biosynthetic pathway (Yamamoto & 
Yamamoto 2015) 
N4BP2 Potential role in repair or recombination (Watanabe et al. 
2003) 
PIM2 Involved in cell survivial and proliferation (Zhang et al. 2015) 
SMG1 Nonsense- mediated mRNA decay, responding 
to cellular stress, telomere integrity, apoptosis, 
responses to hypoxia and regulating the G1/S 
checkpoint. 
(Gubanova et al. 
2013) 




The potential hits from the siRNA screen have a range of functions and some have 
been linked to cancer and more specifically CRC (roles summarised in table 12). 
DYRK2 is a member of the dual specificity kinase family, phosphorylating both 
serine/threonine and tyrosine substrates (Yan et al. 2016). DYRK2 has been shown to 
activate apoptosis, control cell cycle progression through regulating the degradation of 
c-jun and c-myc and inhibiting metastasis (Nihiraa & Yoshidaa 2015; Yan et al. 2016). 
It is thought to act as a tumour suppressor in many cancers including CRC, where 
DYRK2 has been shown to be down regulated in CRC tissues (Yan et al. 2016). 
FN3KRP has not been previously linked to cancer and is thought to be a housekeeping 
gene with an important role in metabolism, potentially deglycating enzymes (Conner et 
al. 2005). MAP3K12 has not been linked to cancer and is thought to be a regulator of 
neuronal degeneration (Huntwork-Rodriguez et al. 2013). NAGK is a kinase converting 
N-acetylglucosamine (GlcNAc) to GlcNAc–Phosphate which is either processed to 
fructose-6-phosphate or to UDP-GlcNAc (Yamamoto & Yamamoto 2015). This forms 
part of the hexosamine biosynthetic pathway, responsible for processing 2-5 % of 
glucose into compounds used for glycosylation (most glucose is processed by 
glycolysis) (Vasconcelos-Dos-Santos et al. 2017). The hexosamine pathway has been 
linked to CRC with key components being upregulated and aberrant glycosylation has 
been reported to promote oncogenic transformation (Yamamoto & Yamamoto 2015). 
The N4BP2 kinase has not been directly linked to CRC. It has been shown to interact 
with Bcl-3 and p300/CBP and might have a role in DNA repair or recombination 
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(Watanabe et al. 2003). PIM2 has been implicated in a range of human cancers. It is 
involved in cell survival and proliferation. PIM2 is mostly increased in hematologic 
malignancies and prostate cancer (Brault et al. 2010). Recently PIM2 has been shown 
to be highly expressed in CRC and promotes tumourigenesis by upregulating aerobic 
glycolysis through mTOR (Zhang et al. 2015). SMG1 has many cellular roles including; 
NMD, responding to cellular stress, telomere integrity, apoptosis, responses to hypoxia 
and regulating the G1/S checkpoint. Additionally, SMG1 may play a role as a tumour 
suppressor in HPV-positive head and neck squamous cell carcinoma and acute myloid 
leukemia (AML) (Gubanova et al. 2012; Gubanova et al. 2013; Du et al. 2014). 
As discussed above the roles of the potential hits are varied and not all are well 
characterised, interestingly some have already been linked to tumourigenesis. Current 
understanding of the genes helps to hypothesise potential mechanisms, although the 
genes could behave differently in different cellular contexts. 
 
1.2 Validation of the potential hit genes from the siRNA kinase 
screen 
1.2.1 Validation of the potential hit genes using a validation plate 
To determine whether our potential hit kinases are synthetically lethal in our APC 
mutated cells, we initially carried out a secondary siRNA screen containing five siRNA 
against each of the following seven potential hit genes; DYRK2, FN3KRP, MAP3K15, 
NAGK, N4BP2, PIM2, SMG1. The secondary siRNA screen contained the same 
SMARTpool siRNA used in the screen and the four deconvoluted siRNA, which make 
up the SMARTpool. To validate the identified potential hits, we followed the same 
protocol used in the screen. We plated 2000 cells/well in 96 well plates, transfected the 
cells with the five different siRNA targeting each kinase and measured cell viability 
using CTG, 96 hours post transfection. To enable us to assess transfection efficiency 
we transfected a negative control referred to as non-targeting siRNA (siCON) and a 
positive control targeting PLK1 (siPLK1). For the potential hit kinases to validate, we 
required at least two siRNAs to cause a greater level of decreased cell viability in the 
APC mutated RKO 2_6 in comparison to the control RKO 7_1. The analysis is different 
to the screen because we do not normalise to the plate median (which is required to 
calculate Z scores), instead we calculate survival fractions upon siRNA transfection. To 
calculate the survival fraction, we normalised the siKinase CTG values to the average 
of the siCON CTG values. 
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Figure 32 shows the combination of two independent experiments transfecting RKO 
7_1 and RKO 2_6 with the siRNA in the validation plate. Silencing three out of the 
seven genes showed a slight difference in cell viability between RKO 7_1 and RKO 
2_6, for two or more of the siRNA targeting each kinase. Two deconvoluted siRNA 
targeting DYRK2 (siDYRK2*1 and siDYRK2*2) and the SMARTpool decreased survival 
by 10-20 % in the APC mutant RKO 2_6 cells in comparison to RKO 7_1. Two of the 
deconvoluted siRNA (siDYRK*3 and siDYRK*5) do not cause a greater decreased cell 
viability in RKO 2_6 compared to RKO 7_1. Three of the deconvoluted siRNA targeting 
NAGK (siNAGK*1, siNAGK*4 and siNAGK*17) show a 10-20 % greater decrease in 
survival in RKO 2_6 compared to RKO 7_1. We do not see an effect with the siNAGK 
pool, this could be explained by the significant toxicity seen when siNAGK*3 is 
transfected alone. One of the deconvoluted siRNA (siN4BP2*3) and the pool cause a 
5-10 % greater reduction in survival in the RKO 2_6 compared to RKO 7_1. None of 
the siRNA in the secondary screen, targeting FN3KRP, MAP3K15, PIM2 and SMG1 
cause a larger decrease in survival in the RKO 2_6 compared to RKO 7_1. 
Unfortuanetly the effects seen are not consistant or large enough and therefore this 
data does not support any of the genes validating as hits. 
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Figure 32 Validation plate in RKO 2_6 
Validation of the potential hits identified from the screen using the SMARTpool siRNA 
(used in the screen) and the four deconvoluted siRNA in 96 well plates. CTG read 96 
hours post transfection. Results are from two repeats and error bars show SEM. 
Control cell line RKO 7_1 (red) and  APC mutant cell line RKO 2_6 (blue). Two way 
anova (post hoc Bonferroni) performed for each and all ns.  
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1.2.2 Validation in new single colony selected cells 
Having identified residual full length APC in the RKO 2_6 cell line (as discussed in 
results chapter 1, section 4.3), we hypothesised that potentially the residual full length 
APC may have influenced the results from the secondary siRNA screen. To rule this 
out, we carried out the secondary screen as above in the new single colony selected 
cell lines RKO 2_21, RKO 2_22, RKO 2_30 and RKO 2_36 (Figure 33). Upon siRNA 
transfection, the four APC mutant cell lines show varying sensitivities to the siRNA 
targeting the seven potential hit kinases. For the siRNA targeting DYRK2 we observed 
a 5-20 % reduction in survival for both siDYRK2*1 and siDYRK2*2 in both RKO 2_21 
and RKO 2_22 in comparison to the APC wt RKO 7_1 and RKO 7_2 cell lines. Upon 
silencing of NAGK in the new APC mutant cell lines, we observed that siNAGK*1, 
siNAGK*4 and siNAGK*17 were the most effective in RKO 2_21 and RKO 2_22, 
causing a 5-20 % reduction in survival compared to the controls RKO 7_1 and RKO 
7_2. Silencing N4BP2 is most effective in RKO 2_21 which shows a 5-10 % reduction 
in survival compared to the controls with four of the siRNA targeting N4BP2 
(SMARTPool, siN4BP2*2, siN4BP*3 and siN4BP2*17). siRNA targeting FN3KRP, 
MAP3K15 and SMG1 do not decrease survival in RKO APC mutant lines compared to 
RKO 7_1. Previously we did not see an effect in PIM2 however in the clone RKO 2_21 
we see a 10-20 % reduction in survival for two of the deconvoluted siRNA (siPIM2*1 
and siPIM2*4) compared to the controls RKO 7_1 and RKO 7_2. 
The results are similar to the secondary siRNA screen in the original APC mutant RKO 
2_6 cell lines. Therefore we concluded that removal of the residual full length APC had 
not increased the effect on cell viability when silencing the potential hit genes in the 
APC mutant lines. Taken together upon analysis of the results from the secondary 
screen performed in all the cell lines we conclude that none of the potential hit genes 
validated. 




Figure 33 Validation plate in RKO 2_21, RKO 2_22, RKO 2_30 and RKO 2_36 
Validation of the hits identified from the screen by transfecting the SMARTpool siRNA 
(used in the screen) and the four deconvoluted siRNA in the new cell lines, performed 
in 96 well plates. CTG read 96 hours post transfection. Results are from two repeats 
and error bars show SEM. Each bar for each siRNA is arranged in the same order as 
listed in key; Control cell line RKO 7_1 and RKO 7_2 (red) and APC mutant cell lines 
RKO 2_21, 2_22, 2_30 and 2_36 (blue). Two way anova (post hoc Bonferroni) 
performed for each and all ns.  
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1.3 Further investigation into the silencing of DYRK2, NAGK 
and N4BP2 
Upon analysis of both secondary screens performed in all cell lines, the genes DYRK2, 
NAGK and N4BP2 when silenced with siRNA, cause a slight reduction in survival in our 
RKO APC mutant lines in comparison to the APC wt control cells. We further 
investigated this by individually silencing the three genes and measuring cell viability at 
both 72 hours and 96 hours post transfection using CTG (Figure 34A). This analysis 
would enable us to determine whether we had missed the synthetic lethal effect when 
previously validating. The primary and secondary screens were both analysed at 96 
hours. Interestingly for all six of the siRNA targeting the three genes we see greater 
effects at 96 hours (Figure 34A). The two individual siRNA targeting NAGK have 
different effects on cell viability between the APC wt and APC mutant lines. The 
deconvoluted siRNA siNAGK*1 has the same effect on cell viability between the APC 
wt and APC mutant lines, in comparison the second siRNA siNAGK*4 causes a 5-10 % 
reduction in survival in the APC mutant lines compared to the APC wt at 96 hours post 
transfection. The deconvoluted siRNA targeting DYRK2 (siDYRK2*1 and siDYRK2*2) 
do not cause a greater decrease in cell viability in the APC mutant lines compared to 
the control cell lines at either 72 or 96 hours. Both siN4BP2*2 and N4BP2 SMARTpool 
cause a 5-10 % reduction in cell viability in the APC mutant lines RKO 2_22, RKO 2_30 
and RKO 2_36 compared to the APC wt controls. 
Throughout the validation of NAGK, DYRK2 and N4BP2 silencing these genes has 
inconsistently caused a slight decrease in cell viability in the APC mutant lines, in 
comparison to the wildtype APC cell lines and therefore these potential hit genes do 
not validate. Unfortunately to utilise this effect in the clinic the difference in cell viability 
needs to be consistantly greater because our aim is to selectively cause loss of cell 
viability only to the APC mutant cells, leaving the APC wt cells unharmed by the 
treatment. To further understand our results we could analyse the effectiveness of each 
siRNA to silence the target gene. We would collect lysates 96 hours after transfection 
with each siRNA and analyse protein levels of the target gene by western blotting. If 
the level of the protein has not significantly reduced then this could explain the small 
effects seen on cell viability when using the siRNA. 




Figure 34 Further investigation into the effect of silencing NAGK, DYRK2 and N4BP2 
A) Transfection of two siRNA against each gene and read 72 hours (white bars) and 96 
hours (grey bars) post transfection, performed in 96 well plates. Experiments 
performed twice, error bars are SEM. Two way anova (post hoc Tukey) was performed 
and all ns. B) Dose response curve for harmine with six doses, experiment performed 
twice, representative shown, error bars are SD. Drugged twice, total treatment time 96 
hours. Control cell line RKO 7_1 and 7_2 (red) and  APC mutant cell line RKO 2_30 
and RKO 2_36 (blue) C) Dose response curve for 3-O-Methyl-N-acetyl-D-glucosamine 
with 6 doses, experiment performed twice, representative shown, error bars are SD. 
Drugged twice, total treatment time 96 hours. Control cell line RKO 7_1 and 7_2 (red) 
and APC mutant cell line RKO 2_30 and RKO 2_36 (blue).  
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In addition to validating with siRNA we also tested commercially available inhibitors 
targeting the hit kinases. We used the DYRK2 inhibitor, harmine and the NAGK 
inhibitor, 3-O-Methyl-N-acetyl-D-glucosamine. Compounds can be more effective at 
inhibiting the function of the kinase. siRNA reduces the level of the protein but any 
residual protein left could be sufficient to fulfill the given role, preventing an effect being 
seen. We treated our cell lines with increasing doses of harmine and 3-O-Methyl-N-
acetyl-D-glucosamine for 96 hours and measured cell viability using CTG. We found no 
selectivity between our controls (7_1 and 7_2) and APC mutant cell lines (RKO 2_30 
and RKO 2_36) (Figure 34B/C). Further work is required to establish if the drugs are 
efficient at targeting DYRK2 and NAGK in our cell lines. Taken together the validation 
data shows we did not identify any genes upon silencing to be synthetically lethal with 
the APC mutation in our in vitro model. 
 
2 mTOR is not synthetically lethal in our RKO APCmut 
lines 
2.1 siRNA targeting mTOR and FLT3 do not show selectivity 
Upon completion of the siKinome synthetic lethal screening in our APC wt and mutant 
cell lines, we next attempted to validate the potential hits and unfortunately none of 
these validated. Therefore in parallel we investigated the literature, to determine 
whether there were any studies highlighting potential synthetic lethality with mutant 
APC that we could investigate in our newly generated cell lines. A study in mice 
suggested mutant APC was synthetically lethal with mTOR pathway inhibition (Faller et 
al. 2014). Furthermore, our initial analysis of the siKinome screen identified two siRNA 
targeting components of the mTOR pathway, which showed a small degree of synthetic 
lethality in our APC mutant cells. These kinases were the fms related tyrosine kinase 3 
(FLT3), which is upstream of mTOR and also mTOR itself (Figure 35A). Based on 
these two findings, we decided to investigate this potential synthetic lethal relationship 
further. The availability of mTOR inhibitors made this a potential means of 
therapeutically targeting this pathway in APC mutant CRC patients. Firstly we 
attempted to validate our findings by silencing FLT3 and mTOR using SMARTpool 
siRNA in the APC wt control cells (RKO 7_1 and RKO 7_2) and the APC mutant cell 
lines (RKO 2_30 and RKO 2_36). We measured cell viability using CTG, 96 hours post 
transfection and calculated survival fractions as described in section 1.2 (Figure 35B). 
The siRNA targeting FLT3 and mTOR did not cause a greater effect on cell viability in 
the APC mutant cell lines compared to the controls. 




Figure 35 Validation of FLT3 and mTOR 
A) Z scores for FLT3 and mTOR from both replicates of the siRNA screen. Control cell 
line RKO 7_1 (red) and  APC mutant cell line RKO 2_6 (blue) B) Survivial fractions 
shown for siRNA targeting non-targeting control (siCON), FLT3 (siFLT3), mTOR 
(simTOR) and PLK1 (siPLK1) 96 hours after transfection. siCON is negative control 
(blue) and siPLK1 is positive control (red). Experiment performed twice, error bars are 
SEM, 2 way anova (post hoc Bonferroni) performed (** p≤ 0.01).  
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2.2 mTOR inhibitors do not show selectivity 
To further assess the hypothesis that APC mutations are synthetically lethal with 
mTOR inhibition, we analysed the response of our RKO in vitro model cell lines to 
commonly used inhibitors of mTOR; rapamycin and ridaforolimus. To this end, we 
treated the APC mutant lines RKO 2_21, RKO 2_22, RKO 2_30 and RKO 2_36 and 
the APC wt control cells RKO 7_1 and RKO 7_2 with increasing concentrations of 
either rapamycin or ridaforolimus (Figure 36A). We analysed cell viability after 96 hrs 
and determined that our APC mutant cells were not more sensitive to rapamycin or 
ridaforolimus in comparison to the APC wt control cells. To further investigate the effect 
of mTOR inhibition and APC mutations, we decided to test a panel of CRC cell lines 
comprising of a range of APC wildtype and APC mutant cell lines. Figure 36B shows 
dose response curves for rapamycin and ridaforolimus in the following APC wildtype 
cell lines (HCT116, RKO and SW48) and APC mutant cell lines (DLD1, HT29 and 
SW620). To highlight the differences in sensitivity to the mTOR inhibitors, figure 36C 
shows the survival fractions for each cell line at 30 μM. The two most sensitive lines 
are the APC mutant DLD1 followed by APC wildtype RKO. Upon analysis of our CRC 
cell line panel, we did not observe any correlation between APC mutation and mTOR 
inhibitor sensitivity. Taken together, based on our siRNA and inhibitor analysis, our 
data suggests there is no link between the presence of an APC mutation and response 
to rapamycin and ridaforolimus in our panel of CRC cell lines. 
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Figure 36 Analysing the sensitivity to rapamycin and ridaforolimus 
A) Dose response curves for rapamycin and ridaforolimus in the RKO controls (red) 
and RKO APC mutant cell lines (blue) 96 hours of treatment in 96 well plate. 
Experiment performed three times and error bars are SEM. B) Dose response curves 
for rapamycin and ridaforolimus in the CRC panel 96 hours of treatment in 96 well 
plate. APC and β-catenin wildtype cell lines (red), APC wildtype, β-catenin mutant cell 
lines (black) and APC mutant cell lines (blue). Experiment performed three times and 
error bars are SEM. C) Comparison of the survival fractions after treatment with 30 μM 
rapamycin and ridaforolimus in the CRC panel. Error bars are SEM and one way anova 
(post hoc tukey) performed (* p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001, **** p≤ 0.0001).  
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2.3 Correlation between mTOR protein levels and response to 
mTOR inhibitors 
To determine whether the lack of sensitivity of our APC mutant cell lines to mTOR 
inhibition was due to different levels of mTOR expression in our panel of cell lines, we 
next immunoblotted whole cell lysates from our CRC panel and analysed levels of total 
mTOR and mTOR phosphorylated at serine 2448 (ser2448 p-mTOR). The serine 2448 
residue of mTOR is phosphorylated by a protein downstream known as protein S6 
kinase (S6K) and this is thought to have a role in regulating mTOR. Research suggests 
mTOR phosphorylated at ser2448 indicates activation of the mTORC1 complex 
(Rosner et al. 2010; Copp et al. 2010). Figure 37 shows the levels of total mTOR and 
ser2448 p-mTOR are generally correlated, such that when total mTOR was highly 
expressed, mTOR was highly phosphorylated at ser2448 in our CRC panel. HCT116 
shows the highest expression level of both total mTOR and ser2448 p-mTOR. The cell 
lines most sensitive to rapamycin and ridaforolimus DLD1 and RKO have the lowest 
levels of total mTOR and the most sensitive line DLD1 additionally has the lowest level 
of ser2448 p-mTOR. Low levels in DLD1 and RKO of the vital pathway mTOR is likely 
to explain the sensitivity to mTOR inhibitors. The pathway is required for activating 
macromolecule synthesis, cell cycle progression, growth, metabolism, cytoskeletal 
organisation, cell survival and the inhibition of autophagy. Potentially reducing all these 
processes in the cell reduces the level of these functions below a threshold the cells 
can tolerate inducing cell death. In comparison a cell line highly expressing the mTOR 
pathway may still function even with a slight decrease in the processes controlled by 
mTOR. However, other factors must also be involved because the HT29 cell line has a 
similar level of total mTOR to RKO but is more resistant to rapamycin and 
ridaforolimus. To further investigate this work it would be interesting to see if the 
pattern was the same when analysing other phosphorylated forms of mTOR, such as 
ser2481 which is thought to indicate activation of mTORC2 (Copp et al. 2010). 
Our data does not support a synthetic lethal relationship between mTOR inhibition and 
APC mutation. This may be due to the fact that this synthetic lethality may occur in a 
small therapeutic window early in the development of CRC. Faller et al. (2014) used 
two in vivo models; Lgr5CreErAPCfl/fl and APCmin/+. Lgr5CreErAPCfl/fl develop APC 
mutations just in Lgr5 positive stem cells (specific to colorectal epithelial cells) at codon 
580 when induced with Cre recombinase and develop adenomas within four weeks 
(Shibata et al. 1997; Faller et al. 2014). The APCmin mice have an APC mutation at 
codon 850 and develop ~30 polyps in the small intestine (Young et al. 2013). Firstly the 
Lgr5CreErAPCfl/fl mice were treated 10 days after Cre induction with rapamycin for 30 
Results - Chapter 2 Page 132 
 
days and this prevented the formation of any adenomas (Faller et al. 2014). Next both 
the Lgr5CreErAPCfl/fl and APCmin/+ were left to establish adenomas before treatment with 
rapamycin for 30 days began, rapamycin treatment resulted in a loss of clinical 
symptoms of disease and increased the lifespan of the mice compared to the control 
mice (Faller et al. 2014). Both in vivo models represent early stage disease and 
demonstrate the effectiveness of rapamycin treatment in mice. In comparison our 
human CRC cell lines are derived from patients with well established tumours and 
therefore, the selectivity may either only be effective in mice or at early stage disease. 
Further research would be needed to understand if this is the reason why we did not 
observe any synthetic lethal effect. 
 
 
Figure 37 Protein levels of mTOR in the CRC panel 
A) Whole cell lysates from the CRC panel were immunoblotted for total mTOR and 
ser2448 p-mTOR, β-actin used as a loading control. Three repeats were conducted, a 
representative is shown. B) C) show quantification from westerns in A) Density of 
bands was quantified and a % was calculated which was then normalised to % β-actin 
then DLD1. One way anova (post hoc Tukey) performed (* p ≤0.05).  
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We have used our in vitro model of APC mutation to perform a siRNA screen for 
kinases and kinase related genes to identify genes synthetically lethal with the APC 
mutation. From the primary screen, we identified seven potential hit kinases, some with 
roles in cellular processes such as DNA recombination, cell proliferation, cell survival 
and metabolism. Some had interesting links with tumourigenesis, such as PIM2 which 
has been linked to many cancers including CRC. For the secondary screen we used 
the SMARTpool siRNA from the screen alongside the deconvoluted siRNA for each 
potential hit gene. From the validation none of the seven potential hits validated.  
Two mTOR pathway components were potential hits in one of the siRNA screen 
replicates and researchers have suggested mTOR inhibition may be selectively lethal 
with APC mutation (Faller et al. 2014). Therefore, we decided to investigate this further 
and we found silencing mTOR and FLT3 with siRNA did not cause a greater decrease 
in cell viability in the APC mutant lines compared to the APC wt controls (RKO in vitro 
model). Additionally when performing dose response curves with the mTOR inhibitors 
rapamycin and ridaforolimus we did not see any discrimination between the APC 
mutant and APC wt lines (RKO in vitro model and CRC panel). The sensitivity to mTOR 
inhibitors in the CRC panel seemed to correlate with low mTOR levels and not APC 
status. We hypothesised that perhaps the use of mTOR inhibitors in APC mutant 
cancers has a small therapeutic window and this could be restricted to early tumour 
development. 
We have explored a number of avenues from the siRNA screen against kinases in our 
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Chapter 3 - A FDA-approved compound 
screen identified compounds showing 
synthetic lethality with mutant APC in our in 
vitro model 
 
1 An FDA-approved compound screen identified 
compounds causing synthetic lethality with mutant 
APC in our in vitro model 
1.1 Conducting the FDA-approved compound screen 
To identify drugs causing synthetic lethal relationships with truncated APC in our in 
vitro model, we performed a compound screen testing 1120 FDA-approved drugs. The 
same setup was used in a study which identified Triamterene to be selectively lethal 
with DNA mismatch repair (MMR) deficiency in a range of tumour cells (Guillotin et al. 
2017). Screening FDA-approved compounds is advantageous because the findings 
can be translated into the clinic more quickly because the safety profiles are already 
characterised. The FDA-approved compounds were aliquoted over 14 x 96 well plates 
and each plate contained controls including; media only and DMSO (<0.01 %). We 
performed the FDA-approved compound screen in triplicate in two cell lines, control 
APC wt RKO 7_1 and APC mutant RKO 2_36. On day 1 both cell lines were plated at 
2000 cells/well and the following day the cells were drugged with the compound library. 
The cells were then re-drugged on day 4, and on day 6 cell viability was analysed using 
CellTiter-glo (CTG) (Figure 38A). The luminescence readings from the CTG were log 
transformed and normalised to the median signal per plate. Next Z scores were 
calculated to standardise the values. Z scores show how many standard deviations the 
value varies compared to the mean, indicating the effect of the compound on the cells 
in comparison to the rest of the data. In a compound screen most Z scores will be close 
to 0 indicating the effect of the compound on survival does not differ much from the 
mean, any outliers are likely to be potential hits (Figure 38B). We compared the Z 
scores between the control APC wt RKO 7_1 and APC mutant RKO 2_36 cell lines and 
compounds were selected as potential hits if the Z score was <-1.5 only in the APC 
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Figure 38 FDA-approved compound screen 
A) Schematic showing the screen layout. The library was aliquoted over 14 x 96 well 
plates. On day 1 cells were plated, followed by drug treatment on day 2 and day 4. 
Then on day 6 cell viability was measured using CTG. B) The Z score values were 
plotted for each compound in the screen for both cell lines to illustrate the spread of 
data, results are from replicate 1. Control 7_1 shown in red and APC mutant 2_36 
shown in blue.  
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1.2 Statins are synthetically lethal with mutated APC 
From the FDA-approved compound screen we identified 11 potential hit compounds. A 
compound was identified as a potential hit if the Z score in the APC mutant 2_36 was 
<-1.5 and ideally the Z score in the APC wt 7_1 cell line was close to 0. The following 
drugs were selected as potential hits because they resulted in a lower Z score in the 
APC mutated RKO 2_36 cell line compared to the control cell line in the majority of 
repeats; tizanidine HCL, tolnaftate, troxipide and diclofenac potassium (Figure 39). We 
also chose the following compounds as potential hits because these drugs were very 
effective at causing greater loss of cell viability in the RKO 2_36 cell line compared to 
the control RKO 7_1 in the first repeat only, we hypothesised that the drugs may have 
degraded over the course of the repeats; losartan potassium, moxifloxacin 
hydrochloride, saxagliptin, mesalamine and desonide (Figure 39). Additionally, we 
selected two compounds from a family of drugs known as statins; lovastatin and 
mevastatin. Both compounds caused loss of cell viability in both the control and APC 
mutant cell lines, however the effect was greater in the APC mutant RKO 2_36 (Figure 
39). We hypothesised that we could identify concentrations lower than the 10 μM used 
in the screen which would have less impact on the viability of the control cells, whilst 
significantly reducing the viability of the APC mutant lines. 
The compounds identified as potential hits have a broad range of action, interestingly 
some of the compounds have been suggested to have chemopreventive effects. 
Tizanidine HCL is a α2-adrenoceptor agonist and is used to treat muscle spasticity 
(Henney & Runyan 2008). Tolnaftate is an anti-fungal agent (Munguia & Daniel 2008). 
Troxipide is an anti-ulcer compound used to treat gastric ulcers or gastritis (Kusugami 
et al. 2000). Diclofenac potassium is an NSAID and NSAIDs are suggested to have 
chemopreventive effects (McNeely & Goa 1999; Rao & Reddy 2004). Losartan 
potassium is an angiotension II receptor antagonist and is used to treat hypertension 
and heart failure (Al-Majed et al. 2015). Moxifloxacin hydrochloride is an antibiotic 
(Keating & Scott 2004). Saxagliptin is a peptidase-4 inhibitor used to treat type 2 
diabetes (Dhillon 2015). Mesalamine (also known as 5-ASA) is used to treat ulcerative 
colitis and crohns disease, mesalamine has also been suggested to have a 
chemoprotective effect (Criscuoli et al. 2013; Rousseaux et al. 2013). Desonide is a 
corticosteroid (Kahanek et al. 2008). Lovastatin and mevastatin are members of the 
statin compound family, commonly used to lower cholesterol in patients with 
cardiovascular disease or at high risk (Alberts 1990). 





Figure 39 The 11 compounds selected as potential hits from the screen to validate 
The Z scores for each potential hit compound are plotted for each cell line and each 
replicate of the screen. The control RKO 7_1 is shown in red and the APC mutant RKO 
2_36 is shown in blue.  
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To validate the compounds as selectively lethal in APC mutant cells, we performed 
dose response curves in 96 well plates with a range of concentrations in our APC wt 
controls RKO 7_1, RKO 7_2 and APC mutant RKO 2_30 and RKO 2_36. We 
performed the validation using a similar treatment approach to the compound screen. 
We drugged the control and APC mutant cells on day 2 and day 4 and analysed cell 
viability using CTG after a total drug treatment of 96 hours. Nine of the eleven 
compounds did not show greater sensitivity in the APC mutant RKO 2_30 and RKO 
2_36 compared to the control APC wt RKO 7_1 and 7_2 (Figure 40 and 41). Lovastatin 
and mevastatin validated as hits in our in vitro model, such that the APC mutant RKO 
2_30 and RKO 2_36 were more sensitive to lovastatin and mevastatin than the APC wt 
control cells (Figure 42A). Additionally we identified concentrations lower than the 
concentration (10 μM) used in the screen which caused minimal loss of cell viability in 
the control cell lines, whilst still causing significant loss of cell viability in the APC 
mutant lines. Lovastatin was less potent than mevastatin. At a concentration of 4 μM 
lovastatin, the APC mutant lines were 40 % viable and controls were 100 %. At 4 μM 
mevastatin, the APC mutant cells were just 20 % viable whilst the controls were 80 %. 
Additionally we performed dose response curves with another statin compound, 
simvastatin which is modified from lovastatin and known to show higher potencies 
(Alberts 1990). We altered the concentration range for the dose response curves and 
found the same sensitivity in the APC mutant cell lines (Figure 42B). With simvastatin 
treatment, we observed a significant difference between the APC wt and APC mutant 
cell lines at lower concentrations, such that at 2 μM we saw 20 % viability in the APC 
mutant lines and 90 % in the controls. From the FDA-approved compound screen 
testing 1120 compounds we have shown lovastatin and mevastatin validate, showing a 
synthetic lethal relationship with the APC mutation in our in vitro model. This synthetic 
lethal relationship also extends to a more potent statin, known as simvastatin. 






Figure 40 Validation of troxipide, diclofenac potassium, tolfonate and tizanidine 
Drug dose response curves for troxipide, diclofenac potassium, tolfonate and 
tizanidine. Cells were plated in 96 well plates and treated with drug on day 2 and 4. 
After 96 hours of drug treatment CTG was used to measure cell viability. Survival 
fractions were calculated and plotted. The controls RKO 7_1 and RKO 7_2 are shown 
in red and the APC mutant RKO 2_30 and RKO 2_36 are shown in blue. Performed 
twice, a representative is shown, error bars are SD.  
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Figure 41 Validation of mesalamine, saxagliptin, moxifloxacin HCL, losartan potassium 
and desonide 
Drug dose response curves for mesalamine, saxagliptin, moxifloxacin HCL, losartan 
potassium and desonide. Cells were plated in 96 well plates and treated with drug on 
day 2 and 4. After 96 hours of drug treatment CTG was used to measure cell viability. 
Survival fractions were calculated and plotted. The controls RKO 7_1 and RKO 7_2 are 
shown in red and the APC mutant RKO 2_30 and RKO 2_36 are shown in blue. 
Performed twice, a representative is shown, error bars are SD. 




Figure 42 Validation of statins as synthetically lethal with the APC mutation 
Dose response curves for three statins. Cells were plated in 96 well plates and treated 
with drug once, total drug treatment was for 96 hours. Cell viability was measured with 
CTG and survival fractions were calculated and plotted. Controls RKO 7_1 and RKO 
7_2 shown in red, APC mutant RKO 2_30 and RKO 2_36 shown in blue. Graphs 
represent three experiments and error bars are SEM. Two way anova (post hoc Tukey) 
was performed (**** p≤ 0.0001) A) Graphs show lovastatin and mevastatin B) Graph 
shows simvastatin.  
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2 Statins cause a reduction in Wnt signalling in the APC 
mutant lines 
Having identified statins as a drug family, causing a synthetic lethal relationship with 
the APC mutation in our in vitro model, we next investigated the mechanism of 
selectivity. A significant difference between our RKO control APC wt and RKO APC 
mutated lines was the level of Wnt signalling activation. Therefore, we began our 
mechanistic investigations by analysing whether statin treatment alters levels of Wnt 
signalling. 
Firstly we analysed protein levels of total β-catenin and unphosphorylated β-catenin 
(unphosphorylated at ser33, ser37 and thr41) after statin treatment to investigate if 
levels of the Wnt pathway was altered. β-catenin is a key protein in the Wnt signalling 
pathway and the level indicates activation of the pathway. When the pathway is 
inactive, β-catenin is phosphorylated at ser33, ser37 and thr41 and this signals β-
catenin to be degraded, resulting in significantly reduced levels. When the pathway is 
active, β-catenin is unphosphorylated at ser33, ser37 and thr41 and this enables β-
catenin to accumulate in the nucleus and activate Wnt target genes. To investigate 
protein levels of β-catenin, we treated the controls APC wt RKO 7_1, RKO 7_2, and the 
APC mutant RKO 2_30 and RKO 2_36 in 6 well plates for 72 hours with vehicle, 2 μM 
lovastatin and 4 μM lovastatin or vehicle, 0.5 μM simvastatin and 1 μM simvastatin. 
After 72 hours of statin treatment, we collected whole cell lysates and immunoblotted 
for total β-catenin and unphosphorylated β-catenin (unphosphorylated at ser33, ser37 
and thr41). The westerns suggest a slight decrease in both total and unphosphorylated 
β-catenin (Figures 43A/C, figure 44A/C), however upon quantification of three repeats, 
we found there was no significant difference between the vehicle and either the 
lovastatin or simvastatin treated at the protein level (Figure 43B/D, figure 44B/D).  
To further our analysis of the Wnt signalling pathway, we performed the TCF/LEF 
luciferase assay, this uses a reporter to measure the level of TCF/LEF binding to TRE 
and is an indicator of the activation of the Wnt signalling pathway. We treated the cells 
in a 96 well plate for 72 hours with vehicle or 2 μM lovastatin and then performed the 
assay. The results shown in figure 43E show the level of Wnt activation remains low 
upon statin treatment in the two controls APC wt RKO 7_1 and RKO 7_2. In 
comparison the APC mutant RKO 2_30 and RKO 2_36 show a decrease in Wnt 
activation after 72 hours of treatment with lovastatin, however the decrease in 
activation is small and not significant. 




Figure 43 Lovastatin treatment causes a slight reduction in Wnt signalling 
A) C) Cells were treated with 0 μM, 2 μM and 4 μM lovastatin for 72 hours and whole 
cell lysates were collected. Lysates immunoblotted and probed for total and 
unphosphorylated β-catenin. β-actin or β-tubulin used as loading control. Blots 
performed three times, representative blot shown. B) D) Quantification of three 
westerns detecting levels of total β-catenin or unphosphorylated β-catenin. Normalised 
to loading control. Error bars are SEM and one way anova (post hoc Tukey) was ns E) 
TCF/LEF Wnt assay performed on cells treated with 0 μM or 2 μM lovastatin for 72 
hours in a 96 well plate. Normalised to the untreated negative control of each cell line 
then normalised to untreated 7_1 negative control. Three experiments combined, error 
bars are SEM and a one way anova (post hoc Tukey) was ns.  




Figure 44 β-catenin levels after simvastatin treatment 
A) C) Cells were treated with 0 μM, 0.5 μM and 1 μM simvastatin for 72 hours and whole cell lysates were collected. Lysates were electrophorised 
and levels of total and unphosphorylated β-catenin were detected. Westerns were performed twice and a representative is shown. β-actin was used 
as a loading control. B) D) Quantification of two westerns detecting levels of total β-catenin or unphosphorylated β-catenin, normalised to β-actin. 
Error bars are SEM and one way anova (Tukey post hoc) was ns. 
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Overall investigating the levels of the protein β-catenin and performing the TCF/LEF 
luciferase assay has suggested statins cause a slight reduction in the level of the Wnt 
signalling pathway. 
 
3 The Wnt signalling target gene survivin decreases 
upon statin treatment 
3.1 Statin treatment causes a greater decrease in survivin 
levels in the APC mutant lines compared to the APC wt controls 
We decided to investigate proteins which had previously been linked to statin induced 
apoptosis in CRC and we began by analysing protein levels of SMAD4 and survivin 
upon statin treatment (Kodach et al. 2007; Chang et al. 2013; Kaneko et al. 2007). 
Firstly we analysed SMAD4 levels, SMAD4 expression had previously been linked to 
cell lines sensitive to statins and no SMAD4 expression was associated with cell lines 
more resistant to statins (Kodach et al. 2007). We hypothesised the APC wt control cell 
lines may be absent of SMAD4 or have very low levels, whilst the APC mutant cell lines 
would highly express SMAD4. To analyse SMAD4 levels we plated the controls APC wt 
RKO 7_1 and RKO 7_2 and the APC mutant RKO 2_30 and RKO 2_36 in 6 well plates 
and treated with vehicle or 1 μM or 2 μM lovastatin for 72 hours. After treatment we 
collected whole cell lysates, immunoblotted the samples and probed for SMAD4. 
Figure 45 shows SMAD4 protein levels are similar across the cell lines with and without 
lovastatin treatment, suggesting SMAD4 is not part of the mechanism of the synthetic 
lethality between statins and the APC mutation in our in vitro model. 
Another avenue we explored was levels of the Wnt target gene called survivin. The 
downregulation of survivin has previously been linked to the mechanism of statin 
induced apoptosis in CRC (Chang et al. 2013; Kaneko et al. 2007). Survivin is an anti-
apoptotic protein and its downregulation results in apoptosis. To investigate the role of 
survivin in sensitivity to statins, we analysed the protein levels of survivin after statin 
treatment. We plated the controls APC wt RKO 7_1 and RKO 7_2 and the APC mutant 
RKO 2_30 and RKO 2_36 in 6 well plates and treated with either vehicle, 1 μM or 2 μM 
lovastatin or vehicle, 0.5 μM or 1 μM simvastatin for 72 hours. After 72 hours of statin 
treatment we collected whole cell lysates and immunoblotted for survivin levels. We 
found that statin treatment caused a greater decrease in survivin levels in the APC 
mutant lines compared to the APC wt cell lines (Figure 46A/C). The westerns were 
quantified and the results are shown in figure 46B/D. At 1 μM lovastatin the level of 
survivin is over 80 % lower in RKO 2_30 and RKO 2_36 compared to RKO 7_1. Whilst 
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at 2 μM lovastatin the difference remains similar in RKO 2_30, this cell line shows a 80 
% lower level of survivin compared to RKO 7_1. In the APC mutant RKO 2_36 cells, 
the survivin level is 40 % lower than RKO 7_1. Simvastatin is more potent and 
therefore the decrease in survivin occurs at lower concentrations. At 0.5 μM 
simvastatin RKO 2_30 is 90 % lower and RKO 2_36 is 70 % lower. Whilst at 1 μM 
simvastatin the level of survivin has decreased to a low level in the control line too so 





Figure 45 SMAD4 levels after lovastatin treatment 
Cells were treated with 0 μM, 1 μM and 2 μM lovastatin for 72 hours and whole cell 
lysates were collected. Lysates were immunoblotted and probed for SMAD4. β-actin 
used as loading control.  
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Figure 46 Survivin levels after 
lovastatin or simvastatin treatment  
A) Cells were treated with 0 μM, 1 
μM and 2 μM lovastatin for 72 hours 
and whole cell lysates were 
collected. Lysates were 
immunoblotted and probed for 
survivin. Performed in triplicate, 
representative shown. β-actin or β-
tubulin used as loading control B) 
Quantification of three westerns 
detecting levels of survivin (both 
bands) and normalised to loading 
control. Error bars are SEM and 
one way anova (post hoc Tukey) 
was ns C) Cells were treated with 0 
μM, 0.5 μM and 1 μM simvastatin 
for 72 hours and whole cell lysates 
were collected. Lysates were 
immunoblotted and probed for 
survivin and β-actin used as loading 
control D) Quantification of survivin 
levels (both bands) normalised to β-
actin.
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From our analysis of the survivin protein levels with and without statin treatment, we 
found the level decreases more in the APC mutant cell lines compared to the APC wt 
cell lines in our in vitro model. We hypothesise because the level of the anti-apoptotic 
protein survivin is lower in the APC mutant lines RKO 2_30 and 2_36 in comparison to 
the control lines, the statin induced reduction in survivin may reduce its level beyond a 
survival threshold resulting in apoptosis at lower concentrations of statins than seen in 
the controls. As we have seen a slight decrease in the Wnt signalling pathway upon 
statin treatment and survivin is a Wnt target gene we propose the decrease in Wnt 
signalling is responsible for the decrease in survivin. However, the decrease in survivin 
levels could also be due to alterations in other pathways responsible for regulating 
survivin transcription including; microRNA, RTK, PI3K/Akt, MEK/MAPK, mTOR, 
STAT3, p53, hypoxia, TGF and Notch (Chen et al. 2016). Further experiments would 
be required to confirm if the decrease in survivin levels is as a result of the statin 
induced decrease in Wnt signalling. 
 
3.2 Does survivin influence levels of β-catenin? 
We have shown levels of survivin decrease upon statin treatment and β-catenin levels 
slightly decrease upon statin treatment. A striking difference upon the effect of statin 
treatment on survivin and β-catenin protein levels is the concentration required to see a 
change, survivin decreases at lower statin concentrations compared to levels of total 
and unphosphorylated β-catenin. This could imply that rather than β-catenin being 
upstream of survivin in the mechanism that perhaps β-catenin is downstream of the 
reduced survivin levels. Therefore the reduction in β-catenin could be an effect of 
reduced survivin, for example, cells switching on apoptosis (due to a decrease in 
survivin) would also reduce pathways promoting proliferation such as Wnt signalling 
resulting in reduced levels of total and unphosphorylated β-catenin. To investigate a 
direct link of survivin on β-catenin levels, we decided to investigate the effect of 
silencing survivin using siRNA on β-catenin levels. In 6 well plates we transfected a 
non-targeting control (siCON), siRNA against survivin and siRNA against PLK1 in the 
APC wt RKO 7_1 and RKO 7_2 and the APC mutant RKO 2_30 and RKO 2_36. 
Ninety-six hours post transfection, we collected whole cell lysates and immunoblotted 
the samples for survivin and β-catenin levels. Probing the westerns for survivin levels 
enabled us to determine the efficiency of the siRNA transfection. Strikingly this 
experiment emphasises the differences in survivin levels without statin treatment, RKO 
7_1, RKO 7_2 and RKO 2_36 have higher levels compared to RKO 2_30. Using siRNA 
against survivin, reduces survivin protein levels in all four cell lines to a similar level 
(figure 47A/B). We probed for total and unphosphorylated β-catenin levels to determine 
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if silencing survivin effects the levels of β-catenin and we found silencing survivin had 
no effect on the levels of β-catenin (Figure 47A/D). Quantification of the westerns 
further confirmed this (Figure 47C/E). Based on this result it is unlikely that survivin 




Figure 47 The effect of silencing survivin with siRNA on levels of β-catenin 
A) D) Cells were transfected with siRNA against siCON and siSURVIVIN. After 96 hrs 
whole cell lysates were collected. Lysates were immunoblotted and levels of survivin, 
unphosphorylated β-catenin and total β-catenin were detected. β-actin used as a 
loading control. Two experiments performed and a representative blot is shown. B) C) 
E) Quantification of two westerns, normalised to β-actin. Error bars all SEM. One way 
anova (post hoc Tukey) was performed (** p≤ 0.01).   
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3.3 Silencing levels of survivin in the wildtype RKO cell line 
increases statin sensitivity 
To test our hypothesis that survivin levels are important in the sensitivity to statins, we 
investigated if silencing survivin in the wildtype RKO cell line altered the cell lines 
sensitivity to statins. We transfected the wildtype RKO cell line with siRNA targeting 
survivin, siCON and siPLK1. After 24 hours, we treated both the cells transfected with 
siSURVIVIN and siCON with increasing doses of Lovastatin (0.5-10 μM) for 72 hours. 
We measured cell viability using CTG and plotted dose response curves (Figure 48A). 
Upon depletion of survivin, cells treated with 1 μM lovastatin were significantly more 
sensitive to lovastatin than the siCON transfected RKO cells. Upon 4 μM lovastatin the 
cells transfected with siSURVIVIN showed a 60 % decrease in survival whilst the cells 
transfected with siCON only showed a 15 % decrease in survival. This experiment 
shows silencing survivin in the wildtype RKO cell line increases the cell lines sensitivity 
to lovastatin. To confirm the siRNA targeting siSURVIVIN caused a decrease in protein 
levels of survivin, we collected whole cell lysates 72 hours after transfection with siRNA 
against survivin and immunoblotted the samples. Upon detection of survivin levels and 
quantification of the westerns we found the levels of survivin were 70 % lower when 
transfected with siSURVIVIN compared to siCON (Figure 48B/C). This data supports a 
role of survivin levels in the response to statins. 
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Figure 48 In RKO WT cells 
silencing survivin sensitises cells 
to lovastatin 
A) In a 96 well plate RKO WT 
cells were transfected with siCON 
or siSURVIVIN, the following day 
cells were drugged with 
increasing doses of lovastatin.  
After 72 hours of drug treatment 
cell viability was measured using 
CTG and survival fractions were 
calculated. Experiment performed 
in triplicate, error bars are SEM 
and a two way anova (post hoc 
Sidak) was performed (**** p≤ 
0.0001). B) In a 6 well plate RKO 
WT cells were transfected with 
siCON or siSURVIVIN and 72 
hours later whole cell lysates 
were collected. Samples were 
immunoblotted and levels of 
survivin were detected. Two 
experiments performed, 
representative shown. C) 
Quantification of the two blots 
performed in B) unpaired t-test (* 
p≤ 0.05). 
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4 Do statins act through the Mevalonate pathway to 
cause synthetic lethality with the APC mutation 
4.1 Silencing HMGCR was unsuccessful 
The known mechanism of action of statins is inhibiting HMGCR therefore we first 
looked at whether silencing HMGCR would have a similar effect as statin treatment. In 
the APC wt RKO 7_1, RKO 7_2 and APC mutant RKO 2_30 and RKO 2_36 we 
performed assays in 96 well plates and transfected a SMARTpool siRNA targeting 
HMGCR, siCON and siPLK1 to enable us to analyse the impact on survival of HMGCR 
silencing (Figure 49A). We measured cell viability using CTG 96 hours post 
transfection and calculated the survival fraction of the cells. We found no difference in 
survival upon silencing HMGCR in our controls RKO 7_1 and RKO 7_2 compared to 
the APC mutated cells RKO 2_30 and RKO 2_36. To confirm the siRNA against 
HMGCR was reducing protein levels we collected whole cell lysates from cells 
transfected with siHMGCR and siCON. The lysates were then immunoblotted and 
probed for HMGCR as shown in figure 49B and the quantification results are shown in 
figure 49C. The results show silencing HMGCR with siRNA has no effect on the protein 
levels of HMGCR and therefore we cannot determine if silencing HMGCR has the 
same effect on our in vitro model as statins do. 
To investigate if the poor transfection was specific to our in vitro model we analysed the 
same transfection into HEK293T cells which are known to transfect efficiently. In 6 well 
plates we transfected siHMGCR and siCON into HEK293T cells and collected lysates 
96 hours after the transfection. We found transfecting siHMGCR caused no change in 
HMGCR protein levels in HEK293T cells either (figure 49D). HMGCR may have a high 
turnover and we may have missed the effect of the siRNA. Therefore we would need to 
look at the effect of HMGCR silencing at earlier time-points such as 24 and 48 hours. 
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Figure 49 Silencing HMGCR using siRNA 
A) Cells transfected in 96 well plate with siCON or siRNA against HMGCR (siHMGCR) 
or siPlK1 for 96 hours. CTG used to measure cell viability and these values were used 
to calculate survival fractions. The controls siCON (blue) and siPLK1 (red) indicate 
transfection efficiency. Experiment performed twice, error bars SEM and two way 
anova (post hoc Tukey) performed (* p≤ 0.05). B) In a 6 well plate cells were 
transfected with siHMGCR for 72 hours and whole cell lysates were collected. Lysates 
were immunoblotted and probed with HMGCR. β-actin was used as a loading control. 
Performed twice, representative blot shown. C) Quantification of two westerns, 
normalised to β-actin. Error bars show SEM, one way anova (post hoc Tukey) 
performed was ns. D) HEK293T cells transfected in a 6 well with either siCON or 
siHMGCR for 96 hours. Whole cell lysates collected and immunoblotted for HMGCR 
(lower band at 102 kDa is HMGCR, band above is non specific). β-actin used as a 
loading control.  
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4.2 Mevalonic acid does not rescue the effect of statin 
treatment in the APC mutated cell lines 
HMGCR catalyses the conversion of HMG-CoA into Mevalonate, also known as 
Mevalonic acid (MVA). We investigated if adding MVA rescues the effect of statin 
treatment in our in vitro model because statins reduce the level of MVA in the cell. We 
plated the APC wt RKO 7_1 and RKO 7_2 and APC mutant RKO 2_30 and RKO 2_36 
in 96 well plates, the following day we pre-treated cells for an hour with and without 100 
μM MVA, followed by the addition of vehicle or 4 μM or 6 μM lovastatin for 48 hours 
(Figure 50A). We observed a greater decrease in cell viability in all cell lines when cells 
were pre-treated with MVA followed by lovastatin treatment for 48 hours. For example, 
pre-treatment with MVA then 6 μM lovastatin treatment resulted in a further 20-30 % 
decrease in cell viability in all cell lines compared to no MVA pre-treatment. Pre-
treatment with MVA does not rescue the effect of statins in the APC mutant RKO 2_30 
and RKO 2_36. This result was unexpected but could help us decipher the mechanism. 
Cancer cell lines are thought to have lost the negative feedback mechanisms 
controlling the Mevalonate pathway, whereby downstream products act to negatively 
regulate the levels of HMGCR (Demierre et al. 2005; Tsai et al. 2012). It is possible 
that the RKO cell line still has some of these feedback mechanisms and therefore 
adding MVA further decreases HMGCR levels enhancing the effect of statins and 
resulting in an increased reduction in cell viability rather than rescuing the effect. 
 
4.3 Treatment with GGTI shows selectivity in the APC mutant 
cells 
To further investigate the role of the Mevalonate pathway in statin sensitivity, we 
analysed downstream of HMGCR and looked to see if inhibiting GGTase or FTase with 
geranylgeranyltransferase inhibitor (GGTI) or farnesyltransferase inhibitor (FTI) 
respectively would show the same pattern of sensitivity as statins in our in vitro model. 
GGTI prevents the formation of GGPP prenylated proteins and FTI prevents the 
formation of FPP prenylated proteins. 
To this end, we tested the sensitivity of GGTI-298 and FTI-277 on our control APC wt 
RKO 7_1, RKO 7_2 and APC mutated cell lines RKO 2_30 and RKO 2_36. We plated 
the four cell lines in 96 well plates and treated with 0 μM GGTI-298, 20 μM GGTI-298 
or 0 μM FTI-277, 20 μM FTI-277 and 40 μM FTI-277. Additionally, we treated with 0 μM 
lovastatin, 4 μM lovastatin and 6 μM lovastatin to enable us to compare the effect of 
the GGTI-298 and FTI-277. We treated the cells with lovastatin, GGTI-298 and FTI-277 
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for 48 hours and measured cell viability using CTG. We found the APC mutant RKO 
2_30 was more sensitive to 20 μM GGTI compared to the controls APC wt, whilst RKO 
2_36 was only slightly more sensitive to 20 μM GGTI-298 compared to the controls 
(Figure 50B). This result suggests statins may mediate their effect through proteins 
which undergo GGPP prenylation, this includes protein families such as Rac, Rho and 
Cdc42 (Demierre et al. 2005). In comparison treatment with 20 μM FTI-277 and 40 μM 
FTI-277 in all the cell lines showed the same sensitivity, such that treatment with 40 μM 
FTI-277 resulted in 65 % viability in the APC wt and APC mutant lines (Figure 50C). 
We do not see increased sensitivity to FTI-277 in the APC mutant lines which suggests 
the mechanism is not through FPP prenylated protein families such as Ras and Rheb 
(Demierre et al. 2005). To further confirm that GGPP prenylated proteins are important 
in our mechanism and FPP prenylated proteins are not we would need to investigate if 
the addition of GGPP or FPP alongside statin treatment rescues the sensitivity to 
statins in the APC mutant RKO 2_30 and 2_36. However, taken together these 
experiments do support a role for statins acting through the Mevalonate pathway. 
We hypothesised that proteins which undergo GGPP prenylation could have a role in 
the mechanism of synthetic lethality between statins and the APC mutation. A protein 
of particular interest was Rac1 because it undergoes GGPP prenylation and has been 
linked to the Wnt signalling pathway either by transporting β-catenin into the nucleus or 
by promoting the formation of β-catenin-TCF/LEF complexes (Wu et al. 2008; 
Jamieson et al. 2015). Hyperactivation of the Wnt signalling pathway is an important 
consequence of the APC mutation and therefore if statins decrease Rac1 activity 
through the reduction in isoprenylation, Wnt signalling may also decrease causing a 
subsequent decrease in the activation of Wnt target genes including survivin. 
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Figure 50 Effect of treating with MVA (followed by statins), GGTI or FTI. 
All experiments carried out with controls RKO 7_1, RKO 7_2 and APC mutant RKO 
2_30 and 2_36. Two repeats were performed, two way anova (post hoc Tukey) 
performed (* p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001, **** p≤ 0.0001), error bars are SEM. A) 
Cells were pre-treated with 0 μM or 100 μM MVA for an hr then treated with either 0 
μM, 4 μM and 6 μM lovastatin for 48 hrs in 96 well plates. Measured cell viability using 
CTG, normalised to each conditions 0 μM lovastatin. B) Cells were treated with 0 μM 
lovastatin, 4 μM lovastatin, 6 μM lovastatin or 20 μM GGTI-298 for 48 hours in 96 well 
plates. Cell viability was measured using CTG and survival fractions were calculated. 
C) Cells were treated with 0 μM lovastatin, 4 μM lovastatin, 6 μM lovastatin, 20 μM FTI-
277 or 40 μM FTI-277 for 48 hrs in 96 well plates. Cell viability was measured using 
CTG and survival fractions were calculated.  
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5 Is Rac1 involved in the statin induced decrease in 
survivin levels 
5.1 Active Rac1 levels increase upon statin treatment 
We hypothesised the statin induced reduction in isoprenylation could result in a 
decrease in active Rac1 and/or Rho proteins (RhoA, RhoB and RhoC). Rac1 and Rho 
are GTPase proteins and are active when bound to GTP. To detect levels of Rac1-GTP 
and Rho-GTP we used specifically designed pull down kits which are commonly used. 
For analysis of active Rac1/Rho, we treated the RKO controls 7_1 and 7_2 and the 
RKO APC mutant 2_30 and 2_36 with and without 2 μM lovastatin for 72 hours and 
collected whole cell lysates. For analysis of active Rac1/Rho, 500 μg lysate per 
condition was run through a column containing a resin with a GST-fusion protein. For 
active Rac1, the GST-fusion protein contained the p21(rac1)-binding domain (PBD) of 
the Rac1 effector Pak1, where active Rac1 interacts with Pak1. This enables the active 
Rac1 to be separated from inactive Rac1. For active Rho, the GST-fusion protein 
contained the Rhotekin-binding domain (RBD) of the Rho effector Rhotekin, which only 
active Rho binds to. We performed two controls alongside the other reactions, a 
positive control where lysates were treated with GTPyS (0.1 mM for 15 minutes at 30 
°C) or a negative control where lysates were treated with GDP (1 mM for 15 minutes at 
30 °C). Upon immunoprecipitation, the control lysates and test lysates were then 
electrophorised on an SDS-PAGE gel and probed for Rac1 or Rho (RhoA/B/C). This 
analysis would detect only Rac1/Rho bound to GTP. We also included an input column 
which detected total Rac1/Rho. 
We observed that the APC wt lysates from RKO 7_1 and RKO 7_2 cells had a similar 
level of active Rac1, before and after lovastatin treatment (Figure 51A/C). Whereas the 
APC mutant lines RKO 2_30 and RKO 2_36, firstly have a lower level of active Rac1 
without lovastatin treatment compared to the controls. However, upon statin treatment, 
the level of active Rac1 dramatically increases. To determine whether this was due to 
different levels of total Rac1, we treated cells in 6 wells with 0 μM, 2 μM and 4 μM 
lovastatin and after 72 hours collected cell lysates. The lysates were then 
immunoblotted and probed for Rac1 (Figure 51E). The lower basal active Rac1 seen in 
RKO 2_30 and RKO 2_36 appears to be partly contributed to differences in the total 
level of Rac1 as these cells have lower levels of total Rac1 without statin treatment in 
comparison to the control RKO 7_1. The increase in active Rac1 after 2 μM lovastatin 
treatment in the APC mutant lines does not appear to be due to an increase in total 
Rac1 because levels of total Rac1 remain similar. Interestingly, the finding that levels of 
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active Rac1 increase upon statin treatment in the APC mutant lines is the opposite of 
our original hypothesis, as we thought Rac1 activation might decrease due to a 
decrease in isoprenoids. 
For analysis of active Rho, we detected no change in the level of active Rho upon 
lovastatin treatment in all four cell lines (Figure 51B/D). We also analysed levels of total 
Rho in whole cell lysates collected from 6 well plates which had been treated with 0 μM 
and 2 μM lovastatin for 72 hours (Figure 51F). The level of total Rho upon statin 
treatment did not appear to change in the four cell lines, however we did observe that 
the level of total Rho between the cell lines was slightly lower in the APC mutant cell 
lines. It is interesting we see a change in active Rac1 levels and not active Rho 
proteins and this suggests Rac1 may be important for the selective effect observed 
with statin treatment on APC mutant cells. 
 
5.2 Inhibiting the activation of Rac1 does not cause greater loss 
of cell viability in the APC mutant cell lines compared to the 
APC wt controls 
As we observed a significant activation of Rac1 upon statin treatment in the APC 
mutant cell line, we next investigated whether Rac1 activation was causing the 
selectivity in our in vitro model. Firstly, we treated our cells with the Rac1 inhibitor 
EHT1864 which prevents Rac1 binding to GTP and therefore prevents its activation 
(Onesto et al. 2008). Other Rac1 inhibitors block Rac1 indirectly by inhibiting GAP 
responsible for activating Rac1 (Onesto et al. 2008). EHT1864 has a Kd value of 40 nM 
showing it has a high binding affinity for Rac1, therefore we initially performed a dose 
response curve with doses around this Kd value (Shutes et al. 2007). We performed 
the dose response curves in 96 well plates in the APC wt RKO 7_1 and RKO 7_2 and 
the APC mutant RKO 2_30 and RKO 2_36. We drugged for 96 hours and measured 
cell viability using CTG. Figure 52A shows we did not see a difference in response 
between the controls (RKO 7_1 and RKO 7_2) and APC mutant cell lines (RKO 2_30 
and RKO 2_36). The highest dose 1000 nM (1 μM) did not significantly alter cell 
viability in the cell lines, and therefore, we next tested a higher dose range up to 15 μM 
EHT1864. Figure 52B illustrates that we did not see selectivity between the controls 
and APC mutant cell lines when increasing the dose range to 15 μM EHT1864. These 
results suggest inhibiting the activation of Rac1 does not have the same impact on the 
cells as statins. 
 




Figure 51 Active Rac1 and active Rho pull down experiments 
A) B) C) D) Cells were treated with 0 μM and 2 μM lovastatin for 72 hours. Then whole 
cell lysates were collected and 500 μg was used for the pull down kits. After the pull 
down assays were performed, samples were immunoblotted, we loaded 10 μg for 
input, 10 μL for controls (GTPyS/GDP) and 40 μL for samples. Total Rac1 or total Rho 
antibody was used for the detection. The input lane shows levels of total Rac1/Rho. All 
performed twice, representative shown. A) Active Rac1 pull down in 7_1 and 2_30 B) 
Active Rho pull down in RKO 7_1 and RKO 2_30 C) Active Rac1 pull down in RKO 7_2 
and RKO 2_36 D) Active Rho pull down in RKO 7_2 and RKO 2_36 E) Cells were 
treated with 0 μM, 2 μM and 4 μM lovastatin for 72 hours and whole cell lysates 
collected. Lysates immunoblotted and levels of total Rac1 detected. β-tubulin used as a 
loading control. F) Cells were treated with 0 μM and 2 μM lovastatin for 72 hours and 
whole cell lysates collected. Lysates immunoblotted and levels of total Rho detected. β-
tubulin used as a loading control.  
 





Figure 52 Investigating the potential role of Rac1 in the mechanism 
A) B) In 96 well plates dose response curves were performed with two different dose 
ranges of EHT1864. Cells treated with EHT1864 for 96 hours and cell viability 
measured with CTG. Control cell lines RKO 7_1 and RKO 7_2 shown in red and APC 
mutant cell lines RKO 2_30 and RKO 2_36 shown in blue. Error bars are SD. C) In 96 
well plates cells were treated twice with either no drug, 100 nM EHT1864, 6 μM 
lovastatin or 100 nM EHT1864 & 6 μM lovastatin for a total treatment time of 96 hours. 
Cell viability was analysed with CTG. Control cell lines RKO wt RKO 7_1 and RKO 7_2 
shown in red and APC mutant cell lines RKO 2_30 and RKO 2_36 shown in blue. 
Performed in triplicate, error bars SEM. Two way anova (post hoc Tukey) was 
performed showing just the results for 6 μM lovastatin vs 100 nM EHT1864 & 6 μM 
lovastatin (* p≤ 0.05, ** p≤ 0.01). D) Cells were treated with 0 μM or 2 μM lovastatin for 
72 hrs and lysates collected. Additionally RKO wt cells were treated for 24 hrs with 
GDP or GTPyS as controls. Lysates were immunoblotted and probed for pPAK1/2/3 
and total PAK1. β-actin used as a loading control, performed twice, representative blot 
shown. 
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5.3 Inhibiting Rac1 activation in combination with statin 
treatment does not rescue the selectivity 
Our results suggest that in APC mutated cells, Rac1 is activated upon statin treatment. 
Therefore to further understand if the increase in active Rac1 upon statin treatment is 
key to the mechanism of synthetic lethality, we investigated if inhibiting Rac1 activation 
in combination with statin treatment would rescue the effect in the APC mutant cell 
lines. To this end, the parental cell line RKO wt, APC wt controls RKO 7_1, RKO 7_2 
and the APC mutant RKO 2_30 and RKO 2_36 were plated in 96 well plates. On day 2 
and day 4 the cells were treated with the following combinations 1) vehicle 2) 100 nM 
EHT1864 3) 6 μM lovastatin 4) 6 μM lovastatin and 100 nM EHT1864. Cell viability was 
measured using CTG, after 96 hours of total drug treatment. Figure 52C shows that 
addition of EHT1864 did not rescue the effect of lovastatin on the APC mutant cell 
lines. This suggests the statin induced increase in Rac1 activation is not responsible for 
the reduced cell viability in the APC mutant cell lines, however, it does not completely 
rule Rac1 out of the mechanism of synthetic lethality. 
 
5.4 The phosphorylation levels of the Rac1 effector Pak1 at 
ser144 reduces upon statin treatment 
To determine whether the increase in active Rac1 observed is indeed functional in the 
canonical Rac1 activation pathway, we analysed Pak1 phosphorylation upon statin 
treatment in the APC wt and APC mutant cell lines. Pak1 is a serine theronine kinase 
downstream of Rac1 and Pak1 is also activated by PDK1, Pi3K and AKT (Kumar et al. 
2006). Pak1 activation by the GTPases Rac1 and Cdc42 is the best characterised 
mechanism of activation (Kumar et al. 2006). Pak1 activates many pathways and has a 
role in regulating the cytoskeleton, cell growth and cell survival (Ye & Field 2012). We 
analysed phosphorylation at ser144 in the kinase inhibitory domain of Pak1 (unique to 
activation by Rac1 and Cdc42), this results in a conformational change, enabling the 
kinase domain to autophosphorylate for full Pak1 activation (Chong et al. 2001). 
To investigate Pak1 phosphorylation, the parental cell line RKO wt, APC wt controls 
RKO 7_1, RKO 7_2 and the APC mutant RKO 2_30 and RKO 2_36 were plated into 6 
well plates on day 1. On day 2 each cell line was treated with either vehicle or 2 μM 
lovastatin for 72 hours. Alongside these wells two controls were performed in just the 
parental RKO wt cell line, on day 4 either 400 μM GDP (inactives Rac1) or 40 μM 
GTPyS (activates Rac1) was added to the cells for 24 hour treatment. On day 5, 
protein lysates were collected from all the treated wells and samples were 
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immunoblotted and probed for total Pak1 and phosphorylated Pak1 at ser144. Due to 
structural similarity the antibody also detects phosphorylated ser141 of Pak2 and 
phosphorylated ser139 of Pak3 (Rane & Minden 2018). Our results show levels of total 
Pak1 are the same for all cell lines regardless of statin treatment and the untreated 
cells all contain the same level of phosphorylated Pak1/2/3 (Figure 52D). Upon statin 
treatment only the APC mutated cell lines RKO 2_30 and RKO 2_36 show a 
substantial decrease in levels of phosphorylated Pak1/2/3, suggesting statins reduce 
the activation of Pak1. Interestingly in the control wells treated with GDP to inactive 
Rac1 we do not see a substantial change in the phosphorylation of Pak1/2/3 in 
comparison to the cells treated with GTPyS to active Rac1. Perhaps treatment with 
GDP/GTPyS was not sufficient to see an alteration at this part of the pathway. We 
hypothesise the decrease in phosphorylation of Pak1 despite increased levels of active 
Rac1 suggests the localisation of the Rac1 could be altered upon statin treatment, 
preventing the phosphorylation of Pak1 and full activation. Statins decrease levels of 
prenylation and unprenylated Rac1 would be unable to localise to the plasma 
membrane. Pak1 is recruited to the membrane for activation and this is where 
prenylated Rac1 would also locate (Kumar et al. 2006; Wennerberg & Der 2004). 
 
5.5 Rac1 localisation with cadherin upon statin treatment 
To further understand the effects of statin treatment on Rac1 in our in vitro model, we 
investigated the localisation of Rac1 in relation to its role in mediating cell-cell 
adhesion. Cadherins regulate intercellular adhesion through calcium dependent 
homophilic interactions. Epithelial cadherin (E-cadherin) is a type of cadherin found in 
epithelial cells (Fukata & Kaibuchi 2001). Rac1 has been shown to co-localise with E-
cadherin and this indirectly induces activation of Rac1 through additional proteins 
(Nakagawa et al. 2001). We performed immunofluorescence in RKO wt cells, RKO 
7_1, RKO 7_2, RKO 2_30 and RKO 2_36 to investigate the localisation of both Rac1 
and cadherin. For each cell line we plated 100,000 cells/well onto coverslips in 24 well 
plates and treated with 0 μM lovastatin or 2 μM lovastatin for 72 hours. Additionally we 
performed two controls in just the RKO wt cells, these cells were treated for just 24 
hours with either 80 μM GTPyS (to activate Rac1) or 400 μM GDP (to inactivate Rac1). 
The cells were then fixed and stained with DAPI, total Rac1 and pan-cadherin (detects 
all forms of cadherin including E-cadherin) to enable us to understand if statins alter the 
localisation and activation of Rac1 in relation to its role in cell-cell adhesion.
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Figure 53 Localisation of Rac1 and cadherin 
upon statin treatment in RKO WT 
For the controls RKO WT cells were treated 
with 400 μM GDP or 80 μM GTPyS for 24 
hours before fixing. The drug treated cells 
were treated with 0 μM or 2 μM lovastatin for 
72 hrs before fixing and preparing for 
confocal. DAPI staining is in blue, total Rac1 
is in green and pan-cadherin is in red. 
Merged image is a composite of DAPI, total 
Rac1 and pan-cadherin. Scale bar indicates 
20 μM. Representative images shown.  
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Figure 54 Localisation of Rac1 and cadherin 
upon statin treatment in RKO 7_1 and 7_2 
The drug treated cells were treated with 0 
μM or 2 μM lovastatin for 72 hrs before fixing 
and preparing for confocal. DAPI staining is 
in blue, total Rac1 is in green and pan-
cadherin is in red. Merged image is a 
composite of DAPI, total Rac1 and pan-
cadherin. Scale bar indicates 20 μM. 
Representative images shown.  
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Figure 55 Localisation of Rac1 and cadherin 
upon statin treatment in RKO 2_30 and 2_36 
The drug treated cells were treated with 0 μM 
or 2 μM lovastatin for 72 hrs before fixing and 
preparing for confocal. DAPI staining is in blue, 
total Rac1 is in green and pan-cadherin is in 
red. Merged image is a composite of DAPI, 
total Rac1 and pan-cadherin. Scale bar 
indicates 20 μM. Representative images 
shown.  
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Firstly our immunofluorescence images indicate that Rac1 and pan-cadherin do co-
localise in the APC wt RKO cell lines (Figures 53-55). It is difficult to draw conclusions 
from the data because the pan-cadherin staining is not strictly associated with the 
membrane and this made the images difficult to interpret and quantify. RKO cells are 
small and the nucleus takes up a large portion of the total cell volume and there is often 
a small cytoplasm. The staining for both Rac1 and pan-cadherin is throughout the 
cytoplasm but the strongest staining typically appears to be at the plasma membrane 
often at sites resembling cell-cell contacts or lamellipodia. Comparison of the images 
for the controls GDP and GTPyS show the differences between cells with very little 
active Rac1 (GDP treated) and cells with lots of active Rac1 (GTPyS treated). The 
RKO WT cells treated with GDP show lower intensity Rac1 staining with fewer foci of 
intense staining compared to the GTPyS (Figure 53). For the RKO WT, RKO 7_1 and 
RKO 7_2 the staining is more intense without lovastatin treatment, upon lovastatin 
treatment we generally see less foci (Figure 53/54). In the untreated RKO APC mutant 
lines 2_30 and 2_36 the staining looks similar to the GDP control with just light 
staining. Whereas the treated RKO 2_30 and 2_36 have stronger staining and this 
appears to be throughout the cytoplasm rather than at specific sites such as cell-cell 
contacts and lamellipodia (Figure 55). These observations may suggest statins affect 
Rac1 in both cell lines but the effect is more prominent in the APC mutant cell lines and 
is suggestive of dysfunctional Rac1 signalling upon statin treatment. 
We attempted to quantify the images based on the assumption that a cell positive for 
active Rac1 showed co-localisation of Rac1 and cadherin at the membrane. This was 
difficult to score because the pan-cadherin staining was not restricted to the plasma 
membrane. We compared the number of cells positive for Rac1 and cadherin at the 
membrane to the total number of cells which were identified by DAPI staining to 
calculate a percentage of cells containing active Rac1. We counted ~300 cells and 
used this to quantify the effect of statin treatment on the number of cells showing active 
Rac1 (Figure 56). The controls RKO wt, RKO 7_1, RKO 7_2 show a similar % of cells 
displaying active Rac1 upon statin treatment compared to untreated. In comparison the 
APC mutant RKO 2_30 and RKO 2_36 have a 20 % lower percentage of cells showing 
active Rac1 without statin treatment. In agreement with the active Rac1 pull down data 
upon statin treatment we see an increase in the percentage of APC mutant cells 
showing active Rac1. The effect is more prominent in the RKO 2_30 cell line which is 
the same as the active Rac1 pull down data (section 5.1). This analysis supports 
previous data showing the RKO APC mutant cell lines do have lower basal levels of 
active Rac1 and statin treatment caused an increase in active Rac1. Additionally statin 
treatment potentially caused the Rac1 staining to be evenly cytoplasmic instead of 
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stronger at cell-cell contacts and lamellipodia suggesting aberrant Rac1 signalling. 





Figure 56 Summary of the % cells containing active Rac1 upon statin treatment  
The drug treated cells were treated with 0 μM or 2 μM lovastatin for 72 hrs before fixing 
and preparing for confocal. Approximately 300 cells were counted per condition per cell 
line and the % of cells with active Rac1 staining was calculated based on Rac1 and 
cadherin co-localising at the membrane. Represents results from three experiments 
and error bars are SEM. Two way anova (post hoc Bonferroni) was performed (* p≤ 
0.05, ** p≤ 0.01).  
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6 The statin induced increase in active Rac1 causes β-
catenin to be transported into the nucleus 
6.1 Statin treatment increases β-catenin transport into the 
nucleus 
Our data suggested that Wnt signalling and the Wnt target gene survivin decrease 
upon statin treatment. Therefore we analysed whether statins alter the localisation of β-
catenin in our in vitro model using immunofluorescence. We plated the control cells 
RKO 7_1 and RKO 7_2 and the APC mutant RKO 2_30 and RKO 2_36 onto 
coverslips, using a density of 40,000 cells/well. Next the cells were treated with 0 μM or 
4 μM lovastatin for 72 hours. The cells were then fixed and stained with DAPI and total 
β-catenin to enable us to compare the number of cells with β-catenin in the nucleus 
and cytoplasm. 
Representative images are shown for the control APC wt cells in figure 57 and APC 
mutant lines in figure 58. As expected without lovastatin, the APC wt RKO 7_1 and 
RKO 7_2 had low β-catenin staining in the cytoplasm and the nucleus, in comparison 
to the APC mutant cells RKO 2_30 and RKO 2_36 which showed higher levels of both 
cytoplasmic and nuclear staining, indicating active Wnt signalling. Approximately 200 
cells were analysed for each condition, the percentage of cells with β-catenin staining 
in the cytoplasm and percentage of cells with β-catenin staining in the nucleus was 
calculated and the results are illustrated in figure 59. Statin treatment in the APC 
mutated cells caused a decrease in cells with cytoplasmic β-catenin and an increase in 
cells with β-catenin in the nucleus. This result is interesting because we would expect 
an increase in nuclear β-catenin to result in more β-catenin binding to TCF/LEF and 
activating Wnt target genes. Therefore this result is not in agreement with our previous 
data, suggesting statins cause a decrease in Wnt signalling. Perhaps β-catenin 
accumulates in the nucleus but is prevented from activating Wnt target genes, this is 
further discussed in section 6.2. 




Figure 57 Levels of total β-catenin upon statin treatment in RKO 7_1 and 7_2 
Cells were treated with 0 μM or 4 μM lovastatin for 72 hrs before fixing and preparing 
for confocal. DAPI staining is in blue, total β-catenin is in red. Merged image is a 
composite of both DAPI and total β-catenin. Scale bar indicates 20 μM. Representative 
images shown.  




Figure 58 Levels of total β-catenin upon statin treatment in RKO 2_30 and 2_36 
Cells were treated with 0 μM or 4 μM lovastatin for 72 hours before fixing and preparing 
for confocal. DAPI staining is in blue, total β-catenin is in red. Merged image is a 
composite of both DAPI and total β-catenin. Scale bar indicates 20 μM. Representative 
images shown. 




Figure 59 Summary of total β-catenin levels upon statin treatment 
Cells were treated with 0 μM or 4 μM lovastatin for 72 hrs before fixing and preparing 
for confocal. Approximately 200 cells were counted per condition per cell line and the 
% of cells with A) cytoplasmic staining and % cells with B) nuclear staining was 
calculated. A) B) Error bars are SEM, one way anova (post hoc Tukey) was performed 
for both graphs (** p≤ 0.01).  
 
6.2 The Rac1 inhibitor EHT1864 prevents the statin induced 
transport of β-catenin into the nucleus 
Rac1 has previously been shown to play a role in the Wnt signalling pathway through 
two potential mechanisms. Rac1 may be required for β-catenin to be transported into 
the nucleus, whereby active Rac1 activates JNK2, which then phosphorylates β-
catenin at ser191 and ser605, enabling β-catenin to translocate to the nucleus (Wu et 
al. 2008). More recent research suggests Rac1 plays a role in enhancing the formation 
of β-catenin-TCF/LEF complexes (Jamieson et al. 2015). Jamieson et al. (2015) also 
suggests Rac1 activation mediates the activation of JNK2 and the phosphorylation of 
β-catenin at ser191 and ser605 by JNK2. The phosphorylation of β-catenin at these 
residues is believed to enhance its binding to TCF/LEF and not facilitate its transport 
into the nucleus. Additionally Rac1 has been shown to play a key role in CRC 
tumourigenesis. Myant et al. (2013) showed the level of active Rac1 is upregulated 
after APC is mutated and this promotes tumourigensis. Rac1 is suggested to act 
downstream of Wnt signalling (in contrast to the research mentioned earlier) to promote 
progenitor cell proliferation and the expansion of LGR5 ISC cells in the colonic crypts 
(Myant et al. 2013). Espina et al. (2008) demonstrated overexpression of Rac1 in a 
APC mutant SW620 xenograft model accelerated tumourigenesis, whilst the 
suppression of Rac1 prevented tumourigenesis. Based on the link of Rac1 with both 
CRC and Wnt signalling we hypothesised the increase in active Rac1 upon statin 
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treatment in the APC mutant lines was responsible for the increase in β-catenin being 
transported from the cytoplasm to the nucleus. 
To investigate if Rac1 was involved, we inhibited Rac1 using EHT1864 in combination 
with lovastatin treatment in the APC wt RKO 7_1 and APC mutant RKO 2_30 and used 
confocal microscopy to analyse levels of total β-catenin in the cytoplasm and nucleus. 
We plated RKO 7_1 and RKO 2_30 on coverslips at a density of 40,000 cells/well and 
treated with 1) vehicle, 2) 4 μM lovastatin, 3) 1 μM EHT1864 or 4) 4 μM lovastatin and 
1 μM EHT1864. We treated the cells for 72 hours, then fixed the cells and stained with 
DAPI and total β-catenin. Representative images for RKO 7_1 are shown in figure 60 
and for RKO 2_30 in figure 61. Approximately 150 cells were analysed per condition 
and the percentage of cells with β-catenin staining in the nucleus and β-catenin 
staining in the cytoplasm was quantified (Figure 62). The APC wt RKO 7_1 cells show 
between 10-40 % cells with cytoplasmic total β-catenin staining in the different 
conditions but all conditions show no cells with nuclear staining. The variation in 
cytoplasmic staining could be related to these results being from one experiment 
because previously when treating RKO 7_1 with and without lovastatin we saw less 
than 10 % cells with cytoplasmic β-catenin staining. The results show no RKO 7_1 cells 
with nuclear staining and this is because of the low activation of the Wnt signalling 
pathway in this cell line. Figure 62A shows that lovastatin treatment alone in RKO 2_30 
reduces the percentage of cells with total β-catenin in the cytoplasm as seen 
previously, compared to the levels when treated with EHT1864 alone and vehicle. 
When lovastatin and EHT1864 are combined the percentage of cells with β-catenin in 
the cytoplasm is just below the level seen in the vehicle and EHT1864 alone, indicating 
that Rac1 inhibition using EHT1864 prevented the reduction in β-catenin staining in the 
cytoplasm upon lovastatin treatment. In agreement with these results the increase in 
percentage of cells with β-catenin nuclear staining is only seen when the RKO 2_30 
cells are treated with lovastatin alone (Figure 62B). When the RKO 2_30 cells are 
treated with EHT1864 and lovastatin together, the percentage of cells with β-catenin in 
the nucleus is similar to the vehicle treated. This data supports our hypothesis that the 
statin driven increase in active Rac1 is causing β-catenin to be transported from the 
cytoplasm into the nucleus. 
 




Figure 60 Effect of EHT1864 and statin treatment on β-catenin in RKO 7_1 
Control RKO 7_1 were untreated or treated with 4 μM lovastatin or 1 μM EHT1864 or 4 
μM lovastatin & 1 μM EHT1864 for 72 hrs before fixing and preparing for confocal. 
DAPI staining is in blue, total β-catenin is in red. Merged image is a composite of both 
DAPI and total β-catenin. Representative images shown.  




Figure 61 Effect of EHT1864 and statin treatment on β-catenin in RKO 2_30 
APC mutant RKO 2_30 were untreated or treated with 4 μM lovastatin or 1 μM 
EHT1864 or 4 μM lovastatin & 1 μM EHT1864 for 72 hours before fixing and preparing 
for confocal. DAPI staining is in blue, total β-catenin is in red. Merged image is a 
composite of both DAPI and total β-catenin. Representative images shown.  





Figure 62 Summary of the effect of EHT1864 and statin treatment on β-catenin  
Cells were untreated or treated with 4 μM lovastatin or 1 μM EHT1864 or 4 μM 
lovastatin & 1 μM EHT1864 for 72 hours before fixing and preparing for confocal. At 
least 150 cells were counted per condition per cell line and the % of cells with 
cytoplasmic staining A) and % cells with nuclear staining B) was calculated.  
 
 
In our in vitro model we have shown that statins cause an increase in active Rac1, this 
increase in active Rac1 is not responsible for the synthetic lethality we see between 
statins and the APC mutation. The increase in active Rac1 is responsible for an 
increase in β-catenin being transported from the cytoplasm into the nucleus. Results 
discussed earlier from immunoblotting both total and unphosphorylated (active) β-
catenin (Figure 43/44) and the TCF/LEF reporter assay (Figure 43E) do not 
demonstrate an increase in Wnt signalling after statin treatment. This implies statins 
may cause β-catenin to accumulate in the nucleus, but the β-catenin is unable to active 
Wnt signalling. Our results do not support one of the hypothesised roles of Rac1 in the 
Wnt signalling pathway, suggesting that Rac1 enhances the formation of β-catenin-
TCF/LEF complexes. If this were true, we would expect to observe an increase in 
transcription of Wnt target genes (measured through the TCF/LEF assay) with the 
increase in active Rac1, results discussed earlier (section 2 and 3.1) showed a 
decrease in the TCF/LEF assay and a decrease in expression of the Wnt target gene 
survivin. The recent data on the phosphorylation of Pak1 may explain this discrepancy 
in increased nuclear β-catenin and a decrease in TCF/LEF activation. β-catenin has 
been described as a Pak1 effector, Pak1 has been shown to phosphorylate β-catenin 
at ser675 and this stabilises β-catenin and enhances transcription of Wnt target genes 
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(Zhu et al. 2012). We have shown statins prevent the phosphorylation and subsequent 
activation of Pak1 and we hypothesise this is through the mislocalisation of Rac1, due 
to the decrease in prenylation. This could be responsible for the reduction in 
transcription of Wnt target genes regardless of increased levels of nuclear β-catenin. 
To test this hypothesis we could add active Pak1 to the cells, whilst treating with statins 
and see if this rescues the synthetic lethality. Additionally, we could test a Pak1 
inhibitor and see if this mirrors the synthetic lethal effect seen in the APC mutant cell 
lines. 
 
7 Silencing APC does not sensitise wildtype RKO cells 
to statins 
We investigated whether silencing APC in the wildtype RKO cell line would cause an 
increase in statin sensitivity. In 96 well plates, we transfected the wildtype RKO cell line 
with the two siRNA previously used to target APC (siAPC*3 and siAPC*6; Figure 19 
from chapter 1) and then treated with increasing doses of lovastatin. After 72 hours of 
drug treatment, we measured cell viability using CTG and plotted dose response 
curves. The results show the transfection of siAPC*3 appears to sensitise the wildtype 
RKO cell line to statins, whilst the siAPC*6 does not show an increase in sensitivity 
(Figure 63A). To investigate why we see a difference, we analysed whether both siRNA 
targeting APC cause a decrease in APC protein and additionally if either siRNA 
targeting APC alters survivin levels. We collected whole cell lysates from RKO cells 
transfected with siAPC*3, siAPC*6 and siCON and immunoblotted for APC and survivin 
levels (Figure 63B/C). We found both siRNA targeting APC reduce full length APC 
levels, however neither siRNA altered the levels of survivin. Potentially, we did not see 
an increased sensitivity in wildtype RKO cells when silencing APC because using 
siRNA is not the same as the mutation we created using CRISPR-cas9, because any 
full length APC remaining could be enough to fullfill the roles of APC, preventing a 
decrease in survivin levels and an increase in sensitivity. 
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Figure 63 In RKO WT silencing APC 
does not sensitise cells to lovastatin 
A) In a 96 well plate RKO WT cells 
were transfected with siCON or 
siAPC, 5 hours later cells were 
drugged with increasing doses of 
lovastatin.  After 72 hours of drug 
treatment cell viability was measured 
using CTG and survival fractions 
were calculated. Experiment 
performed in triplicate, error bars are 
SEM, a two way anova (post hoc 
Dunnet) was performed and the 
significance values are shown for 
siCON vs siAPC*3 (** p≤ 0.01 **** p≤ 
0.0001). B) C) In a 6 well plate RKO 
WT were transfected with siCON, 
siAPC*3 and siAPC*6 and 72 hours 
later whole cell lysates were 
collected. β-tubulin or β-actin used as 
a loading control B) Levels of APC 
were detected by western blotting. C) 
Levels of survivin were detected by 
western blotting. 
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8 Investigating the response of a CRC panel to statin 
treatment 
8.1 Response to lovastatin, mevastatin & simvastatin 
In our in vitro model we have validated a synthetic lethal relationship between statins 
and the APC mutation. Next we wanted to investigate if this synthetic lethal relationship 
extended to other CRC cell lines with varying background mutations in addition to APC. 
In particular we wanted to see if cell lines with an APC mutation were more sensitive 
than the APC wt cell lines. In our cell line panel, the DLD1, HT29 and SW620 have 
APC mutations and RKO, HCT116 and SW48 are APC wildtype. In 96 well plates, we 
performed dose response curves in the DLD1, HCT116, HT29, RKO, SW48 and 
SW620 cells with increasing concentrations of lovastatin, mevastatin and simvastatin. 
The cells were drugged twice and the total treatment was for 96 hours. Cell viability 
was measured using CTG and dose response curves were plotted using survival 
fractions (Figure 64). We found the six cell lines show the same pattern of sensitivities 
to each statin such that the DLD1, RKO and SW48 cells were more sensitive than the 
HCT116, HT29 and SW620 cells to statin treatment. Interestingly, the APC mutant cells 
were not in general more sensitive to lovastatin, mevastatin and simvastatin (Figure 64 
APC mutant = blue, APC wt = black/red). Additionally we analysed whether sensitivity 
to statins correlated with activation of the Wnt signalling pathway because RKO (shown 
in red) does not show Wnt activation and this cell line is among the more sensitive cell 
lines. DLD1, HT29 and SW620 (blue) show Wnt activation due to APC mutations, 
SW48 and HCT116 (black) show Wnt activation due to β-catenin mutations. However 
no correlation was seen. We also considered if other common mutations including, 
mutations in BRAF, KRAS and p53, could correlate with sensitivity to statins. However, 
these do not explain the pattern of sensitivity (Table 9 shows the status of each line). 
Therefore the sensitivity of the panel of CRC cell lines is likely to be explained by a 
combination of factors or a particular APC mutation. Testing more cell lines would help 
our understanding of this and the impact of different APC mutations. 
 




Figure 64 Statin sensitivity in the CRC cell line panel 
Dose response curves performed in RKO, HCT116, SW48, DLD1, HT29, SW620 with 
lovastatin, mevastatin and simvastatin. Colour scheme is; APC and β-catenin wt (red), 
APC wt & β-catenin mutation (black), APC mutant (blue). Experiments performed in 
triplicate, error bars SEM. Cell lines were treated with lovastatin A) mevastatin B) 
simvastatin C). 
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8.2 Do the basal levels of survivin in the CRC panel and RKO in 
vitro model explain the sensitivities to statins? 
We have shown that a decrease in survivin levels induces sensitivity to statin 
treatment. To further our understanding of the different sensitivities we see in our CRC 
cell line panel, we analysed the basal levels of survivin in our different cell lines. We 
hypothesised the differences in statin sensitivities described above could be related to 
differences in levels of the protein survivin. A summary of the survival fraction at 10 μM 
lovastatin for all the cell lines is shown in figure 65A. We collected whole cell lysates 
from the CRC panel and our RKO in vitro model cell lines (RKO 7_1, RKO 7 _2, RKO 
2_30 and RKO 2_36) and immunoblotted for levels of survivin (Figure 65B). The 
survivin blots show two bands which could represent three isoforms because wt 
survivin encodes a 16 kDa protein, survivin ∆Ex3 encodes a 15 kDa protein and 
survivin 2B encodes a 18 kDa protein (Necochea-Campion et al. 2013). Therefore the 
top band may represent levels of survivin 2B and the lower band could represent wt 
and survivin ∆Ex3. We quantified both bands of survivin together and these are shown 
in figure 65C. The levels of survivin are very variable across the panel. RKO 2_30 had 
a lower basal level of survivin then the controls APC wt RKO 7_1 and RKO 7_2, whilst 
the results for RKO 2_36 show high variability between the repeats. Interestingly the 
cell lines DLD1 and HT29 appear to express lower levels of survivin than RKO 2_30 
and RKO 2_36 but are less sensitive to statins, the reason for this is unclear. In support 
of our hypothesis one of the most resistant cell lines HCT116 has the highest levels of 
survivin across the ten cell lines. 
To further investigate a possible relationship between basal survivin expression and 
statin response we first plotted both variables against each other for all cell lines. 
Figure 66A shows when looking at the data from all the 10 cells lines there is no 
correlation between survivin expression and statin response. Next we subdivided the 
cell lines into groups to see if this changed the correlation pattern. Firstly we looked in 
terms of APC and Wnt signalling status (Figure 66B/C/D/E) and found the strongest 
correlation (R2 0.8442) was within the cells showing no Wnt activation. This data 
suggests a higher survivin level correlates with higher sensitivity to statins, however 
this finding is limited because it is based on three RKO cell lines. We then looked in 
terms of KRAS, BRAF and TP53 status and found the highest R2 value of 0.5532 in the 
TP53 mutant (DLD1, HT29 and SW620), the greater survivin expression the more 
resistant to statins, however this result is based on data from three cell lines (Figure 
67). Weaker correlations (R2 ~0.4) were shown in the KRAS mutant, BRAF wildtype 
and TP53 wildtype. These all suggest a weak positive relationship between survivin 
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expression and statin response. The correlation strengths are limited because the 
graphs display data from up to 10 cell lines and the cell lines are biased towards the 
RKO characteristics. It would be interesting to see if studying more cell lines provides 




Figure 65 Do survivin levels explain the statin sensitivity in CRC? 
A) For all cell lines the survival fraction at 10 μM lovastatin was plotted, data from the 
dose response curves performed with lovastatin. Combination of three experiments, 
error bars SEM. B) Whole cell lysates were collected from 6 well plates and 
immunoblotted. Levels of survivin were detected and normalised to β-actin. Performed 
twice, representative blot shown. C) Both survivin bands in the western blots from B) 
were quantified together and normalised to the loading β-actin and RKO WT. Error bars 
are SEM, one way anova (post hoc Tukey) performed ns. D) For each cell line the % 
density for the upper and lower survivin bands were calculated and plotted. 




Figure 66 Do survival fractions at 10 μM lovastatin and survivin expression correlate 
Plotted survival fraction at 10 μM lovastatin against survivin expression, R2 values 
calculated. A) For all cell lines B) For APC wt C) For APC mutant D) For no Wnt 
hyperactivation E) For Wnt hyperactivation.  




Figure 67 Do survival fractions at 10 μM lovastatin and survivin expression correlate 
Plotted survival fraction at 10 μM lovastatin against survivin expression, R2 values 
calculated. A) For KRAS wt B) For KRAS mutant C) For BRAF wt D) For BRAF mutant 
E) For TP53 wt F) For TP53 mutant.  
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Next we investigated if the pattern of sensitivity to statins was due to the ratio of the top 
and lower bands. We believe these bands represent different isoforms, the lower band 
at 16 kDa could be a mixture of wildtype survivin and survivin ∆Ex3. The higher band at 
18 kDa could represent survivin-2B. Survivin-2B is an interesting isoform because a 
few studies have shown it is downregulated in later tumour stages (Mahotka et al. 
2002; Meng et al. 2004). One study in leukaemia has suggested survivin-2B may have 
a pro-apoptotic role (Zhu et al. 2004). However, at the moment there is no solid 
evidence supporting a role for the alternately spliced survivin isoforms in tumourigensis 
(Li 2005). Figure 65D shows a graph displaying the ratio of upper and lower survivin 
bands. The results show all the RKO (wildtype and in vitro model) cell lines have a 
higher percentage of the lower than the upper band. In comparison DLD1, HCT116, 
HT29, SW48 and SW620 all show the opposite and have a higher percentage of the 
upper than lower band. Additionally, we see a difference when comparing within our in 
vitro model, the APC mutant RKO 2_30 and RKO 2_36 show slightly more upper band 
than the lower band compared to the controls RKO 7_1 and 7_2. It would be interesting 
to analyse the RT-PCR levels of each of the survivin splice variants and see if this 
corresponds to the protein levels we see on the westerns. Additionally it would 
establish if the lower band represents both wildtype survivin and survivin ∆Ex3 and if 
the higher band is survivin-2B. Overall statin sensitivity doesn’t seem to directly 
correlate to survivin levels or the ratio of the upper and lower survivin bands in our 
CRC cell line panel and in vitro model. It is possible that survivin levels are one of 
multiple factors which influence response to statins. 
 
 
In this chapter we have investigated the mechanism responsible for the synthetic lethal 
relationship between statins and the APC mutation in our in vitro model. Figure 68 
shows our proposed mechanism. Firstly, statins inhibit HMGCR which lowers levels of 
isoprenoids. This reduces prenylation of Rac1 causing mislocalisation. We also see an 
unexplained increase in levels of active Rac1 in just the APC mutant cell lines and this 
is responsible for driving the transport of β-catenin into the nucleus. However the 
accumulation of β-catenin into the nucleus does not result in the activation of the Wnt 
pathway. The Rac1 effector Pak1 showed decreased phosphorylation at ser144 
(resulting in less fully active Pak1), which we propose is due to the mislocalisation of 
Rac1. This results in lower Pak1 activation and potentially this causes a reduction in 
the phosphorylation of β-catenin at ser675. β-catenin phosphorylated at ser675 is more 
stable and transcriptionally active. Therefore the reduction in active Pak1 would also 
decrease levels of Wnt signalling and the Wnt target gene survivin. The decrease in the 
anti-apoptotic protein survivin below a level the APC mutant cells can tolerate, results 
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in apoptosis. The APC wt controls are not vulnerable because they do not show 
hyperactivation of the Wnt signalling pathway. 
Further work is required to strengthen our findings and establish how transferrable the 
mechanism is to other types of APC mutation found in CRC cell lines. Additionally in 




Figure 68 Proposed mechanism of statins in our in vitro model 
Statins inhibit HMGCR, reducing isoprenoids and levels of prenylated Rac1. 
Unprenylated Rac1 is unable to bind GDI, therefore Rac1 accumulates in its active 
form in the cytoplasm. Cytoplasmic Rac1 is unable to interact and activate Pak1. 
Reduced Pak1 activation reduces Pak1 directed phosphorylation of ser675 on β-
catenin. This reduces the stability of β-catenin and reduces transcription of Wnt target 
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1 Creating an in vitro model of APC deficiency 
There are a wide range of colorectal cancer cell lines available to perform studies in 
and they represent the broad range of mutations found in CRC. However, to enable us 
to identify synthetic lethal relationships specific to APC loss we wanted to create a new 
in vitro model where the cell lines only differed in the APC status. 
 
1.1 Use of RKO cell line for our in vitro model 
As a starting point for our in vitro model we wanted to select a cell line which was 
wildtype for APC to enable us to edit this gene. Additionally, we did not want any 
mutations in other Wnt signalling components, such as the CTNNB1 gene (encodes β-
catenin) to ensure the cell line did not show hyperactivation of the Wnt signalling 
pathway. After applying this criteria the number of cell lines to select from was limited, 
this reflects the high rate of APC mutations and the role of the Wnt signalling pathway 
in driving CRC tumourigenesis. For example, we identified many APC wildtype cell 
lines which contain β-catenin mutations such as HCT116, SW48 and LS174T (Ilyas et 
al. 1997; Gayet et al. 2001). We identified both RKO and Co115 cell lines to be APC 
and β-catenin wildtype (Gayet et al. 2001; da Costa et al. 1999). Our group had 
experience of working with the RKO cell line, we felt this would be beneficial to us and 
would help the CRISPR-cas9 process. Research has suggested the RKO cell line has 
a mutation in the gene NKD1, a negative regulator of the Wnt pathway upstream of the 
β-catenin destruction complex (Guo et al. 2009). The paper identified the mutation in 
the RKO cell line and then the rest of the work was in either xenopus embryos or cell 
lines other than RKO (including HEK293T and Co115 cells). We analysed protein 
levels of total β-catenin and unphosphorylated ser33/ser37/thr41 β-catenin (active) in 
whole cell lysates from the RKO cell line alongside a panel of CRC cell lines with 
known APC or β-catenin mutations. The RKO cell lines showed no detectable increase 
in either total or unphosphorylated β-catenin in comparison to the cell lines with known 
APC or β-catenin mutations. Therefore, it seems unlikely the NKD1 mutation identified 
in the RKO cell line has a phenotypic effect on levels of Wnt signalling. Having 
confirmed the RKO cell line did not display hyperactivation of the Wnt signalling 
pathway, we investigated whether the RKO cell line would functionally respond to 
altered APC expression. We silenced APC with siRNA and measured the level of Wnt 
signalling through a TCF/LEF reporter assay and found that levels of the pathway 
increased upon reducing APC expression. This result indicated the RKO cell line was 
an ideal starting point for our in vitro model. 
Discussion Page 188 
 
The RKO cell line is characterised as showing MSI and has mutations in key genes 
known to contribute to the development of CRC including; BRAF and PIK3CA (Ahmed 
et al. 2013). This mutational background does not reflect all the mutations found in 
CRC and therefore our in vitro model may behave differently to cell lines displaying 
MSS and cell lines with mutations in other key genes. To overcome this limitation we 
tested our findings in a panel of CRC cell lines representing both MSI and MSS and the 
different key mutations found in CRC. Another important consideration is the RKO cell 
line is tumourigenic independent of the Wnt signalling pathway, therefore other 
pathways are important in driving and maintaining the tumourigenic state. The 
implication of this is manipulating the Wnt pathway by mutating APC may not have the 
same consequences as in a cell line which has naturally developed hyperactivation of 
this pathway. Despite the potential limitations of our in vitro model, our approach has 
the advantage that the cell lines have the same mutational background and only differ 
in their APC status, helping to identify synthetic lethal relationships specific to the APC 
mutation. 
An alternative approach would have involved using a normal colon cell line and editing 
the APC gene using CRISPR-cas9. As with all models this approach had its own 
limitations, normal cell lines do not grow so well in culture and this would have made 
the CRISPR-cas9 editing process more difficult, especially during the single colony 
selection. If we had failed to single colony select we would have had to work with a 
pool of cells containing a mixture of wildtype APC and edited APC genes. This would 
have made it harder to uncover synthetic lethal relationships. Additionally an APC 
mutation alone is thought to not be sufficient for a cell line to become fully 
tumourigenic, the cell line would not have any of the additional mutations in key 
pathways characteristic of CRC and this would have increased the risk that our findings 
did not translate to a panel of CRC cell lines (Matano et al. 2015). A recent paper used 
a normal HCEC cell line known as 1CT and the normal colon cell line was modified 
using a combination of shRNA against TP53 and APC, alongside ectopically 
expressing plasmids for KRAS G12V and APC1309 (Zhang et al. 2016). This model 
successfully identified the drug TASIN-1 which shows a synthetic lethal relationship 
with the APC mutation. This approach did not involve CRISPR-cas9 and therefore did 
not require single colony selection. Interestingly, the paper also identified a drug 
targeting the cholesterol synthesis pathway, which supports the use of our in vitro 
model and highlights the potential of targeting this pathway for APC mutant CRC. 
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1.2 Use of CRISPR-cas9 to generate our in vitro model of APC 
mutation 
CRISPR-cas9 has been shown to be an effective gene editing technique and we 
decided to use it to try to generate a full APC knockout. The APC gene covers 8535 nt 
and therefore could be difficult to eliminate expression of the entire protein. Matano et 
al. (2015) used CRISPR-cas9 to edit APC along with TP53, KRAS and PIK3CA in 
human intestinal organoids and demonstrated their resulting tumourigenic potential in 
vivo. The group targeted exon 8 of APC resulting in a truncated APC product, it is 
interesting they did not target exon 15 at the MCR to generate a ‘typical’ APC mutation. 
They showed the organoids with altered APC also displayed altered Wnt signalling 
activation. This was shown by analysing levels of β-catenin by western blotting and 
because removal of the Wnt factors Wnt and R-spondin from the media only effected 
growth of the APC wildtype organoids. 
We designed gRNA targeting exon 2 and the exon 15 (covers 80 % coding region) 
using a freely available online tool called dna2.0 CRISPR-cas9 design tool (now called 
atum) and used two different methods. The gRNA #8 and #9 target exon 2 and we 
used a transient system from Dharmacon called Edit-R. This system involved 
transfecting all three components into the cells together. Advantages of this approach 
are the cas9 is only transiently expressed reducing off target effects and the process is 
quick because the components are ready to transfect and the selection of edited cells 
is shorter. However because all 3 components are delivered separately, the selection 
process will select cells which 1) received the cas9 plasmid, 2) received the cas9 
plasmid + tracrRNA 3) received the cas9 plasmid + tracrRNA + crRNA. Therefore the 
single colony selection process may require more cells to be grown up and analysed. 
The target sites of the gRNA used with this method were more likely to produce a full 
APC knockout, however we did not identify any clones with edited APC using this 
approach. 
The gRNA #2 - #6 targeted exon 15 and we used a lentiviral system. This system had 
the advantage that all components required were delivered on one vector, therefore 
after the puromycin selection all cells which survived would contain all the components 
required for editing to have occurred. Using this method we didn’t manage to generate 
a full APC knockout, however the gRNA #2 generated a line with an APC truncation on 
both alleles resulting in only 25 % of the APC product remaining. An in vitro model with 
an APC truncation represent patients better because this is more common, full loss of 
APC expression is rare. However, the position of our APC truncation in the armadillo 
7th repeat is not in the MCR (region commonly mutated). Additionally, in FAP patients 
Discussion Page 190 
 
mutations in this region generate a less severe phenotype than those with mutations in 
the MCR (Zeineldin & Neufeld 2013). In support of our in vitro model generated, there 
are two in vivo mice models (APC716 and APCmin) with mutations in a similar region of 
APC which are commonly used to model CRC (Young et al. 2013). 
Alongside the RKO APC truncated cell line we generated two matched control cell 
lines. The control lines were targeted with a non-targeting gRNA and underwent the 
same process to enable us to minimise the effects of the CRISPR-cas9 editing 
process. One downside of the cell lines we generated using the lentiviral system was 
the cell lines still express cas9 and this could result in more off target effects. Papers 
have reported a wide range of factors contributing to off target effects with the 
CRISPR-cas9 editing approach, including the type of cas9 used, dose of cas9/gRNA 
and the design of the gRNA (Fu et al. 2013; Hsu et al. 2013; Wu et al. 2014). At the 
time of performing the CRISPR-cas9 stage of the project wildtype spCas9 was 
commonly used and this has been shown to induce more off target effects than other 
cas9. The main other cas9 available at the time was a cas9 nickase which makes 
single stranded breaks, reducing off target effects (Sanjana et al. 2014; Hsu et al. 
2014). Since completing our CRISPR-cas9 editing, more specific cas9 have been 
identified including the high fidelity cas9 (HF-cas9) which has been shown to cause no 
detectable off target effects (Kleinstiver et al. 2016). Despite the potential for off target 
effects in our in vitro model, we have used CRISPR-cas9 to generate two control cell 
lines and an APC mutant cell line derived from the same RKO parental line. 
In retrospect if time was not limited we should have used the gRNA #8 and #9 
(targeted exon 2) with the lentiviral method to attempt to generate a full APC knock-out. 
Although it is possible the region of exon 2 may be less accessible to the cas9 and 
gRNA due to the chromatin structure (Daer et al. 2017; Wu et al. 2014). Additionally to 
improve our CRISPR-cas9 methodology we could have used either the T7 
endonuclease 1 or surveyor assay, to help us estimate the mutation frequency and 
determine how many clones to pick. Although these approaches have limitations 
because they have been shown to underestimate the mutation frequency, they cannot 
detect events were the same mutation has occurred on both alleles (Kim et al. 2014). 
Once we had generated our lines RKO control (7_1 and 7_2), RKO APC mutant (2_6) 
we checked the cells showed the phenotype we would expect. We analysed the Wnt 
pathway using the TCF/LEF reporter assay and immunoblotted for levels of β-catenin 
and found the RKO APC mutant line showed hyperactivation of the Wnt signalling 
pathway. Unfortunately soon after generating these lines it became apparent that the 
RKO APC mutant line 2_6 still expressed a low level of full length APC. This could 
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have happened through poor single colony selection or contamination of the cell line 
with an APC wildtype line. We decided to re-single colony select the line and generated 
the RKO APC mutant lines 2_20, 2_21, 2_30 and 2_36, we focused on four cell lines 
because we were conscious that these cells had undergone two cycles of single colony 
selection. We confirmed all the lines had the same APC mutation by topocloning and 
displayed activation of the Wnt signalling pathway. An important consideration of our in 
vitro model cell lines is whether they activate the ‘right’ level of Wnt signalling. Many 
studies have supported the hypothesis that the two APC mutations are interdependent, 
to generate a specific level of Wnt signalling (Zeineldin & Neufeld 2013). In our APC 
mutant cell lines both APC copies are mutated at the same position in the armadillo 7th 
repeat, almost identical mutations and mutations in this region are unusual for patients 
with CRC. This means there is a chance that our in vitro model may activate Wnt 
signalling too little or too much. To help this concern after re-single colony selection we 
mostly worked with RKO 2_30 and RKO 2_36 because they appeared to have different 
levels of Wnt signalling, despite having the same mutation in APC. To clarify whether 
the level of Wnt activation is ‘correct’ we could perform the TCF/LEF assay in parallel 
with CRC cell lines harbouring classical APC mutations in the MCR to enable a direct 
comparison. 
 
1.3 Alternative approaches to generate model 
Approaches we could have utilised to generate our in vitro model include shRNA, zinc 
finger nuclease (ZFN) or transcription activator-like effector nuclease (TALENS). 
shRNA constructs express either miRNA or shRNA and are processed into siRNA 
resulting in gene silencing. This type of RNAi results in long term gene silencing 
because the construct is integrated into the host genome. Groups have used this to 
investigate APC function for example Dow et al. (2015) used an inducible shRNA 
system in mice to regulate APC expression. The main drawback for us was shRNA 
reduces protein expression and does not alter the gene. Another approach discussed 
in section 1.1 used shRNA to silence APC followed by the ectopic expression of 
APC1309, this reduced full length APC expression whilst inducing the expression of a 
truncated form of APC. A potential problem of this approach is ensuring the correct 
level of expression of APC1309 (Zhang et al. 2016). 
Alongside CRISPR-cas9 technology there are other nuclease based approaches which 
can edit genes known as ZFN and TALENs. Both ZFN and TALENS use the Fok1 
nuclease and are designed to create a double stranded break which is then repaired by 
HDR or NHEJ, similar to CRISPR-cas9 technology. Generally ZFN has a lower 
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success rate than both TALENS and CRISPR-cas9 (Kim & Kim 2014). The target site 
requirement for the genome editing is one of the major differences which would 
influence the technology selected. ZFN require GNN repeat regions which are often 
limited, TALENs can be designed to target any genomic region and require a thymine 
at the 5’ end, whilst CRISPR requires NGG if using wildtype spCas9 (Kim & Kim 2014; 
Sander & Joung 2014). Despite a wide range of other approaches available to us we 
selected CRISPR-cas9 because it was an exciting novel approach and our institute had 
growing expertise in this field. 
 
2 Searching for synthetic lethal interactions with APC 
in CRC 
2.1 Existing synthetic lethal interactions identified with APC 
mutation 
Many studies searching for synthetic lethal relationships in CRC have focused on 
looking for relationships with other major mutations such as KRAS (Costa-Cabral et al. 
2016; Luo et al. 2009; Steckel et al. 2012). Interestingly one group identified TP53 to 
be synthetically lethal with two components of the Wnt signalling pathway CSNK1E 
(encodes CK1α) and CTNNB1 (encodes β-catenin) (Tiong et al. 2014). Other research 
supports this link between TP53 and Wnt signalling in CRC, Kim et al. (2011) showed 
loss of TP53 lead to the reduction in miR-34 repression of TCF/LEF, resulting in Wnt 
signalling activation. This supports the potential to use inhibitors against either CK1α or 
β-catenin in patients with TP53 mutations and this could benefit up to 40-50 % of CRC 
patients (Tiong et al. 2014). 
Some studies have identified specific synthetic lethal relationships with APC mutations. 
One group identified that APC mutant CRC was synthetically lethal with NSAIDs 
(Leibowitz et al. 2014). Mutant APC increased levels of the Wnt target gene c-Myc, 
resulting in higher B3 interacting-domain death agonist (BID) activation and NSAIDs 
further activated BID, resulting in APC mutant cell specific death, leaving the normal 
APC wildtype cells unharmed (Leibowitz et al. 2014). Also NSAIDs have been reported 
to inhibit COX2 which is thought to be synthetically lethal with APC mutations because 
APC mutant cells show increased expression of COX2 and inhibiting COX2 is effective 
against APC mutant cells (Lesko et al. 2014; Oshima et al. 1996). Additionally there is 
potential to target TNKS and upstream of TNKS to selectively kill APC mutant cells. 
TNKS destabilises Axin which is the rate limiting component of the β-catenin 
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destruction complex, therefore the inhibition of TNKS increases Axin and levels of the 
β-catenin destruction complex, resulting in the inhibition of Wnt signalling (Huang et al. 
2009). Interestingly, the length of the APC mutation has been linked to the sensitivity to 
TNKS inhibitors, cell lines lacking all seven 20aa repeats were more sensitive than 
those with two or more 20aa repeats (Tanaka et al. 2017). Unfortunately TNKS 
inhibitors are reasonably toxic to normal intestinal cells, a recent paper has identified 
an approach to exploit this pathway with reduced effects on normal cells (Zhong et al. 
2016; Lau et al. 2013; Kang et al. 2017). Kang et al. (2017) identified PrxII regulates 
TNKS only in APC mutant CRC and the inhibition of PrxII results in APC mutant cell 
specific death. Another avenue being explored to treat APC mutant cells is the potential 
of the compound TASIN-1. TASIN-1 inhibits a component of the cholesterol synthesis 
pathway and it is thought that APC mutant cells are defective in responding to 
decreases in cholesterol, resulting in APC mutant specific cell death (Zhang et al. 
2016). An important consideration when identifying synthetic lethal relationships with 
APC is that although APC mutations account for up to 80 % of CRC patients, the 
relationships identified may just be applicable to a subset of patients. Within the 80 %, 
patients will have different types of APC mutations and different additional mutations in 
other genes such as KRAS, BRAF, PIK3CA, PTEN and TP53. To take this into account 
any synthetic lethal relationships identified in our in vitro model were also analysed in a 
panel of CRC cell lines. 
 
2.2 siRNA kinome screen to identify genes synthetically lethal 
with APC mutation when silenced 
2.2.1 Design of the siRNA kinome screen 
To identify potential genes synthetically lethal with the APC mutation we screened a 
library of 720 siRNA targeting kinases and related genes. We chose to investigate 
potential synthetic lethal relationships with kinases as target genes identified may have 
an existing inhibitor available or it would be relatively easy to design one. The library 
and approach we adopted has been used previously to search for synthetic lethal 
relationships (Martin et al. 2011; Mendes-Pereira et al. 2012). The library was made up 
of SMARTpool siRNA, each pool consisted of four individual siRNA targeting different 
parts of the same gene, using pooled siRNA has been shown to result in a greater 
phenotypic effect and a higher number of hits identified from the screens (Parsons et 
al. 2009). The siRNA was used at a concentration of 50 nM, this may not be the 
optimal concentration for all siRNA in the library, however, this concentration was 
successfully used to identify synthetic lethal relationships in the papers mentioned 
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above. Each well contained a different SMARTpooled siRNA and the screen was 
performed in duplicate because we prioritised biological repeats to increase the 
number of hits which would validate. 
 
2.2.2 Validation of the hit kinases 
From the siRNA screen targeting kinases and related genes we selected seven 
potential hit genes to follow up. Interestingly one of our potential hits SMG1 also 
appeared in a transposon screen in APCmin mice as a candidate driver gene, however 
this gene failed to pass our secondary screen validation so we did not investigate it 
further (March et al. 2011). To confirm the results seen in the screen we ordered a 
validation plate consisting of the SMARTpool siRNA (used in the screen) alongside the 
four individual siRNA, which make up the pool. Three of the genes (NAGK, DYRK2 and 
N4BP2) showed a slight trend of lower survival in the RKO APC mutant lines however 
the effect is not consistent or large enough for the genes to validate as hits. This result 
could indicate a limitation of our screening approach or our in vitro model. Another 
consideration is the possibility of limited major synthetic lethal kinases with the APC 
mutation. Perhaps investigating genes other than kinases may yield a gene, which 
shows a greater synthetic lethal effect with the APC mutation. However as discussed 
earlier in section 2.2.1 we chose this approach to improve the chances of translating 
the finding into the clinic, especially if we identified a kinase which had an inhibitor 
readily available. 
Two of the genes (NAGK and DYKR2) which showed a slight effect upon silencing had 
inhibitors available which we tested in our in vitro model; 3-O-Methyl-N-acetyl-D-
glucosamine inhibits NAGK and Harmine inhibits DYRK2. 3-O-Methyl-N-acetyl-D-
glucosamine is a competitive inhibitor of NAGK with a Ki of 17 μM, additionally it is a 
non-competitive inhibitor of N-acetylmannosamine kinase with a Ki of 80 μM (Zeitler et 
al. 1992). The highest dose we used was 40 μM which would limit the impact of this 
compound also inhibiting N-acetylmannosamine kinase. Harmine inhibits all the DYRK 
family, the IC50 for DYRK1 is 80 nM, DYRK3 is 800 nM and DYRK2 is 900 nM, 
additionally Harmine has also been shown to inhibit PIM3 at 4.3 μM and casein kinase 
1 (CK1) at 1.5 μM (Bain et al. 2007). CK1 is involved in the Wnt signalling pathway and 
research has shown the use of Harmine does inhibit the canonical Wnt signalling 
pathway when stimulated in HEK293T cells and preadipocytes (Waki et al. 2007). 
Other research showed Harmine also inhibits Cdk1/Cyclin B, Cdk2/Cyclin A and 
Cdk5/p25 (IC50 values 17 μM, 33 μM and 20 μM respectively) (Song et al. 2004). The 
highest Harmine dose we used was 10 μM and therefore this would have limited the 
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effect on the cyclin-dependent kinases mentioned. This demonstrates the problem with 
using inhibitors as they often inhibit a broad range of proteins especially at higher 
concentrations. The inhibitor data agreed with the siRNA data, neither NAGK or 
DYRK2 validated as hits. 
To further understand why none of the potential hits validated it would be interesting to 
analyse the effectiveness of the siRNA targeting the genes, by investigating the protein 
level after silencing. If the level of knock-down is not significant then this could explain 
the lack of validation and we could identify new siRNA targeting the gene which is more 
effective. Another avenue to explore would be investigating silencing two of the genes 
which showed a slight effect simultaneously to potentially increase the reduction in cell 
viability in the APC mutant cell lines. This could be advantageous because targeting 
different pathways at the same time reduces rates of resistance in therapies. 
 
2.3 Is the mTOR pathway synthetically lethal with APC 
deficiency 
Our siRNA kinome screen data suggested that silencing FLT3 and mTOR may be 
synthetically lethal with the APC mutation, these genes were potential hits in the first 
screen replicate only. Additionally research in vivo (using two different APC mutant 
mice models) had suggested mTOR inhibitors such as rapamycin were synthetically 
lethal with the APC mutation in early stage disease (Faller et al. 2014). Mechanistically 
without mTOR inhibition the cells showed increased Wnt signalling, increased c-myc, 
increased inhibition of eEF2K (via mTORC1) and activation of translation elongation, 
promoting tumourigenesis. The inhibition of mTOR halted this mechanism driving 
tumourigenesis, resulting in tumour regression (Faller et al. 2014). Based on this we 
investigated whether silencing FLT3 and mTOR with siRNA resulted in a greater loss of 
cell viability in the APC mutant cell lines in our in vitro model, we did not see an effect. 
Additionally, we tested the mTOR inhibitors rapamycin and ridaforolimus and again we 
did not see selectivity in the in vitro model or CRC panel cell lines we tested. Our 
results suggest two possibilities, either the relationship identified by Faller et al. (2014) 
is only present in mice or there could be a small therapeutic window in early CRC 
development were mTOR inhibitors would be effective. The human CRC cell lines we 
used were from established tumours, with many additional mutations (compared to the 
mice models used in the paper) and protein synthesis through the mTOR pathway may 
no longer be a driver in tumourigenesis. To further understand the differences in our 
results we could analyse levels of proteins involved in the mechanism the paper 
suggested for example c-myc and eEF2K. In support of our data, clinical trials using 
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mTOR inhibitors as a monotherapy have not been very effective especially in 
metastatic disease. Clinical trials are exploring the use of mTOR inhibitors in 
combination with other drugs such as VEGF inhibitors (Wang & Zhang 2014). 
However, it is possible to gain the full benefit of mTOR inhibitors in CRC, treatment 
needs to be started early on. 
 
3 Statins are synthetically lethal with APC 
3.1 A compound screen of FDA-approved drugs identifies 
statins to be synthetically lethal with APC mutation 
3.1.1 Compound screen design 
The compound library and screen design were used previously to successfully identify 
compounds synthetically lethal in MMR deficient CRC (Guillotin et al. 2017). The library 
contained 1120 FDA-approved compounds all dissolved in DMSO at 10 μM. 
Performing a large screen with one drug concentration may result in missing some 
potential hits, however it allows us to investigate the effect of many drugs in one 
experiment. As for the siRNA screen we had one well per compound for each biological 
repeat, we performed three biological repeats to increase our chance of finding a drug 
showing a synthetic lethal relationship with the APC mutation. Screening an FDA-
approved compound library offers the potential to repurpose existing drugs, reducing 
costs and the time it takes for new treatments to reach the clinic. Identifying the 
mechanism of the synthetic lethality can be harder in a compound screen compared to 
a siRNA screen because the main target of the drug may not be responsible for the 
relationship. In comparison in siRNA screening the target gene responsible is known 
because multiple siRNA targeting the same gene are used in the validation phase of 
the screening. 
 
3.1.2 Validation of compounds 
We chose to validate 11 compounds, some performed well over each replicate and 
others performed well in just the first repeat. Potentially some drugs degraded over the 
course of conducting the repeats. Using a separate batch of compound we performed 
dose response curves to analyse the behaviour of the compounds in both cell lines. 
From these we identified lovastatin and mevastatin, which in our in vitro model caused 
a greater decrease in survivial in the RKO APC mutant lines in comparison to the RKO 
APC wildtype cell lines. Additionally we tested simvastatin, which also showed the 
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same effect. From the dose response curves we identified the optimal doses for 
selectivity were lower than the 10 μM used in the screen, emphasising the importance 
of not ruling out drugs which cause loss of cell viability in both cell lines. Our drug 
curves show the three statins display different potencies, simvastatin is the most 
effective at the lowest doses. Mevastatin was derived from Penicillium citrinum 
(P.citrinum), lovastatin was derived from Aspergillus terreus (A.terreus) and scientists 
modified lovastatin to create simvastatin (Endo 2004; Alberts 1990). Simvastatin has 
been reported to be more potent then lovastatin, supporting why it shows the best 
selectivity between our APC wildtype and APC mutant lines at the lowest 
concentrations (Alberts 1990).  
To our knowledge there are no papers, which have identified statins to be synthetically 
lethal with the APC mutation. Although recently a paper has identified a drug targeting 
the cholesterol synthesis pathway (known as TASIN-1) showing a synthetic lethal 
relationship with the APC mutation (discussed further in section 3.2.1) (Zhang et al. 
2016). Potentially this indicates cholesterol synthesis is a vulnerability in APC mutant 
cell lines, which can be exploited. The opportunity to use statins which have FDA-
approval means this potential therapy could reach the clinic quicker than using newly 
developed compounds. 
 
3.2 Statins and CRC 
3.2.1 HMGCR dependent or HMGCR independent 
Statins exert a wide range of effects on cells and these effects either occur through 
HMGCR and/or HMGCR independent mechanisms. For our investigations into the 
mechanism responsible for the synthetic lethal relationship between statins and the 
APC mutation in our in vitro model, we focused on investigating if the effect occurred 
through HMGCR. We did not rule out HMGCR independent mechanisms and these 
could occur alongside the mechanism we identified. Our attempts to inhibit HMGCR 
directly with siRNA to confirm if this mimicked the effect of statins was unsuccessful 
and needs further optimisation before we can draw conclusions. We investigated the 
effect of blocking GGPP and FPP prenylation using inhibitors of GGTase and FTase, 
these steps are downstream of HMGCR. We found the inhibitor of GGPP prenylation 
GGTI-298 showed a similar effect in our cell lines to statins, especially in RKO 2_30. 
This finding suggested GGPP prenylated proteins are important in our mechanism. 
Whereas FTI-277 showed the same level of cell viability in our in vitro model cell lines, 
implying that FPP prenylated proteins do not play a role in our mechanism. Further 
work is needed to examine if adding in GGPP (and not FPP) whilst treating with statins 
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rescues the statin sensitivity in our APC mutant RKO 2_30 and RKO 2_36 cell lines. 
This would fully confirm the importance of GGPP prenylated proteins in the 
mechanism. Also we investigated if pre-treatment with MVA an hour before statin 
treatment would rescue the sensitivity in the APC mutant cells lines. Research has 
shown in CRC that MVA rescues the effects of statins (Zhu et al. 2013; Kaneko et al. 
2007). In our in vitro model MVA pre-treatment enhances the loss of cell viability in all 
the cell lines, this could be because RKO cells have not lost all the negative feedback 
mechanisms controlling HMGCR levels (Demierre et al. 2005; Tsai et al. 2012). 
Typically cancer cells lose their negative feedback mechanisms enabling upregulation 
of HMGCR levels to meet cellular demands. Therefore the presence of feedback 
mechanisms would mean adding MVA may further enhance the effect of statins by 
decreasing HMGCR levels further. 
Other studies into the mechanism of statins in CRC have also shown mechanisms 
acting through the HMGCR pathway. Lovastatin has been shown to cause apoptosis in 
HT29, SW480 and LS180 through the HMGCR pathway, the addition of MVA, FPP and 
GPP reversed the mechanism suggesting both FPP and GPP prenylated proteins are 
important. The suggested mechanism involved the inhibition of Ras mediated activation 
of the PI3K pathway, resulting in a decrease in the anti-apoptopic protein survivin 
(Kaneko et al. 2007). Another study showed mevastatin sensitivity in CaCO-1 cells was 
through the HMGCR pathway, the sensitivity was reversed by the addition of MVA but 
not FPP or GGPP (Wächtershäuser et al. 2001). Not all statin sensitivity is thought to 
occur through the HMGCR pathway. Some studies have suggested statins act through 
the BMP and NF-kB pathways resulting in effects on cell viability (Kodach et al. 2007; 
Cho et al. 2008). Another HMGCR independent mechanism involves simvastatin 
inhibiting angiogenesis by decreasing the expression of VEGF and HER2 (Li et al. 
2017). Additionally pitavastatin has been shown to inhibit CRC stem cells, resulting in 
cell apoptosis (Zhang et al. 2017). Further research is required to understand if all 
statins have the same effects in cancer cells, whether a few mechanisms occur in 
parallel or if one key mechanism is responsible for statins anti-proliferative effect in 
CRC. 
Many papers suggest HMGCR is upregulated in cancers, causing hyperactivation of 
the pathway and promoting tumourigensis (Notarnicola et al. 2004; Chushi et al. 2016; 
Qiu et al. 2016). It is thought the pathway is hyperactivated because cancer cells 
require higher levels of cholesterol and isoprenoids for growth (Notarnicola et al. 2004). 
Isoprenoids are required to prenylate G-proteins promoting a wide range of roles 
(Notarnicola et al. 2004). Higher HMGCR has been shown in a variety of tumour types 
including hepatocellular carcinoma, haematological malignancies, brain tumours, 
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colorectal cancer, gastric cancer and glioblastoma (Notarnicola et al. 2004; Chushi et 
al. 2016; Qiu et al. 2016). This hyperactivation could make cancer cells more sensitive 
to statins than normal cells because they are more dependent on the pathway for 
growth and survivial. It would be interesting to analyse the mRNA and protein levels of 
HMGCR in our in vitro model to see if the RKO APC mutant cell lines express more 
HMGCR compared to the APC wt controls, this could potentially contribute to the 
greater sensitivity to statins. Additionally Kaneko et al. (2007) found survivin and 
HMGCR mRNA levels correlated in colon cancer tissues. High HMGCR and high 
survivin would suggest more cell survival, whilst low HMGCR and low survivin would 
cause more apoptosis. As we identified survivin to play an important role in our 
mechanism it would be interesting to see if the levels of HMGCR and survivin mRNA 
correlate. Interestingly studies in colorectal, breast and ovarian cancers have 
suggested high HMGCR expression is associated with favourable tumour 
characteristics and/or better prognosis (Bengtsson et al. 2014; Borgquist et al. 2008; 
Brennan et al. 2010). This research doesn’t fit with the study by Kaneko et al. (2007) 
and also questions whether HMGCR expression is a predictor for statin response, 
further research is required to understand this. 
As briefly mentioned a recent paper identified a drug known as TASIN-1 as an inhibitor 
of EBP which is downstream of HMGCR to show synthetic lethality with the APC 
mutation (Zhang et al. 2016). The paper shows the APC mutant cell lines (DLD1 and 
HT29) are more sensitive to TASIN-1 then the APC wildtype cell line (HCT116). The 
paper shows the same effect with simvastatin, although the effect is less potent than 
with TASIN-1. The research suggests APC mutant cells are unable to respond to the 
decrease in cholesterol (consequence of TASIN-1 and statin treatment) by upregulating 
SERP2 and SERP2 target genes (Zhang et al. 2016). This supports the mechanism of 
statins in our in vitro model is through the HMGCR pathway. It would be interesting to 
analyse in our in vitro model the level of SERP2 and SERP2 target genes and see if 
this plays a role in the mechanism responsible for the synthetic lethality we identified 
between statins and APC mutations. 
As discussed different studies into the effect of statins on CRC cells have shown either 
HMGCR dependent or independent mechanisms. It is possible statins could exert their 
effects through both and the different mechanisms identified could all integrate into a 
network of statin effects in CRC cells. 
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3.2.2 Statin sensitivity and APC mutations 
In our in vitro model APC status is the differing characteristic between the controls and 
the APC mutant cells. RKO 7_1 and RKO 7_2 are APC wt and RKO 2_6, RKO 2_21, 
RKO 2_22, RKO 2_30 and RKO 2_36 have an APC mutation in the 7th armadillo repeat 
in both alleles. The difference in sensitivity to statins in our in vitro model must be a 
result of the difference in APC because all the cell lines have been through the same 
CRISPR-cas9 process and the pressures of single colony selection. Other studies into 
statin sensitivity in CRC have not looked at sensitivity to statins in relation to APC 
status. Kaneko et al. (2007) looked at lovastatin sensitivity in APC mutant lines (HT29 
and SW480) and APC wildtype (LS180), SW480 were the most sensitive followed by 
LS180 and then HT29. Another group looked at lovastatin sensitivity in the APC 
wildtype HCT116 and APC mutant DLD1, SW480 and HT29 (Kodach et al. 2007). The 
group found the sensitivity was related to expression of SMAD4, the most sensitive 
expressed SMAD4, HCT116 (APC wildtype) and DLD1 (APC mutant). The more 
resistant lines both APC mutant SW480 and HT29 did not express SMAD4 (Kodach et 
al. 2007). Another study looked at lovastatin in the APC wildtype HCT116 and LOVO 
and APC mutant SW480 and HT29 (Agarwal, Bhendwal, et al. 1999). The most 
sensitive lines were SW480 and LOVO followed by HCT116 and HT29. The response 
to statins in these studies does not relate to APC status alone, additional mutations in 
these cell lines must contribute. All the APC mutant cell lines in these studies have 
APC mutations at the MCR and not the 7th armadillo repeat as in our in vitro model. 
The differences between studies could be explained by the type of statin used, dose 
used and treatment length. Additionally all the studies are small, investigating up to four 
cell lines in each paper. These studies do not suggest a clear correlation between 
statin sensitivity and APC mutations. 
Part of our study involved comparing statin sensitivity between our in vitro model and a 
CRC panel of cells (DLD1, HCT116, HT29, RKO, SW48 and SW620). These results 
further support a poor association between statin response and APC status. A key 
difference between our APC mutant in vitro model lines and HT29, DLD1 and SW620 
is the location of the APC mutation and this could explain why our APC mutant in vitro 
model cell lines are substantially more sensitive. DLD1 and SW620 have a mutation in 
the MCR on one allele then the other allele is lost due to loss of heterozygosity. The 
mutation found in the DLD1 cell line is after the 2nd 20aa repeat and results in a 155 
kDa APC protein. The SW620 cell line has a mutation after the 1st 20aa repeat 
resulting in a 147 kDa protein which retains the 1st 20aa repeat. The HT29 cell line has 
two different mutations on different alleles. The mutation on allele one retains the 
armadillo repeats resulting in a 93 kDa protein, the mutation on allele two just after the 
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3rd 20aa repeat results in a 171 kDa APC protein. These cell lines fit the ‘just right’ 
signalling model used to explain the pattern of APC mutations in patients resulting in a 
specific level of Wnt signalling (Zeineldin & Neufeld 2013). It is possible our APC 
mutant in vitro model cell lines respond differently to statins in comparison to the APC 
mutant CRC panel cell lines because of too little or too much Wnt signalling. 
Unfortunately we investigated this within each group (in vitro model and CRC panel) 
separately, as we did not probe for β-catenin levels at the same time on the same blot 
we are unable to compare between the groups. To enable comparison we should 
investigate levels of Wnt signalling across our in vitro model and the CRC panel 
together. Research has linked different types of APC mutations to different drug 
responses. Recent research has suggested this explains why some APC mutant cell 
lines are sensitive to tankyrase inhibitors whilst others are not. The tankyrase inhibitor 
sensitive cell lines/tumours lacked the seven 20aa repeats, whilst the resistant cell 
lines/tumours had 2 or more 20aa repeats. The research linked this effect to the level 
of Wnt signalling activation, the sensitive cell lines showed higher Wnt signalling than 
the resistant lines with 2 or more 20aa repeats (Tanaka et al. 2017). 
Another possibility is the early location of the mutation in the 7th armadillo repeat of 
APC in our in vitro model results in the loss of an APC function, which is retained in the 
CRC panel of cell lines tested and this could be responsible for the differences in statin 
sensitivity. For example, our RKO APC mutant in vitro model cell lines would no longer 
be able to interact with Topo IIα, PCNA, Polβ and Fen-1 through the 15aa repeats, in 
comparison cell lines mutated at the MCR would still retain this ability (Prosperi & Goss 
2011). Additionally there could be unknown interactions with APC between the 
armadillo repeats and the MCR which are important for explaining the differences in 
sensitivity to statins. Nelson & Näthke (2013) highlighted over 100 proteins have been 
reported to interact with APC and understanding these interactions could help uncover 
new APC roles. To help us decipher whether it is a specific section of APC responsible 
for the increased statin sensitivity in our APC mutant in vitro model we could re-express 
plasmids containing different sections of APC and see which sections can rescue the 
effect. 
We have discussed two possible contributing factors explaining statin sensitivity in the 
cell lines we analysed, APC status and expression of HMGCR (discussed earlier in 
3.2.1). Another factor which may be involved is additional mutations in key genes 
known to contribute to CRC. For example, TP53 status might be involved, research has 
shown simvastatin might activate p53 through p38MAPK resulting in survivin 
repression (Chang et al. 2013). We have shown low levels of survivin are important in 
our mechanism and two of the most sensitive cells are wildtype for TP53 (RKO and 
Discussion Page 202 
 
SW48). However, other research in breast cancer cell lines found TP53 mutations 
upregulate levels of the mevalonate pathway, making these cell lines responsive to 
inhibition of the pathway through statins (Freed-Pastor et al. 2012). Additionally 
HCT116 which are also TP53 wildtype are one of the more resistant cell lines. This 
demonstrates there is no clear pattern with TP53 status and it could be a combination 
of factors contributing to statin sensitivity. We looked in terms of KRAS and BRAF 
mutations, typically many CRC cell lines have a mutation in one or the other and this 
showed no clear pattern. Interestingly SW48 do not have a mutation in either KRAS or 
BRAF and is one of the more sensitive lines. Therefore the sensitivity to statins is likely 
to be more complicated than just looking in terms of one mutation alone. The number 
of cell lines used to analyse statin sensitivity is low, making it hard to see clear patterns 
especially when you subdivide into different mutations there are groups with only 1-3 
cell lines in. To further our investigation it would be interesting to analyse statin 
sensitivity in a normal colon cell line and see how this compares to our CRC cell lines. 
Additionally you could introduce mutations in APC, KRAS, BRAF and TP53 individually 
and in combination to see if this alters the response of the normal colon cell line to 
statins. 
Identifying the specific reason why our APC mutant in vitro model cell lines are more 
sensitive than other CRC cell lines with APC mutations, would help us to understand 
who could benefit. 
 
3.2.3 Do statins cause cell arrest or apoptosis? 
Statins have been shown to induce cell arrest and apoptosis in a range of tumour 
types, the two processes are not mutually exclusive because cell arrest can induce 
apoptosis. Cell arrest occurs when cell cycle regulators (eg cdk4 and cdk6) are 
downregulated and cell cycle inhibitors are upregulated (eg p21 and p27). Statin 
induced cell cycle arrest is thought to occur due to the inhibition of ubiquitin 
proteasome mediated proteolysis resulting in an increase in cell cycle inhibitors p21 
and p27 (Rao et al. 1999). Further research is required to understand if there are 
additional mechanisms. 
Most research into statins has focused on the mechanisms leading to apoptosis. Some 
suggested mechanisms involve the downregulation of members of the IAP family (eg 
XIAP, cIAP-1, cIAP-2 or survivin) and other anti-apoptopic proteins (eg Bcl-2, Bcl-XL, c-
FLIP-S) or the upregulation of pro-apoptotic proteins (eg Bax). We hypothesise the 
decrease in the anti-apoptotic protein survivin results in the induction of apoptosis in 
our in vitro model upon lovastatin or simvastatin treatment, however further work is 
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needed to clarify this because we did not analyse levels of apoptosis. Another study 
supports our hypothesis, the research in the colorectal cancer cell line SW480 found 
survivin was downregulated in response to lovastatin treatment, whilst other anti-
apoptotic proteins were not altered (XIAP, cIAP-1, cIAP-2 Bcl-2 and Bcl-XL) (Kaneko et 
al. 2007). In comparison other studies in the colorectal cell lines colo205 and HCT116 
showed simvastatin treatment caused Bcl-2, Bcl-xL, cIAP1 and cFLIP-S to be 
downregulated (Cho et al. 2008). Another study found Bcl-2 was downregulated and 
Bax was increased upon lovastatin treatment in SW480, HCT116, LOVO and HT29 
(Agarwal, Bhendwal, et al. 1999). The variation between studies could be due to the 
use of different cell lines, different statins, different concentrations and treatment 
lengths. It would be interesting to analyse levels of other anti-apoptotic proteins and 
pro-apoptotic proteins in our in vitro model upon statin treatment to see if they are 
altered too. 
Interestingly research has suggested statins have different effects on apoptosis in 
different cellular contexts, in normal cells statins are thought to be anti-apoptotic and in 
tumourigeneic cell lines statins are thought to be pro-apoptotic. Part of this pattern is 
thought to be due to the statin doses used in the different cell types, tumourigenic lines 
are typically given higher doses of statins, inducing pro-apoptotic effects (Wood et al. 
2013). To investigate this we could analyse the response of normal colon cell lines to 
statins using the same dose range we used for our in vitro model cell lines. 
 
3.3 Statin induced survivin downregulation 
3.3.1 Survivin levels decrease upon statin treatment 
We investigated levels of survivin in our in vitro model of APC mutation and found upon 
statin treatment levels of survivin decrease more in the APC mutant lines compared to 
the APC wildtype lines. We hypothesised that in the APC mutant lines the level of 
survivin decreases below a threshold tolerated, resulting in the induction of apoptosis. 
This is supported by research by Kaneko et al. (2007) and Chang et al. (2013). Both 
showed statins induced a decrease in survivin levels, although the upstream 
mechanisms resulting in the decrease differed. This variation could be due to the use 
of different cell lines with different mutational backgrounds. Interestingly in different 
cancer types the downregulation of survivin is also suggested to be part of the 
mechanism of statins, this has currently been shown in lung, hepatocellular carcinoma 
and head and neck squamous cell carcinoma (Hwang et al. 2011; Wang et al. 2007; 
Yen et al. 2016). 
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We have shown statins cause a decrease in survivin levels and this has been shown 
by other studies in CRC and additional cancer types. Survivin appears to be key to the 
mechanism and this is supported by experiments investigating the impact on statin 
response when either silencing survivin or overexpressing survivin in cell lines. For 
example, in the APC mutant cell line SW480 silencing survivin increased statin 
sensitivity, whilst over expressing survivin reduced statin sensitivity (Kaneko et al. 
2007). We followed on this research and analysed if silencing survivin in the original 
RKO cell line (APC wildtype) altered statin sensitivity. We found silencing survivin 
dramatically sensitised the cells to statins. These results suggest survivin levels play a 
key role in the response to statins in CRC. 
To extend our research we could investigate if overexpression of survivin in our in vitro 
model cell lines makes the cells more resistant to statins and whether this fully rescues 
the effect. It would be interesting to see if individually overexpressing either survivin or 
APC fully rescues the effect or if both plasmids are required to rescue the effect of 
statins in the RKO APC mutant in vitro model cell lines. If both are required it would 
suggest it is a combination of both survivin levels and the APC mutation determining 
statin sensitivity. 
Additionally to investigate if the effect on survivin levels occurs through HMGCR 
pathway we could analyse the effect on survivin levels when pre-treating with MVA 
before lovastatin treatment. When we performed these experiments analysing cell 
viability we found MVA pre-treatment enhanced the decrease in cell viability, which 
could be due to feedback mechanisms resulting in MVA further enhancing the 
decrease in HMGCR. Therefore potentially if the cells are pretreated with MVA before 
statin treatment we might see a greater decrease in survivin levels. It would also be 
interesting to see if GGTI and not FTI causes a decrease in survivin levels, we found 
treatment with GGTI had a greater effect on cell viability in just the APC mutant RKO 
2_30 cell line compared to FTI. 
 
3.3.2 Survivin is a Wnt target gene 
In our paired cell line we also see levels of the Wnt signalling pathway slightly decrease 
after statin treatment in our in vitro model APC mutant lines and this mirrors the 
decrease in survivin. Survivin is a well known Wnt target gene, therefore if Wnt 
signalling is inhibited we would also expect a decrease in survivin levels (Zhang et al. 
2001; Kim et al. 2003). Research by Zhang et al. (2001) supports a strong interplay 
between APC and survivin. The group showed in the APC mutant line HT29 the 
introduction of APC caused apoptosis because it decreased levels of survivin. The 
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paper also suggests this interplay is important for maintaining crypt homeostasis, 
survivin expression is high at the crypt with the stem cells whilst APC expression is 
high at the top of the crypt. It is important to note this study emphasises a link between 
APC and survivin but is not investigating in terms of statin response. Our data suggests 
Wnt signalling is inhibited upon statin treatment, to further this we could investigate 
levels of additional Wnt target genes. 
It is possible that Wnt signalling is not responsible for the decrease in survivin levels. 
The effect of statin treatment on the protein levels of total and unphosphorylated β-
catenin are very slight in comparison to the effects on survivin levels at the same statin 
concentrations. This could suggest other pathways are responsible for the statin 
induced decrease in survivin. Potential pathways include; microRNA, RTK, PI3K/Akt, 
MEK/MAPK, NF-kB, mTOR, STAT3, p53, hypoxia, TGF and Notch signalling (Chen et 
al. 2016). However, research has shown Wnt signalling is key to the regulation of 
survivin levels in CRC and in section 3.5.1 we discuss a possible explanation for the 
slight change in protein levels of β-catenin (Kim et al. 2003; Ma et al. 2005). To 
understand the contribution of Wnt signalling on the regulation of survivin levels in our 
in vitro model, we could use known inhibitors against Wnt signalling at various 
concentrations and measure the effect on survivin protein levels. Alongside this you 
could do the same with inhibitors of other pathways shown to regulate survivin levels. It 
is feasible that statins could be altering several pathways which regulate survivin 
levels. 
 
3.3.3 Do basal survivin levels in cell lines explain the response to statins? 
Generally research has shown survivin expression is low in normal cells and high in 
tumour cells (Kaneko et al. 2007; Kawasaki et al. 1998; Ambrosini et al. 1997; Sarela et 
al. 2000). Research suggests in normal tissue survivin expression is concentrated in 
the crypt (Gianani et al. 2001). We analysed survivin protein levels in our RKO in vitro 
model and a panel of CRC cell lines. We hypothesised the in vitro APC mutant RKO 
2_30 and RKO 2_36 might have lower survivin levels compared to the rest of the cell 
lines because these were the most sensitive to statins. This was not the case, DLD1 
and HT29 showed lower basal survivin levels, than RKO 2_30 and RKO 2_36 but are 
less sensitive to statins. Also within our in vitro model only RKO 2_30 had a lower 
basal level of survivin compared to the APC wt controls RKO 7_1 and RKO 7_2. 
Interestingly RKO 2_30 and RKO 2_36 have different basal levels of survivin which 
could be explained by the levels of Wnt signalling, RKO 2_30 shows a lower activation 
of the Wnt signalling pathway and has a lower survivin level than RKO 2_36, however 
the RKO APC wt controls do not fit this explanation. To investigate the relationship 
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between survivin levels and statin sensitivity we plotted survivin expression against the 
survival fraction at 10 μM lovastatin and found no strong correlation. Therefore our data 
does not show a clear pattern and does not suggest basal survivin levels alone explain 
statin sensitivity. 
It is possible the different survivin isoforms prevent a clear association between statins 
and basal survivin levels. On western blots our antibody detected two bands, we 
believe the lower band corresponds to survivin wt and survivin ∆Ex3, whilst the upper 
band may be survivin 2B. Unfortunately there are few antibodies which are specific for 
the survivin isoforms making it difficult to establish protein levels of each (Necochea-
Campion et al. 2013). We analysed the ratio of the upper and lower survivin bands we 
detected to see if this explained statin sensitivity but it did not. This could be because 
the lower band represents two isoforms and the different isoforms may have different 
roles, hiding an effect. Typically papers investigating survivin isoforms use RT-PCR 
because probes can be designed to target specific isoforms, including expression 
levels of the two smallest survivin isoforms, which we could not identify on the western 
due to their size (Suga et al. 2005; Pavlidou et al. 2011). Therefore to further 
understand if there is an association between basal survivin levels and statin response 
we could analyse each survivin isoform individually. 
To investigate if additional factors contribute to statin sensitivity alongside survivin 
levels, we subdivided our data into smaller groups (APC status, Wnt signalling, KRAS 
status, BRAF status and TP53 status) and plotted survivin expression against the 
survival fraction at 10 μM lovastatin. We did not identify any strong correlations by sub-
grouping the data. A key limitation of our investigations into survivin levels is the 
sample size (as discussed earlier in 3.2.2) because once you sub divide the 10 cell 
lines into different groups the sample sizes are small and therefore hard to interpret. 
Increasing our investigation into further cell lines would help solve this. Additionally it 
would be interesting to analyse survivin levels after statin treatment in all 10 cell lines 
because we might see the same pattern as in the in vitro model, a greater decrease in 
survivin levels in the more sensitive lines. Further research is needed to understand the 
extent to which survivin levels can explain the different sensitivities to statins. 
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3.4 Is Wnt signalling altered upon statin treatment 
The involvement of the Wnt signalling pathway in our mechanism is interesting 
because the majority of our data suggests statins cause a decrease in Wnt signalling. 
This is supported by the data from the Wnt assay and the western blotting of whole cell 
lysates for total β-catenin and unphosphorylated β-catenin (active) levels. Additionally 
we see a decrease in the Wnt target gene survivin upon statin treatment. The 
immunofluoresence data on total β-catenin localisation upon statin treatment appears 
to conflict the majority of our data, we see a Rac1 dependent increase in total β-catenin 
transported from the cytoplasm to the nucleus. Potentially the total β-catenin 
accumulated in the nucleus is prevented from activating Wnt target genes and a 
potential mechanism supporting this is discussed in section 3.5.1. To clarify levels of 
Wnt signalling upon statin treatment investigating levels of other Wnt target genes 
would help. Interestingly in normal cell contexts (including neural cells and mouse 
embryonic stem cells) statins have been shown to activate Wnt signalling, however this 
may not be the same in tumour cells (Robin et al. 2014; Salins et al. 2007; Qiao et al. 
2011). The majority of our data supports statins inducing a decrease in Wnt signalling 
in our in vitro model. 
 
3.5 Rac1 and statins 
3.5.1 Is Rac1 the link between Wnt signalling and statins 
Based on the following, we investigated if Rac1 was involved in the mechanism 
responsible for the synthetic lethal relationship between statins and the APC mutation 
in our in vitro model. Our data suggested GGPP prenylated proteins are more 
important in the mechanism than FPP prenylated proteins and Rac1 is one of many 
proteins which undergo GGPP prenylation (Demierre et al. 2005). Rac1 has been 
shown to play a role in the canonical Wnt pathway either by promoting nuclear import 
of β-catenin or the formation of β-catenin-TCF/LEF complexes (Esufali & Bapat 2004; 
Wu et al. 2008; Jamieson et al. 2015). Additionally, Rac1 has been shown to promote 
CRC tumourigenesis (Myant et al. 2013; Espina et al. 2008). 
We analysed the levels of active RhoA/B/C and active Rac1 before and after statin 
treatment. Our analysis showed no increase in the activation of RhoA/B/C. However, 
analysing levels of active Rac1 showed an increase after statin treatment, which was 
not due to an increase in total Rac1. This is potentially supported by the 
immunofluorescence data analysing the localisation of active Rac1 upon statin 
treatment. To further this work we would additionally analyse levels of Cdc42 which is 
also GGPP prenylated (Demierre et al. 2005). Other studies into statins effects on 
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cancer cell lines have also shown an increase in the activation of members of the Rho 
family, including RhoA/B/C, Rac1 and Cdc42. For example, Zhu et al. (2013) found an 
increase in active Rac1, Cdc42 and RhoA in response to simvastatin treatment in the 
CRC cell line HCT116. The group linked the increase in active Rho family proteins to a 
decrease in their interaction with GDI, which normally prevent the activation of Rho 
proteins. This is thought to be due to a decrease in prenylated Rho proteins because 
GDI proteins only bind Rho proteins if prenylated and statins decrease prenylation 
levels (Zhu et al. 2013). Future work would involve confirming if we see a decrease in 
prenylated Rac1 and if the interaction between Rac1 and GDI is decreased in our in 
vitro model. Interestingly, the increase in activation of members of the Rho family upon 
statin treatment has also been reported in other cell types including; myeloid lineage 
cells THP-1 and BV2, the neuroblastoma cell line N2a and the pheochromocytoma 
(PC12) cell line (Cordle et al. 2005). Different studies see increases in the activation of 
different members of the Rho family and perhaps this indicates the activation of 
different pathways upon statin treatment. 
Zhu et al. (2013) found treatment with a Rac1 inhibitor in combination with statins 
reversed the statin sensitivity in HCT116 cells, this indicated the importance of active 
Rac1 in their mechanism in HCT116 cells. We did not see the same effect in our cell 
lines when treating with a Rac1 inhibitor and statins at the same time. Additionally a 
Rac1 inhibitor did not display the same selectivity as statins in our in vitro model. This 
implies the increase in active Rac1 in our in vitro model does not explain the selectivity 
we see between the APC wildtype and APC mutant cell lines. Therefore the 
mechanism identified by Zhu et al. (2013) which involved active Rac1 and RhoA 
stimulating superoxide production, leading to JNK mediated activation of BIM and 
apoptosis, is unlikely to be responsible for the difference in sensitivity we observe. The 
statin induced decrease in isoprenoids would result in increased unprenylated Rac1 
and this would be unable to associate with the plasma membrane. Zhu et al. (2013) 
showed an increase in cytosolic Rac1 upon statin treatment in HCT116 cells supporting 
this hypothesis and future work would involve confirming this in our in vitro model. It is 
predicted that the alteration in Rac1 localisation would have implications on 
downstream effectors. We attempted to analyse Rac1 localisation using microscopy 
but the data is inconclusive and needs further work. Additionally we analysed the 
activation of a key Rac1 effector known as Pak1 by analysing levels of phosphorylated 
ser144 Pak1 which is indicative of active Pak1. We found levels of phosphorylated 
ser144 Pak1 decreased upon statin treatment in our in vitro model, this supports the 
hypothesis that unprenylated Rac1 is unable to localise to the membrane where Rac1 
would normally interact and activate Pak1 (Bustelo et al. 2007). To further confirm this 
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work it would be interesting to see if introducing active Pak1 into the cells alongside 
statin treatment rescues the sensitivity of the APC mutant cells to statins. Additionally if 
Pak1 activation is important for the selectivity we see, treating the cells with a Pak1 
inhibitor should cause the same synthetic lethal effect. Investigating the effects of an 
increase in unprenylated cytosolic active Rac1 on other Rac1 effectors would be 
interesting too. 
We hypothesise that Pak1 activation may explain the discrepancy in the data on Wnt 
signalling (section 3.4). There is evidence that Pak1 plays a role in the Wnt signalling 
pathway. Pak1 has been shown to phosphorylate β-catenin at ser675 resulting in 
stabilisation of β-catenin and enhanced transcription of Wnt target genes (Zhu et al. 
2012). Therefore the decrease in Pak1 activation could be responsible for the decrease 
in levels of the Wnt target gene survivin. This data supports why the immunofluorence 
data showing an increase in nuclear β-catenin induced by an increase in active Rac1, 
does not result in an increased expression of Wnt target genes. Also it supports why 
the protein data on levels of β-catenin before and after statin treatment only show a 
slight decrease because it is the reduction in phosphorylated ser675 β-catenin which is 
impacting the level of Wnt target gene transcription. Additionally this supports why we 
observed the greatest effect on Wnt levels in the TCF/LEF reporter assay. To further 
support this idea we could probe for levels of phosphorylated β-catenin at ser675 and 
see if this decreases in our in vitro model. 
Interestingly, we observed a lower basal level of active Rac1 in the APC mutant lines. 
This result is conflicting with research showing that APC mutations cause a greater 
activation of Rac1 in comparison to APC wt cells. In intestinal epithelial cells derived 
from mice with wt APC and mutant APC, pull down experiments for active Rac1 
showed levels were higher in the cells with mutant APC (Myant et al. 2013). This 
research supports the idea that Rac1 is a key driver in tumourigenesis after APC loss 
(Myant et al. 2013). There are two factors why our data could be different, firstly the 
APC wildtype RKO controls in our in vitro model appear to express a high level of 
active Rac1 independent of a APC mutation, although this is speculation and would 
require comparison to levels of active Rac1 in other CRC cell lines with wt APC and 
mutant APC. An important consideration is the RKO cell line has become tumourigenic 
independent of APC and it is possible Rac1 activation is increased through other 
mechanisms, therefore this could impact the cell lines response to a mutation in APC. 
Another factor is the position of our APC mutation may cause the lower basal levels of 
active Rac1. Our in vitro model APC mutant cell lines are mutated in the 7th armadillo 
repeat and this could alter the interaction with binding partners. ASEF and IQGAP are 
known to interact with APC at the armadillo repeats and both of these proteins interact 
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and activate Rac1 and Cdc42 (Hanson & Miller 2005; Aoki & Taketo 2007). To 
investigate this we could perform immunoprecipitation experiments to determine if our 
APC truncated protein still binds ASEF and IQGAP. 
Taken together our results suggest it is the statin induced effect on the localisation of 
Rac1 and not Rac1 activation, which appears to be important in the mechanism of 
statin selectivity in APC mutant cells. This reduces Pak1 activation, decreasing the 
level of Wnt signalling and the expression of the Wnt target gene survivin. 
 
3.5.2 Does Rac1 directly alter survivin levels 
It is possible that Rac1 may directly alter survivin levels independent of the Wnt 
signalling pathway because many pathways have been shown to regulate survivin 
levels. For example Rac1 regulates NF-kB and NF-kB is a regulator of survivin. A study 
on breast cancer cell lines supports this because inhibiting Rac1 downregulated 
survivin levels through NF-kB (Yoshida et al. 2010). Therefore it is possible that the 
localisation of Rac1 to the cytosol prevents the Rac1-mediated activation of NF-kB and 
subsequent activation of survivin transcription. To investigate this idea we would 
investigate whether statin treatment can influence expression of components of the NF-
kB pathway. 
 
3.6 The potential of statins for the treatment of APC mutant 
CRC 
Our study highlights statins are synthetically lethal with the APC mutation in our in vitro 
model. Unfortunately the effect in other APC mutant CRC cell lines does not support a 
clear selectivity. A few other studies have shown the potential of using statins to treat 
CRC (not in relation to APC mutations). A potential limitation for the use of statins as a 
therapy is the doses required to see an effect are a lot higher than the doses currently 
given for CVD (10-200 nM), some studies have used up to 200 μM (Demierre et al. 
2005). Our study requires concentrations in the lower μM range to see an effect 
(simvastatin 2 μM, lovastatin 4 μM). A phase 1 clinical trial investigating lovastatin 
indicated a concentration range of 0.1-3.9 μM was well tolerated in patients, indicating 
the dose we see an effect with lovastatin could be a successful therapeutic strategy 
(Thibault et al. 1996). This highlights if we can identify the reason why our APC mutant 
in vitro model cell lines are more sensitive then we could use statins to treat patients at 
a tolerated dose. 
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Many studies have investigated the potential of statins in chemoprevention. Case-
control studies have shown varying protective effects, for example one study identified 
statin treatment resulted in a 47 % decreased risk of CRC, whilst other studies have 
shown no protective effect (Poynter et al. 2005; Lochhead & Chan 2013). Many 
randomised studies have not supported a protective effect (Lochhead & Chan 2013). 
The studies used to investigate the association between statins and CRC have been 
designed to test the safety of statins to treat CVD, therefore they are not designed to 
analyse cancer risk, for example the follow up period is often too short. Additionally 
CVD patients are at higher risk of CRC because CVD risk factors also include low 
physical activity and a poor diet (Lochhead & Chan 2013). Interestingly a large meta 
analysis of 42 studies was conducted and included case control studies, cohort studies 
and randomised control trials. The meta analysis concluded statins have a slight 
protective effect but long term use does not seem to influence CRC risk (Liu et al. 
2014). Recent research has suggested the link between statins and reduced cancer 
risk may be due to cholesterol levels and not the result of statin treatment (Mamtani et 
al. 2016). High cholesterol levels (would receive statin treatment) was associated with 
a reduced cancer risk, whilst low cholesterol levels was associated with a higher 
cancer risk (Mamtani et al. 2016). Further studies are required to fully understand the 
link between statins and CRC. 
Instead of using statins it is possible that we could exploit the same synthetic lethal 
relationship by targeting other parts of the mechanism identified. For example, we 
could investigate if inhibiting GGPP prenylation, survivin or Pak1 shows the same 
relationship. Another option is targeting another part of the cholesterol synthesis 
pathway. This is supported by the paper which identified TASIN-1 to inhibit EBP 
downstream of HMGCR and show a more potent synthetic lethal effect with APC 
mutations than statins (Zhang et al. 2016). This indicates the cholesterol synthesis 
pathway could be an ideal target to exploit in APC mutant CRC. The disadvantage of 
these approaches compared to statins is that statins have FDA-approval and have 
been used clinically for decades. 
In summary we have created a new in vitro model of APC mutation in CRC using 
CRISPR-cas9 (APC wildtype and APC Lys736fs). We used the in vitro model to 
perform a siRNA screen against kinases and an FDA-approved compound screen to 
help us identify genes showing synthetic lethality with APC mutation. We failed to 
validate any of the potential hits from the siRNA screen. From the FDA-approved 
compound screen we successfully identified a synthetic lethal relationship between 
statins and the APC mutation in our in vitro model. The mechanism we propose 
involves a decrease in prenylated Rac1, which prevents Rac1 from interacting and 
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activating Pak1 at the membrane. The reduction in Pak1 activation then leads to less β-
catenin phosphorylated at ser675 and reduced transcription of Wnt target genes 
including survivin, leading to apoptosis. The APC mutant cell lines rely more on Wnt 
signalling and are therefore more susceptible to its inhibition. The potential of targeting 
the cholesterol synthesis pathway in APC mutant CRC, is strengthened by the 
research identifying the drug TASIN-1 to be synthetically lethal with the APC mutation. 
Understanding potential overlap between the different research is essential to 
translating these findings into the clinic. 
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Appendix 1 – siRNA 
∆Z scores 
 
Gene Symbol ΔZ #1 ΔZ #2 
AAK1 0.0207 0.4076 
AATK 0.3049 0.3148 
ABL1 -0.7546 -0.1089 
ABL2 1.5950 -0.0745 
ACVR1 -0.4410 0.8516 
ACVR1B 0.1168 -0.9092 
ACVR1C 0.5191 -0.2385 
ACVR2 1.1952 0.4685 
ACVR2B 0.8114 -0.0706 
ACVRL1 -1.8416 -0.1042 
ADCK1 1.9246 0.1760 
ADCK2 -1.1465 0.1833 
ADCK4 -0.2244 1.1683 
ADCK5 -0.1157 0.4022 
ADK -0.8548 -0.3839 
ADP-GK -0.0863 0.5113 
ADRBK1 -0.5313 -0.4415 
ADRBK2 0.1745 -0.1836 
AIP1 2.0440 -0.2167 
AK1 -1.7381 -0.0093 
AK2 1.0797 0.5861 
AK3 0.1617 -0.8467 
AK3L1 0.6128 0.5407 
AK5 0.0804 -0.5688 
AK7 2.8852 0.3087 
AKT1 -0.0360 0.5634 
AKT2 -0.8969 0.1940 
AKT3 -0.8157 -0.3387 
ALK -0.3651 -0.2808 
ALS2CR2 -0.5948 0.2702 
ALS2CR7 1.4414 -0.8302 
AMHR2 0.0214 0.7707 
ANKK1 -0.3349 -1.6978 
ANKRD3 0.9554 1.0115 
ARAF1 -0.9947 -0.4194 
ARK5 -0.3177 0.1717 
ASK 0.7862 1.0378 
ATM -1.6575 1.5452 
ATR -0.0675 0.2176 
AURKA 1.0411 -0.4277 
AURKB -1.1576 0.5057 
AURKC 0.7281 -1.4502 
AXL 1.0691 -1.1434 
BAIAP1 -0.9316 0.0545 
BCKDK -0.7754 -1.3950 
BCR -1.2837 -0.6201 
BLK -0.1299 -0.3982 
BMP2K -1.0901 0.4958 
BMPR1A -0.3036 -0.0156 
BMPR1B 1.0013 1.0947 
BMPR2 -0.6448 -0.1456 
BMX -0.1448 -0.6114 
BRAF -0.1741 0.3854 
BRD2 -0.9115 0.1913 
BRD3 0.1134 0.2362 
BRD4 0.0097 1.4134 
BRDT 0.2712 0.2394 
BTK 0.9914 -0.4401 
BUB1 1.1535 0.3045 
BUB1B -0.2088 -0.9408 
C10ORF89 0.8296 0.1969 
C14ORF20 -0.2181 0.4831 
C7ORF2 1.1502 -0.9487 
C9ORF12 1.0822 0.4754 
C9ORF96 -0.3216 0.5010 
CALM1 -0.1761 -1.7599 
CALM2 0.6460 0.5607 
CALM3 -2.7097 0.4831 
CAMK1 0.1141 0.5504 
CAMK1D 0.8515 0.3808 
CAMK1G 0.1670 3.0527 
CAMK2A 0.4014 0.1848 
CAMK2B -0.1935 -1.8514 
CAMK2D -0.8276 1.8648 
CAMK2G 8.2578 0.7788 
CAMK4 -0.8978 -0.6048 
CAMKIINALPHA -0.3468 1.0743 
CAMKK1 1.3184 -0.0946 
CAMKK1 0.5192 0.3201 
CAMKK2 2.4682 0.2935 
CARKL -0.9729 -0.3068 
CASK 1.5500 1.0916 
CCRK 1.2501 0.1994 
CDADC1 0.4412 0.7092 
CDC2 -0.9477 -0.1360 
CDC2L1 0.0532 -0.2128 
CDC2L2 1.1667 -0.3800 
CDC2L5 0.6710 -0.3242 
CDC42BPA 1.4299 -1.2494 
CDC42BPB 0.1488 0.5939 
CDC7 -1.9995 1.1811 
CDK10 -0.2505 0.1314 
CDK11 0.8793 0.6134 
CDK2 0.4034 0.5871 
CDK3 0.5193 0.5577 
CDK4 1.2192 1.0595 
CDK5 -0.5862 -0.6050 
CDK5R1 1.6689 1.0446 
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CDK5R2 -2.1903 -0.2576 
CDK6 0.6172 1.1526 
CDK7 -0.6772 -0.3938 
CDK8 0.3623 2.0835 
CDK9 -0.0305 0.9146 
CDKL1 0.1234 0.0743 
CDKL2 -0.3403 -1.4356 
CDKL3 0.3890 1.0120 
CDKL4 -0.4865 1.8375 
CDKL5 -0.4491 0.0662 
CDKN1A -0.6112 0.6372 
CDKN1B 1.0451 -0.7672 
CDKN1C 0.8314 0.7180 
CDKN2B -0.5209 0.3744 
CDKN2C -0.9126 0.8517 
CDKN2D 1.7729 1.0600 
CERK -1.3612 0.1829 
CHEK1 0.9521 1.4862 
CHEK2 0.0836 1.2056 
CHKA -0.3122 0.3581 
CHKB -0.2890 0.6650 
CHUK 0.1266 0.8852 
CIB2 0.6015 1.9113 
CIT -0.7601 1.4135 
CKB 1.2144 -0.9690 
CKM 1.6781 -0.3493 
CKMT1B 5.5268 0.5229 
CKMT2 -1.7247 0.1967 
CKS1B -2.6953 0.4772 
CKS2 1.9954 -0.5743 
CLK1 0.7243 -1.1949 
CLK2 0.6057 0.7622 
CLK3 -0.2435 -0.2879 
CLK4 -0.4605 -0.2757 
COASY 2.1441 0.3017 
COL4A3BP -0.7103 -0.6683 
COMMD3 -0.9618 -0.2246 
CPNE3 -1.4854 0.4829 
CRIM1 1.1896 -1.8044 
CRK7 0.2605 -0.9843 
CRKL 0.0074 -1.6503 
CSF1R 1.5917 0.4552 
CSK -1.9482 -0.5215 
CSNK1A1 -1.2462 0.1038 
CSNK1A1L -0.4961 -1.0952 
CSNK1D 0.9221 0.9443 
CSNK1E -2.5729 -0.4679 
CSNK1G1 -2.3381 0.4222 
CSNK1G2 0.7328 0.5733 
CSNK1G3 -0.5650 -0.8939 
CSNK2A1 -0.8679 0.5954 
CSNK2A2 -0.3271 -0.8351 
CSNK2B 1.7667 0.2493 
DAPK1 1.4826 -0.2079 
DAPK2 -0.7558 -0.7508 
DAPK3 0.5069 -1.4070 
DCAMKL1 2.0263 -0.8903 
DCK 0.4990 1.8459 
DDR1 -0.2690 -0.0338 
DDR2 -1.1659 -1.1110 
DGKA 1.1493 -1.0845 
DGKB 1.0146 -0.0655 
DGKD 0.5455 0.6282 
DGKG -1.8927 -1.5862 
DGKH 0.1256 -1.0654 
DGKI -0.0243 -0.7206 
DGKK -1.6827 -0.6996 
DGKQ 2.5633 1.3835 
DGUOK -0.1387 -0.8902 
DKFZP434C131 -0.5487 -0.4634 
DKFZP761P0423 2.1149 1.8044 
DLG1 2.4099 -0.7463 
DLG2 -0.1246 -0.8630 
DLG3 0.1915 -0.6248 
DLG4 -0.6804 -2.2348 
DMPK 0.0061 -2.2751 
DTYMK 1.1569 1.0621 
DUSP21 1.8756 -1.3830 
DUSTYPK 2.9087 1.5248 
DYRK1A 0.0957 -0.0530 
DYRK1B 0.8686 1.9135 
DYRK2 -2.6865 -1.7969 
DYRK3 -0.3056 2.2726 
DYRK4 -2.4605 -0.0891 
EEF2K -0.4049 -1.0612 
EFNA3 -1.1566 -1.9690 
EFNA4 1.0720 2.0711 
EFNA5 0.9840 -0.1056 
EFNB3 2.2965 -0.6483 
EGFR 0.2883 -1.7178 
EIF2AK3 3.4591 0.6340 
EIF2AK4 0.0493 0.3839 
EPHA1 0.7746 0.2111 
EPHA10 1.9402 -1.4827 
EPHA2 0.8706 0.5747 
EPHA3 0.3239 0.1845 
EPHA4 -0.2410 0.1299 
EPHA5 2.2805 -0.7451 
EPHA6 1.2820 0.3529 
EPHA7 0.3830 -1.0220 
EPHA8 -1.8561 -1.4549 
EPHB1 0.8139 0.1038 
EPHB2 0.3498 -0.2009 
EPHB3 -0.6728 -0.0910 
EPHB4 -0.2665 0.4675 
EPHB6 -0.9899 0.8936 
ERBB2 0.6819 2.3483 
ERBB3 -0.7367 -1.2505 
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ERBB4 0.3196 0.6997 
ERK8 7.0267 -1.2375 
ERN1 1.6909 1.5773 
ERN2 -0.0263 1.0587 
ETNK1 -10.4545 0.9367 
EXOSC10 -0.4581 0.9206 
FASTK -1.3020 0.4235 
FER -0.9533 0.4039 
FES -0.7756 -0.4263 
FGFR1 0.6578 0.2121 
FGFR2 -0.7929 -0.7121 
FGFR3 -1.4424 -0.8881 
FGFR4 -0.1689 0.7127 
FGFRL1 0.6983 -0.4342 
FGR 0.4852 2.0944 
FLJ10761 2.1773 -1.3964 
FLJ13052 -0.4805 -0.7147 
FLJ23074 1.3183 2.8586 
FLJ23356 1.0548 1.1843 
FLJ23356 2.2718 -0.0314 
FLJ25006 0.2078 0.1477 
FLJ32685 0.3422 0.7288 
FLJ34389 -1.0803 -0.1108 
FLT1 0.2222 0.3075 
FLT3 -2.1690 -1.3622 
FLT4 -0.3286 -0.5322 
FN3K 1.4463 -0.0902 
FN3KRP -2.7146 -1.3204 
FRAP1 -2.4170 1.2487 
FRDA -1.7470 -0.3009 
FRK -1.9765 -0.5002 
FUK 1.1926 0.2067 
FYN 0.3470 -0.7815 
GAK 1.1968 1.3860 
GALK1 0.7532 -0.7785 
GALK2 -0.9196 1.4815 
GCK -0.0608 0.5307 
GK 0.3017 2.2365 
GK2 -0.2597 -0.1812 
GNE 0.0487 -0.5222 
GOLGA5 -0.5177 0.7666 
GRK1 1.7501 -0.3441 
GRK4 -0.2382 1.0811 
GRK5 0.2553 1.5986 
GRK6 1.5811 0.5113 
GRK7 0.3785 -1.3659 
GSG2 0.8537 -0.0667 
GSK3A -0.1449 0.6535 
GSK3B -0.8925 -0.1320 
GTF2H1 0.3844 0.9356 
GUCY2C -0.4414 0.6049 
GUCY2D 0.8047 -0.3544 
GUCY2F -0.0919 2.1656 
GUK1 -0.8674 0.1486 
HAK 0.0094 0.2019 
HCK 3.9743 -0.5492 
HIPK1 -3.0275 0.1554 
HIPK2 1.3404 0.3132 
HIPK3 0.1717 1.1055 
HIPK4 0.4998 1.0779 
HK1 0.9087 1.8579 
HK2 1.9626 -1.7821 
HK3 0.5264 0.0874 
HRI -0.4206 0.6330 
HSMDPKIN 2.2092 -1.3378 
HSPB8 1.4153 -5.1508 
HUNK 1.2067 1.2947 
HUS1 2.5792 -0.9991 
ICK 0.1528 0.0195 
IGF1R 1.5653 2.1009 
IGF2R -1.3609 -1.1568 
IHPK1 1.3575 1.1626 
IHPK2 -1.9821 -1.1357 
IHPK3 -0.3587 -0.0650 
IKBKAP 0.0428 1.5559 
IKBKB 0.3255 0.2937 
IKBKE -0.4098 -1.2371 
IKBKG -0.6995 -0.1837 
ILK -1.7939 0.0013 
ILK-2 0.8874 1.6093 
INSR 1.2017 0.7668 
INSRR 0.4090 -0.6433 
IPMK -0.2008 0.7088 
IRAK1 -1.1199 -1.5083 
IRAK2 0.1579 0.3657 
IRAK3 0.9217 0.3222 
IRAK4 -1.7045 -0.3610 
ITK -0.5402 0.1212 
ITPK1 -0.7624 -0.0496 
ITPKA -0.6310 -0.7025 
ITPKB 0.8553 0.6879 
ITPKC 0.4892 0.1205 
JAK1 1.0906 1.1155 
JAK2 -0.0037 -0.9114 
JAK3 -2.2027 -0.4918 
JIK -0.7883 1.1824 
KALRN -0.0988 -0.9417 
KCNH2 1.0588 -0.2169 
KCNH8 0.1816 1.9249 
KDR -0.1864 0.2464 
KHK -0.9992 -1.5306 
KIAA0999 0.3743 -1.5829 
KIAA1361 1.3914 -1.3668 
KIAA1639 -1.7201 0.7851 
KIAA1765 -0.5896 1.2246 
KIAA1804 -2.1426 -1.6421 
KIAA1811 0.5801 -0.0690 
KIAA1811 -0.7282 0.3583 
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KIAA2002 0.8877 -1.3971 
KIT 6.6381 0.2321 
KSR 1.3174 -0.5660 
KSR2 0.2664 1.5502 
KUB3 2.2564 -0.7959 
LAK -0.2482 -1.5811 
LATS1 -1.3020 -0.0684 
LATS2 -0.3854 0.7198 
LCK 0.2586 -0.6286 
LIMK1 -0.4854 0.4646 
LIMK2 -0.8628 -0.7116 
LMTK2 1.0166 1.1331 
LMTK3 -0.2492 -0.4022 
LOC340156 -0.4589 -0.2159 
LOC390226 -0.8583 0.0562 
LOC91461 -0.0649 -2.0074 
LRRK1 0.2928 -0.2726 
LRRK2 0.4383 -0.8842 
LTK 0.3384 0.5836 
LYK5 -1.4045 0.3597 
LYN -2.1283 1.4570 
MAGI-3 -0.2466 -0.6777 
MAK 0.3700 1.0239 
MAP2K1 -0.2432 0.4944 
MAP2K2 -0.4127 0.5085 
MAP2K3 -1.7023 0.4875 
MAP2K4 -1.1317 -0.5462 
MAP2K5 -0.5116 -1.8713 
MAP2K6 -1.2467 -0.3892 
MAP2K7 -0.6101 0.6193 
MAP3K1 0.0433 0.7335 
MAP3K10 -0.8687 0.1131 
MAP3K11 -1.2710 -0.4635 
MAP3K12 -1.9726 -0.5550 
MAP3K13 -3.0618 0.6145 
MAP3K14 1.1868 0.8845 
MAP3K15 -1.5571 -1.2711 
MAP3K2 -1.7993 -0.9251 
MAP3K3 -0.0604 0.0051 
MAP3K4 -0.2423 -0.2288 
MAP3K5 -0.3781 -1.4386 
MAP3K6 1.5549 0.4712 
MAP3K7 2.6330 2.6637 
MAP3K7IP1 1.0347 0.3978 
MAP3K8 0.2184 0.3208 
MAP3K9 2.3233 0.1454 
MAP4K1 0.7714 1.0394 
MAP4K2 0.2974 -0.5443 
MAP4K3 0.0520 -0.1817 
MAP4K4 -0.1327 0.7893 
MAP4K5 2.4842 2.9439 
MAPK1 -0.4575 -0.8857 
MAPK10 0.3628 -0.1741 
MAPK11 -0.3230 0.4828 
MAPK12 0.5198 -0.1457 
MAPK13 -0.0350 0.2202 
MAPK14 0.1559 0.8594 
MAPK3 1.2612 -1.3566 
MAPK4 0.2409 -0.9093 
MAPK6 -0.3227 0.4396 
MAPK7 1.7070 -0.5148 
MAPK8 -0.4711 0.3552 
MAPK9 -0.5651 0.2768 
MAPKAPK2 0.3644 0.4042 
MAPKAPK3 0.0880 1.3017 
MAPKAPK5 -0.3430 0.4108 
MARK1 -1.0412 0.1202 
MARK2 -0.8574 -2.8960 
MARK3 -0.5679 -0.0754 
MARK4 -0.1373 -0.6315 
MAST2 0.5411 0.1617 
MAST3 -0.3265 0.3412 
MAST4 0.2852 1.0901 
MASTL 0.6393 0.3473 
MATK -0.1617 0.3711 
MELK -1.2872 -0.7377 
MERTK -0.6920 0.1069 
MET 0.0568 0.3094 
MGC16169 0.5880 0.1723 
MGC42105 -0.2167 0.1701 
MGC45428 -0.6582 1.9678 
MGC4796 -0.1363 0.3476 
MGC4796 -0.1017 -0.4539 
MGC8407 -0.9706 -1.5554 
MIDORI 0.9201 1.4060 
MINK 0.9079 -2.1200 
MKNK1 0.8100 -0.4861 
MKNK2 -0.7327 0.3316 
MLCK -0.1070 -1.5980 
MOS 0.5079 0.0397 
MPP1 0.0378 -1.9078 
MPP2 0.0473 1.6420 
MPP3 -0.6441 2.6564 
MST1R -0.2839 -0.0193 
MULK -1.4537 -1.1230 
MUSK 0.4938 0.9801 
MVK -0.4954 -0.8051 
MYLK 1.1320 0.7618 
MYLK2 3.5947 -1.0569 
MYO3A 0.5057 -0.2484 
MYO3B -0.5447 -2.4516 
N4BP2 -1.7935 -1.2834 
NAGK -1.0286 -1.8705 
NEK1 -0.1733 -1.5400 
NEK11 0.8944 -0.8181 
NEK2 0.6675 -0.0614 
NEK3 -1.2111 -0.7367 
NEK4 -0.6918 -1.0361 
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NEK5 -0.8753 -1.3336 
NEK6 -1.2071 -0.9997 
NEK7 0.6020 0.5379 
NEK8 -1.8003 1.7785 
NEK9 -1.5770 -0.0211 
NLK -0.0596 -2.0491 
NME1 1.0582 0.2157 
NME2 -0.8374 0.3331 
NME3 1.0347 -0.8854 
NME4 0.3794 0.2626 
NME5 0.1361 -1.1809 
NME6 -0.1284 0.4566 
NME7 -1.0506 -0.4834 
NPR2 1.4909 -0.6280 
NRBP -0.9525 -0.9017 
NRBP2 -0.6530 -0.3006 
NRK -0.1086 -0.5335 
NTRK1 -0.1838 0.7734 
NTRK2 1.0145 0.1352 
NTRK3 0.7250 -0.4339 
NUCKS -0.8536 -0.9962 
NUP62 1.3292 -1.1177 
NYD-SP25 -1.6747 -0.6935 
OSR1 0.7528 -0.2362 
P101-PI3K -0.9790 -0.2266 
PACE-1 0.2287 -0.0455 
PACSIN1 0.2379 1.2284 
PAK1 -1.1203 1.6218 
PAK2 -0.8608 -0.7963 
PAK3 -0.4132 -0.7641 
PAK4 0.8611 -0.1519 
PAK6 0.8155 1.3375 
PAK7 -0.1931 1.1663 
PANK1 -0.8176 1.0309 
PANK2 1.3281 1.1582 
PANK3 -0.0175 0.1639 
PANK4 -0.3686 -0.6018 
PAPSS1 -1.5036 -0.8645 
PAPSS2 -0.3550 -0.1693 
PASK -0.9947 0.2214 
PCK1 0.9022 0.0575 
PCK2 0.7154 0.1014 
PCTK1 1.0163 -0.4656 
PCTK2 1.0366 0.4460 
PCTK3 -1.7213 0.3160 
PDGFRA 0.1290 -0.2241 
PDGFRB 1.0821 -0.7171 
PDGFRL 5.6960 -0.7228 
PDIK1L 0.8883 -1.2319 
PDK1 -0.8108 -0.3888 
PDK2 -1.0857 0.2103 
PDK3 -1.2320 -0.0567 
PDK4 0.2342 0.6877 
PDPK1 0.7128 0.4466 
PDXK 0.4941 -2.8593 
PFKFB1 -0.8748 -0.6342 
PFKFB2 0.0368 -0.6147 
PFKFB3 -0.4701 -0.0234 
PFKFB4 -1.2981 0.1547 
PFKL -3.2312 0.3997 
PFKM 2.6767 -0.6705 
PFKP -1.0121 -0.1843 
PFTK1 2.4085 -1.0355 
PGK1 0.4904 0.4655 
PGK2 -0.1516 0.2207 
PHKA1 0.9630 1.1765 
PHKA2 -1.9557 -0.1824 
PHKB 5.4199 -0.6406 
PHKG1 -3.7328 0.4466 
PHKG2 1.2455 0.3205 
PI4K2B 0.5650 1.7880 
PI4KII 2.3102 -1.9592 
PIK3C2A -0.9598 0.4942 
PIK3C2B 0.2713 0.7196 
PIK3C2G 2.0487 -1.8810 
PIK3C3 1.0319 1.3597 
PIK3CA -1.1422 -0.6734 
PIK3CB -0.9178 -0.9784 
PIK3CD 0.7888 1.0357 
PIK3CG 1.0736 0.4576 
PIK3R1 -0.3238 1.2285 
PIK3R2 0.4607 -0.6189 
PIK3R3 0.0943 -2.4155 
PIK3R4 0.5091 0.4358 
PIK4CA 1.1548 0.9964 
PIK4CB 0.3896 -1.6892 
PIM1 -2.2019 0.4096 
PIM2 -1.8761 -0.4296 
PIM3 -0.1236 1.2530 
PINK1 0.6689 1.0958 
PIP5K1A -0.7568 -0.5562 
PIP5K1B -0.7937 -0.5153 
PIP5K1C -0.3878 0.0205 
PIP5K2A 0.5934 1.8333 
PIP5K2B 1.4990 0.3749 
PIP5K2C -0.9922 0.7276 
PIP5K3 0.0034 -0.6753 
PIP5KL1 -1.2305 0.7087 
PKIA 0.6995 0.3346 
PKIB -0.3679 -1.6227 
PKLR -0.4113 0.5856 
PKM2 -1.2578 2.2023 
PKMYT1 2.4753 0.0705 
PKN3 1.5403 -0.2634 
PLK1 -2.7428 0.2187 
PLK2 1.1262 -1.3528 
PLK3 -0.3758 0.5385 
PLK4 -0.2968 0.2823 
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PMVK 0.3505 -0.2731 
PNCK -0.1162 0.6384 
PNKP -0.1380 1.2622 
PRKAA1 -1.4281 -0.7928 
PRKAA2 0.4065 -0.3820 
PRKAB1 1.4815 0.0186 
PRKAB2 0.8994 -0.1919 
PRKACA -0.5758 -0.6679 
PRKACB -0.4413 -0.3245 
PRKACG 0.0066 -0.1892 
PRKAG1 0.7737 -0.9181 
PRKAG2 -0.5232 0.9881 
PRKAG3 -3.8244 2.1839 
PRKAR1A -0.7587 0.3556 
PRKAR1B 0.2752 -0.3626 
PRKAR2A -0.5415 -0.9677 
PRKAR2B 0.6291 0.7424 
PRKCA -0.4827 0.5311 
PRKCB1 1.9301 0.0904 
PRKCD 1.6623 0.4243 
PRKCE 0.7037 -0.8760 
PRKCG 1.0195 0.1554 
PRKCH -0.4176 -0.7493 
PRKCI -1.5157 -0.2810 
PRKCL1 -0.7923 1.0863 
PRKCL2 0.4806 -0.3230 
PRKCM -0.0690 1.4172 
PRKCN 0.1708 0.5465 
PRKCQ -0.0676 1.1903 
PRKCSH -0.3696 0.1120 
PRKCZ 0.9698 -0.9832 
PRKD2 1.8058 0.1133 
PRKDC 1.0194 -0.6567 
PRKG1 1.7075 0.5131 
PRKG2 0.0119 2.6811 
PRKR -0.0997 -0.1799 
PRKWNK1 2.0763 -2.2575 
PRKWNK2 0.0209 -0.5733 
PRKWNK3 0.8691 1.5878 
PRKX -1.0074 -0.5819 
PRKY -0.5524 0.5581 
PRPF4B 0.8712 -0.0439 
PRPS1 0.1941 -1.0452 
PRPS1L1 -0.2898 -1.5210 
PRPS2 -0.2139 -0.9939 
PSKH1 1.1716 -0.3818 
PSKH2 -0.7950 -0.7524 
PTK2 -0.3297 -0.7850 
PTK2B -0.0487 0.2569 
PTK6 -1.9457 1.2212 
PTK7 2.0483 1.0636 
PTK9 0.1547 -1.0832 
PTK9L -2.2082 1.3600 
PXK 0.3872 1.6570 
PYCS 0.2663 0.6687 
RAF1 -0.3532 0.6189 
RAGE -0.6500 0.3258 
RBKS -0.0599 0.4125 
RELA -0.5942 1.4561 
RET -0.7233 -0.9937 
RFK 0.5473 0.1680 
RFP -1.4112 0.3903 
RIOK1 -1.2531 0.2917 
RIOK2 -1.2395 0.5149 
RIOK3 -0.0710 -0.1895 
RIPK1 -1.7215 -0.4865 
RIPK2 -4.4636 0.8420 
RIPK3 -2.2029 -0.4743 
RNASEL 0.6799 1.4997 
ROCK1 -0.2381 -1.4065 
ROCK2 0.5624 0.8203 
ROR1 1.1187 0.1640 
ROR2 0.5591 -0.9261 
ROS1 1.3953 -0.0931 
RP6-213H19.1 -0.7374 -0.4201 
RPS6KA1 0.6788 -0.4344 
RPS6KA2 0.7966 1.4809 
RPS6KA3 -1.7807 -0.8217 
RPS6KA4 -0.4628 -0.1861 
RPS6KA5 0.3865 1.2880 
RPS6KA6 0.6253 0.3951 
RPS6KB1 -0.2058 1.1139 
RPS6KB2 -1.7411 0.4953 
RPS6KC1 -1.4364 -0.1045 
RPS6KL1 -0.0455 -2.0881 
RYK -2.8169 0.2582 
SAST -1.5256 0.8837 
SBK1 -0.6348 1.1424 
SCAP1 -0.3770 2.5630 
SCYL1 1.4288 -0.1774 
SGK 0.0632 -0.1660 
SGK2 -1.7762 -0.3188 
SGKL -1.1889 -1.6646 
SIK2 -0.2741 0.9159 
SLK 2.7727 0.2067 
SMG1 -1.6225 -1.3109 
SNARK 0.2147 -0.2921 
SNF1LK -0.8404 -1.2999 
SNRK 1.5299 -0.4081 
SPEG 0.1440 0.2671 
SPHK1 -0.4277 1.0565 
SPHK2 0.2414 0.5684 
SRC 0.2303 -0.8214 
SRMS -0.6614 0.5002 
SRP72 0.8813 0.4873 
SRPK1 0.2604 0.5481 
SRPK2 0.5908 0.3593 
SSTK 0.3041 0.4947 
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SSTK -0.7924 -1.7051 
STK10 2.4068 -1.1462 
STK11 0.4554 -0.0515 
STK16 2.0511 2.9406 
STK17A -0.5013 0.2504 
STK17B -0.4423 -0.5595 
STK19 2.0996 -1.0614 
STK22B 0.5263 1.5188 
STK22C -2.0392 0.1098 
STK22D 0.5985 1.9819 
STK22D 0.5391 1.9944 
STK23 0.3854 2.4375 
STK24 -0.5251 0.1933 
STK25 -0.2022 1.7538 
STK29 1.8053 1.1007 
STK3 -0.1324 0.9132 
STK31 0.3458 -0.4115 
STK32A -0.9164 0.8710 
STK32B 2.8962 0.1802 
STK32C 0.3105 0.4587 
STK33 1.0405 -1.3796 
STK35 0.1390 -0.7244 
STK36 0.7367 -1.0666 
STK38 0.1468 0.2513 
STK38L -0.7912 -0.0184 
STK39 1.0991 -1.7949 
STK4 0.1703 1.5708 
STYK1 1.2473 1.3938 
SYK -1.2748 -0.6235 
TAF1 1.5647 0.1588 
TAF1L 0.3473 1.2599 
TAO1 1.4512 1.7873 
TBK1 1.3228 1.2877 
TEC -0.8803 0.6078 
TEK -0.0192 0.1425 
TESK1 -0.2433 -0.0261 
TESK2 -0.3709 0.2435 
TEX14 0.9597 0.4359 
TGFBR1 -2.6567 0.2089 
TGFBR2 0.0587 0.2107 
TGFBR3 -1.0196 -0.1687 
THNSL1 0.1994 -1.7096 
TJP2 -0.0818 -0.0856 
TK2 -0.2244 -1.1718 
TLK1 0.1550 0.6415 
TLK2 -0.3280 -0.4490 
TNIK -1.8187 -0.1865 
TNK1 -3.2477 0.4269 
TNK2 0.2206 1.6887 
TNNI3K 1.4093 0.0892 
TOPK 1.7739 -0.1181 
TP53RK 0.1992 -0.7268 
TPK1 0.0194 -0.1080 
TRIB1 0.0572 -1.6484 
TRIB2 -0.0784 -0.6261 
TRIB3 0.4693 0.2263 
TRIO -2.4375 0.4341 
TRPM6 -0.6779 -0.3872 
TRPM7 0.7709 0.1185 
TSKS -0.7309 -1.3108 
TTBK1 2.5677 2.5737 
TTBK2 -1.4695 -0.2068 
TTK -1.9768 0.3898 
TYK2 -0.1172 -0.5141 
TYRO3 -0.2307 -1.4299 
UCK1 -0.9025 0.2666 
UHMK1 -0.1244 -0.6012 
ULK1 -1.0577 -1.2222 
ULK2 1.0027 -0.2804 
ULK4 0.4486 0.2965 
UMP-CMPK -0.0100 0.6638 
UMPK 2.8611 0.6725 
URKL1 2.3885 1.1394 
VRK1 0.3108 0.3542 
VRK2 -2.2871 0.0497 
VRK3 0.1525 0.4058 
WEE1 1.0142 0.6812 
WNK4 -0.2157 0.3298 
XYLB -1.3166 -1.1431 
YES1 1.3790 -0.6388 
ZAK 0.1750 0.9461 
ZAP70 0.6145 -0.5348 
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Appendix 2 – Compound screen Z scores 
 
 
Z SCORES RKO 7_1 Z SCORES RKO 2_36 
GeneSymbol REP1 REP2 REP3 REP1 REP2 REP3 
 Procaine (Novocaine) HCl 0.1622 0.2126 0.3561 0.3297 0.9715 0.2202 
(+,-)-Octopamine HCl 0.4362 0.8509 0.8462 0.8023 0.6781 0.9496 
(R)-(+)-Atenolol -0.6322 -0.0523 -0.4164 -0.3405 -0.1572 -0.0437 
(R)-baclofen -0.1492 0.7536 1.8347 0.2110 0.0052 0.1413 
10-DAB (10-
Deacetylbaccatin) -11.8684 -12.3488 -14.6504 -7.6914 -6.9877 -10.3499 
1-Hexadecanol -1.4850 -0.1672 -1.5434 -0.3510 -0.4106 -1.3155 
2-Methoxyestradiol -14.8565 -18.6584 -19.8087 -10.7349 -12.7432 -15.3284 
2-Thiouracil -1.3519 -1.1993 -0.9526 -0.4600 -0.4455 -1.2402 
5-Aminolevulinic acid 
hydrochloride -1.1641 -0.7847 -0.2418 -1.4877 -0.4563 -1.5119 
9-Aminoacridine -15.0808 -19.8020 -21.1082 -10.4683 -12.2624 -15.1969 
Abacavir sulfate -0.3080 0.0618 -0.4497 0.3209 0.1792 0.2868 
Abiraterone (CB-7598) 0.5831 1.2705 0.6821 1.2603 1.1222 0.7426 
Abiraterone Acetate 
(CB7630) 0.0385 0.0264 -0.5928 0.4249 -0.4249 -0.3054 
Abitrexate (Methotrexate) -5.5437 -7.7046 -8.9878 -1.0992 -2.7438 -4.0782 
Acadesine 0.4101 1.7371 0.6392 0.2597 1.1409 0.5914 
Acarbose 0.5912 0.9156 1.0395 -0.3101 -0.8517 -0.0969 
Acebutolol HCl -0.6357 -0.0330 -0.6009 -0.2347 -0.8134 -1.3998 
Aceclidine HCl -0.5370 0.3603 -0.4744 -0.6078 -0.7930 -0.2091 
Acemetacin (Emflex) 0.8875 0.3692 0.7107 1.0501 0.9640 1.2578 
Acetanilide (Antifebrin) 0.0597 -0.3097 0.4639 -0.3210 -0.6579 0.5325 
Acetarsone 0.7822 0.0321 0.8144 0.4100 0.0563 -0.0140 
Acetylcholine chloride -0.0820 0.7285 0.9047 0.7654 1.0519 0.7979 
Acetylcysteine -1.1468 -1.0936 -1.2925 -13.0043 -1.0006 -1.2638 
Acipimox 0.5132 0.4063 0.9772 0.7616 1.4586 0.7245 
Acitretin 0.4541 -0.2480 0.0455 1.2333 0.7277 0.2863 
Aclidinium Bromide -0.2347 -1.1031 -1.3025 -0.1361 -1.0287 -1.0134 
Acyclovir (Aciclovir) 0.9704 -0.0295 0.9722 0.6374 1.1131 0.8796 
Adapalene 0.6424 0.4383 1.4114 0.2444 -0.3337 0.0969 
Adefovir Dipivoxil (Preveon, 
Hepsera) -10.9209 0.6208 0.5510 -6.4343 0.7507 0.7109 
Adenine -1.1853 1.0522 0.5671 0.8493 1.1070 0.1621 
Adenine hydrochloride 0.5153 1.5205 1.1319 0.8072 1.2709 0.9076 
Adenine sulfate 0.8565 2.0071 1.9036 0.7747 1.3605 0.9250 
Adenosine (Adenocard) -0.4718 -0.0488 -0.2486 -1.4550 -0.7427 -1.0150 
Adiphenine HCl 0.3781 -0.0251 -1.3218 -0.2236 0.0280 -0.8584 
Adrenalone HCl 0.3460 0.7675 0.8432 0.8276 0.3257 0.2780 
Adrucil (Fluorouracil) -2.2657 -5.6376 -5.7841 0.1820 -0.7781 -2.2091 
Afatinib (BIBW2992) -9.2963 -8.6494 -10.0390 -0.7261 -2.0365 -5.7162 
Agomelatine -0.3363 0.2980 1.6004 1.0286 0.0763 0.7933 
Albendazole (Albenza) -2.5687 -4.1677 -5.8641 0.1165 -0.4714 -1.8938 
Albendazole Oxide 
(Ricobendazole) -3.0051 -6.7886 -7.4202 0.2238 -0.8514 -1.5589 
Alendronate (Fosamax) -0.4991 -0.7247 -0.8065 0.0463 -0.3621 -0.0833 
Alexidine HCl -16.3647 -21.3144 -22.6560 -11.6274 -13.1197 -16.5475 
Alfacalcidol -0.2018 1.1120 0.9843 2.0265 1.4753 0.4263 
Alfuzosin hydrochloride 
(Uroxatral) -2.5164 -0.3379 -3.2215 -13.8171 -1.3444 -3.4075 
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Alibendol -0.9881 -0.7777 -0.6899 -0.9472 -2.3613 -1.0425 
Aliskiren hemifumarate 0.3933 0.7944 0.3458 0.6951 0.3217 0.6589 
Allopurinol (Zyloprim) -0.3354 0.4044 0.5186 0.5383 -0.4677 0.4346 
Allylthiourea -0.2604 -0.7577 -0.2124 -1.1681 -2.3783 -1.4432 
Almotriptan malate (Axert) -1.5555 -0.6840 -1.0730 -0.2085 -0.5024 -1.1885 
Alprostadil (Caverject) 0.0671 0.8635 0.6324 1.7225 1.3230 0.7021 
Altrenogest -0.3685 -0.5875 0.0943 0.4543 0.6823 0.4129 
Altretamine (Hexalen) -26.4116 -2.2085 -2.5737 -13.6884 -0.5098 -2.7732 
Alverine Citrate -1.2916 -2.4022 -2.0013 -1.2357 -1.5627 -2.1973 
Amantadine hydrochloride 
(Symmetrel) 0.5026 0.4594 0.5816 -0.6634 -0.6578 0.0309 
Ambrisentan -0.7509 0.0819 -0.7079 0.5620 0.1472 -0.2661 
Amfebutamone (Bupropion) -0.3516 0.1298 0.4784 -0.9589 -0.3350 -0.4247 
Amfenac Sodium 
(monohydrate) -0.5167 -0.3967 -1.5483 -0.6098 -0.1944 -1.8644 
AMG-073 HCl (Cinacalcet 
hydrochloride) -11.2186 -18.5960 -18.6991 -6.9546 -5.3218 -9.6591 
Amidopyrine -0.4756 0.5461 -0.4670 -0.1816 -0.6751 -0.1716 
Amikacin hydrate -0.5665 -0.2029 -0.6778 -0.8938 -0.4201 -0.0102 
Amikacin sulfate 0.0712 -0.0976 -0.8812 -0.4337 -0.3530 -1.2693 
Amiloride hydrochloride 
(Midamor) 0.2137 -0.0094 0.3826 0.2273 1.0703 0.8258 
Amiloride hydrochloride 
dihydrate -0.3557 -0.9717 -0.1406 -0.9610 -1.0657 -0.7497 
Aminocaproic acid (Amicar) 0.8813 0.5535 0.2434 1.3006 1.0709 0.4048 
Aminoglutethimide 
(Cytadren) 0.8896 0.0787 0.4830 0.6839 0.8742 0.1734 
Aminophylline (Truphylline) 0.5672 1.0487 0.0774 0.2875 1.0610 0.3098 
Aminosalicylate sodium -0.5021 0.9246 1.6394 1.2725 0.8469 0.8175 
Aminothiazole -0.3272 0.1631 -0.6718 0.6295 0.1927 0.3206 
Amiodarone HCl -8.5381 -4.3546 -13.7941 -4.4164 -5.8016 -12.0128 
Amisulpride -23.0502 -1.2017 -2.3377 -0.5580 0.3489 -1.3871 
Amitriptyline HCl -1.2577 -2.4324 -1.5152 -0.2141 -0.0052 -0.7310 
Amlodipine (Norvasc) -10.6335 -19.8944 -21.0124 -4.6819 -8.1867 -15.0025 
Amlodipine besylate 
(Norvasc) -6.9964 -19.6254 -21.1197 -4.1129 -9.7419 -14.5436 
Ammonium Glycyrrhizinate 
(AMGZ) 0.5410 -0.3359 0.2755 0.0483 -0.0080 0.1053 
Amorolfine Hydrochloride 0.4086 0.9855 0.2827 0.7631 0.7892 0.5917 
Amoxapine -0.5736 -1.3655 -1.2410 0.0283 -0.6083 -0.5763 
Amoxicillin (Amoxycillin) 0.2455 -0.9756 -0.8445 -0.0062 -0.4878 -0.4698 
Amoxicillin sodium (Amox) 0.6928 -0.5082 -2.1284 -0.0925 -0.3277 -1.5475 
Amphotericin B (Abelcet) 0.2271 0.1737 -0.2007 -0.3009 -0.6638 -0.4662 
Ampicillin sodium 0.6951 1.0230 0.8708 0.8396 0.5204 0.8924 
Ampicillin Trihydrate 0.0547 -0.9027 0.3224 -1.2201 -0.8091 -0.3447 
Ampiroxicam 0.3923 0.0714 -0.4615 -0.4737 -1.1870 -1.1566 
Amprenavir (Agenerase) -0.7384 -0.9926 -0.9506 0.6086 -0.3532 -1.1398 
Amprolium HCl 1.3163 1.0900 0.1086 -0.2445 0.0095 -0.3281 
Anagrelide HCl 1.0244 0.9992 1.0252 1.3012 1.0276 1.2388 
Anastrozole 1.3838 0.0371 1.4620 1.9129 1.0007 1.4883 
Aniracetam -17.2209 -0.3112 -1.4136 0.2435 1.0281 -0.4755 
Anisindione  1.1662 0.8214 0.3012 0.4044 0.4238 0.5767 
Anisotropine Methylbromide  0.5657 0.7490 0.2371 0.6946 0.4433 0.3073 
Antazoline HCl 0.5036 0.7304 0.1930 0.6767 0.4853 0.4065 
Antipyrine 1.3186 1.2911 1.6409 2.0437 1.4162 2.0758 
Apatinib (YN968D1) -1.4183 -0.1333 -0.0223 0.1994 0.0240 0.1765 
Apixaban 0.1090 0.7317 -8.2090 1.6859 0.7888 -1.0410 
Aprepitant (MK-0869) -15.5215 -7.4737 -9.5913 0.8798 -0.0953 -1.4651 
Arbidol HCl -3.1443 -1.6331 -0.2293 0.1403 0.1553 0.4924 
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Arecoline -4.6997 1.1677 1.1248 1.5551 1.3420 1.6717 
Argatroban -17.0285 0.4485 -0.2213 -0.2675 0.1893 -0.7880 
Aripiprazole (Abilify) 0.9632 -0.5659 -0.0068 -0.1783 -0.4914 0.2724 
Artemether (SM-224) -0.1796 0.0963 -0.5886 0.7267 0.4410 -0.1988 
Artemisinin 0.2011 -1.0948 -0.6947 -0.1262 0.6795 -1.0775 
Articaine HCl -0.3517 0.7316 1.3296 0.9214 0.8021 1.0766 
Asenapine -2.1037 -1.7687 -0.7548 1.0998 0.8056 -1.1846 
Aspartame 0.2524 0.7893 0.4018 0.3614 0.4334 0.8184 
Aspirin (Acetylsalicylic acid) 0.1975 -0.0040 -0.7291 -0.1647 -1.0174 -1.0409 
Atazanavir sulfate 0.7235 -0.4014 -0.1638 -0.2894 0.6838 0.6756 
Atomoxetine HCl 0.5512 0.2650 0.4023 0.8346 0.3823 0.8568 
Atorvastatin calcium (Lipitor) -1.8403 -4.4027 -4.9718 -6.7340 -7.9268 -11.5011 
Atovaquone (Atavaquone) 1.0841 0.2487 0.2335 -0.0433 0.0905 0.0187 
ATP (Adenosine-
Triphosphate) 0.6305 1.0177 0.7026 0.6710 0.7336 0.9128 
Atracurium besylate -0.8878 0.8314 -0.4724 0.1684 0.9936 0.7161 
Atropine -0.4338 -0.7118 -1.0427 0.9415 0.6370 -0.0931 
Auranofin -11.9213 -19.6144 -20.8104 -10.5175 -11.9832 -14.9399 
Avanafil -1.2640 -2.7880 -1.8648 -0.7150 -0.0381 -2.8816 
Avobenzone (Parsol 1789) 0.3450 -0.1940 -0.2738 -0.3756 -0.8691 -0.2398 
Axitinib -5.0412 -1.5133 -4.5447 -2.1244 -2.9112 -3.1033 
Azacitidine (Vidaza) -2.0323 0.1252 1.5655 -1.4760 0.7721 0.5765 
Azacyclonol 0.4158 0.1527 0.3302 0.4541 -0.0807 0.7268 
Azaguanine-8 1.0503 0.6482 0.3212 0.8159 0.7647 0.8307 
Azaperone -15.9859 -1.9654 -0.8245 -0.0124 -0.9418 -0.2712 
Azasetron HCl (Y-25130) 0.7879 0.1787 0.3226 0.7244 0.0785 0.8945 
Azatadine dimaleate -0.4322 0.3265 0.2611 0.3441 -0.0470 0.6155 
Azathioprine (Azasan, 
Imuran) -3.9787 -5.6306 -6.6368 -1.4592 -2.2611 -3.9012 
Azelastine hydrochloride 
(Astelin) -18.2738 -5.7539 -9.7728 -3.1137 -3.7709 -11.7123 
Azelnidipine -4.0751 -0.6533 -0.0947 -0.6408 -1.3856 -1.4235 
Azilsartan (TAK-536) -0.2783 -0.1319 -0.1096 -0.7501 -1.2374 -0.1082 
Azilsartan Medoxomil (TAK-
491) 0.4833 -0.0284 -0.5004 -0.7877 -0.4577 -0.4977 
Azithromycin (Zithromax) 0.3132 0.7359 -0.2038 0.2952 0.6940 0.3205 
Azithromycin Dihydrate -0.5347 -0.7108 0.2148 -1.3544 -0.0107 -0.8576 
Azlocillin sodium salt 0.9173 0.5548 1.3065 1.0136 0.4443 0.9811 
Aztreonam (Azactam, 
Cayston) 0.7514 1.0940 0.8576 1.9134 0.9779 0.9716 
Bacitracin -15.3874 -0.0042 0.6793 -0.5144 -0.1807 -0.2315 
Bacitracin zinc 1.3587 0.0254 0.7085 -0.0016 0.5818 0.6908 
Balofloxacin -0.1063 0.1123 -0.3127 -0.9460 -1.9078 -0.4847 
Bazedoxifene HCl -11.7223 -14.2629 -15.4713 -7.1863 -8.2855 -10.5535 
Beclomethasone 
dipropionate -0.0937 -5.1421 -0.9349 0.7269 0.2647 -1.2617 
Bekanamycin  0.5475 -0.1579 0.0842 0.4042 0.1242 -0.7137 
Bemegride 0.2242 0.7300 -0.4612 -0.0480 0.2731 -0.1165 
Benazepril hydrochloride 1.2501 0.6455 0.8567 0.0469 0.6463 -0.2662 
Bendamustine HCL 1.0241 0.8120 2.2462 1.5909 0.3945 1.6075 
Bendroflumethiazide 1.0957 0.3762 0.8693 0.7951 -0.0503 -0.0060 
Benfotiamine -0.9029 -0.6250 -0.8251 0.1019 -1.6081 -0.5223 
Benidipine hydrochloride -0.2596 0.2164 -0.8505 0.6644 1.3400 -0.5572 
Benserazide 0.1026 0.5097 0.3264 -1.6193 -0.9367 -0.2939 
Bentiromide  1.0237 -0.2159 0.6929 0.5384 -0.0690 0.0115 
Benzbromarone -1.0030 -1.5032 -0.4415 -0.6177 -1.0678 0.1634 
Benzethonium chloride -9.4001 -9.6733 -15.9560 -6.6547 -4.1505 -12.5931 
Benzocaine -0.3476 -0.0978 -0.2864 0.3338 0.1927 -0.3358 
Benzoic acid -0.3156 0.1974 -0.7571 -0.1078 0.9964 -0.0208 
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Benzthiazide 1.4534 0.6252 0.7549 0.4016 0.3416 0.6676 
Benztropine mesylate -3.1106 -5.3744 -4.8403 -0.7398 -1.8386 -3.2015 
Benzydamine Hydrochloride -0.4857 -0.2921 -0.5285 1.1413 0.9106 0.3865 
Benzylpenicillin sodium -0.5079 -0.2399 -1.1363 -0.2399 -0.0720 -1.3378 
Bephenium 
Hydroxynaphthoate 0.0063 -0.3773 0.0551 -0.2142 -0.7193 -0.7567 
Bepotastine Besilate -1.2736 -3.3231 -1.4632 -0.1306 -1.4115 -1.6305 
Bergapten 1.2264 -0.3187 0.1775 0.5769 0.2271 -0.1646 
Besifloxacin HCl (Besivance) -0.1722 -0.7185 -0.9382 -0.3444 -0.5818 -0.7243 
Beta Carotene -1.3069 0.0595 0.7472 -0.2205 -1.8058 -0.4618 
Betahistine 2HCl 1.0257 0.7021 0.3098 0.9918 0.3742 1.0439 
Betamethasone (Celestone) -0.6173 -1.4303 -1.2306 -14.7850 -0.3859 -0.9891 
Betamethasone Dipropionate 
(Diprolene) -0.2511 0.0361 0.5127 1.4213 1.1927 0.4374 
Betamethasone valerate 
(Betnovate) 0.8202 1.1911 -0.1221 1.7378 0.9324 0.7040 
Betamipron 0.9932 1.4000 0.8373 1.1649 0.7208 0.9718 
Betapar (Meprednisone) 0.0502 0.8733 0.1944 1.8527 1.1645 0.5789 
Betaxolol (Betoptic) 0.7473 -0.3756 0.1860 0.2213 0.3630 0.4941 
Betaxolol hydrochloride 
(Betoptic) 0.9187 1.0502 0.5215 0.3684 1.3397 0.4890 
Bethanechol chloride -0.1874 -0.4444 -0.7254 -1.2923 -0.0832 -1.4729 
Bexarotene 0.4256 -0.3386 -0.3653 0.9948 0.2988 0.2122 
Bextra (valdecoxib) 0.6376 1.7926 1.3902 1.2267 1.0135 0.8738 
Bezafibrate -0.9145 -0.7594 -0.0997 -0.4516 -0.3368 0.4262 
Biapenem 0.5106 -0.0715 0.2831 1.6231 0.9094 0.1514 
BIBR 953 (Dabigatran 
etexilate, Pradaxa) 0.6231 0.6672 0.1870 0.6856 0.0753 0.7024 
BIBR-1048 (Dabigatran) -4.0837 -1.3184 -1.2459 0.0066 -0.9088 -1.4864 
Bicalutamide (Casodex) 0.0984 0.4426 1.7718 2.0501 0.9293 1.3733 
Bifonazole -0.2931 0.1244 0.2084 0.1424 -0.1974 0.1930 
Bimatoprost 0.3782 0.2238 0.1748 -0.0816 -0.6560 0.3945 
Bindarit -1.5449 -0.2418 -1.1475 -0.5110 -0.9706 -1.5976 
Biotin (Vitamin B7) 0.2845 0.6993 0.7658 0.4604 0.7628 0.8960 
Biperiden HCl -6.7443 -1.0175 -1.8572 -0.6064 0.1999 -1.8864 
Bisacodyl -2.7901 -0.3528 -0.6271 -0.1508 0.1534 -0.1838 
Bismuth Subcitrate 
Potassium 0.7206 -0.0400 -1.1579 0.0849 -0.5390 -0.0098 
Bismuth Subsalicylate -1.0140 -0.0498 0.0019 -0.4963 -0.6468 -1.3781 
Bisoprolol 1.8932 0.2180 1.2923 1.0538 0.7732 1.8257 
Bleomycin sulfate -4.7169 -7.2017 -4.7086 -2.3153 -3.9043 -2.2969 
Blonanserin (Lonasen) -0.2919 0.9803 0.1557 0.7983 0.4444 0.5770 
Bortezomib (Velcade) -18.9038 -20.9956 -20.2880 -9.8179 -11.0859 -14.6831 
Bosutinib (SKI-606) -19.7269 -1.3244 -1.6782 0.3885 0.7850 0.3089 
Brinzolamide 1.1308 1.2435 0.4384 0.7979 0.1020 0.7634 
Bromhexine HCl -1.0254 -0.0453 -0.9604 -1.6316 -1.8558 -0.5135 
Bromocriptine Mesylate 0.0474 -0.6523 -2.1921 -0.7278 0.3858 -1.6191 
Brompheniramine 0.5415 -0.5302 -0.0570 0.6385 0.3162 0.8104 
Broxyquinoline -0.2136 -0.3036 0.1543 0.1503 -0.1306 0.5672 
Brucine 0.1381 -0.7832 -0.6118 0.1259 -0.7209 -0.3832 
Budesonide 1.0207 -1.4721 -0.3663 0.5190 0.2009 -1.0855 
Bufexamac -2.1067 0.1416 0.2033 0.2909 0.1009 0.4568 
Buflomedil HCl -8.1483 -0.7300 -1.0762 -0.0045 -0.6190 -0.6275 
Bumetanide 0.5929 -0.2192 0.0364 -0.0469 0.1150 0.0639 
Bupivacaine hydrochloride 
(Marcain) -1.2121 -2.3990 -4.1916 -2.2429 -0.9580 -3.8674 
Busulfan (Myleran, Busulfex) 0.0084 1.8709 0.4923 1.3880 1.1895 1.2072 
Butacaine 0.1826 -0.7474 -0.4471 0.1299 -0.0458 0.1854 
Butenafine HCl -0.8258 0.0145 1.7913 1.9625 1.2235 1.7956 
Appendix 2 Page 236 
 
Butoconazole nitrate -0.2390 -0.7021 -2.1484 0.5822 0.9994 -1.1582 
Cabazitaxel (Jevtana) -14.9912 -16.7893 -16.6494 -8.7442 -9.7098 -12.1952 
Calcifediol -0.0848 0.4540 1.5615 1.8079 1.5481 0.4359 
Calcitriol (Rocaltrol) -1.4371 0.5232 0.6960 -0.1075 0.8855 0.4593 
Calcium Gluceptate  -0.0678 -0.0666 0.4537 -0.2685 -0.4754 -0.0053 
Calcium levofolinate 
(Calcium Folinate) 1.0317 0.3577 0.1607 0.5156 0.6667 0.9121 
Camptothecin -13.6721 -18.5241 -20.1805 -9.1975 -10.9609 -14.1493 
Camylofin Chlorhydrate -0.5058 -2.1563 -2.4512 -1.5535 -0.9289 -2.1351 
Candesartan (Atacand) -0.1422 0.0450 0.3129 0.5843 0.2742 0.5333 
Candesartan cilexetil 
(Atacand) -14.9835 1.0334 0.7739 0.5608 0.3125 0.6780 
Capecitabine (Xeloda) 0.1875 0.9310 1.5442 1.3344 0.9169 1.3532 
Captopril (Capoten) 0.7760 0.2028 0.3799 0.0116 -0.9807 0.0239 
Carbachol -1.1198 0.1267 -0.3831 -0.6024 0.1300 -0.5982 
Carbadox -1.5746 -1.6076 -0.3680 -0.1382 -1.2951 -0.4653 
Carbamazepine (Carbatrol) -0.2902 1.8084 0.0586 1.2979 0.6495 0.7170 
Carbazochrome sodium 
sulfonate -0.4654 0.1751 0.5070 1.0224 0.7331 1.0480 
Carbenicillin disodium 0.2716 0.4658 -0.4742 -0.3984 -0.6561 -0.0999 
Carbenoxolone Sodium -0.2565 0.0733 0.1364 -0.4325 -0.6791 -0.4364 
Carbidopa 0.2867 1.2914 0.2481 0.1736 0.2058 0.6617 
Carbimazole -0.4429 0.9393 1.3791 0.5441 1.1681 1.0088 
Carboplatin 0.4167 -1.1246 -1.1805 1.1583 -0.3601 -0.3574 
Carfilzomib (PR-171) -18.0611 -20.4626 -22.0115 -10.7297 -12.2674 -15.2139 
Carmofur -1.9882 -5.2142 -7.5099 -0.7639 -2.8992 -5.6296 
Carprofen 1.0910 1.4097 0.2173 -0.3879 0.1077 -0.2880 
Carvedilol 0.1959 -2.0285 -3.4256 -0.2726 0.0402 -2.6876 
Caspofungin acetate 0.8507 0.1916 0.8522 -0.0917 0.2144 0.0392 
Catharanthine -1.4641 -3.1059 -3.6941 -0.4900 -0.8735 -2.0280 
Cefaclor (Ceclor) -8.1520 -9.5028 -12.0223 -2.9849 -4.4705 -5.7510 
Cefdinir (Omnicef) 0.1156 1.4452 1.0647 1.9483 0.7336 0.7889 
Cefditoren pivoxil -1.0279 0.0155 -0.0049 -1.3517 -0.8943 -0.3444 
Cefoperazone (Cefobid) 1.0666 -0.1085 0.4508 1.1466 0.6257 0.5455 
Cefoselis sulfate 1.1246 0.8443 0.6879 1.8463 0.9701 0.6721 
Cefprozil hydrate (Cefzil) 0.2810 0.0288 0.2085 0.4591 0.0461 -0.0483 
Ceftazidime Pentahydrate -0.2740 0.1970 0.0310 0.3895 0.1659 0.1312 
Ceftiofur hydrochloride 0.3483 0.1065 0.9052 0.0032 -0.3533 0.1340 
Celecoxib 1.0022 0.4066 1.0815 0.6068 0.0853 0.2192 
Cephalexin (Cefalexin) 0.5725 0.7517 0.6162 1.0785 1.1843 0.6589 
Cephalomannine -13.5720 -23.8257 -25.2395 -13.1532 -14.7074 -18.1675 
Cephapirin Sodium -0.0587 -0.1250 0.1664 0.0008 0.3102 0.1413 
Cepharanthine 0.7508 -0.3108 -2.6140 0.0124 0.1207 -3.3523 
Cetirizine Dihydrochloride -9.3594 -2.0760 -1.7198 -14.1653 -0.1878 -2.0202 
Cetrimonium Bromide -13.3925 -18.1436 -18.9717 -7.7224 -10.8479 -13.2248 
Cetylpyridinium Chloride -15.4059 -19.8812 -21.4477 -11.3375 -12.4066 -15.1635 
Chenodeoxycholic acid -0.9214 1.0622 0.4571 0.2443 1.5830 1.2001 
Chloramphenicol 
(Chloromycetin) 0.4176 0.2680 0.0996 0.7245 0.5257 0.5146 
Chlormezanone (Trancopal) 0.9083 0.8274 0.3486 0.4607 0.8143 0.8340 
Chlorocresol -0.9166 -0.2858 -0.4701 -0.0920 -0.1142 -0.7220 
Chloroquine Phosphate 1.0149 0.7334 -0.2114 0.6118 0.3157 0.6722 
Chlorothiazide 0.8150 0.2395 -0.5694 -0.3994 -0.2393 -1.2443 
Chloroxine -0.8821 -4.4658 -7.5147 -0.7460 0.2088 -3.3201 
Chlorpheniramine Maleate -0.4145 -0.4994 0.0267 -0.1265 0.1050 0.1863 
Chlorpromazine (Sonazine) -11.6692 -11.4532 -18.2642 -7.4661 -7.4087 -14.0343 
Chlorpropamide 1.3185 1.1400 0.9007 1.3082 1.1272 1.3107 
Chlorprothixene -1.5456 -0.4243 -0.1635 -1.5641 -0.9099 -1.3132 
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Chlorquinaldol -8.1736 -14.1329 -17.5343 -6.7519 -6.2780 -11.0264 
Chlortetracycline HCl 0.5064 0.8222 0.4765 0.3618 0.4651 0.6622 
Chlorzoxazone 0.9827 1.0842 0.4499 1.0226 0.5142 0.7305 
Cholesterol 0.9534 0.9369 0.4080 1.1110 0.7530 1.0523 
Choline Chloride 0.1275 0.6172 0.7041 0.1780 0.3797 0.8333 
Chromocarb -1.8130 -1.0506 -1.4559 -0.4512 -0.6244 -1.9505 
Ciclopirox (Penlac) -10.9037 -16.7473 -16.7789 -4.1814 -9.0407 -11.9996 
Ciclopirox ethanolamine -15.1966 -17.8054 -18.8827 -6.2333 -8.3477 -13.1308 
Cidofovir (Vistide) -1.7849 -2.1909 -1.6968 -10.5834 -0.0098 -0.6586 
Cilazapril monohydrate 
(Inhibace) -0.4069 -1.1724 -1.0454 -1.0350 -0.7239 -1.5733 
Cilnidipine -9.4801 -1.7831 -1.2979 -2.3010 0.3454 -1.3216 
Cilostazol -0.1667 0.6480 -0.3470 0.9946 0.9203 -0.3151 
Cimetidine (Tagamet) 1.0515 0.9169 0.4024 0.3987 1.6882 0.9352 
Cinchophen 1.4484 1.3736 1.3271 1.5813 0.9095 1.3996 
Cinepazide maleate 0.3033 -0.4016 0.0666 -0.1112 -1.1375 -0.2010 
Cinoxacin -0.0357 -0.0155 -0.1227 -0.1500 0.7239 -0.1553 
Ciprofloxacin (Cipro) 0.1968 0.6568 -0.3773 0.1142 -0.0807 -0.4219 
Cisatracurium besylate 
(Nimbex) -2.3236 0.7700 0.1359 0.8629 0.3547 0.0539 
Cisplatin 0.5906 1.2701 1.8670 1.1070 0.6946 1.2895 
Cladribine -15.8501 -17.7529 -20.9595 -11.1080 -12.5189 -14.9737 
Clafen (Cyclophosphamide) 1.6957 0.7462 0.6137 1.0393 0.5838 0.5191 
Clarithromycin (Biaxin, 
Klacid) -0.9047 -0.1390 -0.2596 -0.7555 0.1212 -1.1764 
Clemastine Fumarate -11.1801 -16.2232 -16.1032 -8.0984 -8.9347 -11.7662 
Cleviprex (Clevidipine) 0.5830 0.1826 0.4109 -1.2260 -0.0545 -0.4468 
Climbazole 0.4450 1.5039 1.2908 1.0697 1.4629 1.1895 
Clinafloxacin (PD127391) -0.1033 -0.3184 -0.3252 -0.7687 -1.4019 -0.0740 
Clinafoxacin HCl -0.8082 0.5121 0.6356 0.4344 0.7213 0.4856 
Clindamycin 0.1364 -0.5541 -0.8635 -0.2949 -0.6048 -1.2294 
Clindamycin hydrochloride 
(Dalacin) 0.8196 0.4710 -0.5200 -0.2548 0.5481 -0.8640 
Clindamycin palmitate HCl -16.7863 0.2128 -0.0064 0.8233 0.8366 0.6141 
Clindamycin phosphate -0.4662 -0.0545 0.2770 0.3663 -0.3297 -0.0749 
Clobetasol propionate -0.5630 -0.5491 -0.5187 1.1205 1.4247 0.7754 
Clodronate Disodium -2.4555 -1.7356 -1.8678 -1.1789 -0.8715 -1.5089 
Clofarabine -13.4568 -19.4684 -18.1162 -9.3040 -11.0447 -12.2790 
Clofazimine -3.1193 -3.0348 -4.7994 -1.6789 -0.9909 -3.3037 
Clofibrate (Atromid-S) 0.0199 -0.1909 0.5665 -0.1623 -0.2552 0.2948 
Clofibric acid -0.5679 -0.1776 0.2199 0.1324 -0.4244 0.5975 
Clofoctol -0.1012 -0.3620 0.0232 0.1970 0.0053 -0.2612 
Clomifene citrate 
(Serophene) -14.1878 -17.9639 -18.6574 -9.7207 -11.0496 -13.8927 
Clomipramine hydrochloride 
(Anafranil) -4.4217 -1.3439 -2.3141 -3.4594 -1.0800 -2.1991 
Clonidine hydrochloride 
(Catapres) 0.3846 0.2261 0.3223 -0.2937 0.4555 -0.1964 
Clopamide 0.8818 0.4264 0.4056 0.8478 0.5877 0.5757 
Clopidogrel (Plavix) -4.9672 -0.3845 -2.6323 -1.5323 -1.6238 -2.3005 
Clorgyline HCl 1.2388 0.9094 0.8559 0.9789 1.0758 0.8300 
Clorprenaline HCL 1.4668 0.2511 0.1526 -0.0597 0.6007 -0.5387 
Clorsulon 0.3141 0.6079 0.6380 1.4983 1.1337 1.3760 
Closantel 0.3840 -0.7216 -0.8635 -0.5020 -1.6350 -0.4670 
Closantel Sodium 0.6651 -0.0203 -0.1889 -0.3345 -0.8573 -0.1335 
Clotrimazole (Canesten) -5.0189 -4.8524 -8.4438 -1.2731 -1.9813 -8.2663 
Cloxacillin sodium 
(Cloxacap) -0.7619 -0.6632 0.4061 -1.8629 -1.1292 -0.6756 
Clozapine (Clozaril) -0.0145 -0.3768 -2.5106 0.0806 0.8625 -1.6263 
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Cobicistat (GS-9350) -4.9726 0.0597 -0.5334 0.8173 0.7341 0.1661 
Colistimethate Sodium 0.8921 0.9324 0.7031 1.1961 1.1803 0.5060 
Colistin Sulfate 0.4355 -0.1754 1.2355 0.7412 0.4477 0.6248 
Conivaptan HCl (Vaprisol) -1.0113 1.2407 1.3067 1.4121 1.1416 0.1586 
Cortisone acetate (Cortone) -0.9496 -0.1303 0.1163 -0.6347 -0.8893 -0.7595 
Coumarin 1.5791 1.1790 0.9120 1.0112 0.3299 0.8791 
Creatinine -0.2584 -0.1944 -0.6494 -0.6744 0.3339 -0.2253 
Crizotinib (PF-02341066) -15.2921 -21.2435 -21.9181 -10.9600 -12.9553 -15.2946 
Crystal violet -14.4666 -19.4228 -20.3584 -10.5469 -13.1443 -14.6120 
Curcumin 0.0529 -13.9428 -14.4655 0.0260 -7.9628 -11.2884 
Cyclamic  acid -0.4634 -0.7212 0.2615 -0.9096 -1.3542 -1.0694 
Cyclandelate 1.6909 2.4272 1.5650 1.7539 1.2522 1.5013 
Cyclophosphamide 
monohydrate -1.6210 0.7505 -0.8174 -0.9050 -1.9406 -0.8463 
Cyclosporine (Neoral) -5.0803 -6.3557 -5.7836 1.8357 -3.6409 -5.0723 
Cyproheptadine HCl 
(Periactin) -7.5071 -2.6071 -2.2792 -0.9044 -1.2345 -2.4841 
Cyromazine 0.9093 1.4541 0.4936 1.5291 0.6838 1.0575 
Cysteamine HCl 0.7060 0.1240 0.7938 0.2909 0.6255 0.8206 
Cytarabine -16.3276 -19.9782 -22.3615 -12.0422 -11.9558 -17.1878 
Cytidine -22.6062 0.0933 -3.1822 -2.4697 -1.7446 -2.3762 
Dabrafenib (GSK2118436) -3.9378 -5.1932 -3.8231 -0.0725 -0.3042 -1.6154 
Dacarbazine (DTIC-Dome) 2.3533 0.0463 1.3184 0.6419 0.2655 1.3577 
Daidzein 0.3956 0.9556 0.8233 0.4944 1.3954 0.9975 
Danofloxacin Mesylate 0.1475 -0.2602 -0.5716 -0.6225 -1.2893 -1.6831 
Dapoxetine hydrochloride 
(Priligy) -0.0125 -3.6755 -1.5953 -0.4346 0.9213 -0.2476 
DAPT (GSI-IX) 0.6307 -0.0009 0.4447 0.5832 0.6847 0.1475 
Daptomycin 0.9784 1.6536 1.1764 1.8511 0.8751 0.7587 
Darifenacin HBr -1.1972 -4.3303 -3.4385 0.3516 -0.0511 -1.2693 
Darunavir Ethanolate 
(Prezista) -0.2678 -0.3057 -0.1478 1.7380 -0.2590 0.1305 
Dasatinib (BMS-354825) -4.0556 -13.1842 -8.8843 0.5369 -2.6262 -5.4324 
Daunorubicin HCl 
(Daunomycin HCl) -19.2045 -21.8824 -22.9886 -11.2825 -13.3896 -16.0797 
D-Cycloserine 0.3439 2.1588 1.7495 1.0206 1.7869 1.2655 
Decamethonium bromide -1.5946 0.9537 0.9093 0.5649 0.8636 0.3014 
Decitabine -2.5186 -2.0314 -0.3640 -0.8319 -0.8400 -0.4672 
Decoquinate 1.2616 0.7351 0.4322 0.0124 0.2758 -0.0410 
Deferasirox (Exjade) -6.2130 -6.7461 -10.1991 -1.6623 -2.3407 -5.9663 
Deferiprone 0.1042 1.4676 1.4228 1.3185 0.5988 0.9423 
Deflazacort (Calcort) 0.4651 1.0433 0.4902 0.6263 0.8576 0.3520 
Dehydroepiandrosterone 
(DHEA) 0.7118 0.1944 0.2787 0.6170 0.7102 0.9017 
Deoxyarbutin -0.5603 -0.2998 -2.0882 -1.4437 0.0058 -2.8966 
Deoxycorticosterone acetate 1.2522 -0.3258 0.1797 0.1554 -0.0203 0.2163 
Dequalinium chloride -7.2642 1.0812 0.9837 -6.7320 0.8130 0.4403 
Desloratadine -2.3305 -3.0598 -3.2789 -0.7318 -1.8027 -3.7860 
Desonide -0.2624 -0.0802 0.0049 -15.1495 -0.2940 0.2133 
Detomidine HCl 0.4258 -0.2634 0.2769 -0.0248 -0.0799 -0.0248 
Dexamethasone -4.9290 -1.5203 -1.3839 -9.1297 -0.3095 -0.8698 
Dexamethasone acetate -0.3528 -1.4666 -0.2998 0.1315 -0.6643 -1.1134 
Dexlansoprazole 0.1633 0.2088 -0.1162 -0.3138 -0.2604 -0.5200 
Dexmedetomidine 0.7162 -0.1953 0.7339 0.6859 0.3051 -0.0297 
Dexmedetomidine HCl 
(Precedex) 1.0614 -0.3724 0.3059 0.4574 0.2801 0.1908 
Dexrazoxane Hydrochloride 1.9516 0.5882 1.2241 1.5396 0.5250 1.2053 
Dextrose (D-glucose) -0.5447 -0.2120 -0.7810 -0.0556 -0.6270 -0.9150 
Dibenzepine HCl 1.7101 1.1440 0.7020 1.1774 0.5672 0.8145 
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Dibenzothiophene 1.4560 1.0398 0.1107 1.1607 -0.1006 0.6461 
Dibucaine HCL -1.4976 -0.3754 -0.4680 0.0151 1.0805 -0.4381 
Dichlorisone Acetate 0.5580 0.0027 0.4951 0.1367 0.0241 0.0977 
Dichlorphenamide 
(Diclofenamide) 1.3679 1.2221 0.5821 0.8590 0.3883 0.6843 
Diclazuril 0.2051 0.5650 -0.3588 0.5572 0.4621 0.1160 
Diclofenac -0.1168 0.1684 -0.0198 0.2789 -0.6297 -0.1644 
Diclofenac Diethylamine -0.6467 -0.1140 -0.7753 -0.7848 -0.7500 -2.4278 
Diclofenac Potassium 0.2364 0.4000 0.0064 -1.4101 -1.5970 -0.7271 
Dicloxacillin Sodium -0.7885 -1.5714 -0.9835 -1.0542 -0.5836 -1.2384 
Dicyclomine HCl -1.4387 0.1678 -1.0523 -0.9204 -0.6268 -0.7029 
Didanosine (Videx) -0.4098 -1.0309 -0.6075 -0.3799 -0.2311 -1.0866 
Dienogest 0.1238 0.0243 1.0724 0.2442 -0.5343 0.1003 
Diethylstilbestrol (Stilbestrol) 0.2156 -0.9149 -4.1415 0.4913 0.8750 -0.5867 
Difloxacin HCl 0.0570 -0.7795 -1.4080 -0.0077 0.1486 -1.7090 
Difluprednate -2.6577 -0.8932 -1.3865 -0.2636 -0.4300 -0.7936 
Digoxigenin -15.4290 -19.4685 -19.8133 -10.5151 -11.2464 -13.9755 
Diltiazem HCl (Tiazac) -0.1450 0.2520 0.0148 -0.1372 1.3057 -0.3060 
Dimaprit 2HCl 1.0791 1.0308 0.1428 1.2952 0.4451 0.8147 
Dimethyl Fumarate 0.8881 0.7698 0.7995 0.6452 0.5802 0.7038 
Diminazene Aceturate 0.2012 -0.1057 -0.8972 0.1254 -0.9492 -0.7332 
Diperodon HCl -0.2656 -0.0027 0.0669 -0.2313 0.3142 -0.1124 
Diphemanil methylsulfate -1.5153 -0.2819 -0.4362 -0.4334 -0.0217 -0.3563 
Diphenhydramine HCl 
(Benadryl) 0.2894 0.8916 0.1515 0.6685 1.6297 0.7152 
Diphenylpyraline HCl  0.6826 -0.5012 -1.1648 0.1000 0.2813 0.0205 
Dipyridamole (Persantine) 0.0669 0.7563 0.1941 0.3673 0.0178 0.3979 
Dirithromycin -0.0174 -0.0908 -0.3203 0.6147 -0.3745 0.1154 
Disodium Cromoglycate -0.5231 -0.5659 -1.7879 -1.5995 -1.4367 -1.6052 
Disopyramide Phosphate  0.5669 -0.3191 0.1378 0.3573 -0.1448 0.4486 
Disulfiram (Antabuse) -7.9672 -20.3400 -16.8864 -5.4661 -12.5624 -9.4431 
Divalproex sodium -0.5233 0.6385 -0.0756 0.8722 0.4123 -0.1535 
DL-Adrenaline -0.0118 -0.2352 0.0162 -0.0944 -0.5315 0.5794 
DL-Carnitine hydrochloride -0.2573 -0.5029 0.3925 0.3505 -0.1051 0.1291 
DL-Mevalonic Acid Lactone 0.2350 -0.7352 0.5594 -0.0158 -0.7413 0.4069 
D-Mannitol (Osmitrol) 0.4593 -0.3055 -0.1213 -0.1168 -0.9355 0.1550 
Docetaxel (Taxotere) -15.1958 -20.0611 -19.4495 -9.2052 -10.8575 -13.2620 
Docosanol (Abreva) -1.8434 -0.2783 -1.3717 -14.0907 -1.1113 -2.8871 
Dofetilide (Tikosyn) -0.2448 -1.4133 -1.1075 -1.9172 -0.0995 -2.3763 
Domiphen Bromide -7.5761 -5.9195 -15.7650 -5.4265 -2.6346 -12.8630 
Domperidone (Motilium) 0.4016 -0.1153 -0.3785 0.8196 0.4432 -0.1712 
Donepezil HCl (Aricept) -0.8987 -2.4599 -2.0393 -0.0032 -0.7101 -1.1545 
Dopamine hydrochloride 
(Inotropin) 0.4119 0.7283 0.2538 0.3408 0.7300 0.2528 
Doripenem Hydrate -2.2127 1.9058 1.2256 2.1245 1.3824 1.3143 
Dorzolamide HCL -0.0334 -0.5714 -0.7132 1.4282 0.8841 -0.4893 
Doxapram HCl -0.1564 0.7978 1.2615 1.1795 1.2574 0.6459 
Doxazosin mesylate -8.1741 -2.5661 -2.7497 -3.2104 -0.3543 -2.0814 
Doxercalciferol (Hectorol) 0.9399 0.6127 0.5279 0.4245 1.3235 0.6746 
Doxifluridine -5.3527 -3.3779 -3.3550 -4.6394 -3.9544 -4.9251 
Doxofylline 0.7793 0.7412 0.7205 0.9316 0.9303 0.9364 
Doxorubicin (Adriamycin) -14.4094 -19.5300 -20.2657 -9.1604 -10.9781 -13.3064 
Doxycycline HCl 0.1278 -0.6300 -0.4505 0.0165 -0.9412 -0.3593 
Doxylamine Succinate 1.3024 -0.1994 -0.1633 0.3074 -0.2958 0.2045 
D-Phenylalanine 0.7521 0.7252 0.4384 0.7807 0.8935 0.3516 
Dronedarone HCl (Multaq) -12.9741 -14.4409 -15.8376 -7.7557 -9.2255 -11.0494 
Droperidol -1.3051 -0.6576 -0.4348 -0.2393 -0.7454 -0.6167 
Dropropizine 0.8020 1.2917 0.2102 -0.6177 0.7935 -0.0130 
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Drospirenone 0.8346 0.4465 0.7033 1.5689 0.6062 1.0423 
Droxidopa (L-DOPS) 0.7130 0.1449 0.2519 0.0318 -0.5283 -0.1589 
Duloxetine HCl (Cymbalta) -13.6294 -11.7984 -18.7323 -4.2365 -6.7303 -12.7428 
Dutasteride 1.7945 1.1967 0.8784 1.2563 0.6502 0.9251 
Dyclonine HCl -18.4983 -0.1748 -1.6287 -0.3549 -0.6069 -1.4024 
Dydrogesterone 0.2243 -0.1989 0.2395 -0.0814 -0.2950 -0.3618 
Dyphylline (Dilor) 0.1922 -10.3086 0.7808 1.6180 0.9839 0.8007 
Econazole nitrate 
(Spectazole) -0.6540 -1.6959 -2.2708 0.0792 -0.4826 -1.7110 
Edaravone (MCI-186) -0.9361 0.4038 -0.1968 0.8181 1.0439 0.2254 
Ellagic acid -15.9969 0.6380 0.2814 -2.0561 1.2234 0.5650 
Eltrombopag (SB-497115-
GR) -3.7662 -4.7620 -7.0491 -2.5600 -2.6493 -3.7897 
Elvitegravir (GS-9137) -0.9644 0.8322 0.5697 0.4772 1.0547 0.0471 
Emetine -15.5395 -20.7078 -21.6164 -11.3343 -12.9869 -15.2299 
Emtricitabine (Emtriva) -0.0033 0.5673 0.6919 1.3756 0.8802 0.5897 
Enalapril maleate (Vasotec) 2.2971 -0.8129 0.6458 -0.2524 0.4572 0.2136 
Enalaprilat dihydrate 0.4232 -0.2166 0.2931 -0.9432 0.8775 -1.1913 
Enoxacin (Penetrex) 0.0033 0.8189 -0.2607 0.0253 -0.6606 0.1818 
Enrofloxacin -0.0818 -0.1224 -0.2142 -1.2852 -1.1476 -0.7451 
Entacapone -1.3027 -0.5828 -0.3753 -0.1706 -0.5188 -0.7387 
Entecavir hydrate -1.6296 -0.0243 -1.7011 -0.0475 -0.4074 -1.2559 
Epalrestat 0.7038 1.6044 0.9301 0.4210 0.3113 0.8392 
Epinephrine bitartrate 
(Adrenalinium) -15.2071 0.3064 -0.1494 0.2593 0.2908 0.6756 
Epirubicin Hydrochloride -15.4791 -19.6445 -20.2139 -10.3724 -11.6198 -14.5850 
Eplerenone 0.6367 1.8440 1.6870 1.1789 1.5255 1.2936 
Eprazinone 2HCl 0.7202 0.5186 -0.6983 -0.8310 -0.0083 -0.6895 
Eprosartan Mesylate 0.4943 -0.0997 0.2420 -0.1996 -0.6427 -0.1348 
Erdosteine -0.7754 1.2481 -0.0592 -0.7655 0.8347 0.2919 
Erlotinib HCl 1.6170 0.9861 0.7146 -0.2086 1.2128 1.2447 
Erythromycin (E-Mycin) 0.2265 0.0996 -0.0107 1.0850 -0.6268 0.0759 
Erythromycin Ethylsuccinate -0.3149 0.8060 0.9012 0.9422 1.2298 0.6867 
Escitalopram oxalate 0.4293 1.2723 1.2896 0.9766 1.2108 0.7223 
Esmolol HCl 0.6795 0.1304 0.3364 0.0749 -0.4425 -0.3836 
Esomeprazole magnesium 
(Nexium) -1.1866 -0.3520 -1.4074 0.7364 -0.1189 -0.2210 
Esomeprazole sodium 
(Nexium) -1.1833 -0.5953 -0.5778 -0.0066 -0.9088 -0.6184 
Estradiol 0.0359 1.5015 0.4123 0.8022 0.6534 0.7003 
Estradiol valerate -1.6512 0.7646 1.0058 -0.8229 0.6817 0.9024 
Estriol 0.3361 0.0350 -0.3890 -0.2577 -0.4190 -0.2795 
Estrone -0.3682 -1.2128 -0.2328 -13.1768 -0.5449 -1.5674 
Ethacridine lactate 
monohydrate -13.9470 -16.6158 -19.3961 -8.0572 -7.4497 -13.5361 
Ethambutol HCl 0.1942 -0.4357 0.0321 -0.0165 -0.8248 -0.2200 
Ethamsylate 0.4972 0.7174 0.6580 0.6765 0.6211 0.6131 
Ethinyl Estradiol -4.2122 -4.8760 -7.4334 -0.9944 -1.5639 -0.8565 
Ethionamide -19.8093 -0.8982 -0.5389 -2.2093 -0.8726 -1.5695 
Ethisterone -4.5386 0.5006 0.4328 1.1370 0.7037 1.1627 
Ethoxzolamide -0.6429 0.3566 0.0031 0.0679 0.7151 0.0018 
Ethynodiol diacetate 0.4068 0.1410 0.4159 0.5686 0.1243 0.3424 
Etidronate (Didronel) 1.3926 0.6989 0.1990 0.6259 0.9637 0.6504 
Etodolac (Lodine) 0.7981 1.2450 0.5333 0.6823 1.2637 0.5688 
Etomidate 1.0789 1.1569 0.4990 1.9790 1.2360 0.7985 
Etoposide (VP-16) -10.4238 -13.7146 -8.7377 -6.0473 -8.2853 -10.0720 
Etravirine (TMC125) -11.5373 -15.9187 -11.2334 -4.9578 -2.3131 -5.2097 
Everolimus (RAD001) -4.6198 -5.2525 -4.2277 -0.2628 -1.0743 -2.4355 
Evista (Raloxifene 0.2537 -0.1284 0.7097 1.2504 0.0285 0.6540 
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Hydrochloride) 
Exemestane -3.8310 -3.8389 -1.9273 -0.8740 -0.9222 -0.7664 
Ezetimibe (Zetia) 0.7204 -0.1472 -0.5020 -1.1706 0.5447 -1.7364 
Famciclovir (Famvir) 0.2048 0.0492 -0.9223 -0.6204 -0.7512 -0.4584 
Famotidine (Pepcid) 1.0341 -0.0489 -0.2363 -0.1169 0.2811 -0.0248 
Famprofazone -0.0002 0.6216 -0.0721 0.2686 0.6624 0.4507 
Febuxostat (Uloric) 0.0281 1.0877 1.5579 -0.9459 1.1183 0.9997 
Felbamate 1.0499 1.0641 0.6443 1.6527 1.1600 1.0312 
Felodipine (Plendil) 0.4304 1.0187 0.5962 0.6184 1.0657 0.7861 
Fenbendazole (Panacur) -16.2105 -20.5474 -20.5367 -11.7349 -12.4479 -16.8960 
Fenofibrate (Tricor, Trilipix) 1.2773 -0.2210 0.2062 -0.5218 -0.5915 0.0513 
Fenoprofen calcium 0.0017 -1.0460 -0.1403 -0.6187 -0.4030 -0.7819 
Fenoprofen calcium hydrate -0.2476 0.4294 -0.2782 0.3326 0.0806 0.6197 
Fenspiride HCl 0.8945 1.2419 0.3782 0.5658 0.6129 0.7240 
Fenticonazole nitrate -2.7232 -1.1279 -1.7818 -1.2295 -0.5769 -3.4037 
Fesoterodine fumarate 
(Toviaz) -15.5232 -1.0975 -0.6859 -0.0180 -0.4043 -0.6708 
Fexofenadine HCl 0.2357 0.1436 -0.1741 -0.2821 -0.5621 -0.1956 
Fidaxomicin -0.1699 -0.7922 -1.1535 -0.5699 -0.3667 -1.5810 
Finasteride -0.7147 0.3655 1.7691 1.1409 0.5834 1.4399 
FK-506 (Tacrolimus) -0.2649 1.5154 0.8975 0.5259 1.0640 0.7902 
Flavoxate HCl 0.8845 0.2472 0.4296 1.0319 0.3218 0.3847 
Fleroxacin (Quinodis) 0.5340 -0.2196 -0.1621 -0.8200 0.4753 -0.7150 
Florfenicol 0.3748 1.1150 0.6749 -0.4225 -0.8123 -0.5660 
Floxuridine -16.0811 -8.7570 -11.2684 -2.8708 -3.9931 -8.4896 
Flubendazole (Flutelmium) -15.3100 -18.3149 -10.0407 -10.1088 -4.1458 -5.8952 
Fluconazole 0.5680 1.2214 0.4350 1.1948 0.9330 0.8633 
Flucytosine (Ancobon) -0.0176 -1.6428 -0.6923 -1.4695 -0.2320 -2.2145 
Fludarabine (Fludara) -1.1565 -9.4185 -16.4303 -5.2339 -11.2766 -14.5040 
Fludarabine Phosphate 
(Fludara) -0.0914 0.2341 -11.8682 0.5179 -2.7831 -13.1029 
Flumazenil 0.2741 0.2190 0.5855 1.6663 0.8278 0.8311 
Flumequine -0.5717 -1.1479 -0.6925 -0.4206 -0.7455 -1.1074 
Flumethasone 0.2599 1.2328 0.9975 0.8744 0.7446 0.7469 
Flunarizine 2HCl -3.4982 -0.5798 -2.8256 -0.4537 0.1520 -2.7148 
Flunixin meglumin 0.6935 -0.2553 0.3741 -0.3542 -0.1043 0.1604 
Fluocinolone acetonide 
(Flucort-N) 0.4425 -0.0041 -0.1001 0.1137 0.5073 -0.3986 
Fluocinonide (Vanos) -2.6597 0.3132 0.0552 0.2418 0.7985 0.4646 
Fluorometholone Acetate -0.5941 -1.2487 -0.8268 -0.4730 -0.7499 -1.1106 
Fluoxetine  HCl -11.3325 -8.5124 -14.7462 -7.6157 -4.5745 -10.3968 
Flurbiprofen (Ansaid) 0.4032 -0.0447 -0.0492 0.2125 0.1379 0.2505 
Flutamide (Eulexin) -0.0872 -0.0072 -0.2448 -0.5300 -1.0409 -0.3092 
Fluticasone propionate 
(Flonase, Veramyst) -23.7230 -1.4421 -0.8071 -0.2579 -0.1743 -1.1425 
Fluvastatin sodium (Lescol) -8.8460 -12.9437 -13.6339 -11.0069 -12.6580 -14.6145 
Fluvoxamine maleate -2.0057 -1.8617 -1.7058 0.1878 -0.6880 -0.3749 
Formoterol hemifumarate 0.7688 1.4789 1.0098 0.6409 1.0360 0.9850 
Fosaprepitant dimeglumine -0.8642 -0.6387 -1.0652 0.0298 -0.8826 -0.7486 
Fosfomycin Tromethamine -6.7932 0.2049 0.1321 0.2798 -0.2701 -0.1831 
Fosinopril sodium (Monopril) 0.5059 -0.1726 0.5923 -0.6999 -0.1125 -0.1917 
Ftorafur 0.9269 1.1926 -0.0292 1.5359 0.9846 0.0455 
Fudosteine 1.1786 1.3596 1.5793 0.9913 0.6518 1.2059 
Fulvestrant (Faslodex) 1.4361 0.9815 1.8215 1.8653 0.7159 1.9987 
Furaltadone HCl -1.2914 0.4231 -1.6773 1.1807 0.8656 0.2078 
Furosemide (Lasix) 1.7311 1.8864 1.7751 2.3518 1.5402 1.5091 
Gabapentin (Neurontin) 0.6307 0.6915 0.2564 0.5207 0.2933 0.6118 
Gabapentin Hydrochloride -3.1134 -1.3827 -1.2855 -12.8004 -0.2560 -1.2348 
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Gabexate mesylate 0.3358 1.1231 0.3031 1.0169 0.6945 0.5311 
Gadodiamide (Omniscan) 0.1374 1.0525 0.1212 0.2017 -0.4073 0.3440 
Gallamine triethiodide 
(Flaxedil) 0.5240 0.5729 -0.0714 0.0680 0.9062 0.0002 
Ganciclovir 0.3570 0.4756 0.2053 0.5319 -0.8849 0.4070 
Gatifloxacin -1.0360 -0.0356 -0.0292 -0.0927 0.6544 -0.0030 
Gefitinib (Iressa) 0.2412 0.5113 1.0701 0.4575 1.2907 1.0662 
Gemcitabine (Gemzar) -14.5593 -19.1529 -19.4363 -14.1531 -11.3536 -13.9292 
Gemcitabine HCl (Gemzar) -16.0814 -22.1106 -20.4528 -9.9750 -12.0502 -13.8284 
Gemfibrozil (Lopid) 0.5368 -0.2334 -0.0136 -2.1706 -0.2813 0.4883 
Genipin -0.4762 0.6656 -0.7973 -0.3786 -0.2105 -0.0057 
Geniposide -1.3793 0.1163 -0.7063 -0.4088 -0.4339 -0.1467 
Geniposidic acid -0.6540 -0.2048 -0.4054 -0.1661 -0.4195 -0.3598 
Genistein -5.2849 -0.8852 -1.2623 1.1188 0.7407 -1.3727 
Gestodene 0.0334 0.8086 0.8285 1.4888 0.8121 0.3041 
Gimeracil -1.8555 0.9196 -1.4302 -0.8469 -1.9980 -0.7476 
Ginkgolide A -16.7096 -0.3850 -1.1562 -0.5019 -0.5040 -1.4139 
Glafenine HCl -0.2357 -0.0067 -0.3128 0.0263 0.3539 -0.2137 
Gliclazide (Diamicron) 0.0096 0.2735 0.7459 1.2326 1.0469 1.3310 
Glimepiride 0.7576 0.7071 0.6405 1.1779 1.0166 0.4460 
Glipizide (Glucotrol) -3.5358 -5.8073 -6.9278 0.0307 -0.8688 -3.3012 
Gliquidone -0.0670 0.8150 1.3019 1.0823 0.7593 1.1140 
Glyburide (Diabeta) -1.1956 0.5814 -0.2373 0.5417 0.6577 0.0847 
Granisetron HCl 0.6277 1.3556 0.3181 1.6649 1.0929 0.8485 
Guaifenesin (Guaiphenesin) 0.6319 0.4624 0.1485 0.7944 -0.4626 0.7153 
Guanabenz acetate -0.2458 1.6634 1.2038 0.7836 1.1989 0.9910 
Guanethidine Sulfate 0.7473 0.9973 0.4091 0.7758 0.7320 0.6306 
Guanidine HCl -1.0879 -1.1327 0.1651 -0.1489 -0.2882 -0.9010 
Halobetasol Propionate -0.0570 0.1674 0.4068 1.1478 1.0555 0.4168 
Haloperidol (Haldol) -0.3058 -0.8762 -1.3535 -1.2030 -2.1633 -1.1478 
Hemicholinium Bromide 1.3073 1.2034 0.9153 1.0327 0.9202 0.7816 
Hexamethonium bromide 0.0276 0.1245 -0.1902 -0.1330 -0.1280 0.0098 
Histamine Phosphate -0.3098 -0.7482 -1.5333 -0.7587 -1.0749 -1.1237 
Homatropine Bromide 0.6190 0.5928 1.1959 0.8044 1.1500 0.2786 
Hydralazine hydrochloride -0.0668 0.4035 -0.2754 -0.9096 -0.8720 -0.3279 
Hydrastinine HCl -8.8155 -0.6547 -2.7037 -0.9999 -0.2504 -2.2171 
Hydrochlorothiazide 0.4490 2.3820 1.3385 1.6083 1.4321 1.8096 
Hydrocortisone (Cortisol) -0.3933 1.1514 0.2291 0.8753 0.5629 0.7961 
Hydroxyurea (Cytodrox) 0.3860 -0.1291 -0.0148 0.1342 -0.6134 -0.2006 
Hydroxyzine 2HCl -0.4911 -0.6558 -0.1777 0.5959 0.1025 -0.4189 
Hygromycin B -6.8979 0.2631 0.0658 0.8228 0.4600 0.9265 
Hyoscyamine (Daturine) 0.7903 -0.3261 0.1195 -0.6142 -1.0778 -0.7835 
Ibandronate sodium -0.1469 -0.6511 -1.1506 0.1265 0.2234 0.0053 
Ibuprofen (Advil) -1.0237 -1.1458 -0.8151 -1.4892 -0.9961 -1.5265 
Ibuprofen Lysine 
(NeoProfen) 0.3898 0.4361 0.2718 -11.9433 1.1981 0.5371 
Ibutilide fumarate -14.5554 -0.2512 -1.0817 0.4853 0.0080 -0.1340 
Idarubicin HCl -15.5734 -21.0031 -22.3033 -10.6653 -13.3241 -15.8876 
Idebenone 1.0801 0.1617 0.8142 1.0417 0.6729 0.5264 
Idoxuridine -0.1411 -1.4714 -2.1804 0.5950 0.5147 -0.5372 
Ifosfamide 0.9025 0.8140 0.1972 1.6112 0.8861 0.3658 
Iloperidone (Fanapt) -0.9749 -0.1867 -0.2953 1.0014 0.9168 0.3020 
Imatinib (Gleevec) 0.7774 0.6362 0.5764 0.4591 0.7489 0.2870 
Imatinib Mesylate -1.6133 -4.0062 -0.2591 -1.0867 1.1149 0.8262 
Imidapril (Tanatril) -0.5802 -0.0476 -0.6218 -0.3301 -0.5628 -0.8162 
Imipramine HCl -0.8304 -0.4992 -1.7375 -0.9188 -0.8235 -0.4403 
Imiquimod 1.3218 0.7266 1.7321 1.3770 0.7066 1.4803 
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Indacaterol Maleate -0.9319 -4.3317 -2.2611 0.5853 -0.5421 -1.4628 
Indapamide (Lozol) 0.3967 -1.0726 -0.3532 0.1316 -0.2042 -0.1393 
Indomethacin (Indocid, 
Indocin) 1.3166 1.6252 2.0126 1.5363 1.2002 1.3843 
Ipratropium bromide -0.1745 -1.6423 -1.3464 -0.9799 -0.2456 -1.6032 
Irbesartan (Avapro) 0.5105 0.9186 0.9411 1.5803 1.2817 0.8915 
Irinotecan -12.5543 -18.0149 -19.3948 -6.1833 -8.6883 -11.9457 
Irinotecan HCl Trihydrate 
(Campto) -14.5704 -17.6514 -17.8728 -5.4812 -8.0787 -11.4649 
Irsogladine -0.9109 -0.2292 -0.2238 -0.8201 -2.5463 -0.7758 
Isoconazole nitrate 
(Travogen) -0.0733 -0.8002 -0.0967 -0.0166 0.2908 0.0716 
Isoetharine Mesylate 1.3567 1.6666 0.9329 1.1442 1.6148 1.2089 
Isoniazid (Tubizid) 0.8242 -0.3823 -0.0420 -0.0069 0.4581 -1.0209 
Isoprenaline hydrochloride -5.8869 0.1693 -0.4708 -0.6270 0.6439 -0.7317 
Isosorbide 1.0491 1.0662 0.4445 0.8567 0.3371 0.6059 
Isotretinoin 0.5326 0.1425 0.2756 -0.0677 -0.4459 0.6580 
Isovaleramide 0.2731 -0.4841 -0.7349 -0.9938 -0.8435 -1.3541 
Isoxicam 0.5016 0.8161 1.0875 0.1637 0.0910 0.5517 
Isradipine (Dynacirc) 0.0179 -1.0137 -0.0550 -1.5413 0.6089 -0.8666 
Itraconazole (Sporanox) 0.6660 0.3838 0.4376 0.5327 0.6551 0.4358 
Ivabradine HCl (Procoralan) -0.3552 -0.0211 0.0461 0.4376 0.2013 -0.0465 
Ivacaftor (VX-770) 0.9727 0.6271 1.1303 1.6798 0.9594 0.5016 
Ivermectin -1.7352 1.6864 1.5111 1.8168 1.3866 0.8571 
Ketoconazole 0.7737 1.4392 1.2720 1.7083 1.0968 0.9089 
Ketoprofen (Actron) 0.5992 0.3545 0.3134 -1.4550 -0.3959 -0.9281 
Ketorolac (Toradol) -0.4581 -0.3124 -0.1153 -1.0854 -0.9821 -1.1398 
Ketotifen fumarate (Zaditor) -0.0446 0.0423 -0.7810 0.3505 0.1889 0.1457 
Lacidipine (Lacipil, Motens) -19.9185 0.5034 -0.3038 0.0099 0.5264 -0.7342 
L-Adrenaline (Epinephrine) 0.2139 0.2874 -0.5724 0.6423 0.2334 0.6142 
Lafutidine -0.2782 -0.8015 -0.5526 -1.3525 -1.8190 -0.3420 
Lamivudine (Epivir) 0.2877 1.1986 0.2120 1.5251 1.0894 0.9392 
Lamotrigine 0.6719 0.2983 0.2052 0.3274 -0.0094 0.6133 
Lansoprazole -0.2914 0.9368 0.7893 1.1157 0.8499 0.5676 
Lapatinib -14.9973 -0.0405 -3.8396 -9.7540 0.6779 -7.4882 
Lapatinib Ditosylate (Tykerb) 0.5592 1.5408 0.4795 0.1233 0.7313 1.1676 
L-Arginine HCl 1.0027 1.2163 1.4016 1.5807 0.7939 1.5039 
L-carnitine (Levocarnitine) 0.1378 -0.8939 0.3500 -0.2837 -0.6541 -0.0079 
Leflunomide 0.9959 0.4523 1.7410 1.3279 0.2175 0.8087 
Lenalidomide 1.3938 1.4515 0.3380 -0.7753 0.8069 0.6329 
Letrozole -4.7950 0.0718 -0.0206 0.2061 0.1106 0.2442 
Leucovorin Calcium 1.3848 0.9248 1.8873 -0.0728 0.5780 0.8537 
Levamisole Hydrochloride 
(Ergamisol) 1.1944 -1.7421 0.1803 0.2990 0.1452 -0.0992 
Levetiracetam 0.0974 0.6676 1.2974 1.1670 0.6382 0.9697 
Levobetaxolol HCl -1.1179 0.3330 0.1772 0.6960 0.1940 0.3526 
Levodopa (Sinemet) 0.3323 1.3819 0.6655 1.3237 0.4731 0.9396 
Levofloxacin (Levaquin) 1.8676 -1.5168 1.0926 0.0979 0.4541 -0.0825 
Levonorgestrel (Levonelle) 0.6384 0.7807 1.0733 0.5264 0.0492 0.7822 
Levosimendan -3.7755 -8.9451 -5.3226 0.9666 -0.7276 -0.9766 
Levosulpiride (Levogastrol) 0.7310 0.6335 0.0646 0.9149 0.5121 0.9766 
L-Glutamine -0.0345 0.5801 0.5901 0.2038 -0.6601 0.0486 
Licofelone 0.1521 -0.5939 -0.1501 -0.2638 -0.0398 -0.4499 
Lidocaine (Alphacaine) -0.2434 0.7212 0.7245 0.8553 0.2257 0.9175 
Linagliptin (BI-1356) 0.0781 -0.0511 -0.3924 -0.3370 -0.4035 -0.0752 
Lincomycin hydrochloride 
(Lincocin) 0.4038 -0.0509 0.1924 0.3557 0.5207 0.3627 
Linezolid (Zyvox) -0.3870 -0.9899 -0.0068 -2.0216 -0.7034 -0.5155 
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Liothyronine Sodium 0.1701 -0.6291 -0.1383 0.5471 -0.0277 0.2477 
Liranaftate -0.1692 1.6129 1.0383 0.3381 1.1832 0.7049 
Lisinopril (Zestril) 0.5276 0.3581 0.1508 0.0094 0.2256 0.0071 
Lithium Citrate 0.9418 0.1498 0.8507 0.6605 -0.1105 0.6586 
Lithocholic acid 0.5122 -0.2353 0.0131 -0.3066 -0.5955 0.0525 
Lofexidine  HCl 0.7819 0.2879 0.5858 -0.0267 -0.3070 0.5251 
Lomefloxacin hydrochloride 
(Maxaquin) -1.3090 -1.2067 -0.5003 -1.3427 -1.1654 -1.2566 
Lomerizine HCl -6.0190 -1.8567 -3.1430 -0.8090 -0.3672 -1.8093 
Lomustine (CeeNU) 0.7110 1.0453 0.3584 0.3690 1.3381 0.6933 
Lonidamine -1.0933 0.3149 0.0219 1.0925 0.9571 0.6817 
Loperamide hydrochloride -1.6465 -3.2059 -4.2386 -0.5466 -0.4240 -4.2492 
Lopinavir (ABT-378) -6.4202 -0.6315 -1.3693 -12.8225 0.0597 -1.1820 
Loratadine 0.1198 0.4932 0.3798 -0.5805 -0.0597 0.8725 
Lornoxicam (Xefo) -0.9590 0.1959 0.5317 -0.3070 -0.7285 -0.0066 
Losartan potassium -0.6905 -0.8488 -1.4241 -12.4703 -0.1374 -0.9076 
Loteprednol etabonate 0.5580 0.2708 0.3885 0.8446 0.9335 -0.0928 
Lovastatin (Mevacor) -3.2518 -4.7577 -5.9034 -8.0289 -10.1331 -12.2193 
Loxapine Succinate -0.0568 0.1480 -0.4951 0.8167 0.4565 0.1710 
L-Thyroxine -0.3852 0.7310 0.2833 1.1362 0.8187 1.2430 
Lurasidone HCl -0.4005 -1.0843 -0.7522 -0.4261 -0.6721 -0.1198 
Malotilate -17.5674 0.7215 1.6739 1.2209 0.9771 1.0163 
Manidipine (Manyper) 0.5841 -0.3398 0.0210 0.3361 -0.1988 0.4469 
Maprotiline hydrochloride -3.7875 -14.3239 -15.9320 0.7378 -8.5244 -12.0014 
Maraviroc 0.0472 0.2083 0.0527 0.1034 0.5233 0.5217 
Marbofloxacin 0.0181 -1.4163 -0.5939 -1.6114 -0.0845 -0.6479 
Masitinib (AB1010) -3.4527 -11.1173 -11.4852 -1.3519 -5.5434 -7.8142 
MDV3100 (Enzalutamide) 0.6067 0.6693 1.2377 0.4465 -0.0274 0.2325 
Mecarbinate 0.9813 0.8134 -0.0655 0.1437 0.2143 -0.3867 
Meclizine 2HCl -1.0601 -0.4290 -1.3018 -0.2641 0.5634 -1.7991 
Meclocycline Sulfosalicylate  1.7366 1.2935 0.5721 1.3737 1.3598 1.2517 
Medetomidine HCl -0.0362 -0.8774 -0.2085 -1.6273 -1.4414 -0.8067 
Medroxyprogesterone 
acetate 1.7614 0.5330 -0.1060 0.1652 0.9521 0.0776 
Medrysone 1.2029 1.2958 0.7221 1.1231 0.7814 0.8424 
Mefenamic acid 1.0093 1.4727 1.3932 1.2314 0.9646 0.8921 
Megestrol Acetate 0.5733 0.3127 0.0373 1.1338 1.1282 0.6482 
Meglumine 0.7657 -1.0666 0.0100 0.5066 0.1879 0.3649 
Melatonin 1.9918 0.2130 1.5891 1.3335 1.0725 1.2855 
Meloxicam (Mobic) 0.4708 0.7746 0.1390 1.6747 0.2378 0.7409 
Memantine HCl (Namenda) -2.3951 0.1403 -0.8337 -0.1529 -0.3786 -0.8463 
Menadione 1.8089 -0.8143 0.7616 -0.3051 0.3968 0.1092 
Mepenzolate Bromide -0.9249 0.0304 -1.0543 -0.3685 -0.6558 -0.4226 
Mepiroxol 1.2397 0.8045 0.6016 0.6533 0.4710 0.5198 
Mepivacaine HCl 0.4111 0.8683 1.5686 1.6085 0.9251 1.6606 
Meptazinol HCl -0.2377 0.0373 -1.0001 -0.2282 -0.7716 -0.5856 
Mequinol 0.7705 1.6381 1.8884 1.6350 1.3901 1.1863 
Mercaptopurine -6.4568 -10.0261 -11.6080 -2.1011 -3.6267 -7.0696 
Meropenem -5.8929 -0.9924 -0.3762 0.4280 -0.1037 -0.2649 
Mesalamine (Lialda) 0.2591 -1.2911 0.1538 -15.2441 -0.6824 -0.1616 
Mesna (Uromitexan, 
Mesnex) 0.5854 0.9509 0.8044 1.1309 0.0920 0.7568 
Mesoridazine Besylate 0.3937 0.1263 0.2399 0.2031 0.2057 0.4387 
Mestranol 1.5999 0.8110 0.6559 0.7129 0.4084 0.5393 
Metaproterenol Sulfate -0.1964 0.5266 0.6711 -1.6034 -0.5074 0.4272 
Metaraminol Bitartrate -1.2187 -0.3726 -0.3312 0.0358 -0.8355 -0.6001 
Metformin hydrochloride 
(Glucophage) 2.0855 1.0757 0.4198 0.2540 0.3731 0.1030 
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Methacycline hydrochloride 
(Physiomycine) 0.4659 0.2628 -0.1074 -0.3503 -0.0021 -0.0002 
Methapyrilene HCl -1.0123 -0.2385 -0.7850 0.1961 -0.0200 -0.1951 
Methazolamide -0.0048 0.8383 1.2543 0.2826 1.0294 0.0301 
Methazolastone 0.6721 -0.1140 1.2321 0.9122 -0.0978 0.7018 
Methenamine (Mandelamine) 0.7448 0.8340 0.9104 0.9931 0.8167 1.1229 
Methimazole (Tapazole, 
Northyx) -0.1077 -2.3372 -1.5740 -12.9831 -0.4995 -1.2090 
Methocarbamol (Robaxin) 0.6581 1.1082 1.1897 0.7874 0.3090 0.7272 
Methoxamine HCl 0.0509 0.2404 0.1518 0.4043 0.5518 0.3222 
Methoxsalen (Oxsoralen) 2.1586 -2.2475 0.0686 0.1496 0.0492 -0.0233 
Methscopolamine (Pamine) -17.0303 0.6273 -0.6351 0.3007 0.4117 -0.4267 
Methyclothiazide -0.0042 0.9599 0.1404 -0.0715 -0.0796 0.3444 
Methyldopa (Aldomet) 0.0043 0.7205 -0.6793 -0.5411 -0.5071 -1.2889 
Methylhydantoin-5-(D) -0.5415 -0.0193 0.0024 -0.2127 -0.8746 -0.4087 
Methylprednisolone 0.6756 0.4363 0.2344 0.9337 0.4017 0.5101 
Methylthiouracil 0.2048 0.2316 1.5198 1.2989 1.1320 1.4251 
Meticrane 1.0260 0.6849 0.4909 0.7190 0.7997 0.5417 
Metolazone (Zaroxolyn) -0.1918 0.1608 0.0685 0.4085 0.3308 0.3306 
Metoprolol tartrate -0.4905 0.6551 -0.1204 0.2698 0.4751 0.1715 
Metrizamide -1.2132 0.0067 -0.1176 -1.1206 -1.2404 -0.3253 
Metronidazole (Flagyl) 0.1126 0.2219 -0.4442 0.0322 -0.4804 -0.1696 
Mevastatin -3.9117 -4.1191 -5.8697 -7.3662 -6.6369 -13.4623 
Mexiletine HCl -1.0152 -1.4454 -1.1760 -0.4464 -1.3683 -1.6912 
Mezlocillin Sodium 0.8910 1.5908 1.1424 1.7003 1.3709 1.4887 
Mianserin hydrochloride -6.4130 -0.6419 -0.3918 1.6596 0.4409 -0.1953 
Miconazole (Monistat) 0.1984 -0.5109 -1.1822 0.2659 -0.1552 -0.0582 
Miconazole nitrate -1.1147 -3.3779 -1.1567 -3.0015 -1.3255 -1.1851 
Mifepristone (Mifeprex) 0.1169 -0.8245 0.5975 -0.0901 0.2681 -0.2623 
Miglitol (Glyset) 1.0720 0.4204 0.1367 0.5292 0.6479 0.6259 
Milnacipran HCl 0.6267 0.7561 0.4469 1.0073 0.8394 1.1794 
Milrinone (Primacor) 0.2935 -0.6179 -0.3027 0.5116 -0.0862 0.0665 
Minocycline HCl 0.3840 -1.0589 -1.4426 -0.9517 -0.4944 -1.6462 
Minoxidil 0.4410 0.7402 0.6623 0.9330 0.4200 0.1421 
Mirabegron (YM178) 0.0409 -0.9308 -0.1614 -0.5994 -1.5030 -1.2571 
Mirtazapine (Remeron, 
Avanza) 1.1928 1.8027 1.3254 0.7198 1.5655 0.8307 
Misoprostol -0.3288 0.4067 -0.1960 -0.1016 0.4505 -0.1482 
Mitiglinide calcium 1.4900 0.5738 -0.4156 -0.1749 0.3458 -0.4270 
Mitotane (Lysodren) -1.8173 -0.1993 -0.4827 -0.4009 -0.0999 -0.2660 
Mitoxantrone Hydrochloride -16.4397 -21.3701 -22.7289 -11.9894 -13.1412 -15.9883 
Mizolastine (Mizollen) 0.1255 -0.4825 0.3320 0.5080 -0.1270 0.1136 
Mizoribine (Bredinin) 0.6673 1.0569 0.9826 1.1326 0.4381 0.5586 
Moclobemide 0.3724 -0.6328 -0.9451 0.7447 0.1789 0.4149 
Moexipril HCl 0.4793 0.5954 -0.3202 -0.7336 0.2196 -0.1955 
Moguisteine 0.3409 0.4318 0.5424 0.0982 0.7484 0.4149 
Mometasone furoate -1.2434 -1.7790 -1.4245 0.6238 0.5625 0.0066 
Monobenzone (Benoquin) -1.9348 -4.7348 -4.0244 1.2368 -0.2307 -2.8530 
Montelukast Sodium -0.0573 -0.1030 0.0738 0.5461 -0.0058 0.3331 
Moroxydine -5.3783 -0.1322 -0.6010 -1.1736 -0.2290 -1.1306 
Mosapride citrate -2.8543 1.0965 1.0335 1.1769 0.4244 0.7018 
Moxalactam Disodium 1.1719 1.4537 0.6864 0.7345 1.1190 0.8122 
Moxifloxacin hydrochloride -0.0337 -1.8151 -0.6220 -13.8659 0.2505 -0.4028 
Moxonidine 0.0829 -0.0737 -1.3096 -1.9944 -1.1336 -2.9759 
Mycophenolate mofetil 
(CellCept) -9.3939 -11.4656 -10.3635 -6.0970 -6.8133 -8.3940 
Mycophenolic 
(Mycophenolate) -7.6569 -9.6620 -10.1976 -5.6809 -4.1499 -8.5527 
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Nabumetone 0.8938 2.0053 1.9785 1.3440 1.3547 1.2212 
Nadifloxacin 0.4771 1.1154 1.0058 1.0372 0.8094 0.7078 
Nafamostat mesylate 1.0042 0.3424 0.9909 1.1089 0.3922 0.7976 
nafcillin sodium monohydrate 0.0286 0.8281 0.9245 0.6495 0.5654 0.3378 
Naftifine HCl -0.2052 0.3592 0.5612 0.8198 0.8231 1.4472 
Naftopidil (Flivas) -0.3100 -0.3984 -0.6922 1.1596 0.3217 0.0057 
Nalidixic acid (NegGram) -0.0385 -0.4122 0.1937 0.1371 -0.3231 0.0404 
Nalmefene HCl 1.4980 1.3651 0.9794 0.9982 1.5791 1.1264 
Naloxone HCl -5.8963 -0.5062 0.6112 0.3237 0.6257 -0.0909 
Naltrexone HCl -0.1465 0.0009 0.1484 0.8910 0.7256 0.7253 
Naphazoline hydrochloride 
(Naphcon) 0.9565 0.6540 0.5063 -7.9706 0.5559 0.5226 
Naproxen (Aleve) -0.0043 -0.2100 0.0929 0.7485 -0.2223 0.1061 
Naratriptan HCl 0.4308 0.7040 0.2985 1.0110 1.2454 0.5949 
Natamycin (Pimaricin) -1.5993 -0.0765 0.3624 -13.7604 0.8134 0.2781 
Nateglinide (Starlix) 0.5649 0.7743 0.5727 0.6117 0.9514 0.0799 
Nebivolol (Bystolic) -15.1549 -10.2550 -3.8440 -9.5709 -5.1347 -3.0481 
Nefiracetam (Translon) 0.8057 0.9557 0.8144 0.2537 0.6851 0.4172 
Nefopam HCl 0.3226 1.1624 0.6480 1.3147 1.0163 1.0401 
Nelarabine (Arranon) 1.5556 0.1091 1.6266 0.7708 0.5314 1.4367 
Neomycin sulfate 1.5861 0.6850 0.3428 0.5388 0.9159 0.7223 
Neostigmine bromide 
(Prostigmin) 0.4905 0.7061 0.6849 0.6432 0.8518 0.3581 
Nepafenac 0.1059 1.2766 -0.4194 -0.5897 0.0274 -0.5935 
Netilmicin Sulfate 0.2367 0.7278 1.4150 1.0815 1.1120 1.2215 
Nevirapine (Viramune) -0.9165 -0.3403 -1.5711 -1.0432 -0.7751 -0.9747 
Niacin (Nicotinic acid) -0.1222 -0.2272 -0.6395 0.9853 -0.6882 0.3727 
Nialamide 1.6468 1.1725 0.5456 0.9167 1.2772 1.0421 
Nicardipine HCl -0.0492 0.8551 0.4785 0.6771 0.5875 0.8474 
Niclosamide (Niclocide) -13.5934 -17.6291 -19.4847 -7.4789 -10.9830 -13.6458 
Nicorandil (Ikorel) 1.0290 -0.0563 0.0993 0.5789 0.4962 0.3156 
Nicotinamide (Niacinamide) -15.7510 0.0072 -0.3958 -0.2181 -0.3724 -0.3407 
Nicotine Ditartrate -1.7219 -0.2033 -1.2477 -1.0965 -0.5572 -1.2488 
Nifedipine (Adalat) 1.2319 0.4786 1.1611 0.3408 1.4306 1.2880 
Nifenazone -0.1987 -0.3709 0.8604 -0.2604 -0.7687 0.0945 
Niflumic acid -0.3866 -2.6978 -1.0599 -0.0717 -2.2558 -0.2250 
Nifuroxazide -3.6785 0.0042 -3.9980 0.0593 0.9147 -1.1710 
Nilotinib (AMN-107) 1.2357 0.6318 0.0211 -0.8833 0.3627 0.8954 
Nilvadipine (ARC029) 0.1618 -0.0515 0.4717 1.0746 0.7180 0.2344 
Nimesulide -24.9744 -0.7653 -1.2359 -0.4690 -0.7529 -1.5325 
Nimodipine (Nimotop) -0.4760 0.1340 0.0199 1.2784 -0.4351 0.4431 
Nisoldipine (Sular) -0.4145 0.4224 0.2647 0.6537 -1.0415 -0.1252 
Nitarsone -0.9714 -0.8113 -1.2065 -0.5485 -0.2571 -0.8418 
Nitazoxanide (Alinia, Annita) -3.3001 -5.0858 -6.0246 1.3378 -1.0208 -2.1935 
Nithiamide -1.4070 -1.9229 -0.3269 -1.1703 -1.6410 -0.7524 
Nitrendipine 0.8889 0.8043 1.0858 0.3253 0.9722 0.5162 
Nitrofurazone (Nitrofural) -0.2790 0.3527 -0.2639 -1.1200 -0.8802 -0.7889 
Nizatidine -14.0715 0.7765 0.6066 0.5100 0.6592 0.6551 
Nomifensine Maleate 0.2962 -0.5320 -3.1018 -1.2864 0.0153 -3.2472 
Noradrenaline bitartrate 
monohydrate (Levophed) 0.5498 1.1476 0.9487 1.2721 1.3749 1.3651 
norethindrone 0.0827 0.8743 1.4420 0.6075 0.7635 0.6345 
Norfloxacin (Norxacin) 0.5259 0.4767 0.7692 1.2011 0.5415 0.6599 
Noscapine HCl -0.6372 -0.7763 -1.1506 -0.2429 0.4247 -0.3235 
Novobiocin sodium 
(Albamycin) 1.2087 1.1229 1.5132 0.3231 1.1196 0.6846 
Nystatin (Mycostatin) -0.0001 -1.5886 -2.4411 0.0069 -0.1212 -1.9744 
Ofloxacin (Floxin) 0.0309 -0.6313 -0.7540 -1.3672 0.0696 0.0113 
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Olanzapine (Zyprexa) 0.8715 1.1182 0.8985 0.6223 0.7523 0.6722 
Olmesartan medoxomil 
(Benicar) 1.4476 1.2968 1.5279 2.4843 1.4362 1.1777 
Olopatadine hydrochloride 
(Opatanol) 0.5049 0.9688 0.5283 1.8727 0.4519 0.4517 
olsalazine sodium 0.1465 1.4144 0.9566 0.5681 0.8963 0.2314 
Omeprazole (Prilosec) 0.3195 1.1112 1.0442 0.9468 0.4091 0.7286 
Ondansetron (Zofran) -1.8462 0.9597 0.7709 0.5250 1.2037 0.3674 
Ondansetron hydrochloride 
(Zofran) 0.2477 -0.1865 1.0388 0.7673 0.1117 0.7001 
Orbifloxacin -0.9690 0.3994 -0.9983 0.2063 0.4908 -0.2752 
Orlistat (Alli, Xenical) -0.7589 -0.1326 0.2809 1.2321 -0.5951 0.2866 
Ornidazole 0.1947 -0.5991 -0.3448 -0.0255 0.2956 0.1299 
Orphenadrine citrate 
(Norflex) -4.4906 -0.5172 -2.5087 -1.6129 -2.0676 -2.3608 
Oseltamivir phosphate 
(Tamiflu) -7.4738 0.3306 0.3528 0.8960 0.8117 1.3019 
OSI-420 (Desmethyl 
Erlotinib) -1.5099 -0.6595 0.9641 1.2755 0.6951 0.6633 
Otilonium Bromide -1.2193 -0.2414 -1.7478 -0.9189 -1.7478 -2.8283 
Ouabain -14.5743 -18.0745 -19.2405 -10.0950 -12.5043 -14.4039 
Oxacillin sodium 
monohydrate -0.6476 -1.2618 0.0369 -0.3570 -1.2752 -0.2110 
Oxaliplatin (Eloxatin) -0.7504 -0.0677 1.4068 0.6545 0.1237 1.2832 
Oxaprozin -0.8664 -0.1966 -0.8630 -0.3333 -1.0071 -0.9231 
Oxcarbazepine 0.1096 0.2924 0.8247 0.7113 -0.1768 0.7700 
Oxeladin Citrate -0.6670 -1.5358 -2.3931 -0.8380 -0.3145 -1.6921 
Oxethazaine -0.2183 -1.8077 -8.0459 -0.1711 0.1226 -1.7440 
Oxfendazole 0.9351 0.6358 0.3050 0.8920 1.4005 0.9249 
Oxibendazole -0.4314 1.3571 -0.5924 -0.0390 1.4583 0.0031 
Oxiglutatione Disodium Salt -0.4167 0.0786 -0.8058 0.1384 0.2405 -0.1867 
Oxprenolol HCl 0.6476 0.6352 0.1968 0.3262 0.5298 0.6280 
Oxybuprocaine HCl -1.1119 -1.7029 -0.8640 -0.3615 -1.3055 -1.6063 
Oxybutynin (Ditropan) -1.1268 0.4866 -0.6737 -0.0253 -0.7096 -0.6264 
Oxybutynin chloride 0.0629 -1.5079 -0.6009 0.2528 0.1415 -0.2153 
Oxymetazoline hydrochloride 0.0788 -0.1453 0.0176 0.2595 0.2610 0.3053 
Oxymetholone 0.0599 0.8367 0.1115 0.9051 0.7172 0.5864 
Oxytetracycline (Terramycin) -0.9289 -0.0968 -0.3417 -0.9432 -1.6819 -0.6744 
Oxytetracycline dihydrate -0.3435 -0.9994 -0.4360 -1.1971 -1.2357 -0.1012 
Ozagrel 0.6009 0.5612 0.5755 0.4966 0.1513 0.7182 
Ozagrel HCl 0.2331 0.1683 -1.4577 -0.8050 -0.1954 -1.3992 
Paclitaxel (Taxol) -12.8785 -17.1843 -16.4073 -8.8346 -11.1252 -13.2573 
Paeoniflorin -0.6244 0.2938 -0.7730 -0.4118 -0.3996 -0.7013 
Paliperidone (Invega) 0.4410 1.1861 -0.2612 1.1181 0.7660 0.9333 
Palonosetron HCl -5.8641 -6.1709 -6.8281 -2.1667 -2.6293 -4.3563 
Pamidronate Disodium 0.4522 0.4354 -0.0342 1.0050 0.4047 0.3374 
Pancuronium (Pavulon) -0.3022 -0.8007 0.2151 0.1327 -0.4609 0.0060 
Pantothenic acid 
(pantothenate) -1.0140 0.2312 -0.8017 -0.7533 0.0021 -0.8418 
Paromomycin Sulfate -0.8305 -0.2118 0.2433 -0.0648 -0.5269 0.5092 
Paroxetine HCl -13.0419 -15.9596 -16.6356 -8.1625 -9.6875 -12.2333 
Pasiniazid 0.6628 0.5245 0.0773 0.1334 0.5500 0.2879 
Pazopanib 0.4753 0.6961 0.5134 0.7989 0.1466 0.5163 
Pazopanib HCl 0.8175 -0.1727 -0.7941 1.2082 0.5266 -0.7185 
PCI-32765 (Ibrutinib) -0.9143 -0.3300 0.2523 1.3940 0.8922 0.6820 
Pefloxacin mesylate 0.1934 -1.3740 -1.3483 -1.0458 -0.2048 -1.1091 
Pemetrexed -8.3408 -9.3603 -6.0839 -2.3502 -2.7256 -6.3718 
Pemirolast (BMY 26517) 
potassium -0.5690 -0.7828 -1.8418 -1.4751 -1.4124 -1.9791 
Penciclovir -0.2291 0.3927 -1.2501 -0.1750 0.1188 -1.3269 
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Penfluridol -14.6812 -19.9258 -21.7764 -10.2445 -11.4777 -15.1825 
Penicillamine (Cuprimine) 0.8139 0.9125 0.2428 0.0016 0.4523 0.4961 
Pentamidine -4.7780 -3.6510 -9.3059 -2.6711 -2.0928 -8.8573 
Pentoxifylline 0.6608 0.5147 0.9734 0.4862 0.4669 0.5956 
Peramivir Trihydrate 0.5068 0.4188 0.3508 1.0863 0.4416 0.9279 
Pergolide mesylate -0.6748 -1.4834 -1.2294 -0.3814 -0.7083 -0.5675 
Perindopril Erbumine 
(Aceon) 0.9944 1.6793 0.9195 1.8764 1.2225 0.9405 
Phenacetin -0.0096 0.4840 -0.1733 0.2597 -0.0746 -0.5460 
Phenazopyridine HCl 0.9771 -0.1117 -1.1794 -0.0543 0.0251 -1.4994 
Phenformin hydrochloride -0.4917 -0.6063 -0.2034 -1.1986 -0.5123 -1.4205 
Phenindione (Rectadione) 0.6505 0.0116 -0.2986 -0.8571 -1.4212 -0.4176 
Pheniramine Maleate -0.8460 -0.6062 -0.5040 -0.2424 -0.8993 -1.2353 
Phenothrin 0.1431 0.0938 -0.4342 -0.0333 0.4877 0.1796 
Phenoxybenzamine HCl -0.6104 0.5661 0.0839 -1.0296 0.8907 -0.1275 
Phentolamine mesilate -0.0399 -0.9385 -1.6902 -0.4793 -1.3528 -2.5783 
Phenylbutazone (Butazolidin, 
Butatron) 0.3493 -0.6435 -0.0389 -0.9702 0.5795 -0.8802 
Phenylephrine HCl 1.4557 0.8394 0.1701 0.2514 1.0205 0.9653 
Phenytoin (Lepitoin) -15.6653 0.3760 0.4469 0.0149 0.2124 -0.1008 
Phenytoin sodium (Dilantin) -8.3459 0.0188 -0.4664 -0.9750 -0.5063 -0.8932 
Phosphatidylcholine 0.7486 -0.2638 0.8080 0.1006 -0.1265 0.6654 
Phthalylsulfacetamide 0.0002 0.2456 -0.1165 0.2668 0.0200 -0.1590 
Physostigmine Hemisulfate 
Salt -2.4906 -1.4973 -0.6770 -0.3387 -0.4534 -0.3389 
Physostigmine Salicylate -0.4498 0.4403 0.1209 -0.1353 0.0920 0.3493 
Picrotoxinin -0.7382 0.5429 0.3543 0.3433 0.5879 0.2889 
Pidotimod 0.5384 0.1358 1.0541 0.5613 1.1500 0.4307 
Pilocarpine HCl -0.2897 0.0312 -0.6741 -0.6525 -0.8902 -0.4611 
Pimecrolimus -7.1664 -5.1884 -2.7224 -2.8749 0.2719 -4.3037 
Pimobendan (Vetmedin) -7.4951 -11.3442 -9.6497 1.0051 -2.1632 -3.7072 
Pimozide -5.5403 -7.9833 -6.4931 -3.2058 -4.0109 -11.8801 
Pinacidil  -0.0030 -0.0159 -0.2378 -0.2406 0.0933 -0.1140 
Pindolol 0.7316 0.3280 0.4775 0.2759 0.1513 0.4046 
Pioglitazone (Actos) 0.3096 -0.2606 -0.4554 -0.2954 0.0094 0.2255 
Pioglitazone hydrochloride 
(Actos) -0.2140 0.4098 -0.1159 -0.3515 -0.5956 -0.0497 
Pipenzolate Bromide -1.1435 -1.3185 -0.3805 -0.1970 -1.2618 -0.9323 
Piperacillin Sodium -2.5386 -1.2224 -2.5921 -1.7634 -1.2305 -3.5359 
Piromidic Acid -0.9554 -0.3496 0.4944 0.3035 0.1194 0.0595 
Piroxicam (Feldene) -0.1764 0.6728 -0.3346 -0.5002 0.0286 0.6975 
Pitavastatin calcium (Livalo) -10.9673 -17.6993 -18.1431 -13.0390 -12.3249 -15.0414 
Pizotifen malate -2.1729 -1.7416 -1.1946 -0.7454 -0.8759 0.0030 
Plerixafor (AMD3100) 0.2404 0.6959 0.5270 0.1475 0.5979 0.6804 
PMSF (Phenylmethylsulfonyl 
Fluoride) 0.5742 0.3975 0.2465 0.6384 -0.0328 0.4858 
Pomalidomide -0.1228 0.1783 0.8687 1.4097 0.0300 0.5493 
Ponatinib (AP24534) -14.9295 -21.0552 -21.9585 -11.0630 -12.4707 -15.8762 
Posaconazole 0.0772 -4.4954 -2.7065 -2.8185 -5.7219 -2.2523 
Potassium Canrenoate -0.7129 -0.0458 -0.8916 -0.2846 -0.0349 -0.3838 
Potassium iodide -1.3407 -1.5949 -1.8276 -1.3180 -1.0868 -1.4865 
Pralatrexate (Folotyn) -7.0099 -9.1791 -12.3447 -2.4599 -4.2683 -5.6332 
Pramipexole (Mirapex) 0.6048 0.5706 -0.0162 0.0486 0.2252 0.0137 
Pramipexole dihydrochloride 
monohydrate -1.6646 1.3245 0.6115 0.3492 1.0289 0.1967 
Pramiracetam -3.4857 0.0219 -0.3105 0.2508 0.5970 0.4345 
Pramoxine HCl 0.4879 0.5675 -0.2330 0.4029 -0.2226 0.3190 
Pranlukast 1.0182 1.4116 0.3914 1.0636 1.6563 0.9575 
Pranoprofen -1.7660 -0.0423 0.0532 0.4337 0.8268 -0.1798 
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Prasugrel (Effient) 0.6883 0.9017 1.1983 0.0170 0.2907 0.1115 
Pravastatin sodium -5.8246 -0.0609 -0.3767 0.1150 -0.9230 -0.2732 
Praziquantel (Biltricide) 0.4910 1.3827 0.6541 1.0352 1.0962 1.0500 
Prazosin HCl -3.5996 -11.9036 -14.4620 -2.5371 -5.7377 -10.6782 
Prednisolone 
(Hydroretrocortine) 0.1320 1.3434 0.8654 0.8653 0.2491 0.9620 
Prednisolone acetate 
(Omnipred) 1.1314 1.1126 0.9010 -0.0764 1.2460 0.6622 
Prednisone (Adasone) 0.4220 0.2340 0.9953 0.1608 -0.4529 0.3595 
Pregnenolone -0.4338 -0.8738 -0.6165 -0.6295 -1.3508 -0.5412 
Pridinol Methanesulfonate -2.9844 -0.6429 -2.1782 -1.0893 -0.3719 -1.1474 
Prilocaine 0.9331 0.5006 0.2265 1.2107 0.0626 0.6559 
Primaquine Diphosphate -0.1537 -0.7108 -3.9813 0.0889 -0.2118 -2.8064 
Primidone (Mysoline) 1.0301 0.5736 0.7332 0.4645 1.0396 0.3611 
Proadifen HCl -2.8932 -1.0677 -3.5078 -1.3642 0.0570 -2.6619 
Probenecid (Benemid) 0.1518 0.1531 0.8227 0.7382 0.7584 0.1889 
Probucol 0.6603 0.7927 0.0996 0.7371 0.2623 0.7628 
Procarbazine HCl (Matulane) -2.9997 1.1889 0.6616 0.4390 1.0309 0.0647 
Prochlorperazine Dimaleate -9.3795 -4.0504 -2.8504 -7.1394 -1.5488 -7.6176 
Procodazole 1.1067 1.0539 0.7886 0.4284 0.4850 0.6505 
Procyclidine HCl  -1.6216 -0.4259 -0.0490 0.5204 0.6190 0.0845 
Progesterone (Prometrium) -0.2043 0.4601 -0.1699 1.9343 0.8584 0.5737 
Propafenone (Rytmonorm) -1.8425 -0.3274 -1.4112 0.5132 0.6316 -1.0670 
Proparacaine HCl -0.5326 1.3887 0.5837 0.8054 1.5780 1.0934 
Propranolol HCl 0.8246 2.1710 2.4687 1.7071 1.5033 0.9864 
Propylthiouracil 0.4786 -0.3592 0.0332 -0.1893 -0.7518 0.2031 
Protionamide 
(Prothionamide) 0.4225 0.1062 -0.4800 -0.0293 0.1883 -0.0261 
Pyrazinamide (Pyrazinoic 
acid amide) -1.9976 -0.3219 -0.9526 -1.0257 -0.9386 -1.7169 
Pyridostigmine Bromide 
(Mestinon) -0.0741 0.5740 0.2791 0.4352 -0.5575 0.4819 
Pyridoxine hydrochloride 0.5858 -0.0145 0.8971 0.7114 1.0884 0.7497 
Pyrilamine Maleate -0.1681 -0.0132 -1.6759 -0.6833 0.6706 -1.8132 
Pyrimethamine -23.2058 -12.3167 -12.7116 -5.1386 -6.4014 -9.0433 
Pyrithione zinc -13.1152 -16.2778 -16.9965 -8.6108 -9.7110 -12.3542 
Quetiapine fumarate 
(Seroquel) -1.1563 -1.4225 -0.6602 -0.0631 -1.1614 -0.8044 
Quinapril HCl (Accupril) -1.1034 0.9810 0.6148 0.8141 1.0829 0.8164 
Quinine hydrochloride 
dihydrate -0.0338 1.2508 -0.2685 0.5823 0.7610 0.1462 
Quipazine Maleate 0.2261 0.6420 0.4532 0.5235 0.2644 0.5835 
R-(-)-Apomorphine HCl 
Hemihydrate -1.1344 -0.2397 0.0318 0.5001 0.8607 0.1270 
Racecadotril (Acetorphan) 0.6980 1.3116 1.2611 0.2452 0.9290 0.7142 
Ractopamine HCl 0.2049 0.8035 0.6677 0.2655 0.8546 0.2378 
Raltegravir (MK-0518) 0.2832 -0.2019 -0.0269 -0.4572 -0.4148 0.5144 
Ramelteon (TAK-375) -0.2020 0.3558 -1.9394 -0.2715 -1.5582 -0.4714 
Ramipril (Altace) 0.9190 -0.8412 0.1775 -0.2452 -0.0178 0.2737 
Ranitidine (Zantac) -0.3774 0.9548 0.0680 -0.1583 0.6060 0.1575 
Ranolazine (Ranexa) 0.2699 -0.7738 -0.0997 -0.7582 -0.1088 -1.0055 
Ranolazine dihydrochloride -21.2032 0.3931 -0.7201 -0.5572 -0.8782 -1.3096 
Rapamycin (Sirolimus) -2.0838 -2.8404 -4.2730 0.1587 -0.2349 -2.1860 
Rasagiline mesylate 0.0642 0.1766 0.2062 1.0312 0.8094 0.6404 
Rebamipide 0.9836 0.9676 0.9280 0.4369 0.4968 0.7786 
Reboxetine mesylate 0.6952 -0.2903 0.2014 0.3726 0.0328 0.5659 
Regorafenib (BAY 73-4506) -0.4735 -2.1645 -1.4530 -7.2809 -0.1247 -1.0484 
Repaglinide -20.3068 0.1275 -0.4008 -0.5817 -0.7440 -0.7265 
Reserpine -0.9825 0.9674 0.3848 1.8150 0.9776 0.4329 
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Resveratrol -3.0915 -2.0404 -2.5731 -13.2592 -1.1826 -1.7971 
Retapamulin -1.6026 -1.0408 -1.9213 0.9268 0.9057 -1.0371 
Ribavirin (Copegus) 1.4720 2.0087 2.0970 1.4410 2.3943 1.5193 
Riboflavin (Vitamin B2) 0.3625 -0.0327 -0.4146 -0.2016 0.0435 -0.5832 
Rifabutin (Mycobutin) -0.2230 -1.5760 -0.9281 -0.1798 -0.4263 -0.2241 
Rifampin (Rifadin, 
Rimactane) -0.8561 -0.1850 -2.3559 -0.3167 -0.7120 -0.2303 
Rifapentine (Priftin) 0.1738 -0.7129 -1.6533 -14.8838 -0.0316 -0.3223 
Rifaximin (Xifaxan) 1.4886 0.2959 2.0263 1.0790 1.7531 1.5210 
Riluzole (Rilutek) 0.4491 0.5370 0.6734 1.5705 0.0958 -0.4078 
Rimantadine (Flumadine) 0.6038 0.7421 0.9442 0.4206 0.7864 0.1637 
Rimonabant (SR141716) -12.3898 -1.2240 -1.5645 0.3802 -0.2126 -0.4827 
Risedronate sodium -18.6245 -0.2306 -1.0737 -1.4712 -0.7689 -1.2340 
Risedronic acid (Actonel) 0.3610 1.3575 0.3443 0.4757 1.1677 0.9427 
Risperidone (Risperdal) -0.1296 -0.6363 -0.4469 0.8628 -0.2088 0.2199 
Ritodrine hydrochloride 
(Yutopar) 0.7599 0.0041 0.4962 0.5038 0.7205 0.5574 
Ritonavir 0.5097 1.5156 1.3551 2.0487 0.8373 0.9030 
Rivaroxaban (Xarelto) 0.4667 0.9279 1.5442 1.3117 0.9681 1.2651 
Rivastigmine tartrate 
(Exelon) -0.1252 0.3088 0.0144 0.5546 0.2564 0.4487 
Rizatriptan Benzoate 
(Maxalt) 0.8305 0.4437 0.4330 1.6024 0.0147 0.6029 
Rocuronium bromide -1.3781 -0.9850 -1.0258 -0.0743 -0.5491 -0.8191 
Rofecoxib (Vioxx) 0.6950 0.1016 0.0631 0.0045 -0.6943 -0.2299 
Roflumilast (Daxas) 0.8606 0.4829 0.3958 0.5624 0.4718 0.5956 
Rolipram -15.7604 0.2046 -0.4037 -0.7499 -0.9644 -0.5895 
Rolitetracycline 0.7307 0.4132 0.9046 0.4935 1.0098 0.5536 
Ronidazole 0.3466 1.1507 1.4050 1.0209 1.1759 1.1208 
Ropinirole HCl 0.2806 0.0193 0.5148 1.1459 0.2257 0.9247 
Ropivacaine HCl -1.5426 -1.9709 -0.0019 -0.1932 -0.7425 -1.0591 
Rosiglitazone (Avandia) -0.4915 -0.5265 -0.1832 -0.7581 -0.5375 -0.9160 
Rosiglitazone HCl 0.3912 0.6956 -0.2278 0.0337 0.2769 0.0258 
Rosiglitazone maleate 0.5367 1.4346 1.9136 0.7826 1.0419 1.0506 
Rosuvastatin calcium 
(Crestor) 1.2033 0.0509 0.2812 0.6823 0.5067 0.3627 
Roxatidine acetate HCl -0.0441 -0.3539 -1.2594 -0.7589 -0.8154 -1.5306 
Roxithromycin (Roxl-150) 0.7301 0.8074 0.9902 0.9688 0.2782 0.6508 
Rufinamide (Banzel) 1.1217 0.2242 1.0027 -0.0393 0.3846 -0.4340 
Ruxolitinib (INCB018424) 0.2456 0.9242 0.6832 0.9978 0.1503 0.8252 
S-(+)-Rolipram -0.1382 0.5493 0.5992 0.7801 0.3293 0.5423 
Salbutamol sulfate 
(Albuterol) 0.4281 0.6106 0.6722 0.3745 0.2597 0.7520 
Salicylanilide 1.2394 1.7550 0.8814 0.9112 0.4610 0.8506 
Sarafloxacin HCl -23.3387 -1.5896 -1.1165 -1.2056 -0.3445 -1.1524 
Sasapyrine 1.5599 1.5670 1.0843 1.3838 1.1449 1.1772 
Saxagliptin (BMS-
477118,Onglyza) 0.9208 1.9538 1.6308 -7.9878 1.6912 1.2600 
Scopine 0.0608 -0.4669 0.6151 0.2328 -0.4305 0.2397 
Scopolamine hydrobromide 0.4136 0.0326 0.5100 0.1055 0.0673 0.7834 
Secnidazole (Flagentyl) 0.4136 0.6808 0.4672 0.2418 -0.0875 0.7106 
Serotonin HCl 0.7749 -0.4823 0.9803 0.0087 -0.0962 0.2731 
Sertaconazole nitrate -1.9846 0.1041 0.0103 -0.6132 0.2455 0.9180 
Sertraline HCl -14.3300 -17.3068 -18.7919 -9.5329 -10.3890 -13.6602 
Sevelamer HCl 0.0042 -0.7846 -0.7937 -0.9916 -2.1171 -1.5093 
Sildenafil citrate -0.3024 0.5604 -0.3056 -0.0582 -0.5725 -0.1197 
Silodosin (Rapaflo) -0.6481 -0.2439 -0.6843 0.9417 0.0495 -0.1466 
Simvastatin (Zocor) -4.1669 -0.3975 0.4566 -0.0862 0.5942 0.9729 
Sitafloxacin hydrate 0.7478 -0.1614 0.3287 -0.0652 -0.0571 -0.1389 
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Sodium 4-aminohippurate 
Hydrate -1.8234 -0.0835 -0.2280 0.3131 0.6639 -0.1642 
Sodium ascorbate 1.0541 -0.2115 0.0129 -0.3492 -0.6866 -0.3113 
Sodium butyrate 0.4997 2.1532 1.7584 0.7282 1.1733 1.1867 
Sodium Gluconate -0.0123 0.7602 -0.5456 0.1324 0.8765 0.1185 
Sodium 
Monofluorophosphate   0.0315 -0.9173 0.1582 -0.0535 -0.9001 -0.6232 
Sodium nitrite 0.3855 0.7445 1.2182 1.2518 0.5994 1.0280 
Sodium Nitroprusside -2.0278 0.9129 0.5594 -0.0545 0.9934 0.5694 
Sodium orthovanadate 0.0137 1.5381 0.9317 0.6533 1.2105 0.7653 
Sodium Picosulfate -1.0616 -0.3998 -1.1442 -0.7073 0.1314 -1.4616 
Sodium salicylate 0.4145 0.7459 1.2687 1.6868 1.2732 1.4091 
Solifenacin succinate -6.3335 -3.6164 -4.2369 -2.3957 -2.2532 -4.4557 
Sorafenib (Nexavar) -0.0772 -4.1520 -0.5537 0.1793 0.8935 -0.1636 
Sorbitol (Glucitol) -0.0645 -1.8897 -0.3876 -0.4601 -0.8969 -0.2859 
Sotalol (Betapace) -0.0089 -0.4959 0.0666 -0.2504 0.0231 0.4620 
Sparfloxacin 0.6894 0.7761 -0.1463 1.0080 0.8344 0.6648 
Spectinomycin  
hydrochloride -8.8095 -0.4604 -1.1606 -0.4353 -0.2041 -0.7340 
Spiramycin -1.5858 -0.6685 -0.9756 -0.6482 -0.6739 -1.7190 
Spironolactone 0.4000 0.7238 0.7204 1.8319 0.9885 0.6930 
Stavudine -0.2635 -0.1205 -0.6947 0.9842 -0.3940 -0.2997 
Streptomycin sulfate 1.5559 0.0040 0.7987 -0.1194 0.6851 0.8084 
Streptozotocin (Zanosar) 0.2182 0.2980 0.0068 0.6017 0.1042 0.3080 
Strontium ranelate (Protelos) 0.0593 -0.6530 0.6787 -0.1459 -0.7762 0.3226 
Sucralose -0.2400 -0.6009 0.1598 0.3307 -0.5282 0.1758 
Sulbactam -20.8159 -1.1543 -1.0452 -0.7365 -0.0492 -1.5937 
Sulbactam sodium (Unasyn) 0.0828 -0.6729 0.3978 -0.4897 -1.0989 0.0312 
Sulconazole Nitrate -1.7696 -1.8737 -9.9213 -2.5111 -2.4339 -8.3635 
sulfacetamide sodium 0.5984 0.4580 -0.1239 -0.2320 -0.2859 0.0177 
Sulfadiazine -1.4876 0.6120 0.1548 -0.5983 -0.8230 -0.4235 
Sulfadoxine (Sulphadoxine) 0.1468 0.7403 -0.1235 0.2328 0.6728 -0.0310 
Sulfaguanidine 0.6133 1.1126 0.4039 0.9832 0.6946 0.7056 
Sulfamerazine 0.6072 0.9816 1.0618 0.8865 1.0242 1.0455 
Sulfameter (Bayrena) 0.1612 0.9754 0.8645 1.4448 0.3888 0.8458 
Sulfamethazine 0.7198 0.9349 1.1243 1.0188 1.0862 1.3384 
Sulfamethizole (Proklar) 1.6284 -1.4647 0.2535 -0.5927 -0.6460 -0.0656 
Sulfamethoxazole -0.0625 -0.5305 -0.1616 -0.5138 -1.6148 -1.2774 
Sulfanilamide 0.3776 -0.0155 -0.3562 0.7459 0.8652 0.0781 
Sulfapyridine (Dagenan) 1.1899 0.6761 1.3683 1.4084 0.7888 0.8617 
Sulfasalazine (Azulfidine) 0.5118 -1.9050 -1.5411 -13.5020 -0.4684 -0.7711 
Sulfathiazole 0.1647 -0.1016 0.7868 0.8922 0.4691 0.4815 
Sulfisoxazole -0.6085 -1.0853 -0.7977 -0.5110 -2.5494 -0.9496 
Sulindac (Clinoril) -14.3232 0.5320 -0.1566 0.2377 0.1873 -0.3050 
Sulphadimethoxine -0.3585 -0.2420 0.7043 0.4071 1.0550 0.2142 
Sumatriptan succinate 0.6742 0.5684 0.1511 -0.7894 -0.7296 0.0071 
Sunitinib Malate (Sutent) -18.3043 -8.4696 -0.8621 -8.8448 -0.1817 -0.9142 
Suplatast tosylate 0.0577 1.2955 0.9088 0.4311 1.2363 0.6488 
Suprofen (Profenal) -1.9810 -1.5397 -1.0477 -2.6881 -1.4308 -1.6256 
Suxibuzone 0.0220 -0.0870 0.6492 -0.2336 -0.2102 -0.0018 
Tacrine HCl -0.4939 -0.2409 -0.7408 -0.2316 -0.3537 -0.1994 
Tadalafil (Cialis) -0.6354 0.0306 0.0107 1.5244 -1.5666 0.2616 
Talc -0.8733 0.2859 0.0157 0.0462 -0.1591 -0.0831 
TAME -0.2084 0.1692 -0.0144 -0.4412 -0.2274 0.1489 
Tamoxifen Citrate (Nolvadex) -8.0163 -13.2273 -11.6527 -7.0781 -8.7592 -11.5833 
Taurine -7.6979 1.2333 0.2823 0.5272 0.8320 0.3342 
Tazarotene (Avage) 0.2460 0.3455 0.3309 1.2830 0.0098 0.5851 
Tebipenem pivoxil (L-084) -0.8139 -0.2458 -0.1859 0.6900 0.0986 0.0415 
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Teicoplanin 0.7130 0.5549 0.1511 0.6418 -0.0814 -0.4903 
Telaprevir (VX-950) -2.8497 0.5179 -0.2481 -1.7497 1.2616 -0.0113 
Telbivudine (Sebivo, Tyzeka) 0.4662 -0.5397 -0.4710 -0.8404 0.6480 -1.3204 
Telmisartan (Micardis) -0.2511 1.8174 0.5395 0.6164 -0.5525 1.0045 
Temocapril HCl 0.7419 0.4925 0.3031 1.0713 0.7745 0.4563 
Temsirolimus (Torisel) -1.4587 -3.9046 -4.0159 1.1109 -0.2800 -1.5080 
Teniposide (Vumon) -8.5722 -13.5231 -12.7606 -5.9087 -7.8824 -11.2931 
Tenofovir (Viread) -0.1361 0.1871 0.6875 0.0523 -0.4906 -0.0673 
Tenofovir Disoproxil 
Fumarate -0.1314 0.5106 0.6777 0.5057 -0.3486 -0.3525 
Tenoxicam (Mobiflex) 0.2360 0.3558 0.0767 0.7603 0.5867 0.5604 
Terazosin HCl (Hytrin) 0.6843 0.1183 -1.2205 -0.8982 -1.6507 -0.8732 
Terbinafine (Lamisil, 
Terbinex) 0.2713 1.7072 0.4524 1.2610 0.6639 1.0360 
Terbinafine hydrochloride 
(Lamisil) -0.5926 0.0469 -0.7177 0.0683 0.4012 -1.2926 
Terfenadine 0.4883 0.1286 -0.0024 0.4027 0.6233 0.0234 
Teriflunomide 1.5640 1.1230 0.9874 1.5730 1.1938 1.0563 
Tetracaine hydrochloride 
(Pontocaine) 0.8198 0.3446 0.3289 0.1362 0.7044 0.0459 
Tetracycline HCl 1.2966 0.3396 0.2705 -0.3325 0.5631 0.3245 
Tetraethylenepentamine 
5HCl 0.1429 0.5058 0.5729 0.9433 0.2542 0.6430 
tetrahydrozoline 
hydrochloride -0.3160 0.1963 0.6142 0.3970 0.7288 0.5062 
Tetramisole HCl -1.9362 -1.4306 -1.3328 -1.5622 -0.8745 -2.0342 
Thalidomide 0.4338 1.0102 2.5887 1.7490 1.0926 1.7994 
Thiabendazole 0.0740 1.5144 0.1958 1.2173 0.0561 0.8563 
Thiamine HCl (Vitamin B1) 0.6005 0.1436 -0.1696 -0.3408 -0.5856 -0.0169 
Thiamphenicol 
(Thiophenicol) 0.5713 0.9481 0.1567 0.6271 0.3528 0.0564 
Thioguanine -10.6754 -18.6801 -19.3266 -11.8787 -8.7696 -13.2564 
Thioridazine HCl -14.3721 -17.6312 -18.9537 -9.8349 -11.2616 -13.2029 
Thiostrepton -1.5274 -0.4571 -0.6533 -0.4097 0.5411 0.0044 
Thonzonium Bromide -14.6826 -19.0153 -19.6885 -10.4547 -11.6925 -14.7018 
Tianeptine sodium 0.1323 -0.0854 -0.3033 -0.7091 -1.2236 0.3251 
Ticagrelor 0.2968 0.9273 0.4771 1.1020 0.6277 -0.6683 
Ticlopidine HCl 0.7578 1.2686 1.3419 0.7520 1.0767 0.9951 
Tigecycline 0.5229 -0.0379 -0.0544 -0.2171 -1.1177 -0.2263 
Tilmicosin -0.2803 -0.8337 -2.1575 -1.0501 -1.4708 -1.8336 
tinidazole -0.1654 1.3554 0.4206 0.8061 0.6773 0.6993 
Tioconazole -1.1510 -4.6871 -5.4471 -2.8846 -2.4332 -5.4613 
Tiopronin (Thiola) 0.0001 0.4324 -0.0201 -1.1301 -1.6682 -0.3965 
Tiotropium Bromide hydrate -0.2944 -0.0663 0.2217 0.8727 -0.3515 0.1606 
Tioxolone 0.2458 0.5802 0.5523 0.9108 0.7728 1.2103 
Tiratricol -0.5310 0.6887 -0.1218 0.6566 0.6200 0.1355 
Tizanidine HCl -0.1981 -0.6929 -0.9257 -1.8554 -1.5368 -0.0780 
Tobramycin 0.3409 0.5142 0.1530 0.6361 0.7934 0.3867 
Tofacitinib citrate (CP-
690550 citrate) -0.0063 0.5538 0.2630 0.2393 -0.1870 0.1760 
Tolazamide 0.0895 0.2799 0.6102 0.0033 -0.0481 0.3839 
Tolbutamide -7.9273 0.4561 -0.4100 -0.0202 -1.0098 0.0894 
Tolcapone -0.5236 0.0203 -0.6280 0.8103 0.2372 -0.8214 
Tolfenamic acid -12.8670 -0.1833 -0.3504 0.2971 0.3590 -0.5956 
Tolmetin Sodium -0.5122 0.0752 0.1126 -0.4837 0.4454 -0.3404 
Tolnaftate -0.3002 -0.2139 -0.9659 -1.5711 -1.7873 -1.2121 
Tolperisone HCl 0.9059 1.0494 0.4712 1.2326 0.3812 0.8112 
Tolterodine tartrate (Detrol 
LA) -15.8034 -1.6497 -0.6102 -0.5262 -1.0245 -0.8177 
toltrazuril -0.2160 -0.5931 -0.9426 -0.2409 -0.2973 -0.0448 
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Tolvaptan (OPC-41061) -0.2330 -0.6401 -0.3850 -0.0050 -0.1256 -0.5980 
Topiramate 0.3169 -1.0138 -1.0400 -14.1428 0.4690 -0.8537 
Topotecan HCl -19.1564 -25.4352 -25.9321 -12.8996 -15.0655 -18.4084 
Toremifene Citrate 
(Fareston, Acapodene) -8.1031 -10.0865 -21.3402 -14.7827 -3.7350 -13.2901 
Torsemide (Demadex) 0.0488 1.2981 0.4478 -0.6186 0.1927 0.5935 
Tranexamic acid (Transamin) 0.5869 1.4007 0.5743 0.5751 1.2300 0.9116 
Tranilast (SB 252218) 0.5426 -0.5867 -0.9495 -1.9010 0.5293 -0.4760 
Trazodone hydrochloride 
(Desyrel) -4.4070 0.5802 -0.2594 1.0389 0.7016 1.2154 
Tretinoin (Aberela) 0.2615 -1.2410 -0.5434 0.9334 0.7457 0.0918 
Triamcinolone (Aristocort) 0.6691 -2.2040 -3.5674 -1.5431 -0.6645 -2.5491 
Triamcinolone Acetonide 0.4516 0.4949 0.6062 1.0078 -0.7867 -0.0534 
triamterene -0.4317 -0.3462 -0.8222 -0.0284 -0.0045 -1.3301 
Trichlormethiazide (Achletin) -0.2803 0.5863 -0.0214 0.6647 0.6573 -0.1677 
Triclabendazole -0.3169 -1.3623 -0.5384 -0.5262 -0.6642 -1.4201 
Trifluoperazine 2HCl -12.4443 -20.4697 -20.0311 -10.6819 -12.2645 -15.1529 
Triflupromazine HCl -3.6447 -1.1984 -2.5632 -3.1550 -0.7165 -2.1006 
Trifluridine (Viroptic) -7.8237 -8.0698 -8.5713 -5.9743 -5.7880 -7.6520 
Triflusal 0.5578 -0.3703 0.1351 0.1202 -0.3466 0.6253 
Trilostane 0.1628 -0.1956 0.4013 -0.0827 -0.3741 -0.1603 
Trimebutine 0.5261 0.1285 -0.4319 0.6042 0.5468 0.3410 
Trimethoprim -0.2672 0.0692 0.0107 -0.2053 0.2676 0.2528 
Trimipramine Maleate -3.0886 0.0529 -0.9640 -0.4192 0.5568 -0.1457 
Tripelennamine HCl -0.4674 -0.9816 -1.2531 -0.2738 -0.6829 -0.5013 
Trometamol 0.5255 0.9644 0.8254 1.0545 0.9348 0.6548 
Tropicamide 0.3905 -0.0215 -1.2738 -0.9978 -1.5877 -1.1546 
Tropisetron -1.9289 -0.5182 -1.9710 -1.1950 -0.8983 -1.1366 
Trospium chloride (Sanctura) -0.0347 -0.4854 -0.0660 -0.3564 -0.9295 0.5192 
Troxipide -0.3087 -0.0228 -0.7805 -1.4357 -2.0241 -1.0025 
Tylosin tartrate -0.3513 0.2346 -0.4949 -0.1687 -0.4019 0.0214 
Ubenimex (Bestatin) -0.0126 0.0306 -0.0414 1.3151 0.7308 0.1894 
Ulipristal -0.0773 -0.8348 -0.0768 0.6294 0.0278 -0.0053 
Uracil 0.3813 1.5231 0.9578 1.2550 1.0479 1.1241 
Urapidil HCl 0.3941 -0.1944 -0.0727 -0.0779 -0.2718 0.3222 
Uridine 1.1014 1.0035 0.4796 0.5166 0.7053 0.1444 
Ursodiol (Actigal Urso) 0.3791 0.4151 -0.2567 -0.2424 0.0324 -1.2785 
Valaciclovir HCl 0.2907 1.1761 0.2934 0.6461 0.5604 0.8218 
valganciclovir hydrochloride 0.7427 1.8778 1.6495 1.0220 1.3068 1.1894 
Valnemulin HCl -0.5703 -1.1411 -0.8998 0.1473 -0.5932 -1.0175 
Valproic acid sodium salt 
(Sodium valproate) 1.2722 1.3571 1.0362 0.5096 0.4526 0.8541 
Valsartan (Diovan) 0.2528 0.8536 0.4164 0.1891 1.1646 0.5016 
Vancomycin HCl (Vancocin) 0.7436 0.4881 0.2290 -0.1949 0.4639 0.0858 
Vandetanib (Zactima) -18.8177 -0.5205 0.0206 1.0220 0.7915 0.9327 
Vardenafil (Vivanza) -0.2340 0.7937 1.0396 0.9427 0.6865 0.4538 
Varenicline tartrate 1.2635 -0.0306 -0.6962 -1.5200 0.9415 -0.0421 
Vecuronium Bromide 0.4690 -0.3273 0.2302 0.2624 -0.3408 0.1581 
Vemurafenib (PLX4032) -2.4712 -2.9188 -3.7219 1.2111 -0.3111 -2.0052 
Venlafaxine -0.0376 -1.1432 -0.5689 -0.4086 0.8412 -0.0527 
Verteporfin (Visudyne) 0.3460 -0.8762 0.4357 0.3427 0.5967 -0.0031 
Vidarabine (Vira-A) 0.1149 -0.5432 1.8450 0.6286 0.4033 0.6199 
Vildagliptin (LAF-237) -5.0916 -1.5867 -2.3325 -0.7464 -0.9535 -1.4701 
Vinblastine -1.8177 -2.4508 -1.7816 0.0048 -0.6253 -0.3697 
Vincristine -15.5400 -20.7794 -21.4008 -10.4383 -12.2999 -14.2448 
Vinorelbine (Navelbine) -14.0284 -18.2673 -19.1868 -10.5352 -10.2902 -13.0422 
Vinpocetine (Cavinton) -2.0092 0.0066 -1.0378 0.1040 -0.0560 -0.3579 
Vismodegib (GDC-0449) 0.7813 1.1719 1.1563 1.1409 0.5140 0.7940 
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Vitamin B12 -0.0126 0.1085 0.1488 0.1702 -0.2612 -0.0973 
Vitamin C (Ascorbic acid) 0.1053 -0.2871 0.9282 0.6365 0.4848 0.8302 
Vitamin D2 -0.2546 1.0336 1.3545 0.1938 1.0011 0.6224 
Vitamin D3 (Cholecalciferol) 0.6533 1.2663 1.2622 1.1128 1.2766 1.0088 
Voglibose 0.6834 -0.4078 -0.4658 -0.0557 -0.1209 -0.2199 
Voriconazole 1.0313 -0.2458 0.6097 -0.0463 1.1358 0.1926 
Vorinostat (SAHA) -15.6294 -22.6029 -19.8585 -8.2366 -10.9909 -13.4676 
XL-184 (Cabozantinib) -9.3567 -13.2101 -4.5088 -6.9803 -6.5942 -2.8801 
Xylazine HCl 1.1747 1.2848 1.3148 0.5511 1.1307 0.7242 
Xylometazoline HCl 0.5477 -0.9357 -0.3742 -0.7681 -0.0258 -0.4396 
Xylose -0.1057 0.0202 0.2936 0.4408 0.4071 0.0767 
Zafirlukast (Accolate) 0.8814 0.9712 0.8478 0.4647 -0.5360 0.2771 
Zalcitabine 0.0311 1.0892 0.9087 -0.2077 0.1205 -0.9001 
Zaltoprofen 0.2294 0.2963 0.1265 0.9460 0.4797 0.9672 
Zanamivir (Relenza) 0.9905 0.4025 0.4202 1.2118 0.3637 0.9135 
Zidovudine (Retrovir) -3.6228 -0.5415 -0.8731 0.5537 0.7704 0.3104 
Zileuton 1.5071 -0.4374 0.0690 -0.0521 0.9552 0.4325 
Ziprasidone hydrochloride 1.0023 -0.7674 -0.0839 0.0877 0.8746 0.3755 
Zoledronic Acid 
(Zoledronate) 0.4653 -0.5775 -1.5486 -0.5115 -0.3691 -0.5783 
Zolmitriptan (Zomig) -0.9763 -1.1847 -1.2869 -1.4627 0.2249 -2.6822 
Zonisamide 1.1410 -0.6502 0.4285 0.0783 0.9000 0.3394 
Zoxazolamine -1.1918 -1.7772 -0.7709 -0.7736 -2.3510 -0.7684 
 
